SEARCH

SEARCH BY CITATION

Epidemiology

1

  1. Top of page

The Parkinson's disease in Africa collaboration project in Ghana: The story so far

A. Akpalu, M. Cham, R. Cilia, G. Pezzoli (Accra, Ghana)

2

  1. Top of page

Association of cumulative some heavy metal exposure with Parkinson's disease

U. Dashdorj, B. Tserensodnom, B. Bold, U. Chimedregzen, F. Komatsu, Y. Kagawa (Ulaanbaatar, Mongolia)

3

  1. Top of page

Prevalence of neurodegenerative parkinsonism in the isolated population of South-Eastern Moravia, Czech Republic

K. Farníková, P. Kanovsky, L. Mikulicova, P. Jugas, J. Ovecka, M. Kaiserova (Olomouc, Czech Republic)

4

  1. Top of page

Frequency and pattern of movement disorders in a Nigerian rural tertiary health care institution: A preliminary study

M.B. Fawale (Ile Ife, Nigeria)

5

  1. Top of page

Pan-American consortium on multiple system atrophy

E. Gatto, C. Cosentino, P. Chana, J.L. Etcheverry, E. Gallin, M. Miranda, Y. Nuñez, V. Parisi, G. Persi, C. Vecchi, A. Sanguinetti, M. Rodriguez-Violante, J. Aparcana, L. Torres, I. Litvan (Buenos Aires, Argentina)

6

  1. Top of page

The prognosis of psychogenic (functional) motor symptoms: A systematic review

J.M. Gelauff, A.J. Carson, J. Stone (Amsterdam, Netherlands)

7

  1. Top of page

Plasma urate level associates the odds ration of Parkinson's disease (PD): Out-patient-clinic analysis in the neurology department

H. Iwaki, Y. Tamaki, T. Tsujii, N. Nishikawa, M. Nagai, M. Nomoto (Ehime, Japan)

8

  1. Top of page

The incidence of Parkinson's disease in North East England

T.K. Khoo, G. Duncan, A.J. Yarnall, D.J. Brooks, R.A. Barker, D.J. Burn (Newcastle upon Tyne, United Kingdom)

9

  1. Top of page

Epidemiology and age at onset analysis of Parkinson's disease in the eastern region of Cuba (Holguín)

L. Laguna-Salvia, J.A. Valdevila-Figueira, J.M. Laffita-Mesa (Holguín, Cuba)

10

  1. Top of page

The progression markers in the premotor phase (PMPP) of Parkinson's disease study

I. Liepelt-Scarfone, K. Mueller, C. Bormann, K. Gauss, J. Streffer, D. Berg (Tuebingen, Germany)

11

  1. Top of page

Prevalence and progression of mild parkinsonian signs in elderly men and women (Bruneck-study cohort): A population-based study

P. Mahlknecht, H. Stockner, S. Kiechl, J. Willeit, A. Gasperi, G. Rungger, W. Poewe, K. Seppi (Innsbruck, Austria)

12

  1. Top of page

Tracking Parkinson's: The PRoBaND study (Parkinson's repository of biosamples and networked datasets)

N. Malek, N. Bajaj, R. Barker, Y. Ben-Shlomo, D. Burn, T. Foltynie, H. Morris, N. Williams, N. Wood, D. Grosset (Glasgow, United Kingdom)

13

  1. Top of page

Frequency and clinical characteristics of movement disorders at the neurology clinic of the LAUTECH teaching hospital Osogbo Nigeria

A.F. Mustapha (Osogbo, Nigeria)

14

  1. Top of page

Risk factors and early non-motor features for Parkinson's disease: A systematic review and meta-analysis

A.J. Noyce, J. Bestwick, L. Silveira-Moriyama, C.H. Hawkes, G. Giovannoni, A.J. Lees, A. Schrag (London, United Kingdom)

15

  1. Top of page

Peripheral biomarkers of inflammation and Parkinson's disease in women

E.J. O'Reilly, H. Chen, M. Schwarzschild, A. Ascherio (Boston, MA, USA)

16

  1. Top of page

Spectrum of movement disorders at the premier Lagos Movement Disorders Clinic in Nigeria: First year's experience

N.U. Okubadejo, O.O. Ojo, O.O. Oshinaike, I.A. Bankole, C.B. Aiyejusunle (Lagos, Nigeria)

17

  1. Top of page

Physical precipitating factors in functional movement disorders

I. Pareés, M. Kojovic, M. Pires, I. Rubio Agustí, T.A. Saifee, A. Sadnicka, P. Kassavetis, K.P. Bhatia, J. Stone, M.J. Edwards (London, United Kingdom)

18

  1. Top of page

Baseline characteristics for the first Mexican multicentric cohort study: The Parkinson's disease national registry

M. Rodríguez-Violante, C. Zuñiga, M. López, I. Estrada-Bellman, R. Mathieu, C. Ramírez, A. Cervantes-Arriaga (Mexico City, Mexico)

19

  1. Top of page

Head injury and risk of Parkinson's disease: A systematic review and meta-analysis

A. Samii, M. Etminan, F. Aminzadeh, S. Jafari (Seattle, WA, USA)

20

  1. Top of page

Trends in initiation of antiparkinsonian drug treatment among patients with Parkinson's disease in the UK between 1997 and 2010: A population-based analysis

R. Schade, M. Sturkenboom (Rotterdam, Netherlands)

21

  1. Top of page

Incidence and prevalence of primary dystonia in Buenos Aires

C.V. Stefani, J.P. Tartari, A.M. Toral, A.L. Bisonni, D.H. Giunta, D.J. Bauso, E. Cristiano (Buenos Aires, Argentina)

22

  1. Top of page

Clinical and epidemiological features of hemifacial spasm in Buenos Aires, Argentina

J.P. Tartari, C.V. Stefani, D.H. Giunta, E. Cristiano, D.J. Bauso (Buenos Aires, Aruba)

23

  1. Top of page

Prevalence of Parkinson's disease in Ukraine

Y.O. Trufanov (Lugansk, Ukraine)

24

  1. Top of page

Establishing a population-based cohort to investigate Parkinson's disease

S. Tunc, J. Graf, A. Schmidt, V. Tadic, S. Wolff, A. Lorwin, E.J. Vollstedt, J. Hampf, L. Piskol, C. Klein, M. Kasten, J. Hagenah (Lübeck, Germany)

25

  1. Top of page

Stimulant use associated with risk of Parkinson's disease

S.K. Van Den Eeden, K.S. Albers, C.M. Tanner, A.D. Leimpeter, C.P. Quesenberry, L.M. Nelson (Oakland, CA, USA)

26

  1. Top of page

Withdrawn by Author

27

  1. Top of page

Prevalence of restless legs syndrome in Ankara, Turkey

A. Oto, O. Aykac, N. Yilmaz, M.C. Akbostanci (Ankara, Turkey)

28

  1. Top of page

Prevalence of Parkinson's disease and agricultural employment in Austria

H. Zach, H. Cetin, G. Fülöp, W. Pirker, E. Auff, F. Zimprich (Vienna, Austria)

Parkinson's disease: Cognition

29

  1. Top of page

Cognitive dysfunction in early Parkinson's disease: Neuropsychological analysis

C. Adams, R. Fulbright, M. Thomas (Bedford, TX, USA)

30

  1. Top of page

Diurnal sleepiness and executive dysfunctions: A virtual and neuropsychological study in Parkinson's disease and sleep apnea syndrome

G. Albani, L. Priano, P. Cipresso, S. Raspelli, R. Pignatti, P. Ferronato, A. Liuzzi, G. Riva, A. Mauro (Piancavallo, Italy)

31

  1. Top of page

Graded dual task benefits of cognitive tasks on cycling in Parkinson's disease: Effects of kinesia paradoxa

L.J.P. Altmann, E. Stegemöller, A.A. Hazamy, J.P. Wilson, D. Bowers, C.M. Sapienza, M.S. Okun, C.J. Hass (Gainesville, FL, USA)

32

  1. Top of page

Screening for cognitive impairment in Parkinson's disease and age-matched controls using MMSE and MOCA: Which visuospatial tests are most sensitive?

J.E. Alty, S.L. Smith, S. Jamieson (Leeds, United Kingdom)

33

  1. Top of page

Gait pattern and cognition in Parkinson's disease

M. Amboni, P. Barone, L. Iuppariello, I. Lista, R. Tranfaglia, A. Iavarone, A. Fasano, M. Picillo, G. Sorrentino (Naples, Italy)

34

  1. Top of page

Changes of cognitive function in Parkinson's disease following bilateral subthalamic nucleus stimulation: Evaluation by test battery including repeatable battery for the assessment of neuropsychological status

T. Asahi, N. Nakamichi, H. Hamada, A. Takaiwa, M. Koh, M. Kigawa, N. Hayashi, N. Kuwayama, N. Dougu, S. Takashima, S. Endo (Toyama, Japan)

35

  1. Top of page

Effect on cognitive functions of clinical autonomic dysfunction in Parkinson's disease

D. Aygun, K. Akpinar, S.K. Yön, M.K. Onar (Samsun, Turkey)

36

  1. Top of page

DEMPARK: Parkinson's disease and dementia

M. Balzer-Geldsetzer, I.A. Heber, M. Kronenbürger, J.B. Schulz, S. Röske, A. Spottke, U. Wüllner, A. Storch, C. Schneider, O. Riedel, H.U. Wittchen, C. Seifried, R. Hilker, N. Schmidt, K. Witt, G. Deuschl, B. Mollenhauer, C. Trenkwalder, I. Liepelt-Scarfone, S. Gräber-Sultan, D. Berg, T. Gasser, E. Kalbe, A. Petrelli, W.H. Oertel, R. Dodel (Marburg, Germany)

37

  1. Top of page

Comparison of The Movement Disorder Society criteria for Parkinson's disease dementia with routine clinical neuropsychological testing

B.R. Barton, B. Bernard, G.T. Stebbins, J. Goldman, B. Dubois, C.G. Goetz (Chicago, IL, USA)

38

  1. Top of page

Gait training associated with executive functions tasks in subjects with Parkinson's disease: Improvement of performance and effects in motor learning

C. Bedeschi Ferrari, L. Rodrigues, D. Bauer, A. Manfredi, M.E. Pimentel Piemonte (Barueri, Brazil)

39

  1. Top of page

Cognitive characterization of mild cognitive impairment subtypes in Parkinson's disease

R. Biundo, S. Facchini, P. Formento-Dojot, M. Pilleri, A. Antonini (Venice, Italy)

40

  1. Top of page

Impaired judgment of harmful intent in Parkinson's disease: Examining the role of dopamine

E. Gleichgerrcht, G. Gómez Arévalo, S. García, G. Mizraji, F. Manes, O. Gershanik, A. Chade (Buenos Aires, Argentina)

41

  1. Top of page

Motor impulsivity in Parkinson's disease subtypes: Postural instability with gait difficulty versus tremor predominant

D.O. Claassen, S.A. Wylie (Nashville, TN, USA)

42

  1. Top of page

β-amyloid and τ burden in the midbrain across the Lewy body spectrum

Y. Compta, M.J. Marti, E. Gelpi (Barcelona, Spain)

43

  1. Top of page

Is the PFAQ a valid instrument for defining disability due to cognitive impairment in Parkinson's disease?

C.P. Souza, G. Nascimento, G.G.R. Rodrigues, D. Sabino, V. Tumas, J.F. de Oliveira (Ribeirão Preto, Brazil)

44

  1. Top of page

Elevated homocysteine levels predict cognitive dysfunction in an incident cohort of non-demented Parkinson's disease patients

G.W. Duncan, T.K. Khoo, A.J. Yarnall, J.T. O'Brien, D.J. Brooks, R.A. Barker, D.J. Burn (Newcastle upon Tyne, United Kingdom)

45

  1. Top of page

Mechanisms of psychomotor slowing in Parkinson's disease

C. Duru, T. Lelard, M. Roussel, Y. Yerro, O. Godefroy, P. Krystkowiak (Amiens, France)

46

  1. Top of page

Neuropsychological profile in LRRK2-R1441G associated Parkinson's disease

A. Estanga, J. Ruiz-Martínez, A. Gorostidi, MŽaC. Rodríguez-Oroz, J.F. Marti-Masso (San Sebastian, Spain)

47

  1. Top of page

Neuropsychological performance in asymptomatic LRRK2 mutation carriers (R1441G and G2019S)

A. Estanga, A. Bergareche, J. Ruiz-Martínez, A. Gorostidi, MŽaC. Rodríguez-Oroz, J.F. Marti-Masso (San Sebastian, Spain)

48

  1. Top of page

The influence of reward and punishment on probability learning in patients with Parkinson's disease as compared to healthy controls

M. Fritz, D. Weiss, R. Krueger, A. Lindner, T. Waechter (Tuebingen, Germany)

49

  1. Top of page

Evolution of cognitive state in advanced Parkinson's disease

C. Gasca, A. Estanga, I. Lamet, P. Clavero, J. Obeso, M.C. Rodriguez-Oroz (Pamplona, Spain)

50

  1. Top of page

Baseline-dependent effects of levodopa on cognitive performance and rCBF in Parkinson's disease: A PET study

I.K. Goerendt, A.D. Lawrence, M.A. Mehta, D.J. Brooks (Hamburg, Germany)

51

  1. Top of page

Sleep quality indices and cognitive impairment in Parkinson's disease

R. Ghode, G.T. Stebbins, B. Bernard, B. Ouyang, C. Comella, J.G. Goldman (Chicago, IL, USA)

52

  1. Top of page

The neural basis of coordination in social decision-making: Evidence from Lewy body spectrum disorder

R.G. Gross, C.T. McMillan, J. Kitain, K. Rascovsky, R. Clark, M. Grossman (Philadelphia, PA, USA)

53

  1. Top of page

Long term follow-up of executive functions after brain stimulation (DBS) in Parkinson's disease (PD) patients: Preliminary results

N. Schlede, U. Gschwandtner, F. Hatz, R. Zimmermann, E. Taub, M.M. Ehrensperger, A.U. Monsch, P. Fuhr (Basel, Switzerland)

54

  1. Top of page

Survey of cognitive screening in Parkinson's disease across UK centres

S. Hanumantha Reddy, B. Elliott, D. MacMahon, Delegates at the 16th BGS Parkinson's Academy (London, United Kingdom)

55

  1. Top of page

A substantial investigation on psychiatric symptoms in patients with Parkinson's disease-(PD) from our own out-patients survey

K. Hasegawa, T. Yokoyama, E. Horiuchi, E. Kaneko, A. Kumon, N. Kawashima (Kanagawa, Japan)

56

  1. Top of page

Dual task dissociations in cognitive performance in Parkinson's disease

A.A. Hazamy, L.J.P. Altmann, J.P. Wilson, E. Stegemöller, D. Bowers, C.M. Sapienza, M.S. Okun, C.J. Hass (Gainesville, FL, USA)

57

  1. Top of page

Do the sub-types of Parkinson's disease patients respond differently to challenging walking conditions?

T. Herman, A. Weiss, M. Brozgol, S. Shema, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

58

  1. Top of page

Naming dynamic actions in Parkinson's disease

E. Herrera, E. Poliakoff, J. Holler, K. McDonald, F. Cuetos (Oviedo, Spain)

59

  1. Top of page

Subcortical white matter hyperintensities within the cholinergic pathways of Parkinson's disease patients according to cognitive status

J. Shin, S. Choi, J.Y. Hong, J.E. Lee, Y.H. Sohn, P.H. Lee (Seoul, Korea)

60

  1. Top of page

Neurocognitive and atrophic patterns in Parkinson's disease based on subjective memory complaints

J.Y. Hong, J.E. Lee, Y.H. Sohn, P.H. Lee (Seoul, Korea)

61

  1. Top of page

Quantitative assessment of clock drawing test combined with Minimental Status Exam in screening of cognitive impairment in PD

H.Y. Jeong, J.Y. Lee, S.Y. Seo, H.J. Kim, H.K. Park (Seoul, Korea)

62

  1. Top of page

Clinical and neuropsycological profile of patients with Parkinson's disease

D. Joshi, A. Zafar (Varanasi, India)

63

  1. Top of page

Longitudinal course of cognition in elderly women with Parkinson's disease

G.A. Kang, L. Lui, H. Fink, B. Miller, K. Yaffe (San Francisco, CA, USA)

64

  1. Top of page

Brain derived neurotrophic factor G196A polymorphism and cognitive impairment in Parkinson's disease

C. Karakasis, K. Kallinderi, G. Kourtesi, D. Milioni, L. Fidani, Z. Katsarou, S. Bostantjopoulou (Thessaloniki, Greece)

65

  1. Top of page

Pill questionnaire for detecting cognitive dysfunction and its impact on daily living in Parkinson's disease

J.S. Kim, J.H. Kang, B.S. Jeon (Cheongju-si, Korea)

66

  1. Top of page

The relationship between dysphagia and cognitive impairment including frontal lobe function in Parkinson's disease

J.Y. Kim, H.Y. Shin, J.E. Shin, H.R. Na (Seongnam-si, Korea)

67

  1. Top of page

Cognitive impairment in Parkinson's disease: A pilot study with minimental Parkinson's, the clock drawing test and the generation of words by category and code

A.P. Kleinert, E. Rodríguez, L. Romero, H. Juárez (Mexico City, Mexico)

68

  1. Top of page

COMTval158Met genotype and executive function in Parkinson's disease

G. Kourtesi, L. Fidani, Z. Katsarou, K. Kallinderi, T. Katopodi, V. Tsipropoulou, S. Bostantjopoulou (Thessaloniki, Greece)

69

  1. Top of page

The pattern of cortical atrophy in Parkinson's disease with mild cognitive impairment according to the timing of cognitive dysfunction

J.E. Lee, J.S. Kim, K.H. Cho, Y.H. Sohn, P.H. Lee (Seoul, Korea)

70

  1. Top of page

Changes on the mini-mental status examination and Montreal cognitive assessment over time in Parkinson's disease

S.L. Lessig, D. Nie, S. Edland, R. Xu, J.P. Corey-Bloom (La Jolla, CA, USA)

71

  1. Top of page

Parkinson's disease patients with “normal” MMSE score have a broad range of cognitive performance

D. Burdick, S. Watson, J. Trojanowski, A. Siderowf, B. Ritz, S. Rhodes, C. Wood-Siverio, S. Factor, J. Quinn, K. Chung, S. Srivatsal, K. Edwards, T. Montine, C. Zabetian, J. Leverenz (Seattle, WA, USA)

72

  1. Top of page

Neuropsychological assessment in collaborative PD research: A proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington

G.S. Watson, B. Cholerton, R.G. Gross, D. Weintraub, C.P. Zabetian, J.Q. Trojanowski, T.J. Montine, A.D. Siderowf, J.B. Leverenz (Seattle, WA, USA)

73

  1. Top of page

Parkinson's disease patients fulfilling level-I criteria for dementia differ in ADL functions and phenotype

I. Liepelt-Scarfone, D. Prakash, J.B.M. Christ, E. Riedl, I. Csoti, M. Fruhmann Berger, S. Graeber, D. Berg (Tuebingen, Germany)

74

  1. Top of page

A survey of the management of psychosis in Parkinson's disease

J. Lonnen, L. McNeil, E. Capek, C. McCarthy, V. McGill, G. MacPhee, D. Stewart (Larbert, United Kingdom)

75

  1. Top of page

Olfactory dysfunction correlation to non-motor symptoms in Parkinson's disease patients

G.J. Lopez, K. Bayulkem, B. McElroy, M. Brooks, B. Bayulkem, M. Hallett (Bethesda, MD, USA)

76

  1. Top of page

Visual sampling during walking in people with Parkinson's disease and the influence of task complexity

S. Lord, B. Galna, D. Daud, N. Archibald, D. Burn, L. Rochester (Newcastle upon Tyne, United Kingdom)

77

  1. Top of page

Subthalamic deep brain stimulation alters cognitive flexibility and reward-based learning in Parkinson's disease: Preliminary results

U. Lueken, S. Rietzel, M. Wolz, A. Storch, T. Goschke (Dresden, Germany)

78

  1. Top of page

Olfactory dysfunction is associated with cognitive impairment in Parkinson's disease

C. Sáez-Zea, F. Escamilla-Sevilla, M.J. Pérez-Navarro, Á. Ortega-Moreno, C. Carnero-Pardo, A. Mínguez-Castellanos (Granada, Spain)

79

  1. Top of page

Screening for cognitive impairment and dementia in Parkinson's disease using multivariate predictive models

C. Sáez-Zea, F. Escamilla-Sevilla, M.J. Pérez-Navarro, Á. Ortega-Moreno, C. Carnero-Pardo, A. Mínguez-Castellanos (Granada, Spain)

80

  1. Top of page

Identifying frequency of memory impairment in Parkinson's disease clinic

A. Malik, S. Ali, F.S. Khan (Karachi, Pakistan)

81

  1. Top of page

Brain dopaminergic (FluroDOPA PET) correlates of kinematic flexibility in Parkinson's disease

L. Marinelli, S. Morbelli, L. Mori, A. Piccardo, A. Brugnolo, A. Picco, G. Abbruzzese, F. Nobili (Genova, Italy)

82

  1. Top of page

Cerebellar activity increases along with striatal activity after levodopa administration in patients with PD

K. Martinu, M. Oury (Montreal, QC, Canada)

83

  1. Top of page

GBA mutation carriers with Parkinson's disease are not at increased risk for cognitive impairment

I. Mata, J. Leverenz, J. Trojanowski, A. Chen-Plotkin, B. Ritz, S. Rhodes, S. Factor, C. Wood-Siverio, J. Quinn, K. Chung, A. Espay, F. Revilla, K. Edwards, T. Montine, C. Zabetian (Seattle, WA, USA)

84

  1. Top of page

APOE and SNCA predict cognitive performance in Parkinson's disease

I. Mata, J. Leverenz, J. Trojanowski, A. Siderowf, B. Ritz, S. Rhodes, S. Factor, C. Wood-Siverio, J. Quinn, K. Chung, A. Espay, F. Revilla, K. Edwards, T. Montine, C. Zabetian (Seattle, WA, USA)

85

  1. Top of page

Capgras syndrome in Parkinson's disease: A case report

S. Medic, D. Kuljic Obradovic, D. Markovic Zigic (Belgrade, Serbia)

86

  1. Top of page

MRI brain integrity and perfusion measures in Parkinson's disease: Prediction and progression

T.R. Melzer, D.J. Myall, R. Watts, M.R. MacAskill, T.L. Pitcher, R. Keenan, L. Livingston, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)

87

  1. Top of page

Motor learning, retention and transfer after virtual reality-based training in Parkinson's disease: Effect of motor and cognitive demands of games

F. Mendes, J.E. Pompeu, K. Guedes, A. Mondenesi, M.E.P. Piemonte (Sao Paulo, Brazil)

88

  1. Top of page

Baseline data of the DeNoPa-Kassel cohort: Biomarkers and non-motor features of 160 drug naïve PD subjects and 115 matched healthy controls

B. Mollenhauer, E. Trautmann, T. Wicke, J. Ebentheuer, F. Sixel-Döring, C. Trenkwalder, DeNoPa Study Group (Kassel, Germany)

89

  1. Top of page

Prevalence and profile of neuropsychiatric symptoms in Parkinson's disease subjects with mild cognitive impairment

R. Monastero, P. Di Fiore, G.D. Ventimiglia, C.C. Ventimiglia, R.M. Camarda, C. Camarda (Palermo, Italy)

90

  1. Top of page

Effect of COMT and DAT1 polymorphisms on the cognitive profile and patterns of neural activity of patients with PD

O. Monchi, A. Noreau, C. Habak, B. Mejia, A. Nagano, A.L. Lafontaine, S. Chouinard, G.A. Rouleau (Montreal, QC, Canada)

91

  1. Top of page

Attentional set-shifting deficits correlate with severity of freezing of gait in Parkinson's disease

S.T. Moore, J.M. Shine, S.L. Naismith, N.C. Palavra, V. Dilda, T.R. Morris, S.J.G. Lewis (New York, NY, USA)

92

  1. Top of page

Withdrawn by Author

 

93

  1. Top of page

Spatial planning ability in early stage Parkinson's disease patients (ICICLE-PD)

C. Nombela, J.B. Rowe, A. Hampshire, A.M. Owen, D.P. Breen, T.K. Khoo, M. Firbank, A. Yarnall, G. Duncan, J.T. O'Brien, D.J. Burn, D.J. Brooks, R.A. Barker (Cambridge, United Kingdom)

94

  1. Top of page

Levodopa-induced dyskinesia and neurocognitive function in Parkinson's disease

G.D. Oggioni, J. Devoto, R. Cantello, A.J. Espay (Novara, Italy)

95

  1. Top of page

Correlation of cognitive impairment evaluated by Montreal Cognitive Assessment with functional brain imaging of Parkinson's disease patients

K. Ohta, T. Osada, T. Tajima, M. Seki, Y. Shinohara (Tokyo, Japan)

96

  1. Top of page

Assessment of the relationship between total plasma homocysteine and cognitive function in Parkinson's disease

O.O. Ojo, N.U. Okubadejo, O.O. Osinaike, O.O. Oladipo, F.I. Ojini, M.A. Danesi (Idi-araba, Nigeria)

97

  1. Top of page

Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) as screening tools for cognitive impairment among patients with idiopathic Parkinson's disease: A descriptive study

L.A. Penaserada, L.K. Ledesma, R.E. Picar, D.E. Cid Czarina, C.E. Carcel (Makati City, Philippines)

98

  1. Top of page

Mild cognitive impairment and dementia in Parkinson's disease: 5 year follow up

M. Petrovic, E. Stefanova, T. Stojkovic, V. Kostic (Kragujevac, Serbia)

99

  1. Top of page

Self-awareness of dyskinesias in Parkinson's disease

S. Pietracupa, A. Fasano, M.C. Bloise, A. Latorre, G. Fabbrini, A. Berardelli (Rome, Italy)

100

  1. Top of page

Vascular risk factors and dementia in Parkinson's disease

B. Lobb, S. O'Connor, A. Peterson, K. Chung, N. Carney, J. Mack, J.F. Quinn (Portland, OR, USA)

101

  1. Top of page

Long-term verbal memory disorders in Parkinson's disease (PD)

A. Saenz, A. Doe de Maindreville, J. Vaunaize, J.M. Visy, S. Bakchine, N. Ehrle (Reims, France)

102

  1. Top of page

Screening utility of Montreal Cognitive Assessment (MoCA) for detecting cognitive impairment in patients with Parkinson's disease

M. Seki, M. Kobari, B. Mihara, K. Isozumi, K. Ohta, K. Muramatsu, T. Shirai, K. Takahashi, H. Nozaki, J. Gotoh, K. Yamaguchi, Y. Tomita, H. Sato, D. Yasutomi, Y. Nihei, S. Iwasawa, N. Suzuki (Tokyo, Japan)

103

  1. Top of page

Prolonged finger tapping test in Parkinson's disease

V. Senanarong, A. Pisanpong, N. Aoonkaeew, S. Udomphanthurak (Bangkok, Thailand)

104

  1. Top of page

Neural basis of memory impairment in Parkinson's disease: A longitudinal PET study

Y. Shoji, Y. Nishio, A. Takeda, M. Uchiyama, T. Kashinoura, Y. Hosokai, H. Fukuda, E. Mori (Sendai, Japan)

105

  1. Top of page

Genetic influences on cognitive decline in Parkinson's disease

J.F. Morley, S.X. Xie, H.I. Hurtig, M.B. Stern, A. Colcher, S. Horn, N. Dahodwala, J.E. Duda, D. Weintraub, A.S. Chen-Plotkin, V. Van Deerlin, D. Falcone, A. Siderowf (Philadelphia, PA, USA)

106

  1. Top of page

Association between olfactory dysfunction and cognition in the PPMI study

A. Siderowf, J.F. Morley, J.E. Duda, D. Weintraub, For the PPMI Investigators (Philadelphia, PA, USA)

107

  1. Top of page

Utilization of cognitive enhancers in patients with Parkinson's disease. National Parkinson Foundation (NPF) Quality Improvement Initiative

B. Stell, M. Kwansy, O.N. Oguh, T. Simuni, on behalf of the NPF QII Investigators (Chicago, IL, USA)

108

  1. Top of page

Mobility and falls in people with Parkinson's disease with and without cognitive impairment

E. Stack, C. Fitton, A. Ashburn, H. Roberts, K. Amar (Southampton, United Kingdom)

109

  1. Top of page

Severe olfactory dysfunction is predictive of dementia associated with Parkinson's disease: A 3-year longitudinal study

T. Baba, A. Kikuchi, K. Hirayama, Y. Nishio, Y. Hosokai, S. Kanno, T. Hasegawa, N. Sugeno, M. Konno, E. Miura, E. Mori, A. Takeda (Sendai, Japan)

110

  1. Top of page

A novel test for assessing gait under multiple-task conditions: Comparison of the performance among adults, elderly and patients with Parkinson's disease

E. Tardeli, N. Santo, R. Bovi, D. Bertolo, M.E.P. Piemonte (Sao Paulo, Brazil)

111

  1. Top of page

Association between CSF biomarkers and clinical phenotype of early Parkinson's disease in the Parkinson's Progression Marker Initiative (PPMI)

J.H. Kang, C. Caspell, C. Coffey, P. Taylor, M. Frasier, K. Marek, J.Q. Trojanowski, L.M. Shaw (Philadelphia, PA, USA)

112

  1. Top of page

Predictors of cognitive impairment in Mongolian patients with Parkinson's disease

B. Tserensodnom, K. Baatar (Ulaanbaatar, Mongolia)

113

  1. Top of page

Cognitive symptoms in a population-based cohort to study parkinsonism

E.J. Vollstedt, J. Graf, A. Lorwin, J. Hagenah, V. Tadic, N. Brüggemann, A. Schmidt, S. Tunc, J. Hampf, L. Piskol, C. Klein, M. Kasten (Lübeck, Germany)

114

  1. Top of page

Learning and memory deficits are dependent upon level of global cognitive impairment in Parkinson's disease

G.S. Watson, B.A. Cholerton, S.E. Thomas, C.P. Zabetian, J.F. Quinn, K.A. Chung, T.J. Montine, J.B. Leverenz (Seattle, WA, USA)

115

  1. Top of page

Computer-game based therapy for balance rehabilitation in individuals with Parkinson's disease

C.P. Whyatt, C.M. Craig (Belfast, United Kingdom)

116

  1. Top of page

Dual task effects during sentence production in Parkinson's disease

J.P. Wilson, L.J.P. Altmann, A.A. Hazamy, E. Stegemöller, M.S. Okun, C.J. Hass (Gainesville, FL, USA)

117

  1. Top of page

Increasing the cognitive load of a familiar reach-to-grasp task impairs automatic control in patients with Parkinson's disease

P. Yanovich, R.W. Isenhower, E.B. Torres (Piscataway, NJ, USA)

118

  1. Top of page

Comparison of the Montreal Cognitive Assessment and Mini-Mental State Examination in detecting cognitive impairment in South-East Asian patients with Parkinson's disease

L.L.L. Yeo, W.I. Koay, Y. Dong, W.Y. Lee, J.A. Catindig, S. Collinson, C. Chen, E.C.H. Lim (Singapore, Singapore)

119

  1. Top of page

Using ecological event-based acoustic guides to cue gait in Parkinson's disease patients

W.R. Young, M.W.M. Rodger, C.M. Craig (Belfast, United Kingdom)

120

  1. Top of page

Prevalence of mild cognitive impairment subtypes in patients with Parkinson's disease– Comparison of two modes of MCI classification

H. Zach, G. Pusswald, D. Moser, A. Gleiß, E. Auff, W. Pirker, J. Lehrner (Vienna, Austria)

121

  1. Top of page

Cognitive training in patient's with Parkinson's disease

R. Zimmermann, U. Gschwandtner, N. Schlede, F. Hatz, P. Fuhr (Basel, Switzerland)

Parkinson's disease: Neuropharmacology

122

  1. Top of page

To study the safety and efficacy of galanin on motor functions in parkinsonism induced rats

A. Amin, L.D. Iftimi, M. Figura, C. Ene (Srinagar, India)

123

  1. Top of page

Evaluation of oxidative/nitrosative stress markers in non-SN regions of post-mortem Parkinson's disease brain: Neuroprotection by natural antioxidant

M.R. Babu, H. Gangadharappa, C. Venkateshappa, S. Bharath (Bangalore, India)

124

  1. Top of page

Treatment in Parkinson's disease patients aged 65 and older: A hospital-based cohort

D. Barzola, M. Perez Akly, R. Diaz, F. Alvarez, M.M. Esnaola, C. Peralta (Buenos Aires, Argentina)

125

  1. Top of page

Inpatient Parkinson's disease management – Call for immediate attention

P. Boovalingam, M. Ardron (Oxford, United Kingdom)

126

  1. Top of page

[123I] FP-CIT single photon emission computed tomography findings in drug-induced parkinsonism

M. Tinazzi, A. Cipriani, A. Matinella, A. Cannas, P. Solla, A. Nicoletti, M. Zappia, L. Morgante, F. Morgante, C. Pacchetti, M. Sciarretta, C. Dallocchio, S. Rossi, M. Malentacchi, R. Ceravolo, D. Frosini, S. Sestini, T. Bovi, C. Barbui, C. Barbui (Verona, Italy)

127

  1. Top of page

Duodenal levodopa infusion in patients with advanced Parkinson's disease

M.T. Cáceres-Redondo, F. Carrillo, M.J. Lama, M. Carballo, P. Mir (Seville, Spain)

128

  1. Top of page

Δ9-THC is protective in a cell culture model of Parkinson's disease through a PPARγ mediated mechanism resulting in increased expression of PGC1- α

M.L. Zeissler, O. Hanemann, J.P. Zajicek, C.B. Carroll (Plymouth, United Kingdom)

129

  1. Top of page

The role of norepinephrine in rat ultrasonic vocalizations

L.M. Grant, J.N. Basken, M.R. Ciucci (Madison, WI, USA)

130

  1. Top of page

Human microdyalisis during acute high frequency stimulation of internus globus pallidus increases dopamine release and improves parkinsonian symptoms

R.R.C. Martinez, M.C. Carvalho, M.L. Brandão, M.J. Teixeira, J. Navarro, E.T. Fonoff (São Paulo, Brazil)

131

  1. Top of page

Serum uric acid levels in Japanese Parkinson's disease: Their relationship to wearing-off fluctuation and levodopa induced dyskinesia

J. Fukae, K. Ishikawa, T. Hatano, Y. Shimo, N. Hattori (Tokyo, Japan)

132

  1. Top of page

Implicit motor learning is impaired by levodopa, but restored by deep brain stimulation of the subthalamic nucleus

L.M. Hall, S.G. Brauer, P.W. Hodges (Brisbane, Australia)

133

  1. Top of page

A comparison of adverse events with monoamine oxidase inhibitors and catechol-o-methyl transferase inhibitors in combination with levodopa for patients with Parkinson's disease

R. Zhang, A.D. Hohler, M. Saint-Hilaire (Boston, MA, USA)

134

  1. Top of page

Determination of plasma, brain and cerebrospinal fluid levels of L-DOPA in the MPTP-lesioned cynomolgus macaque model of Parkinson's disease

P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, J.M. Brotchie (Toronto, ON, Canada)

135

  1. Top of page

L-745,870 reduces L-DOPA-induced dyskinesia in the MPTP-lesioned primate at doses at which it is a selective antagonist at D4 dopamine receptors

P. Huot, T.H. Johnston, J.B. Koprich, S.H. Fox, J.M. Brotchie (Toronto, ON, Canada)

136

  1. Top of page

The mGlu4 receptor positive allosteric modulator, Lu AF21934, displays anti-parkinsonian effects in the haloperidol-treated rat model of Parkinson's disease

T.H. Johnston, M.A. Uberti, M.D. Bacolod, D. Doller, J.M. Brotchie (Toronto, ON, Canada)

137

  1. Top of page

PYM50028, an orally active neurotrophic factor modulator in development for Parkinson's disease, modulates axon guidance mechanisms related to semaphorin-plexin A-cofilin signaling pathways in the MPTP-lesioned macaque

T.H. Johnston, J.B. Koprich, M. Hill, S.H. Fox, P.A. Howson, J.M. Brotchie (Toronto, ON, Canada)

138

  1. Top of page

Medication reminder service for mobile phones; an open usability study in patients with Parkinson's disease

T. Keränen, S. Liikkanen (Kuopio, Finland)

139

  1. Top of page

Anti-parkinsonian effects of Nurr1 activator in UPS impairment induced animal model of Parkinson's disease

Z. Zhang, W. Xie, S. Hintermann, J. Jankovic, W. Le (Houston, TX, USA)

140

  1. Top of page

Maintenance of constant steady state therapeutic plasma concentrations of levodopa following its continuous subcutaneous administration with carbidopa

O. Yacoby-Zeevi, P.A. LeWitt (West Bloomfield, MI, USA)

141

  1. Top of page

Is chronic levodopa therapy associated with distal symmetric polyneuropathy in Parkinson's disease?

N. Shahrizaila, U.A. Mahamad, A.C. Yap, Y.M. Choo, C. Marras, S.Y. Lim (Kuala Lumpur, Malaysia)

142

  1. Top of page

Chronic transdermal rotigotine reduces levodopa-induced dyskinesias

G.J. Linazasoro, N. Van Blercom (San Sebastian, Spain)

143

  1. Top of page

Rotigotine treatment in Parkinson's disease: Evaluation of its characteristics in our movement disorders unit

L. Martinez, L.J. Lopez del Val, E. López, S. Santos (Zaragoza, Spain)

144

  1. Top of page

An audit of apomorphine in the management of complex idiopathic Parkinson's disease in Ireland

B. Magennis, A. Cashell, D. O'Brien, T. Lynch (Dublin, Ireland)

145

  1. Top of page

Tardive tolerance to dopamine D1 agonists: A novel loss of response dependent upon continuous receptor occupation

R.B. Mailman, K.N. Boyd, K. Neitzel, E. Heinzen (Hershey, PA, USA)

146

  1. Top of page

Peripheral neuropathy during continuous levodopa duodenal infusion: Outcome of 15 patients

F. Mancini, C. Comi, D. Calandrella, M. Lacerenza, G. Riboldazzi, C. Pacchetti, M. Coletti Moia, L. Manfredi, A. Antonini (Milan, Italy)

147

  1. Top of page

Effects of levodopa on postural sway differs with stage of Parkinson's disease

M. Mancini, J.G. Nutt, F.B. Horak (Portland, OR, USA)

148

  1. Top of page

Early inititation of L-dopa, but not pramipexole, restores basal ganglia activity in hemiparkinsonian rats

C. Marin, M. Bonastre, G. Mengod, R. Cortés, J.A. Obeso, A.H. Schapira (Barcelona, Spain)

149

  1. Top of page

Antiparkinsonian therapy and olfactory discrimination in hemiparkinsonian rats

C. Marin, M. Bonastre, J. Mullol (Barcelona, Spain)

150

  1. Top of page

Parkinson's disease responding to smoking

A. Mc Carthy, K. O'Rourke, T. Lynch (Dublin, Ireland)

151

  1. Top of page

Neuroprotection by the dietary polyphenol curcumin: Therapeutic implications for Parkinson's disease

S.B. Muchukunte Mukunda, R.B. Mythri, G. Harish, B.S.S. Rao, J. Veena, K. Misra (Bangalore, India)

152

  1. Top of page

CNI-1493 attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease

C. Noelker, V. Stuckenholz, J.P. Reese, D. Alvarez-Fischer, R. Sankowski, R.C. Dodel, W.H. Oertel, A. Hartmann, S. van Patten, Y. Al-Abed, M. Bacher (Marburg, Germany)

153

  1. Top of page

Glucocerebrosidase deficiency and dopaminergic cell death: Relevance to Parkinson's disease

C. Noelker, D. Alvarez-Fischer, M. Höllerhage, L. Lu, A. Sturn, R. Roscher, E.C. Hirsch, G.U. Höglinger, A. Hartmann (Marburg, Germany)

154

  1. Top of page

Peripheral neuropathy presentation after starting treatment with continuous intraduodenal levodopa infusion in four patients with Parkinson's disease

A. Palasí, O. de Fàbregues, J. Hernández, J.L. Seoane, J. Gámez, R. Velasco, J. Alvarez-Sabin (Barcelona, Spain)

155

  1. Top of page

Neuroprotection by neuropeptide orexin A in a cellular model of Parkinson's disease

T. Pan, Y. Wu, J.X. Zhu, J. Jankovic (Houston, TX, USA)

156

  1. Top of page

Effects of erythropoietin in the executive control in Parkinson's disease

V. Perez-Bocourt, M.L.B. Vega, V.R. Rodríguez (Havana, Cuba)

157

  1. Top of page

Assessment of commercial formulations of Mucuna pruriens seeds for levodopa (L-DOPA) content

A. Soumyanath, T. Denne, A. Peterson, L. Shinto (Portland, OR, USA)

158

  1. Top of page

In vivo antiparkinson activity of drugs acting on A2A-CB1-D2 receptors

A. Pinna, G. Costa, M.T. Armentero, C.E. Müller, R. Franco, N. Simola (Cagliari, Italy)

159

  1. Top of page

Pharmacotherapy of Parkinson's disease in Estonia: Strategies and complications

K. Rallmann, L. Kadastik-Eerme, M. Rosenthal, P. Taba (Tartu, Estonia)

160

  1. Top of page

A multicentre European comparative survey of motor and non motor effects of subcutaneous apomorphine infusion and intrajejunal levodopa infusion in Parkinson's disease

P. Reddy, P. Martinez-Martin, A. Antonini, D. Calandrella, M. Pilleri, P. Odin, A. Martin, T. Henriksen, A. Rizos, R. Katzenschlager, N. Bryndum, A. Glad, L. Timmermann, H. Salimi Dafsari, G. Ebersbach, M.G. Kramberger, M. Trost, Z. Pirtosek, K. Wenzel, V. Tomantschger, A. Storch, H. Reichmann, A. Ceballos-Baumann, K.R. Chaudhuri (London, United Kingdom)

161

  1. Top of page

European multicentre survey of tolerability rates and impulse control behaviour trends of prolonged release dopamine agonists in young and old PD

A. Rizos, P. Martinez-Martin, A. Martin, T. Henriksen, B. Kessel, I. Koch, G. Durner, A. Antonini, P. Odin, C. Falup-Pecurariu, P. Reddy, S. Robinson, M. Silverdale, G. MacPhee, A. Douiri, S. Lindvall, K. Ray Chaudhuri (London, United Kingdom)

162

  1. Top of page

L-dopa response in Parkinson's disease – A study with L-dopa infusion test

H. Saiki, S. Matsumoto (Osaka, Japan)

163

  1. Top of page

Adherence to once-daily dopamine agonists in levodopa-treated Parkinson's disease patients is related to first dopamine replacement therapy

D. Santos-García, M. Prieto-Formoso, R. de la Fuente- Fernández (Ferrol, Spain)

164

  1. Top of page

Factors associated with medication nonadherence in patients with Parkinson's disease at King Chulalongkorn Memorial Hospital

M. Sribanphai, S. Pichayapaiboon, R. Bhidayasiri (BKK, Thailand)

165

  1. Top of page

Nicotine is not neuroprotective in all Parkinson's disease patients – Why?

M.H. Strothjohann (Wolfach, Germany)

166

  1. Top of page

Rapid efficacy of rasagiline on motor symptoms: Experience of a multicenter clinical trial

S. Zambito Marsala, R. Vitaliani, F. Capozzoli, E. Belgrado, C. Borsato, L. Baroni, M. Gioulis, T. Scaravilli, C. Marchini (Belluno, Italy)

Huntington's disease

167

  1. Top of page

Interventional differences among Huntington's disease (HD) patients by disease progression: commercially-insured v. Medicaid

K.E. Anderson, D. Langbehn, J.H. Warner, J. Giuliano, V. Divino, P. Smith, M. Dekoven, W.C. Lee (Baltimore, MD, USA)

168

  1. Top of page

A proposal for a physiotherapy programme to improve gait, balance and functional independence in Huntington's disease

T. Capato, M. Haddad, M.E. Piemonte, E.R. Barbosa (Sao Paulo, Brazil)

169

  1. Top of page

Seizures in juvenile Huntington's disease (JHD): A large multi-center cohort

L. Cloud, A. Rosenblatt, R. Margolis, C. Ross, J. Pillai, J. Corey-Bloom, H. Tully, T. Bird, P. Panegyres, D. Higgins, S. Helmers, R. Jones, S. Factor, C. Testa (Richmond, VA, USA)

170

  1. Top of page

Huntington's disease in an indigneous village in the Peruvian Amazon jungle

M.R. Cornejo-Olivas, N. Mori, I. Alva, J. Zunt, P.E. Mazzetti (Lima, Peru)

171

  1. Top of page

Huntington's disease confirmed by genetic testing in three Malian families

T. Coulibaly, M. Karambe, C.O. Guinto, M. Traore (Bamako, Mali)

172

  1. Top of page

Isolated postural tremor revealing Huntington's disease

T. Nguyen, T.C. Danaila, G.L. Defer (Caen, France)

173

  1. Top of page

Familiarity of GINA among individuals affected by Huntington's disease

K. Darwin, P. Nichols, J. Kwok, C. Bennet, L. Rosenthal, Y. Bombard, E.R. Dorsey, E. Oster (Baltimore, MD, USA)

174

  1. Top of page

Predictors of fitness to drive in Huntington's disease

H. Devos, A. Nieuwboer, W. De Weerdt, M. Tant, W. Vandenberghe (Heverlee, Belgium)

175

  1. Top of page

Clinical assessment of the effect of tetrabenazine on motor function in moderate Huntington's disease

R. Fekete, A. Davidson, J. Jankovic (Valhalla, NY, USA)

176

  1. Top of page

Effect of tetrabenazine on computerized dynamic posturography of Huntington's disease patients

R. Fekete, A. Davidson, W.G. Ondo, H.S. Cohen (Valhalla, NY, USA)

177

  1. Top of page

Recommendations for data collection in Huntington's disease clinical research: The NINDS Huntington's disease Common Data Elements project

W.R. Galpern, on behalf of the NINDS HD CDE Working Group (Bethesda, MD, USA)

178

  1. Top of page

Weight control in a Huntington's disease population

I. Gastón, I. Marañón, L. Torné, D. Martínez, M.A. Ramos, A. Martínez (Pamplona, Spain)

179

  1. Top of page

Theory of mind and social cognition in Huntington's disease patients from Argentina: A preliminary report

E. Gatto, V. Parisi, G. Persi, E. Ruotolo, J.L. Etcheverry, S. Vilas, V. Villar, G. Rojas, A. Leis, S. Vanotti, A. Orellano, R. Allegri, I. Demey (Buenos Aires, Argentina)

180

  1. Top of page

Bilateral globus pallidus deep brain stimulation for Huntington's disease: Long term outcome of chorea

V. Gonzalez, L. Cif, B. Biolsi, M. Zanca, E. Sanrey, A.M. Moura, T. Roujeau, S. James, P. Coubes (Montpellier, France)

181

  1. Top of page

Cognitive decline in Huntington's disease is associated with CAG repeat length

A. Hellman, B. Durbin-Johnson, X. “R.” Chen, D. Harvey, C. Decarli, T. Tempkin, V. Wheelock (Philadelphia, PA, USA)

182

  1. Top of page

Neuropathology of McLeod neuroacanthocytosis syndrome

H.H. Jung, F. Geser, J. Haybäck, B. Bader, A. Danek, P. Fuhr, M. Neumann, R. Reichard, B. Udd, A. Zeman, M. Tolnay (Zürich, Switzerland)

183

  1. Top of page

Licofelone attenuates quinolinic acid induced Huntington's like symptoms: Possible behavioral, biochemical and cellular alterations

H. Kalonia, A. Kumar (Chandigarh, India)

184

  1. Top of page

Assessing willingness to participate in preventative clinical trials

A. Killoran, K.M. Biglan, E. Julian-Baros, N. Yoritomo, C.A. Ross (Rochester, NY, USA)

185

  1. Top of page

Baseline characteristics of the PREQUEL cohort: An interventional trial in pre-manifest Huntington's disease

A. Killoran, K.M. Biglan, E. Julian-Baros, N. Yoritomo, C.A. Ross (Rochester, NY, USA)

186

  1. Top of page

The use of dietary supplements in the PREQUEL cohort

A. Killoran, K.M. Biglan, E. Julian-Baros, N. Yoritomo, C.A. Ross (Rochester, NY, USA)

187

  1. Top of page

Neuroprotective effect of pioglitazone against 3-nitropropionic acid induced animal models of Huntington's disease

P. Kumar, H. Kalonia, A. Kumar (Ludhiana, India)

188

  1. Top of page

Safety and tolerability of tetrabenazine in a Spanish population of Huntingon's disease patients

J.L. López-Sendón, J. García Caldentey, J. García de Yébenes (Madrid, Spain)

189

  1. Top of page

Neuroinflammation in the YAC128 transgenic mouse model of Huntington's disease

C. Connolly, J. Thiele, J. Beck, C. Lefroy, A. Hill, B.R. Leavitt (Vancouver, BC, Canada)

190

  1. Top of page

Neuroprotective effect of statins against QA induced behavioral, biochemical and mitochondrial alteration in rats

J. Mishra, H. Kalonia, A. Kumar (Chandigarh, India)

191

  1. Top of page

Frontal subcortical dysfunction underlying the applause sign: A study in Huntington's disease subjects

S. Nageshwaran, Y. Bordelon, S. Perlman (London, United Kingdom)

192

  1. Top of page

Late onset Huntington's disease simulating corticobasal degeneration

M.T. Perez Saldaña, A. Piera, S. Roig, J. Palau, J.A. Burguera (Manises, Spain)

193

  1. Top of page

The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis

T. Pringsheim, K. Wiltshire, L. Day, T. Steeves, N. Jette (Calgary, AB, Canada)

194

  1. Top of page

An interdisciplinary model of care for Huntington's disease (HD) families

A.K. Rao, C.B. Moskowitz, P.L. Wasserman, K.S. Marder (New York, NY, USA)

195

  1. Top of page

Concomitant use of antidepressants and neuroleptics with tetrabenazine during treatment of Huntington's disease

V. Shen, K. Clarence-Smith, C. Hunter, J. Jankovic (Deerfield, IL, USA)

196

  1. Top of page

Tetrabenazine for moderate vs. severe/disabling chorea associated with Huntington's disease (HD)

V. Shen, K. Clarence-Smith, C. Hunter, J. Jankovic (Deerfield, IL, USA)

197

  1. Top of page

Long-term safety and efficacy of tetrabenazine in the treatment of chorea associated with Huntington's disease

V. Shen, K. Clarence-Smith, C. Hunter, J. Jankovic (Deerfield, IL, USA)

198

  1. Top of page

Repetitive transcranial magnetic stimulation for chorea in Huntington's disease

A.D. Shukla, N. Jayrajan, M. Kesavan, S. Jain (Wardha, India)

199

  1. Top of page

Molecular analysis of Huntington's disease in a Cuban population

Y. Vázquez-Mojena, J.M. Laffita-Mesa, L. Laguna-Salvia, Y. González-Zaldívar, D. Almaguer-Gotay, P. Zayas-Feria, L.E. Almaguer-Mederos, R. Rodríguez-Labrada, L. Velázquez-Pérez (Holguin, Cuba)

200

  1. Top of page

Antisense oligonucleotides as molecular tools to silence prolonged (CAG)n tracts in Huntington's disease

R. Vlamings, M.M. Evers, W.M.C. van Roon-Mom, S.A.M. Mulders, M.L.F. Janssen, R.C. Verheul, J.C.T. van Deutekom, Y. Temel (Maastricht, Netherlands)

201

  1. Top of page

MAPT genotype and its influence on cognitive decline in Huntington's disease

R. Vuono, S.E. Winder-Rhodes, S.J. Sawcer, R.A. Barker (Cambridge, United Kingdom)

202

  1. Top of page

The effects of environmental enrichment as a treatment strategy for patients with Huntington's disease

J.A. Thompson, T. Cruickshank, L. Penailillo, S. Davies, N. Georgiou-Karistianis, R. Barker, M. Ziman (Perth, Australia)

Lewy Body Dementia and other dementias in movement disorders

203

  1. Top of page

Safety, tolerability, and efficacy of armodafinil therapy for hypersomnia associated with dementia with Lewy bodies

B. Boeve, K. Kuntz, D. Drubach, L. Allen, D. Drubach (Rochester, MN, USA)

204

  1. Top of page

Pathological accumulation of α-synuclein and Aβ in Parkinson's disease with dementia

M.C. Campbell, P.T. Kotzbauer, N.J. Cairns, B.A. Racette, S.D. Tabbal, J.S. Perlmutter (St. Louis, MO, USA)

205

  1. Top of page

Dementia with Lewy bodies or probable glioblastoma multiforme?

P.D. Branger, T.C. Danaila, C. Barbier, V. Jaillon-Rivière, G.L. Defer (Caen, France, Metropolitan)

206

  1. Top of page

Cerebral vasculitis mimicking frontotemporal dementia

A. Mc Carthy, E. Mulroy, K. O'Rourke, T. Lynch (Dublin, Ireland)

207

  1. Top of page

The evolutionarily conserved function of HtrA2 in mice prevents neurodegeneration by oligomeric α-synuclein

M.M. Rahman, M.L. Liu, S. Akhter, H.J. Kim, S. T. Hong (Jeonju, Korea)

208

  1. Top of page

Parkinsonism associated dementia among patients from Chinese Asian community: A survey analysis

T. Sosorburam, T. Hussain, L. Zhang, B. Bayarbat (Wuhan, China)

209

  1. Top of page

Neuropsychological differences in mild cognitive impairment (MCI) with symptoms of Lewy body disease (LBD)/Parkinson's disease (PD) and other MCI causes

M.J. García Basalo, D.J. Bauso, J.P. Tartari, C.V. Stefani, N. Cámpora, M. Fernández, J.I. Rojas, E. Cristiano, A. Golimstok (Buenos Aires, Argentina)

210

  1. Top of page

Lewy body disease with no tau and amyloid pathology: Pure form of diffuse Lewy body disease

M. Takanashi, H. Mori, N. Hattori (Bunkyo, Japan)

211

  1. Top of page

Withdrawn by Author

Pediatric movement disorders

212

  1. Top of page

Clinical and therapeutic aspects of secondary dystonia in Tunisian children

H. Benrhouma, I. Rebai, I. Kraoua, H. Klaa, N. Gouider-Khouja (Tunis, Tunisia)

213

  1. Top of page

Beneficial prenatal levodopa therapy in autosomal recessive GTP cyclohydroxylase I deficiency

N. Brüggemann, J. Spiegler, Y. Hellenbroich, T. Opladen, S.A. Schneider, R. Boor, U. Stephani, G. Gillessen-Kaesbach, J. Sperner, C. Klein (Lübeck, Germany)

214

  1. Top of page

Do parental psychological factors influence tic severity and/or quality of life in children with Tourette syndrome and other tic disorders?

P. Bunton, T. Hedderly, M. Longworth (London, United Kingdom)

215

  1. Top of page

Clinical analysis of a pediatric cohort with dystonia

J. Damasio, J. Freitas, M. Santos, I. Carrilho (Porto, Portugal)

216

  1. Top of page

Hand stereotypies distinguish Rett syndrome from Autism disorder

S. Goldman, T. Temudo (New York, NY, USA)

217

  1. Top of page

Chorea as the presenting feature of mitochondrial acetoacetyl-CoA thiolase deficiency

F. Lemieux, D. Buhas, G. Bernard, G. Mitchell, S. Chouinard (Montreal, Canada)

218

  1. Top of page

Building a geographically remote satellite service for children with neurostimulation devices

C.T. Lundy, M. Kaminska, J.P. Lin (Belfast, United Kingdom)

219

  1. Top of page

A transatlantic sibpair diagnosis of dopamine responsive dystonia (Segawa's disease) with leg atrophy and a new mutation

E. Mulroy, D. Costelloe, M. Stevenson, O. Ross, T. Lynch (Dublin, Ireland)

220

  1. Top of page

Niemann-Pick disease type C: Characteristics of five Brazilian patients

P.J. Lorenzoni, H.A.G. Teive, R.P. Munhoz, A.C.S. Crippa, L.C. Werneck, E.H. Cardoso, I. Bruck, C. Lourenco, R.H. Scola (Curitiba, Brazil)

221

  1. Top of page

Clinical assessment in a cohort of children with tics and Tourette syndrome

B. Pérez-Dueñas, B. Caurín, M. Serrano, E. Fernández (Esplugues, Spain)

222

  1. Top of page

Essential tremor in children: Tremor onset at birth

I.T. Rossman, H. Brar, D. Ghosh (Cleveland, OH, USA)

223

  1. Top of page

Juvenile parkinsonism and myopathy caused by a T378P mutation of the phosphoglycerate kinase gene PGK1

M. Rotstein, R. Spiegel, S. DiMauro (Tel Aviv, Israel)

224

  1. Top of page

Transcranial direct-current stimulation in childhood dystonia: Results of an open-label pilot trial

T.D. Sanger, S. Young, M. Bertucco (Los Angeles, CA, USA)

225

  1. Top of page

Homovanillic acid in cerebrospinal fluid as a biomarker of neurological diseases in 1,388 patients

M. Serrano, M. Molero-Luis, A. Ormazabal, B. Perez-Dueñas, A. Garcia-Cazorla, R. Pons, R. Artuch (Esplugues, Spain)

226

  1. Top of page

Thiamine-sensitive encephalopathy due to thiamine transporter 2 deficiency: Case report and review of literature

M. Serrano, M. Rebollo, C. Depienne, A. Rastteter, E. Fernández-Álvarez, J.A. Obeso, R. Artuch, B. Pérez-Dueñas (Esplugues, Spain)

227

  1. Top of page

Presenting symptoms in pediatric restless legs syndrome patients

A. de Weerd, I. Aricò, R. Silvestri (Messina, Italy)

228

  1. Top of page

Saccade abnormalities in Segawa disease –Pathophysiological difference between postural and action dystonia

Y. Terao, H. Fukuda, A. Yugeta, O. Hikosaka, R. Hanajima, Y. Ugawa, Y. Nomura, M. Segawa (Tokyo, Japan)

229

  1. Top of page

Movement disorders in children with acute bilateral lesions of the basal ganglia: A case series

T. Virmani, T. Pearson (New York, NY, USA)

Wilson's disease, storage and metabolic movement disorders

230

  1. Top of page

Recovery from severe neurological Wilson's disease with copper chelation

A. Aggarwal, M. Bhatt (Mumbai, India)

231

  1. Top of page

Study of mutational pattern of patients with Wilson's disease from Western India

A. Aggarwal, T. Todorov, G. Chandhok, S. Tilve, A. Zibert, H.H. Schmidt, M. Bhatt (Mumbai, India)

232

  1. Top of page

Patients with free copper toxicosis in Wilson's disease should be treated with zinc from the beginning

A. Avan, M. Azarpazhooh, H. Kianifar, T. Hoogenraad (Mashhad, Iran)

233

  1. Top of page

Wilson's disease: Follow-up studies in a cohort of 135 neuro-Wilson's patients for more than a decade

M. Bagchi, S.K. Das (Kolkata, India)

234

  1. Top of page

A genetic study of Wilson's disease in the United Kingdom

O. Bandmann, A. Coffey, M. Durkie, M. Rattray, A. Dalton (Sheffield, United Kingdom)

235

  1. Top of page

Analysis of smell in Wilson's disease

M.J. Carvalho, A.A.C. Machado, E.R. Barbosa (Santo André, Brazil)

236

  1. Top of page

Behavior of speech in Wilson's disease

A.D. Estevo, M.J. Carvalho, A.A.C. Machado, E.R. Barbosa (Santo André, Brazil)

237

  1. Top of page

Spectrum of movement disorders in Wilson's disease and its response to penicillamine therapy

J. Kalita, S. Chandra, V. Kumar, U.K. Misra (Lucknow, India)

238

  1. Top of page

Epilepsy in Wilson's disease (WD)

N. Kumar, D. Joshi (Patna, India)

239

  1. Top of page

Neuroradiological profile of Wilson's disease (WD)

N. Kumar, D. Joshi (Patna, India)

240

  1. Top of page

An adult-onset neurodegeneration with brain iron accumulation presented dystonia, dementia, epilepsy and peripheral neuropathy: A clinicopathological study

M. Matsumoto, Y. Kikkawa, S. Toma, K. Arai (Narita, Japan)

241

  1. Top of page

Chewing-induced branchial myoclonus in a patient with Leigh syndrome

J. Navarro-Otano, F. Cardellach, E. Muñoz (Barcelona, Spain)

242

  1. Top of page

Wilson's disease in Ireland: Increasing prevalence over 40 years

M. O'Brien, K. Kinsella, M. Reilly, B. Sweeney, C. Walsh, M. Hutchinson (Dublin, Ireland)

243

  1. Top of page

Chelation-therapy induced restless legs syndrome in Wilson's disease: A novel complication following liver transplantation

M. O'Brien, T. Counihan (Dublin, Ireland)

244

  1. Top of page

Neuropsychiatric manifestations in a series of patients with Wilson's disease

N. Paul, M. Bagchi, M.K. Ghosal, A. Roy, A. Biswas, S.K. Das (Kolkata, India)

245

  1. Top of page

Quality of life in patients with Wilson's disease in Serbia

I. Petrovic, M. Svetel, T. Pekmezovic, A. Tomic, N. Kresojevic, A. Potrebic, R. Jesic, V.S. Kostic (Belgrade, Serbia)

246

  1. Top of page

Myeloneuropathy secondary to excessive copper removal in Wilson's disease

T. Teodoro, D. Neutel, F. Geraldo, M.M. Rosa, L. Albuquerque, J.J. Ferreira (Lisboa, Portugal)

247

  1. Top of page

Transcranial parenchymal sonography in patients with Wilson's disease from Serbia

A. Tomic, M. Svetel, M. Mijajlovic, N. Kresojevic, V.S. Kostic (Belgrade, Serbia)

248

  1. Top of page

Wilson's disease: A European survey to improve the management of this rare disease

J.M. Trocello, E. Ruano, F. Woimant (Paris, France)

249

  1. Top of page

Syndrome of hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia – Caused by mutations in SLC30A10, a manganese transporter in man

K. Tuschl, P.T. Clayton, S.M. Gospe Jr., G. Shamshad, S. Ibrahim, P. Singhi, R.T. Ribeiro, M.S. Zaki, M. Luz del Rosario, S. Dyack, V. Price, R.A. Wevers, P.B. Mills (London, United Kingdom)

250

  1. Top of page

Spontaneous upbeat nystagmus changing to downbeat nystagmus with superior and bilateral gaze in Wernicke's encephalopathy

Y.S. Park, W.T. Yoon, D.Y. Kwon (Seoul, Korea)

251

  1. Top of page

Characteristic of atypical neurological Wilson's disease without Kayser-Feischer ring

J. Youn, H.T. Kim, J.Y. Lee, P.H. Lee, H. Shin, J.S. Kim, J.W. Cho (Seoul, Korea)

Clinical Electrophysiology

252

  1. Top of page

Characterization of neuronal single unit activity in the globus pallidus internus in dystonia and Tourette syndrome

M. Alam, M. Manu, K. Schwabe, H.E. Heissler, H.H. Capelle, J.K. Krauss (Hannover, Germany)

253

  1. Top of page

Scaling of movement is related to pallidal gamma oscillations in patients with dystonia

C. Brücke, J. Huebl, T. Schönecker, W.J. Neumann, K. Yarrow, A. Kupsch, C. Blahak, G. Lütjens, P. Brown, J.K. Krauss, G.H. Schneider, A.A. Kühn (Berlin, Germany)

254

  1. Top of page

Electrophysiological assessment of the effect of levodopa on parkinsonian swallowing

P.B. Tawadros, D. Cordato, I. Cathers, J.A. Burne (Lidcombe, Australia)

255

  1. Top of page

Hyperekplexia due to self-limiting brainstem encephalopathy

B. Cengiz (Ankara, Turkey)

256

  1. Top of page

Long latency reflexes in patients with pure essential tremor, pure Parkinson's disease and esential tremor-Parkinson's disease form

D. Yavuz, A. Gündüz, S. Ertan, A. Sifoglu, M. Kiziltan (Istanbul, Turkey)

257

  1. Top of page

Improvement of psychogenic movement disorders after repetitive transcranial magnetic stimulation

B. Garcin, E. Cognat, M. Vidailhet, E. Fournier, F. Mesrati, E. Roze, B. Degos (Paris, France)

258

  1. Top of page

The duration of long term potentiation-like plasticity of the human motor cortex induced by patterned monophasic repetitive transcranial magnetic stimulation depends on intra-burst pulse number

S.J. Groiss, H. Mochizuki, H. Enomoto, S. Nakatani- Enomoto, K. Nakamura, A. Yoshihiro, T. Furubayashi, Y. Sugiura, T. Kujirai, Y. Ugawa (Fukushima, Japan)

259

  1. Top of page

Difference in facilitation with triad-conditioning TMS technique between Parkinson's disease and focal hand dystonia

R. Hanajima, Y. Terao, Y. Shirota, S. Ohminami, R. Tsutsumi, Y. Ugawa (Tokyo, Japan)

260

  1. Top of page

Brain dynamics responsible for sense of agency by EEG analysis

S.Y. Kang, C.H. Im, F.B. Nahab, M.S. Shim, J. Park, D.W. Kim, J. Kakareka, N. Miletta, M. Hallett (Seoul, Korea)

261

  1. Top of page

Pre-movement potentials in tics: Are these associated with the urge to move?

T. Lampreia, T.A. Saifee, J.A. Chen, I. Pareés, P. Kassavetis, A. Sadnicka, B. Hoffland, K.P. Bhatia, M.J. Edwards (Lisbon, Portugal)

262

  1. Top of page

Electrophysiological study of the coordination between swallowing and breathing in patients with Parkinson's disease

F. Loureiro, A. Dalbem, S. Trentin, I. Gomes (Porto Alegre, Brazil)

263

  1. Top of page

Motor cortical activities represented by Bereitschaftspotential and paired associative stimulation-induced plasticity in Parkinson's disease and essential tremor

M.K. Lu, C.H. Tsai, C.M. Chen, J.R. Duann (Taichung, Taiwan)

264

  1. Top of page

Reduced intracortical inhibition in focal hand dystonia: A study of high frequency oscillations

Z. Mari, V. Venkataraman, C. Urban, M. Matsuhashi, M. Hallett (Baltimore, MD, USA)

265

  1. Top of page

Motor center-surround organization disordered in focal hand dystonia

Z. Mari, G. Nolte, V. Venkataraman, M. Hallett (Baltimore, MD, USA)

266

  1. Top of page

Electrophysiological, clinical and neuropsychological correlations of event-related potential (P300) in Parkinson's disease

N.E. Marinho, R.B. Gomes, A.C. Piccolo, H.M. Tavares, M.S.G. Rocha (Sao Paulo, Brazil)

267

  1. Top of page

Eye movements during the visual memory and visual search tasks in patients with spinocerebellar degeneration

S. Matsuda, H. Matsumoto, T. Furubayashi, H. Fukuda, R. Hanajima, S. Tsuji, Y. Ugawa, Y. Terao (Tokyo, Japan)

268

  1. Top of page

Kinematic classification of gait patterns using a neural network evaluation system

J.F. Balej, M.J. Crespo, D.A. Ballesteros, M.D. Rossi, J.E. Arena, A. Cervio, C. Cuello Oderiz, A.D. Rivero, D.F. Cerquetti, M. Risk, M.J. Merello (Ciudad Autónoma de Buenos Aires, Argentina)

269

  1. Top of page

Hemi-masticatory spasm due to a pontine cavernoma: A case report and literature review

L.S. Rosenthal, K. Darwin, Z. Mari, M. Hallett, H.A. Jinnah (Baltimore, MD, USA)

270

  1. Top of page

Use of an implantable bi-directional neural interface for long-term cortical recording in a nonhuman primate

E.S. Ryapolova-Webb, K. Bankiewicz, P.A. Starr (San Francisco, CA, USA)

271

  1. Top of page

Enhancement of the pre-movement potential of a psychogenic movement using a sequential movement paradigm

T.A. Saifee, P. Kassavetis, I. Pareés, T. Lampreia, N. Murase, B. Hoffland, A. Sadnicka, J.C. Rothwell, K.P. Bhatia, M.J. Edwards (London, United Kingdom)

272

  1. Top of page

Electrophysiological analyses of anti-NMDA receptor encephalitis

T. Shimizu, R. Hanajima, R. Tsutsumi, Y. Shirota, S. Ohminami, S. Matsuda, T. Yamamoto, J. Goto, J. Shimizu, Y. Terao, Y. Ugawa, S. Tsuji (Tokyo, Japan)

273

  1. Top of page

Globus pallidus internum oscillatory activity during slow and fast drawing movements

A. Singh, K. Bötzel (Munich, Germany)

274

  1. Top of page

Acute impedance changes of DBS system? corresponding stimulation estimates

G.K. Steinke, M.A. Moffitt, S. Carcieri, A. Jackson, J. Makous, W. Stoffregen, L. Wojick (Valencia, CA, USA)

275

  1. Top of page

Conditioning intensity dependent interaction between interhemispheric inhibition and short-latency afferent inhibition

R. Tsutsumi, R. Hanajima, Y. Shirota, S. Ohminami, Y. Terao, Y. Ugawa (Tokyo, Japan)

276

  1. Top of page

Role of the basal ganglia in postural control during gait initiation in human

A. Demain, B. Forgeot d'Arc, S. Fernandez-Vidal, M.C. Do, B. Dubois, A. Hartmann, L. Schmidt, Y. Agid, E. Bardinet, N. Chastan, M.L. Welter (Paris, France)

History

277

  1. Top of page

Are patients with psychogenic movement disorders more likely to be healthcare workers?

C. Perry, K. Holmes, A. Gruber-Baldini, K. Anderson, L. Shulman, W. Weiner, S. Reich (Baltimore, MD, USA)

278

  1. Top of page

Movement disorder as dance: Chorea in history

A. Petithomme Feve, F. Schott Billmann, G. Fenelon (Paris, France)

279

  1. Top of page

Erich Harnack and apomorphine: An historical insight

P. Taba, A.J. Lees, G. Stern (Tartu, Estonia)

280

  1. Top of page

The MDS health professional (non-physician) special interest group update

T.E. Towle (Chicago, IL, USA)

281

  1. Top of page

Gower's Queen Square case notes on chorea

T.C. Vale, A. Lees, F. Cardoso (Belo Horizonte, Brazil)

Rating scales

282

  1. Top of page

Impulse control disorders in Parkinson's disease: More prevalent than reported?

H. Baumann-Vogel, G. Eisele, C.R. Baumann (Zurich, Switzerland)

283

  1. Top of page

Normative data for digitized spiral analysis: Evaluation of age and gender effects

C.W. Hess, C. Wang, Q. Yu, S. Boschung, M. San Luciano, R. Saunders-Pullman, S.L. Pullman (New York, NY, USA)

284

  1. Top of page

Orthostatic hypotension questionnaire as an effective patient reported outcome scale to assess response in patients with symptomatic neurogenic orthostatic hypotension

H. Kaufmann, K. Rosa, A. Hewitt, R. Freeman (New York City, NY, USA)

285

  1. Top of page

Psychological profile stability in psychogenic movement disorders subjects following immediate versus delayed treatment with short term psychodynamic psychotherapy: Randomized parallel trial

K. Kompoliti, B.C. Wilson, G. Stebbins, B. Bernard (Chicago, IL, USA)

286

  1. Top of page

Change in root mean square value of tremor recording correlates strongly with subjective clinical assessment

S. Pallavaram, F. Phibbs, P. Hedera, C. Tolleson, W. Rodriguez, P.F. D'Haese, B.M. Dawant, T.L. Davis (Nashville, TN, USA)

287

  1. Top of page

Validation study of REM sleep behavior disorder questionnaire: Hong Kong (RBDQ-HK)

K.P. Xiong, S.S. Shen, Q. Tang, J. LI, F. Han, C.F. Liu, C. Mao (Suzhou, China)

Parkinson's disease: Rating scales

288

  1. Top of page

Incidence of falls in Parkinson's disease and characteristics of fallers and non-fallers

L.R.S. Almeida, G. Valença, N.N. Negreiros, R.A. Gruber, E. Pinto, J. Oliveira-Filho (Salvador, Brazil)

289

  1. Top of page

Performance on balance measures and balance confidence for functional activities in parkinsonian fallers and non-fallers

L.R.S. Almeida, G. Valença, N.N. Negreiros, R.A. Gruber, E. Pinto, J. Oliveira-Filho (Salvador, Brazil)

290

  1. Top of page

Associations between the UPDRS postural instability and gait difficulty subscale and measures of balance and falls

L.R.S. Almeida, G. Valença, N.N. Negreiros, R.A. Gruber, E. Pinto, J. Oliveira-Filho (Salvador, Brazil)

291

  1. Top of page

How slow is too slow? Objective measurement of bradykinesia in Parkinson's disease using novel non-invasive devices

J.E. Alty, S. Jamieson, M.A. Lones, S.L. Smith (Leeds, United Kingdom)

292

  1. Top of page

Implementation of a short assessment of Parkinson's disease patients from three referral centers in Mexico

A. Cervantes-Arriaga, M. Rodríguez-Violante, M. López, I. Estrada-Bellman (Mexico City, Mexico)

293

  1. Top of page

Self or proxy risk impression indexes and clinical tests to predict driving performance in Parkinson's disease

S. Classen, A.M. Crizzle, D. Lanford, I. Malaty, R.L. Rodriguez, N.R. McFarland, M.S. Okun (Gainesville, FL, USA)

294

  1. Top of page

Construction and validation of the Dynamic Parkinson's Gait Scale (DYPAGS)

J. Crémers, R. Phan Ba, V. Delvaux, G. Garraux (Liège, Belgium)

295

  1. Top of page

Indicators of disease severity as predictors of driving performance in Parkinson's disease

A.M. Crizzle, S. Classen, Y. Wang, D. Lanford, I. Malaty, R.L. Rodriguez, N.R. McFarland, M.S. Okun (Gainesville, FL, USA)

296

  1. Top of page

Direct effects of cognitive impairment on activities of daily functioning in patients with Parkinson's disease

A. Darin, T. Lake, L. Brennan, B. Tran, J. Rick, A. Siderowf (Philadelphia, PA, USA)

297

  1. Top of page

Prosodic variations in Parkinson's disease: Tools and measurements

C. de Looze, A. Ghio, S. Scherer, G. Pouchoulin, F. Viallet (Dublin, Ireland)

298

  1. Top of page

Mood and behavioural evaluation in Parkinson's disease: Validation of a new scale

I. Rieu, I. Chéreau, C. Ardouin, B. Pereira, I. de Chazeron, F. Tison, E. Broussolle, O. Rascol, L. Defebvre, M. Schüpbach, J.L. Houeto, P. Krack, F. Durif (Clermont-Ferrand, France)

299

  1. Top of page

Patient compliance with Parkinson's disease home monitoring system

D. Filipkowski, D. Heldman, A. Espay, J. Mishra, T. Mera, J. Giuffrida (Valley View, OH, USA)

300

  1. Top of page

Methodological challenges in a prospective cohort study of persons with PD: Does a study of exercise behavior naturally bias the study sample?

M.P. Ford, J.T. Cavanaugh, G. Earhart, T. Ellis, B. Foreman, C. Husingh, G. McGwin, L.E. Dibble (Birmingham, AL, USA)

301

  1. Top of page

Charting the progression of disability Parkinson's disease (CHOP PD): Changes in disability over 12 months

M.P. Ford, J.T. Cavanaugh, G. Earhart, T. Ellis, B. Foreman, C. Husingh, G. McGwin, L.E. Dibble (Birmingham, AL, USA)

302

  1. Top of page

Evaluation of outcome measures used in an individual with Parkinson's disease following PPN DBS

B.A. Forrow, C. Joint, W. Thevathasan, A.L. Green, T.Z. Aziz (Oxford, United Kingdom)

303

  1. Top of page

Quantification of motor fatigue in Parkinson's disease

S. Gardon, L. Verhagen, B. Ouyang (Chicago, IL, USA)

304

  1. Top of page

MDS-UPDRS non-English translation program

C.G. Goetz, G.T. Stebbins, N. LaPelle, J. Huang, B.C. Tilley (Chicago, IL, USA)

305

  1. Top of page

Freezing of gait in Parkinson's disease: Associations with disease severity, falls, quality of life and clinical balance measures

R.A. Gruber, L.R.S. Almeida, J.H. Goldstein Elman, N.N. Negreiros, G.T. Valenca (Toronto, ON, Canada)

306

  1. Top of page

Associations of self- reported freezing of gait and timed “Up and Go” performance with and without dual- tasking

R.A. Gruber, L.R.S. Almeida, J.H. Goldstein Elman, N.N. Negreiros, G.T. Valenca (Toronto, ON, Canada)

307

  1. Top of page

Do non motor deficits rapidly worsen in early Parkinson's disease? A longitudinal case-control study

G. Hipp, V. Pieri, M. Vaillant, O. Rufra, N.J. Diederich (Luxembourg-City, Luxembourg)

308

  1. Top of page

Quantifying freezing of gait in Parkinson's disease during the instrumented timed Up and Go test

F.B. Horak, M. Mancini, R. Cohen, J.J. Nutt (Portland, OR, USA)

309

  1. Top of page

Automated ambulatory measurement of dyskinesia and bradykinesia

R. Griffiths, K. Kotschet, W. Johnson, J. Drago, A. Evans, P. Kempster, S. Raghav, M.K. Horne (Parkville, Australia)

310

  1. Top of page

Non-motor symptoms in Parkinson's disease: Preliminary evaluation of the Arabic adapted version of NMSS-PD in Tunisia

I. Kacem, M. Ben Djebara, N. Bouzidi, Y. Hizem, A. Gargouri, R. Gouider (Tunis, Tunisia)

311

  1. Top of page

Developing a tool for remote digital assessment of Parkinson's disease

P. Kassavetis, T.A. Saifee, G. Roussos, L. Drougkas, M. Kojovic, J.C. Rothwell, M.J. Edwards, K.P. Bhatia (London, United Kingdom)

312

  1. Top of page

Prevalence and characteristics of non-motor symptoms in Korean PD patients: Study using non-motor symptoms questionnaire

J.Y. Kim, B.S. Jeon (Seoul, Korea)

313

  1. Top of page

Biosensor based mobile gait analysis detects motor impairment in Parkinson's disease

J. Klucken, J. Barth, P. Kugler, R. Steidl, J. Hornegger, B. Eskofier, J. Winkler (Erlangen, Germany)

314

  1. Top of page

Does rater experience affect UPDRS inter-rater reliability?

A. Kott, J. Swartz (Prague, Czech Republic)

315

  1. Top of page

Validation of the attention questionnaire scale in Korean patients with Parkinson's disease

D.Y. Kwon, M.H. Park, S.B. Koh, K.W. Park (Ansan-city, Korea)

316

  1. Top of page

MDS-UPDRS Spanish version: Confirmatory factor analysis and comparison with the original English version

P. Martinez-Martin, B.C. Tilley, M.M. Kurtis, A. Bergareche-Yarza, A. Mendoza-Rodriguez, J.C. Martinez-Castrillo, O. Gershanik, A. Chade, N. Garretto, T. Arakaki, C. Singer, H. Moore, M. Rodriguez-Violante, M. Alvarez-Sanchez, J. Huang, G.T. Stebbins, C.G. Goetz (Madrid, Spain)

317

  1. Top of page

Attributes related with the MDS-UPDRS Spanish version construct validty

P. Martinez-Martin, M. Alvarez-Sanchez, T. Arakaki, A. Bergareche-Yarza, A. Chade, N. Garretto, O. Gershanik, J. Huang, M.M. Kurtis, J.C. Martinez-Castrillo, A. Mendoza-Rodriguez, H. Moore, M. Rodriguez-Violante, C. Singer, G.T. Stebbins, B.C. Tilley, C.G. Goetz (Madrid, Spain)

318

  1. Top of page

Comparison of patient-rated treatment response with measured improvement in Parkinson's disease

M.B. Davidson, D.J.M. McGhee, C.E. Counsell (Aberdeen, United Kingdom)

319

  1. Top of page

Objective instrument of dyskinesia with inertial sensors

J. McNames, K. Chung, L. Holmstrom, F. Horak (Portland, OR, USA)

320

  1. Top of page

Clinic versus patient association sampling of people with Parkinson's disease

M.H. Nilsson, P. Nyberg, G.M. Hariz, L. Forsgren, P. Hagell (Lund, Sweden)

321

  1. Top of page

The new bradykinesia akinesia incoordination (BRAIN) test: People with Parkinson's disease versus healthy controls

S. Acharya, A. Nagy, C. Budu, C. Treacy, J. Fearnley, A.J. Lees, G. Giovannoni, A.J. Noyce (London, United Kingdom)

322

  1. Top of page

Metric evaluation of a novel scale to assess psychosis in patients with Parkinson's disease

W.G. Ondo, H. Peng (Houston, TX, USA)

323

  1. Top of page

An easy tool to improve accuracy in pre-diagnostic Parkinson's disease population

M. Picillo, M. Amboni, M. Moccia, R. Erro, P. Barone (Naples, Italy)

324

  1. Top of page

Dual-task performance assessment for people with Parkinson's disease: A new tool to measure motor performance of gait, balance, posture and manual skill

S.M.A.A. Pompeu, J.E. Pompeu, É. Okamoto, É.T. Neves, M.E.P. Piemonte (São Paulo, Brazil)

325

  1. Top of page

Prevalence of non-motor symptoms versus motor symptoms in early Parkinson's disease:A preliminary observation

M. Rico, R. Ribacoba, S. González, E. Suárez, M. Para (Oviedo, Spain)

326

  1. Top of page

How should pushing off or the use of assistive devices be incorporated in the timed Up and Go (TUG)?

P.N. Schmidt, J.G. Nutt, M. Guttman, A.D. Siderowf, E.C. Nelson, J. Zamudio, M.S. Okun (Miami, FL, USA)

327

  1. Top of page

Modified Rankin scale as a potential measure of global disability in Parkinson's disease

T. Simuni, S. Luo, K.L. Chou, H. Fernandez, B. He, S. Parashos, on behalf of the NET PD Investigators (Chicago, IL, USA)

328

  1. Top of page

Relation between educational status and motor scales (UPDRS-III, Berg Balance Scale and timed Up and Go Test) in individuals with Parkinson's disease

C.O. Souza, M.C. Voos, F.C. Fonoff, D.F. Valente, H.F. Chien, E.T. Fonoff, E.R. Barbosa (Sao Paulo, Brazil)

329

  1. Top of page

Calibration of the UPDRS to the MDS-UPDRS

G.T. Stebbins, C.G. Goetz, B.C. Tilley (Chicago, IL, USA)

330

  1. Top of page

The association between NT-proCNP, functional capacity and clinical stage in patients with Parkinson's disease

D. Koziorowski, R. Tomasiuk, S. Szlufik, A. Friedman (Warsaw, Poland)

331

  1. Top of page

A comparison of rapid finger tapping and finger flexion-extension tasks in Parkinson's disease

W.P. Teo, J.P. Rodrigues, F.L. Mastaglia, G.W. Thickbroom (Western Australia, Australia)

332

  1. Top of page

Patient-centeredness in Parkinson's disease care: Development and validation of a patient experience questionnaire

M. van der Eijk, M.J. Faber, J.W.M. Aarts, M. Munneke, B.R. Bloem (Nijmegen, Netherlands)

333

  1. Top of page

Short and sweet? An evaluation of six abbreviated scales to detect depression in Parkinson's disease

J.R. Williams, K. Anderson, A.L. Bush, J. Calleo, S.R. Goldstein, S. Grill, E.S. Hirsch, S. Lehmann, J.T. Little, R.L. Margolis, J. Palanci, G.M. Pontone, H. Weiss, P. Rabins, L. Marsh (Cambridge, MA, USA)

334

  1. Top of page

Determining minimal clinically important difference for health-related quality of life scales in Parkinson's disease

Y. Winter, D. Lubbe, W.H. Oertel, R. Dodel (Marburg, Germany)

Spasticity

335

  1. Top of page

Intrathecal baclofen pump: KSA experience

Y.M. Awaad, T.M. Rizk, A.J. Sabbagh, M. Ahmed (Riyadh, Saudi Arabia)

336

  1. Top of page

Ultrasonography for local muscle spasticity management

R.V. Bubnov (Kyiv, Ukraine)

337

  1. Top of page

H-reflex recovery cycle as an electrophysiological correlate of spasticity

A. Karakus, B. Cengiz, M. Zinnuroglu (Ankara, Turkey)

338

  1. Top of page

Abnormal 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy in two patients with spastic paraplegia 11 (SPG11)

H. Furuya, H. Arahata, S. Miura, A. Watanabe, Y. Kawano, E. Araki, H. Kumazoe, N. Fujii (Omuta, Japan)

339

  1. Top of page

Botulinum toxin type A in spastic dystonia of hip adductors in primary progressive multiple sclerosis

S.G. Ochudlo (Katowice, Poland)

340

  1. Top of page

OnabotulinumtoxinA for adult spasticity: A systematic review of the literature

S. Papapetropoulos, L. Nalysnyk, P. Rotella, J. Simeone, K.E. Alter, A. Esquenazi (Irvine, CA, USA)

341

  1. Top of page

Spasticity in Practice (SPACE): An international, non-interventional study of botulinum toxin type A in treatment-naïve patients with spasticity

J. Harriss, O. Simon, N. Roche, C. Cantú-Brito, S. Khatkova, P. Säterö (Frankfurt, Germany)

342

  1. Top of page

A systematic review on the effectiveness of spasticity management using physical interventions in patients with stroke

R. Shukla, E. Sim, D. Tan (Singapore)

Parkinson's disease: Clinical Trials

343

  1. Top of page

An open label, single site, 12 month, phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease

I. Aviles-Olmos, Z. Kefalopoulou, A. Djamshidian, P. Limousin, J. Dickson, A. Lees, T. Foltynie (London, United Kingdom)

344

  1. Top of page

What is the best dopaminergic therapy after subthalamic deep brain stiumlation: Dopamine agonist or levodopa?

J.P. Azulay, C. Breffel, L. Defebvre, T. Witjas, A. Eusebio, K. Dujardin, C. Tranchant, F. Ory, O. Rascol (Marseille, France)

345

  1. Top of page

The ACCORDO study: Evaluating the efficacy of rasagiline on depressive symptoms and cognition in Parkinson's disease patients without dementia

P. Barone, For the ACCORDO study investigators (Salerno, Italy)

346

  1. Top of page

A phase III clinical trial of coenzyme Q10 (QE3) in early Parkinson's disease: Parkinson Study Group QE3 Investigators

M.F. Beal (New York, NY, USA)

347

  1. Top of page

Transcranial sonography of the substantia nigra is not relevant for the diagnosis of idiopathic Parkinson's disease: A prospective cohort study in 196 consecutive patients

A.E.P. Bouwmans, A.M.M. Vlaar, W.H. Mess, A. Kessels, W.E.J. Weber (Maastricht, Netherlands)

348

  1. Top of page

A kinematic and electromyography functional assessment of balance in Parkinson's disease – Pilot study

T. Capato, E.R. Barbosa, M.E. Piemonte (Sao Paulo, Brazil)

349

  1. Top of page

Continuous subcutaneous carbidopa improves levodopa pharmacokinetics in Parkinson's disease patients

Y. Caraco, N. Giladi, S. Oren, P.A. LeWitt (Jerusalem, Israel)

350

  1. Top of page

Benefits of exercise in Parkinson's disease

S.M. Cheon, H.R. Sung, B.K. Chae, H.J. Ryu, J.W. Kim (Busan, Korea)

351

  1. Top of page

A phase II, double-blind, randomized, placebo-controlled 4-way crossover study to evaluate the relative efficacy and safety of OC oral solution (oxybutynin and clonidine) for sialorrhoea in patients with Parkinson's disease

C.T. Chnag, P. Chen (Taipei, Taiwan)

352

  1. Top of page

Correlation of olfactory function and olfactory bulb volume in REM sleep behavior disorder

B. Copeland, Q. Liang, M. Beurlot, T. Ellmore, E. Furr-Stimming, R. Castriotta, M. Schiess (Houston, TX, USA)

353

  1. Top of page

Maximising recruitment to pharmaceutical studies in Parkinson's disease: Recent Northumbria experience

J. Davison, S. Dodds, V. Hetherington, J. Fisher, R. Walker (Newcastle upon Tyne, United Kingdom)

354

  1. Top of page

The effects of aerobic training on cardiorespiratory fitness, gait, quality of life and psychometric outcomes in Parkinson's disease patients

M. Demonceau, C. Rodriguez de la Cruz, F. Robert, S. Le Scanff, D. Maquet, J.L. Croisier, G. Garraux (Liège, Belgium)

355

  1. Top of page

Methylphenidate for freezing of gait and attention deficit in parkinsonian patients under subthalamic stimulation (PARKGAIT-II): A randomised placebo-controlled trial

D. Devos, Parkgait Study Group (Lille, France)

356

  1. Top of page

Ambulatory activity monitoring: Capturing participation-level decline in Parkinson's disease

L.E. Dibble, J.T. Cavanaugh, G. Earhart, T. Ellis, M.P. Ford, K.B. Foreman (Salt Lake City, UT, USA)

357

  1. Top of page

Skeletal muscle quality, muscle function, and mobility of persons with moderate Parkinson's disease improves in response to exercise

L.E. Dibble, O. Addison, R.L. Marcus, K.B. Foreman, P.C. LaStayo (Salt Lake City, UT, USA)

358

  1. Top of page

Exercise and medication induced improvements in postural instability and dynamic balance task performance in persons with Parkinson's disease

K.B. Foreman, O. Addison, R.L. Marcus, P.C. LaStayo, L.E. Dibble (Salt Lake City, UT, USA)

359

  1. Top of page

The effect of visual stimulation on postural control in patients with Parkinson's disease

F. Doná, C.C. Aquino, J.M. Gazzola, F.F.F. Ganança, H.H. Caovilla, V. Borges, S.M.C.A. Silva, H.B. Ferraz (São Paulo, Brazil)

360

  1. Top of page

Parkinson's disease REHAB: Randomised controlled trial to study the effectiveness and cost-effectiveness of physiotherapy and occupational therapy for people with PD

F.P. Dowling, C. Rick, C. Sackley, N. Ives, S. Patel, G.L. Yao, K. Wheatley, C.E. Clarke (Birmingham, United Kingdom)

361

  1. Top of page

Comparison of single-dose motor effects of IPX066 to immediate-release carbidopa-levodopa+entacapone (CLE) in advanced Parkinson's disease (PD) patients

A. Ellenbogen, F. Stocchi, A.P. Duker, A. Hsu, S. Khanna, N. Modi, R. Rubens, S. Gupta (Bingham Farms, MI, USA)

362

  1. Top of page

An international study to investigate rotigotine dose response (2-8 mg/24 h) on ‘off’ time in patients with advanced stage Parkinson's disease

L.W. Elmer, P. Chaná, R. Borgohain, E. Surmann, L. Bauer, J. Whitesides, A.P. Nicholas (Toledo, OH, USA)

363

  1. Top of page

Levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations: Interim safety and motor-symptom endpoints in an ongoing, open-label study

A.J. Espay, A.D. Vanagunas, R.A. Hauser, H.H. Fernandez, D.G. Standaert, P. Odin, Y. Pritchett, K.L. Widnell, K. Chatamra, J. Benesh, R.A. Lenz (Cincinnati, OH, USA)

364

  1. Top of page

Comparison of immediate release (IR) and extended release (ER) carbidopa-levodopa preparations in patients with early Parkinson disease (PD)

S. Fahn, A. Hsu, M. O'Connell, S. Kell, S. Gupta (New York, NY, USA)

365

  1. Top of page

The design of a double-blind, placebo- and active-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo and non-inferiority vs. entacapone

J.J. Ferreira, J.F. Rocha, A. Santos, T. Nunes, P. Soares-da-Silva (Lisbon, Portugal)

366

  1. Top of page

Innovative Web-based matching service, Fox Trial Finder, as a mechanism to improve Parkinson's clinical trial recruitment

M. Frasier, S. Chowdhury, C.C. Meunier, D. Brooks (New York, NY, USA)

367

  1. Top of page

Diurnal and intersubject variability of cerebrospinal fluid biomarkers in Parkinson's disease and healthy volunteers

M.A. Frasier, K. Marek, P. Taylor, C. Caspell, C. Coffey, L. Ereshefsky, M. Yen, T. Sherer (New York, NY, USA)

368

  1. Top of page

Rasagilina and intensive rehabilitation: A randomized controlled study with 12 months follow-up

G. Frazzitta, G. Riboldazzi, G. Bertotti, M. Perini, D. Uccellini, G. Guaglio, M. Turla, C. Comi, G. Pezzoli, R. Maestri (Montescano, Italy)

369

  1. Top of page

Lidocaine injection into external oblique muscle improves upper type camptocormia in Parkinson's disease patients

Y. Furusawa, Y. Mukai, T. Kawazoe, T. Sano, C. Sakamoto, Y. Iwata, M. Wakita, Y. Kobayashi, T. Sakamoto, M. Murata (Tokyo, Japan)

370

  1. Top of page

Pisa syndrome induced by dopamine agonists, in two parkinsonian patients

M.J. Gallardo, J.P. Cabello, S.S. Carrasco, A.A. Hernández, J.J. Dominguez, J.J. Vaamonde (Ciudad Real, Spain)

371

  1. Top of page

Physical exercise in Parkinson's disease: Effects on gait velocity and attention

L.T.B. Gobbi, R. Vitório, C. Teixeira-Arroyo, E. Lirani-Silva, N.M. Rinaldi, F.A. Barbieri, M.P. Pereira, P.C.R. Santos, R.A. Batistela (Rio Claro, Brazil)

372

  1. Top of page

Remote blood pressure monitoring in Parkinson's disease patients

K.M. Biglan, R.V. Evans, M.J. Grana, N.J. Scoglio, T. Simuni, E.R. Dorsey (Rochester, NY, USA)

373

  1. Top of page

Implementation of a telemedicine program for Parkinson's disease: Process and recommendations

K.M. Biglan, M.J. Grana, S.C. Lauver, N.J. Scoglio, E.R. Dorsey (Rochester, NY, USA)

374

  1. Top of page

A placebo-controlled, randomized, multicenter study of rasagiline as add-on therapy to dopamine agonists for the treatment of early Parkinson's disease: The ANDANTE study

R.A. Hauser, A. Choudhry (Tampa, FL, USA)

375

  1. Top of page

Intra- and multi-day home-based monitoring of Parkinson's disease motor symptoms

D.A. Heldman, D. Filipkowski, A. Espay, J. Mishra, J.P. Giuffrida (Cleveland, OH, USA)

376

  1. Top of page

Speech and language therapy for speech problems in Parkinson's disease: A systematic review of randomised controlled trials

C.P. Herd, C.L. Tomlinson, K.H.O. Deane, M.C. Brady, C.H. Smith, C. Sackley, C.E. Clarke (Birmingham, United Kingdom)

377

  1. Top of page

Preladenant in patients with Parkinson's disease and motor fluctuations: Post hoc responder analysis of a phase 2, double-blind, randomized trial

D.J. Hewitt, X. Ha, T.W. Ho, K. Wolski, S. Huyck (North Wales, PA, USA)

378

  1. Top of page

Exploratory analysis of IPX066 on motor fluctuations in advanced Parkinson's disease (PD)

A. Hsu, M. O'Connell, S. Khanna, S. Gupta (Hayward, CA, USA)

379

  1. Top of page

Basal ganglia atrophy in Parkinson's disease

X. Huang, G. Du, C. Dimaio, S. Sen, M. Styner, M. Shaffer, M. Lewis (Hershey, PA, USA)

380

  1. Top of page

Rasagiline in drug-naïve Russian patients with early Parkinson's disease

S.N. Illarioshkin, A.V. Karabanov, A.F. Mirkasimov, I.A. Verejutina (Moscow, Russia)

381

  1. Top of page

Hyperglycemia mitigates Parkinson's disease: In vitro, animal model, and clinical epidemiologic evidence

S.Z. Imam, M.J. Pugh, Z. Binienda, S.F. Ali, M.G. Paule, R.A. Clark (Jefferson, AR, USA)

382

  1. Top of page

The effect of donepezil on a quantitative measure of balance in Parkinson's disease

S.A. Kareus, A. Lai, F.B. Horak, J.G. Nutt, K.A. Chung (Portland, OR, USA)

383

  1. Top of page

Objective quantification of rigidity in Parkinson's disease: A validation of viscoelastic properties of the wrist as an alternative to clinical rigidity measurement

K.R. Karlsen, M.T. Barbe, H.S. Dafsari, D. Nowak, M. Schiek, M. Dafotakis, N. Allert, L. Timmermann (Cologne, Germany)

384

  1. Top of page

Aerobic & balance training class and voice & communication group for community dwelling clients with Parkinson's disease

C. Kelly, S. Durairaj, Y. Fenton, K. Sayers (Tipperary, Ireland)

385

  1. Top of page

Randomized, phase 3, double-blind, double-dummy study of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Functional and quality-of-life outcomes

K. Kieburtz, A. Antonini, C.W. Olanow, H.H. Fernandez, A.J. Espay, D.G. Standaert, S. Hass, K.L. Widnell, W.Z. Robieson, Y. Pritchett, K. Chatamra, J. Benesh (Rochester, NY, USA)

386

  1. Top of page

Design innovations and baseline findings in a long-term Parkinson's trial: NET-PD LS-1

The NINDS NET-PD Investigators, K.D. Kieburtz (Rochester, NY, USA)

387

  1. Top of page

Effect of intravenous amantadine on freezing of gait resistant to dopaminergic therapy: A double-blind, placebo-controlled study

Y.E. Kim, B.S. Jeon, J.Y. Yun, H.J. Yang, H.J. Kim (Seoul, Korea)

388

  1. Top of page

Safety of istradefylline (KW-6002) as adjunctive levodopa therapy in Parkinson's disease with motor complications: A combined meta-analysis of phase IIb and phase III placebo-controlled studies in Japan

T. Kondo, Y. Mizuno (Wakayama, Japan)

389

  1. Top of page

Efficacy of istradefylline (KW-6002) as adjunctive levodopa therapy in Parkinson's disease with motor complications: A combined meta-analysis of phase IIb and phase III placebo-controlled studies in Japan

T. Kondo, Y. Mizuno (Wakayama, Japan)

390

  1. Top of page

Identification of sites of concern in a large PD clinical trial – Preliminary findings

A. Kott, J. Swartz (Prague, Czech Republic)

391

  1. Top of page

Knowledge about cues

J. Kraemmer, W. Pirker, T. Foki, E. Auff (Vienna, Austria)

392

  1. Top of page

A 6-week, double-blind, multicenter RCT in Parkinson's disease patients to explore the efficacy and safety of AFQ056 when combined with increased doses of L-dopa

R. Kumar, R.A. Hauser, J. Mostillo, N. Dronamraju, A. Graf, M. Merschhemke (Englewood, CO, USA)

393

  1. Top of page

A comparison of voluntary and forced exercise in driving neuroprotection in a hemiparkinsonian rat model

M.R. Landers, J.W. Kinney, M.M. Elekonich, D.N. Allen, F. van Breukelen (Las Vegas, NV, USA)

394

  1. Top of page

Effect of dopaminergic medication on postural sway

T.R. Larsh, A. Bhattacharya, A. Duker, C. Cox, P. Succop, F.J. Revilla (Cincinnati, OH, USA)

395

  1. Top of page

The design of a double-blind, placebo-controlled, multi-national phase-III trial in patients with Parkinson's disease and end-of-dose motor fluctuations: Opicapone superiority vs. placebo

A. Lees, R. Costa, C. Oliveira, N. Lopes, T. Nunes, P. Soares-da-Silva (London, United Kingdom)

396

  1. Top of page

Postural control in Parkinson's disease patients is influenced by mood state

T. Lelard, C. Duru, S. Ahmaidi, M. Roussel, O. Godefroy, H. Mouras, P. Krystkowiak (Amiens, France)

397

  1. Top of page

The Washington State Parkinson's Disease Registry validation study – Preliminary results

H.M. Kim, D. Burdick, S.C. Hu, A. Samii, S. Srivatsal, J. Pate, M. Baca, S. Heninges, D. Tsuang, C.P. Zabetian, J.B. Leverenz (Seattle, WA, USA)

398

  1. Top of page

Using interactive virtual rehabilitation for improvement of balance in people with Parkinson's disease: A pilot study

A.P.C. Loureiro, R. Chen, F.R. Stori, C.G. Ribas, T.G. Zotz (Curitiba, Brazil)

399

  1. Top of page

Analysis of Parkinson's disease questionnaire data when missing is not at random

S. Luo, X. Su, B. He, B.C. Tilley (Houston, TX, USA)

400

  1. Top of page

Contrast sensitivity visual acuity deficiency degrades simple and complex walking performance in conditions of low illumination

S. Luby, A. Henkle, A. Martin, F. Milice, C. Swigler, M. Walley, C. Saunders, L. LaPointe, J. Stierwalt, J. Appelbaum, C.G. Maitland (Tallahassee, FL, USA)

401

  1. Top of page

Systematic review of biomarkers for disease progression in Parkinson's disease

D.J.M. McGhee, P.L. Royle, C.E. Counsell (Aberdeen, United Kingdom)

402

  1. Top of page

The cost (and confidence) in diagnosing Parkinson's disease: Is it time to re-evaluate our continuing medical education strategy?

K.P. McLaughlin, J.H. Siddiqui, A. Ahmed, S. Cooper, M. Gostkowski, I. Itin, J. Rudolph, P. Sweeney, H.H. Fernandez (Cleveland, OH, USA)

403

  1. Top of page

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A phase III, randomized, double-blind, placebo-controlled study

Y. Mizuno, T. Kondo (Kanagawa, Japan)

404

  1. Top of page

Disease modifying strategy based upon iron chelation in Parkinson's disease: A translational study

C. Moreau, D. Devos, J. Kluza, C. Laloux, M. Petrault, J.C. Devedjian, G. Ryckewaert, G. Garçon, N. Rouaix, P. Jissendi, K. Dujardin, A. Kreisler, C. Simonin, A. Destée, L. Defebvre, P. Marchetti, R. Bordet (Lille, France)

405

  1. Top of page

A classification algorithm for “camptocormia” in Parkinson's disease patients

Y. Mukai, Y. Furusawa, T. Kawazoe, H. Sato, T. Sano, T. Sakamoto, M. Murata (Tokyo, Japan)

406

  1. Top of page

Efficacy of integrated multidisciplinary care in Parkinson's disease

M.A. van der Marck, B.R. Bloem, W. Mulleners, E.M. Hoogerwaard, G.F. Borm, S. Overeem, M. Munneke (Nijmegen, Netherlands)

407

  1. Top of page

Inter-individual variations of plasma concentrations of ergot derived dopamine agonists in patients with Parkinson's disease

M. Nagai, M. Kubo, N. Nishikawa, M. Nomoto (Toon, Japan)

408

  1. Top of page

Accordion pill carbidopa/levodopa for improved treatment of advanced Parkinson's disease symptoms

P.A. LeWitt, H. Friedman, N. Giladi, T. Gurevich, H. Shabtai, R. Djaldetti, N. Roizen, S. Hassin-Baer, O. Cohen, G. Yahalom, I. Schlesinger, M. Nassar, R. Milo, N. Navon (Jerusalem, Israel)

409

  1. Top of page

Bilateral STN stimulation reduces the occurrence of freezing of gait in Parkinson's disease

H. Devos, G. Vervoort, L. Münks, W. Vandenberghe, B. Nuttin, A. Nieuwboer (Leuven, Belgium)

410

  1. Top of page

Stable levodopa plasma levels with jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients

D. Nyholm, P. Odin, A. Johansson, K. Chatamra, C. Locke, S. Freeman, S. Dutta, A.A. Othman (Uppsala, Sweden)

411

  1. Top of page

Randomized, double-blind, double-dummy study of continuous infusion of levodopa-carbidopa intestinal gel in patients with advanced Parkinson's disease: Efficacy and safety

C.W. Olanow, A. Antonini, K. Kieburtz, H.H. Fernandez, A.J. Espay, D.G. Standaert, A.D. Vanagunas, K.L. Widnell, S. Freeman, W.Z. Robieson, Y. Pritchett, K. Chatamra, J. Benesh, R.A. Lenz (New York, NY, USA)

412

  1. Top of page

Long-term effects of amantadine in parkinsonian (AMANDYSK)

F. Ory-Magne, C. Thalamas, M. Galitsky, A. Salis, A. Sommet, L. Pourcel, J.P. Azulay, P. Damier, A. Destée, F. Durif, L. Lacomblez, F. Tison, F. Viallet, O. Rascol (Toulouse, France)

413

  1. Top of page

Implantable pulse generator lifespan in the PD SURG trial

R.S. Ottridge, C.E. Rick, J. Daniels, S. Patel, N. Ives, S. Gill, T.R.K. Varma, C. Jenkinson, R. Mitchell, N. Quinn, A. Williams, K. Wheatley (Birmingham, United Kingdom)

414

  1. Top of page

The contribution of motor impairments and cognition to balance and mobility in people with Parkinson's disease

S.S. Paul, C. Sherrington, V.S.C. Fung, C.G. Canning (Lidcombe, Australia)

415

  1. Top of page

Familiarization to treadmill walking in unimpaired Parkinson's disease patients

A.I. Perez-Sanpablo, C. Hernandez-Arenas, I. Quiñones-Uriostegui, G. Rodriguez-Reyes, J.R. Garcia-Campillo, M.C. Boll-Woehrlen (Mexico City, Mexico)

416

  1. Top of page

To go or not to go! A matter of mainly impaired anterior-posterior APA?

A. Plate, K. Klein, A. Singh, O. Pelykh, A. Klein, J. Ilmberger, K. Boetzel (Munich, Germany)

417

  1. Top of page

Motor learning based physiotherapy intervention for alleviating freezing of gait in patients with Parkinson's disease

M. Plotnik, M. Dorfman, E. Gazit, M. Borzgol, T. Gurevitch, N. Giladi, J. Hausdorff (Tel Aviv, Israel)

418

  1. Top of page

Estimating the risk of first motor complication using a risk calculator based on data from STRIDE-PD

W. Poewe, A.H. Schapira, K. Kieburtz, O. Rascol, F. Stocchi, H. Nissinen, M. Leinonen, C.W. Olanow, the STRIDE-PD Investigators (Innsbruck, Austria)

419

  1. Top of page

Gait improvement in patients with Parkinson's disease after training in real and virtual environments

J.E. Pompeu, F.A. Mendes, K.G. Silva, T.P. Oliveira, A.M. Lobo, S.M.A.A. Pompeu, A.P. Zomignani, M.E.P. Piemonte (São Paulo, Brazil)

420

  1. Top of page

Functional improvement in patients with Parkinson's disease after balance and cognitive training in real or virtual environments

J.E. Pompeu, F.A. Mendes, K.G. Silva, A.M. Lobo, T.P. Oliveira, A.P. Zomignani, S.M.A.A. Pompeu, M.E.P. Piemonte (São Paulo, Brazil)

421

  1. Top of page

Caffeine for treatment of Parkinson's disease – A randomized controlled trial

R.B. Postuma, A.E. Lang, R.P. Munhoz, K. Charland, A. Pelletier, M. Moscovich, L. Filla, D.R. Zanatta, S. Rios Romenets, R. Altman, R. Chuang, B. Shah (Montreal, QC, Canada)

422

  1. Top of page

Long-term exercise improves and maintains physical function in people with Parkinson's disease

M.R. Rafferty, J.A. Robichaud, F.J. David, C. Poon, D.E. Vaillancourt, C.L. Comella, S. Leurgans, W.M. Kohrt, D.M. Corcos (Chicago, IL, USA)

423

  1. Top of page

Working on asymmetry in Parkinson's disease: A double-blind, randomized, controlled rehabilitation trial

L. Ricciardi, D. Ricciardi, F. Lena, M. Petracca, S. Barricella, N. Modugno, E. Pelosin, G. Zuccalà, A.R. Bentivoglio, A. Fasano (Rome, Italy)

424

  1. Top of page

Does STIMULUS predict the best candidates for deep brain stimulation for PD?

C.E. Rick, F.P. Dowling, J. Daniels, S. Patel, N. Ives, R. Mitchell, S. Gill, T. Varma, C. Jenkinson, N. Quinn, A. Williams, K. Wheatley (Birmingham, United Kingdom)

425

  1. Top of page

Long-term progressive exercise improves bradykinesia and muscle weakness in Parkinson's disease

J.A. Robichaud, F.J. David, C. Poon, M. Rafferty, D.E. Vaillancourt, C.L. Comella, S. Leurgans, W.M. Kohrt, D.M. Corcos (Chicago, IL, USA)

426

  1. Top of page

The addition of aerobic or resistance training to sensory attention focused exercise: An enhanced treatment for Parkinson's disease?

M.A. Sacheli, Q.J. Almeida (Waterloo, ON, Canada)

427

  1. Top of page

Ultrasonography is useful for injecting lidocaine into target muscles inducing camptocormia in Parkinson's disease

T. Sano, Y. Furusawa, T. Kawazoe, H. Satou, Y. Mukai, T. Sakamoto, M. Murata (Kodaira, Japan)

428

  1. Top of page

Risk factors for the development of levodopa-induced dyskinesia

E. Schäffer, H. Huber, I. Liepelt-Scarfone, D. Berg (Tübingen, Germany)

429

  1. Top of page

Development of a risk calculator based on the STRIDE-PD study for predicting dyskinesia in patients with Parkinson's disease

A.H. Schapira, W. Poewe, K. Kieburtz, O. Rascol, F. Stocchi, H. Nissinen, M. Leinonen, C.W. Olanow, the STRIDE-PD Investigators (London, United Kingdom)

430

  1. Top of page

Dopamine agonists and dyskinesia in advanced Parkinson's disease: A network meta-analysis of rotigotine, pramipexole and ropinirole as adjunct therapy to levodopa

E. Senior, P. Dedeken, H. Naci (Brussels, Belgium)

431

  1. Top of page

Therapeutic repetitive transcranial magnetic stimulation over the supplementary motor area in Parkinson's disease

Y. Shirota, Y. Ugawa, H. Otsu, H. Enomoto, M. Hamada, rTMS Committee (Tokyo, Japan)

432

  1. Top of page

Does disease severity influence the efficacy of exercise in Parkinson's disease?

L.M. Shulman, L.I. Katzel, F.M. Ivey, J.D. Sorkin, K. Favors, K.E. Anderson, S.G. Reich, W.J. Weiner, R.F. Macko (Baltimore, MD, USA)

433

  1. Top of page

Strength training outcomes for airway protection in PD

C.M. Sapienza, M. Troche, E.P. Silverman, J. Rosenbek, N. Musson (Gainesville, FL, USA)

434

  1. Top of page

The comparison of the occurring of fatigue symptoms in Parkinson's disease patients and normal age match Thai population

S. Singmaneesakulchai, R. Bhidayasiri (Bangkok, Thailand)

435

  1. Top of page

Pico-tesla external magnetic stimulation does not improve motor function in Parkinson's disease

M. Spindler, E.M. Hummel, T. Roberts, J.E. Duda (Philadelphia, PA, USA)

436

  1. Top of page

Levodopa-carbidopa intestinal gel in Parkinson's disease patients with severe motor fluctuations: Interim quality-of-life endpoints in an ongoing, open-label study

D.G. Standaert, H.H. Fernandez, P. Odin, R.A. Hauser, A.J. Espay, S. Hass, W.Z. Robieson, K.L. Widnell, K. Chatamra, J. Benesh (Birmingham, AL, USA)

437

  1. Top of page

Comparison of IPX066, a novel investigational carbidopa-levodopa (CD-LD) extended-release formulation, and CD-LD-entacapone (CLE) in advanced Parkinson's disease (ASCEND-PD trial)

F. Stocchi, U. Dillmann, A. Mahler, A. Ellenbogen, G. Liang, A. Hsu, S. Khanna, R. Rubens, S. Gupta (Rome, Italy)

438

  1. Top of page

DAT SPECT in early Parkinson's disease

S.R. Suwijn, C.V.M. Verschuur, J. Booij, R.M.A. de Bie (Amsterdam, Netherlands)

439

  1. Top of page

Modulation of pulmonary functions in patients with Parkinson's disease by partial weight supported treadmill training – A randomised controlled trial

S.N. Talakad, M. Ganesan, P. Pramod, G. Anupam, R. Trichur (Bangalore, India)

440

  1. Top of page

The use of a multiple cueing device as an adjunct to conventional physiotherapy to improve gait and quality of life in patients with Parkinson's disease – A pilot study

D. Tan, E.K. Tan, E. Sim, G. Lim, L.W. Tan, C. Tan (Singapore)

441

  1. Top of page

Toxins and Parkinson's disease

S. Telarovic, I. Telarovic, V. Trkulja (Zagreb, Croatia)

442

  1. Top of page

Examination of mean gait acceleration by portable gait rhythmogram in patients with Parkinson's disease

H. Terashi, H. Utsumi, Y. Ishimura, M. Masuda, H. Mitoma (Tokyo, Japan)

443

  1. Top of page

Using a wireless inertial sensor system to characterize gait abnormalities in Parkinson's disease

I. Tien, M.J. Aminoff (Berkeley, CA, USA)

444

  1. Top of page

A randomized recruitment intervention trial in Parkinson's disease to increase participant diversity: Early stopping for lack of efficacy

B.C. Tilley, A.G. Mainous, III, J.J. Elm, E. Pickelsimer, L.H. Soderstrom, M.E. Ford, V.A. Diaz, L.A. Siminoff, K. Burau, D.W. Smith (Houston, TX, USA)

445

  1. Top of page

Futility trials revisited

B.C. Tilley, J.J. Elm, S.T. Luo, K.D. Kieburtz, J. Herson (Houston, TX, USA)

446

  1. Top of page

Parkinson's advocates in research: The impact of peer-to-peer education and outreach on Parkinson's study inquiry and enrollment among people with Parkinson's and care partners

L. Morgan, J. Jimenez-Shahed, V. Todaro, M. Welsh (New York, NY, USA)

447

  1. Top of page

Development and delivery of a multidisciplinary rehabilitation intervention for the SPIRiTT study

H. Gage, K. Bryan, S. Ting, P. Williams, J. Kaye, B. Castleton, P. Trend, D. Wade (Guildford, United Kingdom)

448

  1. Top of page

Comparison between the rate of Parkinson's disease progression and patient gender

Y.O. Trufanov, Y.I. Golovchenko (Lugansk, Ukraine)

449

  1. Top of page

Interdependences between the presence of autonomic dysfunction and severity of disease according to the modified Hoehn and Yahr staging and the Schwab and England Activities of Daily Living Scale in patients with Parkinson's disease

Y.O. Trufanov (Lugansk, Ukraine)

450

  1. Top of page

A comparative study on safety and tolerability of rasagiline versus pramipexole in early Parkinson's disease (PD): The ACTOR study

F. Viallet, S. Pitel, S. Lancrenon, O. Blin (Aix-en-Provence, France)

451

  1. Top of page

Olfaction mix-ups are characteristic for Parkinson's disease: The sniffPD study

D. Volc, A. Wuschitz, N. Halasek, W. Schimetta (Vienna, Austria)

452

  1. Top of page

Plasma homocysteine and its clinical significance in Parkinson's disease

M. Wang, Y. Li, C. Mu (Shjiazhuang city, China)

453

  1. Top of page

Combined interleaving stimulation of STN and SNr for refractory gait disturbances: Preliminary findings of a randomized controlled trial

D. Weiss, M. Walach, C. Meisner, M. Fritz, A. Gharabaghi, C. Plewnia, S. Breit, B. Bender, T. Wächter, R. Krüger (Tübingen, Germany)

454

  1. Top of page

Clinical features of the c.1858G>A mutation in VPS35-associated parkinsonism

A. Weissbach, K.R. Kumar, M. Heldmann, M. Kasten, S. Tunc, C.M. Sue, P. Vieregge, T.F. Münte, K. Lohmann, C. Klein, J. Hagenah (Lübeck, Germany)

455

  1. Top of page

Assessing the benefit and safety of administering intermittent GDNF infusions in PD

S.S. Gill, E. White, N. Barua, A. Bienemann, N. Patel, M. Luz, L. Barclay, E. Mohr, L. Mooney, E. Coulthard, A. Lawrence, S. Daniels, A.L. Whone (Bristol, United Kingdom)

456

  1. Top of page

Lack of pharmacokinetic interaction between the novel mGluR5 antagonist AFQ056 and levodopa/carbidopa in healthy volunteers

A. Chakraborty, M. Ufer, P. Bhad, M. Vandemeulebroecke, B. Gomez-Mancilla, D. Bell, S. Winter, R. Woessner (Basel, Switzerland)

457

  1. Top of page

Comparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease

J.Y. Yun, B.S. Jeon, H.J. Kim, J.Y. Lee (Seoul, Korea)

Gene Therapies and Cell-based Therapies

458

  1. Top of page

Is α-synuclein mediated neurodegeneration amplified in the aged nigrostriatal system?

S.E. Gombash, F.P. Manfredsson, C.J. Kemp, S.L. Wohlgenant, D.L. Fischer, B.F. Daley, T.J. Collier, J.W. Lipton, A. Cole-Strauss, R.J. Mandel, S.M. Fleming, C.E. Sortwell (Grand Rapids, MI, USA)

459

  1. Top of page

Mifepristone inducible caspase-1 expression in embryonic stem cells eliminates tumor formation but spares differentiated dopamine cells

Y. Wang, D. Yang, L. Song, W. Le (Houston, TX, USA)

460

  1. Top of page

Reduced bioavailability of soluble alpha-synuclein due to aggregation leads to toxicity

N.M. Kanaan, N.C. Kuhn, C.S. Sortwell, C. Jiang, F.P. Manfredsson (Grand Rapids, MI, USA)

461

  1. Top of page

A biomaterials approach to modulate striatal toxicity of gene vectors: A comparative study

B. Newland, T. Moloney, P. Mulcahy, E. Dowd, A. Pandit (Galway, Ireland)

Surgical Therapy: Parkinson's disease

462

  1. Top of page

Comprehensive, multi-disciplinary DBS screening for Parkinson's patients: No room for “short cuts”

H. Abboud, A. Machado, M. Deogaonkar, A. Ahmed, M. Gostkowski, S. Cooper, I. Itin, P. Sweeney, M. Pandya, C. Kubu, D. Floden, P. Ford, H. Fernandez (Cleveland, OH, USA)

463

  1. Top of page

Use of an implantable bi-directional neural interface for chronic investigation of brain network dynamics in animal models

S. Stanslaski, P. Afshar, D. Carlson, P. Stypulsowski, J. Giftakis, T. Denison (Minneapolis, MN, USA)

464

  1. Top of page

Subthalamotomy in patients with Parkinson's disease. Evaluation of motor, cognitive, neuropsychiatric and affective effects for six months

M. Alvarez, N. Pavon, R. Macías, I. García, M. Alvarez (Habana, Cuba)

465

  1. Top of page

Subthalamotomy vs. pallidotomy. Retrospective, blinded evaluation of 50 patients with Parkinson's disease

M. Alvarez, M. Lazo, E. Casabona, I. García, R. Macías, M. Alvarez (Habana, Cuba)

466

  1. Top of page

Unilateral STN DBS improves depression in patients with moderate to advanced Parkinson's disease

A.W. Amara, H.C. Walker, G. Cutter, S. Guthrie, R.L. Watts, D.G. Standaert (Birmingham, AL, USA)

467

  1. Top of page

Subthalamic deep brain stimulation modulates small-fiber dependent sensory thresholds in Parkinson's disease

D.C. Andrade, J.P. Lefaucheur, R. Galhardoni, A. Paiva, E. Bohr-Seng-Shu, R. Brant, M. Myczkowski, L. Alvarenga, K. Ferreira, C. Souza, S. Siqueira, M.A. Marcolin, E. Fonoff, E.R. Barbosa, M. Jacobsen (Sao Paulo, Brazil)

468

  1. Top of page

Combining DBS in internal and external pallidum (GPi & GPe) to optimise “peak dose dyskinesia” and “off symptoms” in a small series of patients with Parkinson's disease (PD)

A. Angeli, I.A. Olmos, Z. Kefalopoulou, L. Zrinzo, M. Hariz, P. Limousin, T. Foltynie (London, United Kingdom)

469

  1. Top of page

Role of microelectrode recording in STN DBS electrode implantation

P. Ankathi, R.M. Kandadai, A. Jabeen, M.A. Kannikannan, R. Borgohain (Hyderabad, India)

470

  1. Top of page

Deep brain stimulation and decision making in apathetic patients: A PET study

F. Antonelli, A.P. Strafella, Y.Y. Poon, A.M. Lozano, M. Hodaje, G. Pellecchia, F. Valzania, J.H. Ko, A. Lang, S. Houle, E. Moro (Toronto, ON, Canada)

471

  1. Top of page

DBS stimulation frequencies in PD patients with gait and speech problems

D. Apetauerova, S.A. Scala, J.W. Zani (Burlington, MA, USA)

472

  1. Top of page

Long-term follow-up of bilateral STN DBS in PD: Motor, cognitive and mood outcomes

I. Aviles-Olmos, Z. Kefalopoulou, P. Pradhan, R. Martinez-Fernandez, J. Candelario, A. Tripoliti, A. Angeli, L. Zrinzo, M. Hariz, T. Foltynie, M. Jahanshahi, P. Limousin (London, United Kingdom)

473

  1. Top of page

Competency-based curricula in DBS and ITB therapies for movement disorders

B.J. Bellande, Z. Winicur, D. Charles, B. Gallo, M. Saulino, M. Turner, S. Bennett, S. Heath, M.E. Nelson, C. Reese, J. Boche, A. Larson, K. Cox (Carmel, IN, USA)

474

  1. Top of page

Who is the best candidate to deep brain stimulation in Parkinson's disease – Effects of qualification process based on own experiences

M. Boczarska-Jedynak, A. Gorzkowska, B. Jasinska-Myga, G. Klodowska-Duda, S. Kwiek, P. Bazowski, G. Opala (Katowice, Poland)

475

  1. Top of page

Analysis of stereotactic accuracy in patients undergoing deep brain stimulation using Nexframe and Leksell frame

M. Bot, P. van den Munckhof, R.A.E Bakay, D. Sierens, G.T. Stebbins, L. Verhagen Metman (Chicago, IL, USA)

476

  1. Top of page

Quantitative evaluation of the effects of bilateral subthalamic deep brain stimulation (DBS) on balance in Parkinson's disease (PD)

R. Brant, N. Luna, D.C. Andrade, C. Souza, J. Greve, E. Fonoff, E.R. Barbosa (Belo Horizonte, Brazil)

477

  1. Top of page

Effects of STN DBS on reaching kinematics in Parkinson's disease

M. Burack, V. Khandwala, G. Gdowski, M. Gdowski (Rochester, NY, USA)

478

  1. Top of page

DBS electrode Impedance varies over time in humans

T.C. Cheung, M. Hoffman, M. Katz, C. Kilbane, R.L. Alterman, M. Tagliati (Los Angeles, CA, USA)

479

  1. Top of page

Gender differences in advanced Parkinson's disease treated with subthalamic stimulation

S.M. Chiou, C.H. Tsai, S.Z. Lin (Taichung, Taiwan)

480

  1. Top of page

Convergence insufficiency responsive to bilateral subthalamic nucleus deep brain stimulation in Parkinson's disease

C. Cho, R. Alterman, T. Morris, S. Moore, J. Rucker (New York, NY, USA)

481

  1. Top of page

Acute psychosis following insertion of deep brain stimulator in a patient with Parkinson's disease

G.F. Crotty, B. Sweeney, E. Cassidy (Cork, Ireland)

482

  1. Top of page

Cost-effectiveness of deep brain stimulation in patients with Parkinson's disease

J. Dams, U. Siebert, B. Bornschein, J. Volkmann, G. Deuschl, W.H. Oertel, J.P. Reese, R. Dodel (Marburg, Germany)

483

  1. Top of page

Effect of deep brain stimulation of the subthalamic nucleus on balance in Parkinson's disease

B. de la Casa-Fages, F. Alonso-Frech, C. García-Martos, J. Mira, F. Grandas (Madrid, Spain)

484

  1. Top of page

Saccadic eye movement abnormalities in Parkinson's disease treated by levodopa and deep brain stimulation

M. Dec, M. Rudzinska, M. Tutaj, A. Szczudlik (Kraków, Poland)

485

  1. Top of page

Current controlled stimulation versus voltage controlled stimulation in patients with bilateral subthalamic nucleus deep brain stimulation for advanced Parkinson's disease

C. Del Rio-Oliva, I. Aviles-Olmos, Z. Kefalopoulou, T. Grover, T. Foltynie, L. Zrinzo, M. Hariz, P. Limousin (Málaga, Spain)

486

  1. Top of page

Recognition of facial emotions and limbic circuits are not affected by pallidal stimulation in Parkinson's disease: A clinical and PET study

S. Drapier, F. Lejeune, T.C. Dondaine, P. Sauleau, C. Haegelen, M. Verin (Rennes, France)

487

  1. Top of page

Cost-effectiveness analysis of deep brain stimulation in patients with advanced Parkinson's disease from a UK payer perspective

S. Eggington, F. Valldeoriola, K.R. Chaudhuri, E. Annoni, G. Deuschl (Tolochenaz, Switzerland)

488

  1. Top of page

Expanding the spectrum of the twiddler syndrome: Twiddler by proxy and shoulder raises twiddling

M.A. Ferreira, N. Galvez-Jimenez (Weston, FL, USA)

489

  1. Top of page

Deep brain stimulation of the subthalamic nucleus but not the internal globus pallidus is neuroprotective in a rat model of Parkinson's disease

D.L. Fischer, C.J. Kemp, T.J. Collier, S.L. Wohlgenant, B.F. Daley, K. Steece-Collier, C.E. Sortwell (Grand Rapids, MI, USA)

490

  1. Top of page

Low-frequency stimulation of the pedunculo-pontine nuclei can improve gait in parkinsonian syndromes

I. Galazky, L. Büntjen, S. Stallforth, C. Kluge, H.J. Heinze, J. Voges (Magdeburg, Germany)

491

  1. Top of page

A functional mechanism for deep brain stimulation in Parkinson's disease: The slow axon blockade hypothesis

M.R. García, B.A. Pearlmutter, P.E. Wellstead, M. Verwoerd, R.H. Middleton (Maynooth, Ireland)

492

  1. Top of page

Improving deep brain stimulation case efficiency by application of Virginia Mason Production System (VMPS)

M.T. Gunther, F.R. Farrokhi, J.W. Roberts, J. Berger, K. McHenry (Seattle, WA, USA)

493

  1. Top of page

Bilateral STN DBS is effective in reducing rapid-cycling manic episodes and in-patient psychiatric admissions in a patient with Parkinson's disease and bipolar disorder type I

F. Gupta, S. Yero, H. Azmi (Oradell, NJ, USA)

494

  1. Top of page

Apathy and mania induced by subthalamic nucleus stimulation

H. Guven, B. Kocer, S.S. Comoglu, M. Sorar (Ankara, Turkey)

495

  1. Top of page

Effects of dopaminergic and subthalamic stimulation on musical performance parameters: Dissociating timing, intonation, articulation and emotionality

T.D. Hälbig, E. Altenmüller, M. Schüpbach, F. van Vugt (Berlin, Germany)

496

  1. Top of page

The decision making process leading to deep brain stimulation (DBS) for Parkinson's disease (PD) – The patients' perspective

G.M. Hariz, K. Hamberg (Umeå, Sweden)

497

  1. Top of page

Time to revive pallidotomy for Parkinson's disease?

M. Hariz, J. Vitek, M. Delong, P. Krack (London, United Kingdom)

498

  1. Top of page

Visuo-motor function in Parkinson's disease is not improved by subthalamic nucleus deep brain neurostimulation

S.D. Israeli-Korn, S. Hassin-Baer, O.S. Cohen, E. Schechtman, R. Inzelberg, S. Hocherman (Tel Hashomer, Israel)

499

  1. Top of page

Subthalamic nucleus deep brain stimulation in Parkinson's disease: Postmortem analysis in two patients

H. Ito, S. Odake, F. Uchiyama, T. Kamei (Chigasaki, Japan)

500

  1. Top of page

Can a patient with complex mixed dementia be approved for deep brain stimulation (DBS)?

L.J. Jaffe (San Diego, CA, USA)

501

  1. Top of page

Effects of deep brain stimulation of caudal zona incerta and subthalamic nucleus on pitch level in speech of patients with Parkinson's disease

F. Karlsson, J. van Doorn (Umeå, Sweden)

502

  1. Top of page

Interleaving deep brain stimulation (DBS) parameter settings to optimize outcomes

P. Khemani, S. Miocinovic, S. Chitnis (Dallas, TX, USA)

503

  1. Top of page

Parkin mutation and the outcome of deep brain stimulation

H.J. Kim, J.Y. Yun, Y.E. Kim, J.Y. Lee, J.Y. Kim, H.J. Kim, S.S. Park, S.H. Paek, B.S. Jeon (Seoul, Korea)

504

  1. Top of page

Effect of 60Hz stimulation on gait in STN-DBS patients with Parkinson's disease

M.J. Kim, S.R. Kim, M.C. Lee, S.J. Chung (Seoul, Korea)

505

  1. Top of page

Motor speech after bilateral STN DBS for Parkinson's disease

K.J. Kluin, P. Patil, S. Grube, K. Cummings, L. Zeitlin, C. Persad, K.L. Chou (Ann Arbor, MI, USA)

506

  1. Top of page

Selecting the most optimal trajectories for deep brain stimulation based on microelectrode recording signals

N. Kovács, E. Gasparics, E. Bosnyák, F. Nagy, J. Janszky, I. Balás, I. Hernadi, G. Deli (Pécs, Hungary)

507

  1. Top of page

Recommendations for standardized postmortem autopsy procedures in patients treated with deep brain stimulation

K. Nolte, M. Kronenbuerger, J. Burgunder, V. Coenen, J. Krauss, J. Weis (Aachen, Germany)

508

  1. Top of page

Complex Parkinson's tremor requiring combined ViM and STN stimulation (DBS)

O.C. Kulkarni, K. Czarnecki, E. Papavassiliou, D. Tarsy, L.C. Shih (Boston, MA, USA)

509

  1. Top of page

Differential STN and GPi deep brain stimulation effects on oculomotor function in patients with Parkinson's disease

E.C. Lai, J. Fridley, G. Adams, P. Sun, M.K. York, F. Atassi, A. Viswanathan, R.K. Simpson, D. Yoshor (Houston, TX, USA)

510

  1. Top of page

The effect of STN-DBS's laterality on voice and perception of speech intelligibility of patients with Parkinson's disease

Y. Manor, M. Levy, M. Meshulam, Y. Balash, A. Hilel, N. Giladi, I. Fried, H. Bergman, T. Gurevich, J.T. Cohen (Tel Aviv, Israel)

511

  1. Top of page

Peripheral neuropathy in Parkinson's disease patients treated with duodenal levodopa/carbidopa infusion: A clinical and electrophysiological follow-up study

A. Merola, M. Zibetti, N. Arduino, C.A. Artusi, A. Marchisio, Y. Falcone, M. Troiano, S. Angrisano, L. Rizzi, M.G. Rizzone, D. Cocito, L. Lopiano (Torino, Italy)

512

  1. Top of page

Extended hospital stay following deep brain stimulation for Parkinson's disease under general anesthesia: Related factors

M.E. Moschaki, S.J. Boviatsis, G. Tagaris, P. Stathis, D. Magafosis, P. Lagos, K. Romana, H. Plessia, D.E. Sakas (Athens, Greece)

513

  1. Top of page

How long can patients wait for the surgery? The adequate timing for the subthalamic nucleus deep brain stimulation (STN-DBS) for Parkinson's disease (PD)

Y. Shimo, A. Nakajima, N. Nishikawa, S. Misawa, M. Nakajima, G. Oyama, N. Hattori (Tokyo, Japan)

514

  1. Top of page

The influence of intraoperative microrecording and macrostimulation in Parkinson's disease on proper electrode pleacement

K. Obszanska, E. Papuc, M. Tutaj, Z. Stelmasiak, T. Trojanowski (Lublin, Poland)

515

  1. Top of page

Randomized multicenter trial comparing bilateral subthalamic nucleus DBS and bilateral globus pallidus internus DBS for advanced Parkinson's disease (NSTAPS)

V.J. Odekerken, T. van Laar, A. Mosch, J. van Vugt, P.C. Nijssen, B.A. Schmand, P.R. Schuurman, R.M. de Bie (Amsterdam, Netherlands)

516

  1. Top of page

Racial disparities in access to deep brain stimulation

O.N. Oguh, M. Kwasny, C. Zadikoff, T. Simuni, on behalf of the NPF QII Investigators (Chicago, IL, USA)

517

  1. Top of page

Can cardiac 123I-MIBG scintigraphy predict clinical outcomes of the subthalamic nucleus deep brain stimulation in Parkinson's disease?

G. Oyama, M. Kano, N. Nishikawa, S. Misawa, M. Nakajima, H. Ishii, H. Arai, Y. Shimo, N. Hattori (Tokyo, Japan)

518

  1. Top of page

Case report: Deep brain stimulation in a patient with coexistent Parkinson's disease and corticobasal degeneration

S. Paschen, F. Hofschulte, J. Raethjen, K. Zeuner, G. Deuschl (Kiel, Germany)

519

  1. Top of page

Effect of subthalamic deep brain stimulation (DBS) on pain in Parkinson's disease

J. Pellaprat, F. Ory-Magne, C. Canivet, A. Gerdelat Mas, P. Chaynes, R. Fatai, C. Brefel-Courbon (Toulouse, France)

520

  1. Top of page

Sustained response to deep brain stimulation in LRRK2 parkinsonism with the Y1699C mutation

L.D. Perju-Dumbrava, M. McDonald, D. Thyagarajan (Clayton, Australia)

521

  1. Top of page

Is age a predictor for length of hospital stay in deep brain stimulation?

E.M. Presant, Y. Song, P. Konrad, J. Neimat, F. Phibbs (Nashville, TN, USA)

522

  1. Top of page

The dominant subthalamic nucleus: A gait analysis study

M.G. Rizzone, I. Carpinella, C.A. Artusi, M. Lanotte, L. Lopiano, A. Marchisio, A. Merola, M. Rabuffetti, D.V. Roccatagliata, M. Zibetti, M. Ferrarin (Torino, Italy)

523

  1. Top of page

Bilateral subthalamic nucleus stimulation in Parkinson's disease: Five year follow-up

C. Ruiz Huete, E. Peña (Madrid, Spain)

524

  1. Top of page

Stereotactic neurosurgery for movement disorders in a world perspective. Results from the WSSFN-supported survey

V. Jourdain, G. Schechtmann (Stockholm, Sweden)

525

  1. Top of page

Long-term influence of deep brain stimulation of the subthalamic nucleus on motor and nonmotor disturbances during Parkinson's disease (PD)

I.G. Smolentseva, M.R. Nodel, E.V. Onopchenko, N.A. Amosova, O.V. Krivonos, L.P. Chupina, O.A. Maslyk (Moscow, Russia)

526

  1. Top of page

Long term functional and morphological neuroprotection via deep brain stimulation of the subthalamic nucleus in rats

C.J. Kemp, S.E. Gombash, S.L. Wohlgenant, F.P. Manfredsson, D.L. Fischer, B.F. Daley, K. Steece-Collier, T.J. Collier, C.E. Sortwell (Grand Rapids, MI, USA)

527

  1. Top of page

DBS decision support system based on analysis of microelectrode recorded signals

S. Szlufik, D. Koziorowski, K. Ciecierski, R. Rola, T. Mandat, P. Nauman, Z. Ras, A. Friedman (Warsaw, Poland)

528

  1. Top of page

Simple solution for cerebrospinal fluid loss and pneumocephalus in semi-supine-positioned multitrack deep brain stimulation surgery: Polyethylene glycol hydrogel dural sealant capping

I. Takumi, M. Mishina, M. Hamamoto, S. Kitamura, K. Hironaka, K. Ooyama, A. Yamada, K. Adachi, D. Yoshida, A. Teramoto (Kawasaki, Japan)

529

  1. Top of page

The MDS-UPDRS tracks motor and non-motor improvement due to subthalamic nucleus deep brain stimulation in Parkinson's disease

J.L. Taylor, P.G. Patil, K.S. Cummings, S.V. Grube, K.L. Chou (Ann Arbor, MI, USA)

530

  1. Top of page

Improvement of a developmental stuttering following deep brain stimulation for Parkinson's disease

C. Thiriez, B. Roubeau, J.M. Gurruchaga, S. Palfi, G. Fénelon (Créteil, France)

531

  1. Top of page

Speech changes in 54 consecutive PD patients following one year bilateral STN-DBS and predictive clinical and surgical factors

E. Tripoliti, T. Foltynie, L. Zrinzo, L. Strong, J. Candelario, I. Aviles-Olmos, M.I. Hariz, P. Limousin (London, United Kingdom)

532

  1. Top of page

Stimulation of caudal zona incerta in Parkinson's disease: Effects on jaw movement during speech

J. van Doorn, E. Nordh, H. Zafar (Umeå, Sweden)

533

  1. Top of page

Effects of subthalamic nucleus lesions and stimulation upon corticostriatalafferents in the 6-hydroxydopamine-lesioned rat

R.H. Walker, C. Moore, G. Davies, L. Dirling, R.J. Kock, C.K. Meshul (Bronx, NY, USA)

534

  1. Top of page

Evaluation of electrode design on activation volumes produced during deep brain stimulation

S.N. Washburn, C.R. Butson (Plano, TX, USA)

535

  1. Top of page

Disconnection of the extension pins from the neurostimulator connector block as an unusual cause of sudden worsening of parkinsonism

H.J. Yang, Y.E. Kim, J.Y. Yun, S.H. Paek, B.S. Jeon (Seoul, Korea)

536

  1. Top of page

Parkinson's Study Group Neurosurgical Working Group (PSG-NSWG) deep brain stimulation (DBS) non-motor symptoms (NMS) survey: Real-world preoperative practice patterns

M.K. York, L. Marsh, J. Jimenez-Shahed, M.S. Okun, E. Moro, R. Kumar (Houston, TX, USA)

537

  1. Top of page

Morbidity and mortality of deep brain stimulation surgery patients ≥ age 70: A single center review

P.P. Zhang, R. Shanahan, V. Fennell, C.G. Kalhorn, F.L. Pagan, S.E. Lo (Washington, DC, USA)

538

  1. Top of page

Stereotactic microdialysis of the basal ganglia in Parkinson's disease

P.M. Zsigmond, A. Kullman, L.E. Augustinsson, D. Nezirevicc, N. Dizdar (Linköping, Sweden)

Quality of life/caregiver burden in movement disorders

539

  1. Top of page

Community ambulation is related to walking confidence in people with idiopathic Parkinson's disease

R.M. Lamont, M.E. Morris, M.H. Woollacott, S.G. Brauer (Brisbane, Australia)

540

  1. Top of page

Do patients with parkinsonism use properly sized canes?

K. Holmes, H. Chen, R. Figari, P. Fishman, K. Anderson, L. Shulman, W. Weiner, S. Reich (Baltimore, MD, USA)

541

  1. Top of page

Subthalamic deep brain stimulation and quality of life in Chinese Parkinson's disease patients – A one year prospective study

C.K.Y. Lau, D.T.M. Chan, X.L. Zhu, W.W.S. Poon, A.Y.Y. Chan, K.S. Wong, J.H.M. Yeung, F.C. Cheung, T.L. Poon, P.M.P. Choi, Y.F. Cheung, J.H.M. Chan, K.N. Hung, B. Taw, M.W.Y. Lee, M. Auyeung, V.C.T. Mok (Hong Kong, Hong Kong)

542

  1. Top of page

Clinical predictors of quality of life in patients with newly diagnosed Parkinson's disease

J.H. Lee (Yangsan-si, Korea)

543

  1. Top of page

Suicidal and death ideation in progressive supranuclea palsy

S. Lorenzl, G. Nübling (Munich, Germany)

544

  1. Top of page

Wii balance use as visual and auditory cues in the freezing control in Pakinson's disease

P. Marano, M.R. Seminara, M. Marano (Catania, Italy)

545

  1. Top of page

Health-related quality of life people with Parkinson's disease living in rural settings

M.E. Morris, S.E. Soh, J. McGinley (Carlton, Australia)

546

  1. Top of page

Correlates of health related quality of life (HRQL) in Parkinson's disease (PD)

J.G. Nutt, A.D. Siderowf, M. Guttman, E.C. Nelson, P. Schmidt, J. Zamudio, S.S. Wu, M.S. Okun, QII Investigators (Portland, OR, USA)

547

  1. Top of page

Measures of Parkinson's disease disability that predict caregiver burden: National Parkinson Foundation (NPF) Quality Improvement Initiative

O.N. Oguh, M. Kwasny, T. Simuni, on behalf of the NPF QII Investigators (Chicago, IL, USA)

548

  1. Top of page

Predictors of exercise habits in Parkinson's disease

O.N. Oguh, M.J. Kwasny, B.V. Stell, T. Simuni, on behalf of the NPF QII Investigators (Chicago, IL, USA)

549

  1. Top of page

Increase in quality of life with injection of abobotulinum toxin A(500U) in parotid glands in children with cerebral palsy and adults with brain injury: One year interim report

M.M.O. Oliveira, K. Smpaio (São José dos Campos, Brazil)

550

  1. Top of page

Relationship of visual hallucinations in Parkinson's disease to the duration of various factors

A.Q. Rana, I. Siddiqui, H. Saeed, M.A. Rana (Toronto, ON, Canada)

551

  1. Top of page

A palliative care service for Parkinson's disease: Patient characteristics and service interventions

E. Richfield, D. Adams, E. Jones, M. Johnson, C. Campbell (Hull, United Kingdom)

552

  1. Top of page

A multicenter Italian sleep study: Hypertension in peri and post menopausal women is strongly related to sleep quality, RLS and mood alteration

I. Arico', G. Vita, R. Condurso, E. Bonanni, M. Fabbrini, F. Tramonti, M.R. Bonsignore, A. Zito, G. Russo, M.G. Pagliarulo, B. Guarneri, G. Cerroni, G.F. Mennuni, G. Della Marca, R. Silvestri (Messina, Italy)

553

  1. Top of page

Speech therapy utilization and referral in Parkinson's disease

M. Kwasny, O.N. Oguh, B.V. Stell, T. Simuni, on behalf of the NPF QII Investigators (Chicago, IL, USA)

554

  1. Top of page

Mood disorder prevalence and consequences in an educated internet sample of people with Parkinson's

J. Stamford, S. Riggare, T. Isaacs, H. Matthews (London, United Kingdom)

555

  1. Top of page

Collaborative care in community-based professional networks for Parkinson's disease

M. van der Eijk, M. Munneke, M. Wensing, M.J. Faber, B.R. Bloem (Nijmegen, Netherlands)

556

  1. Top of page

Patient-centered collaborative care for chronic patients in virtual health communities

M. van der Eijk, M.J. Faber, M. Munneke, B.R. Bloem (Nijmegen, Netherlands)

557

  1. Top of page

Irish set dance improves mobility, balance and quality of life in Parkinson's disease

D. Volpe, M. Signorini, A. Marchetto, A. Scutari, S. Zambito Marsala, C. Piggott, T. Lynch (Venice, Italy)

558

  1. Top of page

Quality of life and attitude in Parkinson's disease: A comparison between individuals with and without deep brain stimulation

J.C. Wertheimer, D. Sherman, T. Cheung, M. Tagliati (Los Angeles, CA, USA)

Ataxia

559

  1. Top of page

Somatic mosaicism in SCA2 linked with decreased antioxidant defense. Ataxin-2 polyQ load underlies the antioxidative impairment in SCA2

D. Almaguer-Gotay, J.M. Laffita-Mesa, Y. González- Zaldívar, L.E. Almaguer-Mederos, G. Sánchez -Cruz, S. Mejías-Brito, L.C. Velázquez-Pérez (Holguín, Cuba)

560

  1. Top of page

Evaluation of the thyrotropic axis in spinocerebellar ataxia type 2 Cuban patients. A preliminary case-control study

L.E. Almaguer-Mederos, A. Álvarez-Sosa, R. Aguilera-Rodríguez, D. Almaguer-Gotay, Y. Cutié-Anido, D. Frómeta-Delgado, A. Estupiñan-Rodríguez, D. Cuello-Almarales (Holguín, Cuba)

561

  1. Top of page

Relation between gait and cognition in normal pressure hydrocephalus and in old age subjects

P. Bugalho, L. Alves, O. Ribeiro (Lisboa, Portugal)

562

  1. Top of page

Symptomatic treatment effect with idebenone in very late-onset Friedreich ataxia

I. Beiser, K. Ackermann, W.M.M. Schüpbach, A. Kaelin-Lang (Bern, Switzerland)

563

  1. Top of page

In vivo dopamine transporter density in Machado-Joseph disease: Is cognitive and olfactory impairment mediated by striatal dopamine function?

P. Braga-Neto, A.C. Felício, M.Q. Hoexter, J.L. Pedroso, L.A. Dutra, H. Alessi, T. Minett, R.F. Santos-Galduroz, A.J. da Rocha, L.A.L. Garcia, P.H.F. Bertolucci, R.A. Bressan, O.G.P. Barsottini (São Paulo, Brazil)

564

  1. Top of page

Are Cuban ATXN2 large normal alleles prone to expand? Implications for the prenatal testing program

T. Cruz-Mariño, J.M. Laffita-Mesa, M. Velázquez-Santos, R. Aquilera-Rodriguez, A. Estupiñan-Rodríguez, Y. González-Zaldívar, Y. Vázquez-Mojena, L.C. Velázquez-Pérez (Holguin, Cuba)

565

  1. Top of page

Buccal cell micronucleus frequency is significantly increased in Cuban patients with spinocerebellar ataxia type 2

D.A. Cuello-Almarales, L.E. Almaguer-Mederos, Y. Vázquez-Mojena, D. Almaguer-Gotay, J.M. Laffita-Mesa, R. Aguilera-Rodríguez, P. Zayas-Feria, Y. González-Zaldívar, A. Rodríguez-Estupiñán (Holguín, Cuba)

566

  1. Top of page

Clinical presentation and early evolution of spastic ataxia of Charlevoix-Saguenay (SACS) in the French-Canadian population

A. Duquette, B. Brais, J.P. Bouchard, J. Mathieu (Brookline, MA, USA)

567

  1. Top of page

The Machado-Joseph disease associated mutant form of ataxin-3 promotes clearance of parkin through the mitophagy pathway

T.M. Durcan, E.A. Fon (Montreal, QC, Canada)

568

  1. Top of page

The cost and diagnostic yield of ataxia work up in a movement disorders center

H.H. Fernandez, N.M. Ahmed, A. Ahmed, S. Cooper, M. Gostkowski, I. Itin, J. Rudolph, P. Sweeney (Cleveland, OH, USA)

569

  1. Top of page

Prospective analysis of falls in spinocerebellar ataxias

E.M.R. Fonteyn, T. Schmitz-Hübsch, C.C. Verstappen, L. Baliko, S. Boesch, L. Bunn, P. Giunti, C. Globas, T. Klockgether, B. Melegh, M. Pandolfo, L. Schöls, D. Timmann, B.P.C. van de Warrenburg (Nijmegen, Netherlands)

570

  1. Top of page

Does auditory rhythmical cueing improve temporal control of gait in spinocerebellar ataxia?

L. Rochester, B. Galna, S.E. Lord, D. Mhiripiri, G. Eglon, P. Chinnery (Newcastle upon Tyne, United Kingdom)

571

  1. Top of page

First families diagnosed with Machado Joseph disease/SCA3 in Cuban population

Y. González-Zaldívar, L.E. Almaguer-Mederos, J.M. Laffita-Mesa, Y. Vázquez-Mojena, G. Sánchez-Cruz, T. Cruz-Mariño, D.A. Cuello Almarales, D. Almaguer-Gotay, R. Aguilera-Rodríguez, A. Estupiñan-Rodríguez, R. Rodríguez-Labrada, N. Canales-Ochoa, L.C. Velázquez-Pérez (Holguín, Cuba)

572

  1. Top of page

Screening a UK cohort for spinocerebellar ataxia type 36 (SCA36)

J.S. Hersheson, N.E. Mencacci, P. Giunti, N. Wood, H. Houlden (London, United Kingdom)

573

  1. Top of page

A new SETX mutation together with previously described SETX mutation causing AOA2 in two sibling patients

N. Datta, A. Hohler (Boston, MA, USA)

574

  1. Top of page

Ataxia with vitamin E deficiency and Friedreich ataxia with GAA expansion in Moroccan families: Clinical comparison

F. Imounan, A. Benomar, N. Bouslam, W. Regragui, E.H. Ait Ben Haddou, A. Bouhouche, M. Yahyaoui (Rabat, Morocco)

575

  1. Top of page

Blepharospasm, foot dystonia and cerebellar ataxia associated with multiple autoantibodies

A. Iones, R. Connors, R. Gilbert (New York, NY, USA)

576

  1. Top of page

Prospective study of individuals at risk for SCA1, SCA2, SCA3 and SCA6 (RISCA)

T. Klockgether, H. Jacobi, P. Bauer, S. Tezenas du Montcel (Bonn, Germany)

577

  1. Top of page

Supplemental treatment of deficits in cerebrospinal fluid neurotransmitter levels in spinocerebellar ataxia type 1 correlates with clinical improvement

Q. Liang, B. Copeland, T. Ellmore, M. Schiess (Houston, TX, USA)

578

  1. Top of page

Intra-familial phenotype variability in a Taiwanese family with spinocerebellar ataxia type 2

J.J. Lin, K.C. Yueh, A.C. Chen, W.Y. Chen (Nantou, Taiwan)

579

  1. Top of page

Hypocupremia cause of cerebellar atrophy

D.G. Machado, S.O. Mittal (New Haven, CT, USA)

580

  1. Top of page

A new mutation in anoctamin 10 gene associated with isolated autosomal recessive cerebellar ataxia

C. Marcel, E.J. Kamsteeg, H. Scheffer, M. Koenig, C. Tranchant (Strasbourg, France)

581

  1. Top of page

Exonic deletions of FXN cause early-onset Friedreich's ataxia

L.L. Mariani, P. Calvas, F. Zagnoli, A. Brice, A. Durr, C. Marelli, M. Koenig, M. Anheim (Paris, France)

582

  1. Top of page

Electrophysiological characteristics of cranial nerves in sca2 patients: A follow-up study in 180 subjects

J. Medrano-Montero, L. Velázquez-Pérez, R. Rodríguez-Labrada, N. Canales-Ochoa, A. Peña-Acosta, Y. González-Zaldívar, R. Aguilera-González, A. Estupiñan-Rodríguez (Holguín, Cuba)

583

  1. Top of page

Progressive ophthalmoplegia and ataxia after Campylobacter jejuni infection – A case of Bickerstaff's encephalitis

A. Merwick, D.A. O'Rourke, P. Logan, F. Molloy, G. Mullins, N. Delanty (Dublin, Ireland)

584

  1. Top of page

Clinical course and treatment response of idiopathic opsoclonus myoclonus syndrome (OMS) in adults: A Mexican case-series

H. Morales-Briceño, M. Rodriguez-Violante, A. Cervantes-Arriaga (Mexico City, Mexico)

585

  1. Top of page

Brain MRI study in multiple system atrophy cerebellar subtype (MSA-C) and spinocerebellar ataxia type 3 (SCA3)

E. Muñoz, C. Cardenal (Barcelona, Spain)

586

  1. Top of page

Episodic ataxia type II: Clinical presentation of a novel voltage-gated calcium channel mutation

W. Nachbauer, M. Nocker, A. Eigentler, A. Hotter, E. Wolf, W. Poewe, S. Boesch (Innsbruck, Austria)

587

  1. Top of page

Low-titer anti-GAD-antibody-positive cerebellar ataxia

K. Nanri, H. Niwa, A. Takei, J. Ikeda, M. Okita, T. Harada, M. Takeguchi, T. Taguchi, H. Mitoma, H. Mizusawa (Hachioji, Japan)

588

  1. Top of page

Next generation sequencing (NGS) of genes associated with congenital and neurodegenerative ataxia

A.C. Kwasniewska, M.E. Shanks, S. Lise, M.Z. Cader, K. Talbot, S.M. Downes, I. Ragoussis, A.H. Nemeth (Oxford, United Kingdom)

589

  1. Top of page

Characterization of balance deficits in FMR1 premutation carriers with and without FXTAS reveals a unique profile of impaired vestibular control and postural instability

J.A. O'Keefe, E.J. Dunn, E.M. Berry-Kravis, B. Ouyang, D.A. Hall (Chicago, IL, USA)

590

  1. Top of page

Prism adaptation in spinocerebellar ataxia

S. Ohminami, Y. Shirota, R. Tsutsumi, S. Kitazawa, M. Uchimura, M. Inoue, S. Matsuda, Y. Ichikawa, J. Goto, S. Tsuji, Y. Ugawa, Y. Terao, R. Hanajima (Tokyo, Japan)

591

  1. Top of page

SCA28: A novel gene mutation and clinical presentation in the oldest reported patient

E.K. Orehek, A.D. Hohler (Boston, MA, USA)

592

  1. Top of page

Retinal changes in autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) and other genetic ataxias

M.H. Parkinson, S. Nethisinghe, L. Clayton, S. Vermeer, J.P. Chapple, M. Reilly, F. Bremner, P. Giunti (London, United Kingdom)

593

  1. Top of page

Polysomnographic findings in Machado-Joseph disease: A descriptive analysis of 47 patients

J.L. Pedroso, P. Braga-Neto, E. Yamagushi, L.B.C. Carvalho, L.B.F. do Prado, G.F. do Prado, O.G.P. Barsottini (São Paulo, Brazil)

594

  1. Top of page

Machado-Joseph Disease and sleep disorders: A dopamine transporter imaging study

J.L. Pedroso, P. Braga-Neto, A.C. Felicio, E. Yamagushi, L.B.C. Carvalho, L.F. do Prado, M.Q. Hoexter, L.A. Dutra, R.A. Bressan, G.F. do Prado, O.G. Barsottini (São Paulo, Brazil)

595

  1. Top of page

Atypical features in Hashimoto encephalopathy

G.R. Pelição, E.D.V. Prezzi, C.R.A. Afonso, L.F.R. Vasconcellos (Rio de Janeiro, Brazil)

596

  1. Top of page

Case report: Leukodystrophy with ataxia and primary ovarian insufficiency

S. Petchrutchatachart, N. Limotai, R. Bhidayasiri (Bangkok, Thailand)

597

  1. Top of page

Muscle strength impairments in spinocerebellar ataxia type 2

J.C. Rodríguez-Díaz, R. Rodríguez-Labrada, L. Velázquez-Pérez, R. Aguilera-Rodríguez, O. Soto-Garcés, Y. Vázquez-Mojena, R. Ortega (Holguín, Cuba)

598

  1. Top of page

Antisaccadic task deficits in spinocerebellar ataxia type 2: Insight into CAG repeats role on frontal-executive dysfunctions

R. Rodríguez-Labrada, L. Velázquez-Pérez, C. Oberschmidt, N. Canales-Ochoa, R. Aguilera-Rodríguez, J. Medrano-Montero, A. Estupiñan-Rodríguez, A. Peña-Acosta, Y. González-Zaldívar, Y. Vázquez Mojena, T. Cruz Mariño, G. Auburger (Holgúin, Cuba)

599

  1. Top of page

Reliability and longitudinal changes of saccadic eye movements in spinocerebellar ataxia type 2 patients

R. Rodríguez-Labrada, L. Velázquez-Pérez, N. Canales-Ochoa, C. Oberschmidt, G. Sánchez-Cruz, J. Medrano-Montero, G. Auburger, L.E. Almaguer-Mederos (Holguin, Cuba)

600

  1. Top of page

Copy number loss of (Src homology 2 domain containing)-transforming protein 2 (SHC2) gene: Discordant loss in monozygotic twins and frequent loss in patients with multiple system atrophy

H. Sasaki, M. Emi, H. Iijima, N. Ito, H. Sato, I. Yabe, T. Kato, J. Utumi, K. Matsubara (Sapporo, Japan)

601

  1. Top of page

Clinical characterization of patients presenting with ataxia to a tertiary academic medical center

A. Saxena, L.S. Rosenthal, C. Umeh, Z. Mari, S. Perlman, J. Papp, J. Savitt (Baltimore, MD, USA)

602

  1. Top of page

Analysis of mitochondrial DNA variations in Friedreich's ataxia (FRDA) patients in Indian families: Identification of disease associated markers

I. Singh, F. Mohammed, A. Srivastava, M. Mukerji (New Delhi, India)

603

  1. Top of page

Clinico-genetic study of spinocerebellar ataxia 7 (SCA7) in India: An ethnic predilection in an endogamous population of Northern India

A.K. Srivastava, M. Faruq, S. Singh, V. Suroliya, R. Gupta, T. Dada, A. Garg, M. Mukerji, M. Behari (New Delhi, India)

604

  1. Top of page

Cerebellar ataxia in adult-onset Sandhoff disease: A case report

S. Tazen, J. Goldman, S. Fahn (New York, NY, USA)

605

  1. Top of page

Progression of idiopathic late onset cerebellar ataxia

H.A. Teive, R.P. Munhoz, W.O. Arruda, L.C. Werneck (Curitiba, Brazil)

606

  1. Top of page

Tailoring DBS treatment for tremor and dystonia associated with various ataxia syndromes: A case series

G. Oyama, A.J. Thompson, N. Limotai, N. Maling, M. Abd-El-Barr, K. Foote, S.H. Subramony, T. Ashizawa, M. Okun (Gainesville, FL, USA)

607

  1. Top of page

Ataxia as a rare presenting symptom in neuromyelitis optica (NMO)

R.M. Vatwani (Manama, Bahrain)

608

  1. Top of page

Use of lisuride for treatment of periodic leg movements in spinocerebellar ataxia type 2: An open-label study

L. Velázquez-Pérez, L. Álvarez-González, R. Rodríguez-Labrada, R. Aguilera-Rodríguez, N. Canales-Ochoa, L. Galicia Polo, R. Haro-Valencia, J. Medrano-Montero, Y. Vázquez-Mojena, A. Peña-Acosta, N. Rodríguez Pupo (Holguin, Cuba)

609

  1. Top of page

Frontal-executive dysfunctions precede cerebellar syndrome in spinocerebellar ataxia type 2

L. Velázquez-Pérez, R. Rodríguez-Labrada, R. Aguilera-Rodríguez, A. Estupiñan-Rodríguez, T. Cruz-Mariño, N. Canales-Ochoa, J.M. Laffita-Mesa, J.C. Rodriguez Diaz (Holguin, Cuba)

610

  1. Top of page

Astasia-abasia and demyelination of corpus callosum

P. Vittal, G. Lea (New Orleans, LA, USA)

611

  1. Top of page

Is cerebral white matter involvement helpful in diagnosis of dentatorubral-pallidoluysian atrophy?

W.T. Yoon, Y.S. Park, J. Youn, J.W. Cho (Seoul, Korea)

Myoclonus

612

  1. Top of page

Myoclonus of peripheral origin improved with injections of botulinum toxin type A

F. Bono, D. Salvino, M. Curcio, M. Sturniolo, M. Trimboli, A. Quattrone (Catanzaro, Italy)

613

  1. Top of page

Menstrual-cycle linked cortical myoclonus

A.W.G. Buijink, J.M. Gelauff, M.A.J. Tijssen, A.F. van Rootselaar (Amsterdam, Netherlands)

614

  1. Top of page

A case of amiodarone-induced myoclonus responsive to levetiracetam

A.F. Deik, V.L. Shanker (New York, NY, USA)

615

  1. Top of page

Propriospinal myoclonus secondary to cervical myelopathy, previously misdiagnosed as focal seizures

R. Sundar, R.C.S. Seet, E.C.H. Lim (Singapore, Singapore)

616

  1. Top of page

Opsoclonus-myoclonus syndrome in adults

A. McKeon, J. Klaas (Rochester, MN, USA)

617

  1. Top of page

Simultaneous opsoclonus-myoclonus syndrome in two family members

H. Morales-Briceño, M. Rodríguez-Violante, A. Cervantes-Arriaga, L. Silveira-Moriyama (Mexico City, Mexico)

618

  1. Top of page

A triangle of signs: Palatal myoclonus, dysarthria and progressive ataxia

S.T. O'Dowd, K.A. Roberts, T. Lynch (Dublin, Ireland)

619

  1. Top of page

Spinal myoclonus due to trauma with minimal radiological findings

M.A. Rana, A.Q. Rana, F. Hassan (Toronto, ON, Canada)

620

  1. Top of page

Myoclonic dystonia syndrome due to tyrosine hydroxylase deficiency

M. Stamelou, N. Mencacci, C. Cordivari, A. Batla, H. Houlden, N. Wood, J. Hardy, K. Bhatia (London, United Kingdom)

621

  1. Top of page

Hemifacial spasm in sleep – A polysomnographic study

S. Usar Incirli, C. Akbostanci (Nicosia, Cyprus)

622

  1. Top of page

Glycine receptor antibody-positive progressive encephalomyelitis with rigidity and myoclonus: A disease with variable clinical course

P. Vanacker, E. Peeters, M. Schrooten, M. Woodhall, A. Vincent, W. Vandenberghe (Leuven, Belgium)

623

  1. Top of page

Anti-glycine receptor antibody causing relapsing encephalitis with rigidity and myoclonus

J. Williams, K. O'Connell, S. O'Riordan, C. McGuigan, S. Connolly, A. Vincent, M. Hutchinson (Dublin, Ireland)

Parkinson's disease: Electrophysiology

624

  1. Top of page

Subthalamic activity during diphasic dyskinesias in Parkinson's disease

M. Alegre, J. Lopez-Azcarate, M. Valencia, R. Gonzalez-Redondo, F. Alonso-Frech, M.C. Rodriguez-Oroz, J. Guridi, J. Artieda, J.A. Obeso (Pamplona, Spain)

625

  1. Top of page

Electrocardiographic changes at the OFF medication state in Parkinson's disease

D. Aygun, K. Akpinar, Ö. Yilmaz, M.K. Onar (Samsun, Turkey)

626

  1. Top of page

Gait related local field potentials of the pedunculopontine nucleus and the globus pallidus internum in Parkinson's disease

K. Bötzel, A. Singh, J. Voges, I. Galazky (Munich, Germany)

627

  1. Top of page

Mismatch negativity (MMN) in the nucleus subthalamicus in patients with Parkinson's disease – Intracranial study

M. Bares, E. Minks, P. Jurak, J. Chladek, J. Chrastina, J. Halamek (Brno, Czech Republic)

628

  1. Top of page

EPOrh modulates the ERP N1 source in Parkinson's disease

M.L. Bringas, V. Perez, I. Pedroso, M. Vega, L. Galan, P.A. Valdes (Ciudad Habana, Cuba)

629

  1. Top of page

The effect of alpha stimulation at subthalamic area on ballistic movements in patients with Parkinson's disease

C.C. Chen, W.Y. Lin, H.L. Chan, P.H. Tu, S.T. Lee, C.S. Lu, P. Brown (Taipei, Taiwan)

630

  1. Top of page

Functional convergence of parallel circuits within subthalamic nucleus: Intra-operative multichannel-microelectrode recording study during emotional, cognitive and motor tasks

E.T. Fonoff, M. Edgar, K. Sameshima, M.J. Teixeira, M.A.L. Nicolelis (São Paulo, Brazil)

631

  1. Top of page

L-type calcium channel block and energy implications for substantia nigra neurons

F. Francis, M.R. Garcia, P. Wellstead, R. Middleton (Maynooth, Ireland)

632

  1. Top of page

Ambulatory activity monitor in the evaluation of “de novo” Parkinson's disease patients

P.J. Garcia-Ruiz, L. Lopez Manzanares, M.J. Catalan, J.C. Martinez-Castrillo, N. Lopez Aristegui, J.M. Velazquez, A. Rojo (Madrid, Spain)

633

  1. Top of page

Dynamic causal modeling of oscillatory coupling in patients with Parkinson's disease

D.M. Herz, E. Florin, M.S. Christensen, C. Reck, M.T. Barbe, M.K. Tscheuschler, M. Tittgemeyer, H.R. Siebner, L. Timmermann (Copenhagen Hvidovre, Denmark)

634

  1. Top of page

Impaired pain processing in Parkinson's disease: A study with Aδ fiber stimulation by intra-epidermal needle electrode

M. Hirayama, T. Hara, T. Nakamura, T. Hara, H. Watanabe, G. Sobue (Nagoya, Japan)

635

  1. Top of page

Gait in Parkinson's disease: Value of principal component analysis

C. Holzhoffer, U. Dillmann, Y. Johann, S. Bechtel, J. Spiegel, J. Bürmann, S. Behnke, A. Louis (Homburg/Saar, Germany)

636

  1. Top of page

Dopamine dependent functional connectivity of subthalamic and pedunculopontine rhythms in a parkinsonian patient

Y.T. Hsu, H.Y. Lai, S.M. Chiou, M.K. Lu, Y.C. Lin, Y.Y. Chen, C.H. Tsai (Taichung, Taiwan)

637

  1. Top of page

Impact of theta-burst stimulation over the supplementary motor area on bradykinesia in Parkinson's disease

T.V. Ilic, S. Milanovic, S. Pajic (Belgrade, Serbia)

638

  1. Top of page

Reduced macular thickness and color vision in Parkinson's disease

R. Huna-Baron, S. Hassin-Baer, I. Moroz, O.S. Cohen, G. Yahalom, E. Kozlova, L. Inzelberg, H. Yashar, R. Inzelberg (Tel Hashomer, Israel)

639

  1. Top of page

Subthalamic nucleus neuronal responses are modulated by dopamine and evoked responses from motor, limbic and associative cortical areas are not fully segregated in the rat

M.L.F. Janssen, Y. Temel, D.G.M. Zwartjes, C. Delaville, V. Visser-Vandewalle, A. Benazzouz (Maastricht, Netherlands)

640

  1. Top of page

Long and short duration response of dopaminergic treatment on motor cortex plasticity in Parkinson's disease

A. Kishore, T. Popa, B. Velayudhan, T. Joseph, S. Meunier (Trivandrum, India)

641

  1. Top of page

Functional reorganisation in sensorimotor cortex as a compensatory mechanism in Parkinson's disease

M. Kojovic, P. Kassavetis, M. Bologna, A. Beradelli, J.C. Rothwell, M.J. Edwards, K.P. Bhatia (London, United Kingdom)

642

  1. Top of page

Low frequency stimulation of the subthalamic nucleus increases rigidity in patients with Parkinson's disease

S. Little, R. Joundi, H. Tan, P. Brown (Oxford, United Kingdom)

643

  1. Top of page

Corticostriatal synaptic plasticity in PINK1 heterozygous mice: Effects of mitochondrial complex I inhibition

G. Madeo, F. Alamseged, M. Maltese, T. Schirinzi, G. Martella, E.M. Valente, F. Puglisi, J. Shen, A. Pisani (Rome, Italy)

644

  1. Top of page

Posed smile in Parkinson's disease

L. Marsili, R. Agostino, A. Palma, D. Belvisi, M. Bologna, G. Fabbrini, A. Berardelli (Rome, Italy)

645

  1. Top of page

Task-related changes of resting state EEG in Parkinson's disease

C. Moisello, A. Loggini, B. Perfetti, A. Di Rocco, M.F. Ghilardi (New York, NY, USA)

646

  1. Top of page

Voltage, electric field and current density distributions around a commonly used deep brain stimulation electrode

B. Neagu, R. Chen, E.R. Neagu, C. Dias (Toronto, ON, Canada)

647

  1. Top of page

Effects of dual-tasking on gait parameters in early Parkinson's disease: Evidence for early cognitive training

P. Panyakaew, W. Buated, R. Bhidayasiri (Bangkok, Thailand)

648

  1. Top of page

Square wave jerks during reflexive and voluntary saccade tasks in early Parkinson's disease

J.H. Park, S.A. Park, T.K. Lee, K.B. Sung (Bucheon-si, Korea)

649

  1. Top of page

Effect of high-frequency repetitive transcranial magnetic stimulation (rTMS) applied on the primary motor cortex, on pain threshold in patients with Parkinson's disease: A physiopathological study

J. Pellaprat, A. Gerdelat Mas, M. Simonetta Moreau, E. Dellapina, C. Thalamas, F. Ory-Magne, C. Brefel-Courbon (Toulouse, France)

650

  1. Top of page

Bioelectric brain activity changes caused by Parkinson's disease

A.A. Pilipovich (Moscow, Russia)

651

  1. Top of page

Striatonigral plasticity and levodopa-induced-dyskinesia in Parkinson's disease patients

I.A. Prescott, L.D. Liu, M. Hodaie, A.M. Lozano, W.D. Hutchison (Toronto, ON, Canada)

652

  1. Top of page

Evaluation of short-term effects of repetitive transcranial magnetic stimulation on paraclinical aspects of speech in Parkinson's disease

I. Rektorová, I. Eliasova, J. Mekyska, Z. Smekal (Brno, Czech Republic)

653

  1. Top of page

Gait disturbance in PD: Assessing the contribution of cholinergic dysfunction using short latency afferent inhibition

L. Rochester, R. David, S.E. Lord, A. Yarnall, M.R. Baker, B. Galna, D.J. Burn (Newcastle upon Tyne, United Kingdom)

654

  1. Top of page

Subthalamic local field potentials after seven-years deep brain stimulation in Parkinson's disease. Toward novel biopotential-controlled devices for adaptive deep brain stimulation?

M. Rosa, G. Giannicola, D. Servello, S. Marceglia, E. Scelzo, R. Ferrucci, C. Pacchetti, G. Carrabba, A. Priori (Milan, Italy)

655

  1. Top of page

Modulation of local field potential power of the subthalamic nucleus during incremental isometric force generation in patients with Parkinson's disease

E. Florin, H. Salimi Dafsari, C. Reck, M.T. Barbe, K.A.M. Pauls, M. Maarouf, V. Sturm, G.R. Fink, L. Timmermann (Cologne, Germany)

656

  1. Top of page

Entropy measurements in pallidal neurons in dystonia and Parkinson's disease

M.K. Sanghera, O. Darbin, M. Alam, J.K. Krauss, G. Friehs, J. Jankovic, R.K. Simpson, R.G. Grossman (Temple, TX, USA)

657

  1. Top of page

Standardized handwriting provides quantitative measures to assess bradykinesia, tremor and micrographia in Parkinson's disease

E.J. Smits, A. Tolonen, L. Cluitmans, M. van Gils, B.A. Conway, R.C. Zietsma, N.M. Maurits (Groningen, Netherlands)

658

  1. Top of page

Magnetoencephalography in patients with Parkinson's disease in the on- and off-medication states

M. Spindler, W.C. Goetz, E.M. Hummel, E.S. Schwartz, L.A. Cornew, T. Roberts, J.E. Duda (Philadelphia, PA, USA)

659

  1. Top of page

High incidence of small fiber neuropathy in patients with Parkinson's disease: Electrophysiological and histopathological study

H. Streitová, Š. Buršová, E. Minks, J. Bednarík, M. Bareš (Brno, Czech Republic)

660

  1. Top of page

Muscle activation signals during gait are more rhythmic than normal in Parkinson's disease

T.A. Thrasher, S. Fisher (Houston, TX, USA)

661

  1. Top of page

Oscillatory activity in the subthalamic nucleus in PD, freezing of gait and cognitive dysfunction

J.B. Toledo, M. Alegre, J. López-Azcarate, J. Guridi, J. Iriarte, J. Obeso, J. Artieda, M.C. Rodriguez-Oroz (Pamplona, Spain)

662

  1. Top of page

Assessment of motor function by measuring the maximum pinching force in patients with Parkinson's disease

T. Touge, K. Kume, K. Ikeda, K. Deguchi, Y. Nakamura (Kagawa, Japan)

663

  1. Top of page

Different sub-thalamic nuclear local field potential oscillatory patterns between movement ignition and termination in Parkinson's disease patients

C.H. Tsai, Y.T. Hsu, H.Y. Lai, S.M. Chiou, M.K. Lu, C.C. Chen, H.C. Huang, Y.Y. Chen (Taichung, Taiwan)

664

  1. Top of page

Compensatory activity in the extrastriate body area of Parkinson's disease patients

B.F.L. van Nuenen, R.C. Helmich, N. Buenen, B.P.C. van de Warrenburg, B.R. Bloem, I. Toni (Nijmegen, Netherlands)

665

  1. Top of page

Coupling of subthalamic nucleus activity and EMG in Parkinson's disease

R. Reese, C. Zahra, S. Brandt, F. Steigerwald, M. Pötter-Nerger, D. Falk, G. Deuschl, H.M. Mehdorn, J. Volkmann (Würzburg, Germany)

666

  1. Top of page

Cholinergic dysfunction in Parkinson's disease with mild cognitive impairment: A short latency afferent inhibition study

A.J. Yarnall, L. Rochester, R. David, G.W. Duncan, T.K. Khoo, M.R. Baker, D.J. Burn (Newcastle-upon-Tyne, United Kingdom)

667

  1. Top of page

Saccade-related beta-band desynchronization in the subthalamic nucleus of Parkinson's disease patients during successful antisaccades and error trials

A. Yugeta, W.D. Hutchison, R. Chen (Toronto, ON, Canada)

668

  1. Top of page

Abnormal processing of the nociceptive input in Parkinson's disease occurs in the central nervous system: Evidence from Nd-YAP laser evoked potentials

S. Zambito Marsala, F. Morgante, A. Fornasier, F. Fabris, C. Lo Cascio, C. Marchini, G. Defazio, M. Tinazzi (Belluno, Italy)

669

  1. Top of page

Oscillatory activity patterns in the subthalamic nucleus in parkinsonian patients with L-dopa induced off-dyskinesia

X. Li, P. Zhuang, M. Hallett, S. Guo, Y. Zhang, J. Li, Y. Li (Beijing, China)

Parkinson's disease: Sleep disorders

670

  1. Top of page

Chronic levodopa use negatively influences subjective but not objective sleep quality of Parkinson's disease patients

J.M. Antczak, M.J. Rakowicz, M. Derejko, M. Banach, J. Sienkiewicz, U. Zalewska, W. Jernajczyk (Warszawa, Poland)

671

  1. Top of page

Sleep problems in Korean Parkinson's disease patients with PD sleep scale

J.S. Baik, H.I. Ma (Seoul, Korea)

672

  1. Top of page

Sleep disturbances in Parkinson's disease, progressive supranuclear palsy and controls: A clinical and polysomnographic study

A. Batra, M. Gupta, G.A. Khwaja, D. Chowdhury, A. Dasgupta (New Delhi, India)

673

  1. Top of page

Sleep and circadian rhythm disruption in incident Parkinson's disease – A multimodal analysis

D.P. Breen, R. Vuono, K. Fisher, S. Nawarathna, J.M. Shneerson, A.B. Reddy, R.A. Barker (Cambridge, United Kingdom)

674

  1. Top of page

Effects of dopaminergic medications on objective and subjective sleep in Parkinson's disease

L.M. Chahine, J. Daley, S. Horn, A. Colcher, H. Hurtig, C. Cantor, N. Dahodwala (Philadelphia, PA, USA)

675

  1. Top of page

Use of actigraphy for identifying sleep disorders in patients with Parkinson's disease

A.M. Dutra, R.H. Costa, G.H. Bessa, S.M. Silva, B.de L. Siqueira, H.M. Rodrigues, J.F. Araújo, C. de O. Godeiro, Jr. (Natal, Brazil)

676

  1. Top of page

Quantifying daytime sleepiness in Parkinson's disease

K. Kotschet, W. Johnson, R. Griffiths, M. Horne (Fitzroy, Australia)

677

  1. Top of page

Sleep related problems and excessive day-time sleepiness in patients with Parkinson's disease

D. Kuljic Obradovic, S. Medic, B. Lazic (Belgrade, Serbia)

678

  1. Top of page

Effect of carbidopa, entacapone and levodopa at bed time on sleep quality in Parkinson's disease compared to levodopa and carbidopa-CR

H.I. Ma, J.S. Baik, S.Y. Kang, J.W. Kim, Y.J. Kim (Anyang, Korea)

679

  1. Top of page

Sleep disorder in Parkinson's disease: A retrospective Brazilian study

C. da S. Miguelote, A.B.M. Soldati, L.F. Vasconcellos (Rio de Janeiro, Brazil)

680

  1. Top of page

Simultaneous OSLER test and EEG recording in sleepy Parkinson's disease patients

D. Neutel, R. Peralta, J. Pires, C. Bentes, J.J. Ferreira (Lisbon, Portugal)

681

  1. Top of page

Comparison of clinical characteristics and prognosis in between PD with and without RBD

T. Nomura, Y. Inoue, K. Nakashima (Yonago, Japan)

682

  1. Top of page

Disturbed sleep in Parkinson's disease – An anatomical and pathological study

M.E. Kalaitzakis, S.M. Gentleman, R.K.B. Pearce (London, United Kingdom)

683

  1. Top of page

How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behavior disorder

R.B. Postuma, A.E. Lang, J.F. Gagnon, A. Pelletier, J. Montplaisir (Montreal, QC, Canada)

684

  1. Top of page

Sleep disturbances and dysautonomic dysfunction are associated in patients with Parkinson's disease

S. Realmuto, V. Arnao, A. Cinturino, F. Valentino, G. Famoso, V. Perini, S. Mastrilli, P. Aridon, P. Ragonese, G. Savettieri, M. D'Amelio (Palermo, Italy)

685

  1. Top of page

REM sleep behavior disorder and subtypes of Parkinson's disease

S. Rios Romenets, J.F. Gagnon, V. Latreille, M. Panisset, S. Chouinard, J. Montplaisir, R. Postuma (Montreal, QC, Canada)

686

  1. Top of page

Pathological sleepiness and age in Parkinson's disease

A.I. Sarwar, M. Hirshkowitz (Houston, TX, USA)

687

  1. Top of page

REM sleep without atonia and freezing of gait in Parkinson's disease

A. Videnovic, C.C. Marlin, J. Planetta, L. Alibiglou, D.E. Villancourt, C.D. MacKinnon (Chicago, IL, USA)

688

  1. Top of page

Restless legs syndrome in Korean patients with drug-naïve Parkinson's disease: A nation-wide study

J. Youn, H.Y. Shin, W.T. Yoon, J.S. Kim, H. Shin, J.Y. Ahn, J.W. Cho (Seoul, Korea)

689

  1. Top of page

Continuous intraduodenal L-dopa/carbidopa gel infusion improves nocturnal sleep in advanced Parkinson's disease

M. Zibetti, M.G. Rizzone, V. Ricchi, A. Merola, S. Angrisano, A. Marchisio, C.A. Artusi, L. Rizzi, E. Montanaro, L. Lopiano (Torino, Italy)

Neuroimaging

690

  1. Top of page

Apraxia correlates with fronto-parietal BOLD-signals evoked by dexterous finger movements in Parkinson's disease

E. Abela, M. Bertschi, M. Wapp, A. Federspiel, R. Wiest, J.M. Burgunder, B. Weder, M. Hauf, S. Bohlhalter (Bern, Switzerland)

691

  1. Top of page

Clinical and cognitive correlates of white matter tract damage in progressive supranuclear palsy

F. Agosta, S. Galantucci, K. Davidovic, M. Svetel, M. Copetti, M. Jecmenica Lukic, A. Tomic, G. Comi, V. Kostic, M. Filippi (Milan, Italy)

692

  1. Top of page

MRI imaging of manganism without parkinsonism

A. Ahmed, P.J. Sweeney (Cleveland, OH, USA)

693

  1. Top of page

Effect of dopaminergic medication on the functional connectivity of distinct cerebral networks in Parkinson's disease

H.C. Baggio, B. Segura, J.B. Pereira, F. Valldeoriola, M.J. Martí, Y. Compta, E. Tolosa, C. Junqué (Barcelona, Spain)

694

  1. Top of page

What is the false positive and negative rate of FP-CIT scan in clinical practice?

N. Bajaj, I. Jones, J. Birchall (Nottingham, United Kingdom)

695

  1. Top of page

Stiff person syndrome: Abnormalities of D2 receptor imaging

B. Balint, U. Haberkorn, C. Kratochwil, H.M. Meinck (Heidelberg, Germany)

696

  1. Top of page

Striatal uptake of cis-4-[18F]fluoro-D-proline in patients with akinetic-rigid parkinsonism

M.T. Barbe, K.J. Langen, G. Stoffels, H.H. Coenen, M. Schroeter, L. Timmermann (Cologne, Germany)

697

  1. Top of page

Transcranial sonography in the differential diagnosis of movement disorders

M. Perez Akly, C. Cejas, G. Zanga, C. Ciardi, P. Constantini, H. Graviotto, D. Barzola, R. Diaz, A. Granada, A. Bresas, M.M. Esnaola, C. Peralta (Buenos Aires, Argentina)

698

  1. Top of page

Imaging of fractional anisotropy indicates dysfunction in a midbrain-cerebellar-frontal network in ‘Faller’- Parkinson's disease

S. Baudrexel, M. Hildner, J.C. Klein, C. Oberschmidt, R. Hilker (Frankfurt, Germany)

699

  1. Top of page

What happens to SN negative parkinsonian patients over time?

S. Behnke, U. Dillmann, J. Spiegel (Homburg Saar, Germany)

700

  1. Top of page

Value of transcranial ultrasound for the preclinical diagnosis of Parkinson's disease – The PRIPS study

D. Berg, K. Seppi, S. Behnke, J. Godau, P. Mahlknecht, F.A. Wollenweber, S. Lerche, H. Stockner, I. Liepelt, K. Fassbender, W. Poewe (Tübingen, Germany)

701

  1. Top of page

Normalisation of PET hypometabolism after succesful treatment in a patient with NMDA-receptor antibody encephalitis

B.A. Bergmans, P. Vandamme (Edegem, Belgium)

702

  1. Top of page

Anticholinergic responsive hemiparkinsonism due to coiled posterior cerebral artery aneurysm

H. Kumar, S. Bhattacharjee, S. Mallick, M. Tiwari (Kolkata, India)

703

  1. Top of page

Heterogeneity of the substantia nigra and red nucleus in Parkinson's disease based on the 7T MR images

A.L. Blazejewska, S. Wharton, M.C. Stephenson, S.T. Schwarz, L.A. Martin, M.J. Brooks, D. Price, P.G. Morris, D.P. Auer, N. Bajaj, R. Bowtell, P.A. Gowland (Nottingham, United Kingdom)

704

  1. Top of page

Cerebral amyloid deposition inversely correlates with serotoninergic innervation in Parkinson's disease

N.I. Bohnen, V. Kotagal, M.L.T.M. Muller, R.A. Koeppe, K.A. Frey, R.L. Albin (Ann Arbor, MI, USA)

705

  1. Top of page

BOLD functional MRI of the sensorimotor network using sensorimotor stimulation in a rodent model

S. Boussida, A. Traoré, J.-P. Renou, F. Durif (Saint-Genès Champanelle, France)

706

  1. Top of page

Cerebellar metabolic alterations in Parkinson's disease

L.S. Campos, R.C.G. Landim, T.D. Meneli, G. Castellano, A.C. Amato Filho, L.G. Piovesana, F. Cendes, A. D'Abreu (Campinas, Brazil)

707

  1. Top of page

Reduced cortical and subcortical sensorimotor activation in Parkinson's disease during a kinesthetic illusion task

S.J.A. Carr, K. Borreggine, R.T. Graham, J.L. Vitek, D. Riley, B.L. Walter (Cleveland, OH, USA)

708

  1. Top of page

Identifying striatal and extrastriatal dopaminergic abnormalities of cognitive impairment in Parkinson's disease

L.M. Christopher, C. Marras, Y. Koshimori, A.E. Lang, S. Houle, A.P. Strafella (Toronto, ON, Canada)

709

  1. Top of page

Neural correlates of hypokinetic gait in Parkinson's disease: An fMRI study

J. Crémers, J. Stamatakis, K. D'Ostilio, G. Garraux (Liège, Belgium)

710

  1. Top of page

Resting state functional connectivity in asymptomatic welders with occupational manganese exposure

S.R. Criswell, J.S. Perlmutter, A.Z. Synder, H.P. Flores, B.A. Racette (Saint Louis, MO, USA)

711

  1. Top of page

Dopamine transporter imaging: Importance of medication history?

D. Crosiers, B. Pickut, S. Ceyssens, P. Cras (Edegem, Belgium)

712

  1. Top of page

MRI T2-relaxometry in spinocerebellar ataxia type 3 (Machado-Joseph disease)

B.H.B. Silva, R. Guimaraes, F. Bergo, M.C. França, Jr., A.C.F. D'Abreu, I. Lopes-Cendes, F. Cendes (Campinas, Brazil)

713

  1. Top of page

The use of FDG-PET and MRI in neurodegeneration: An Irish experience

J. Dineen, M. O'Connell, E. Kavanagh, T. Lynch (Dublin, Ireland)

714

  1. Top of page

Overactive somatosensory hand representation in writer's cramp

C. Dresel, V. Wilzeck, Y. Li, F. Castrop, C. Zimmer, B. Haslinger (Muenchen, Germany)

715

  1. Top of page

Different clinical and in-vivo progression in subtypes of Parkinson's disease

C. Eggers, D.J. Pedrosa, D. Kahraman, F. Maier, C.J. Lewis, G.R. Fink, M. Schmidt, L. Timmermann (Cologne, Germany)

716

  1. Top of page

Structural volumes in patients with Parkinson's disease, atypical parkinsonism, and rapid eye movement sleep behavior disorder: Baseline measurements from a prospective longitudinal study

T. Ellmore, B. Copeland, M. Beurlot, Q. Liang, J. Suescun, E. Furr-Stimming, R. Castriotta, M. Schiess (Houston, TX, USA)

717

  1. Top of page

Lentiform fork sign and floating parkinsonian syndrome in a patient with metabolic acidosis

G. Fabiani, H.A.G. Teive, M. Luvizotto, R.B. Gomes (Curitiba, Brazil)

718

  1. Top of page

Dopamine transporter imaging in patients with asymmetric resting tremor

R. Zhang, T. Feng, X. Li, Q. Ouyang (Beijing, China)

719

  1. Top of page

Transcranial sonography of substantia nigra: Computer-evaluated echogenicity

R. de C.L. Fernandes, A.L. Zuma De Rosso, M.B. Vincent, K. Silveira da Silva, N.C. Araujo (Rio de Janeiro, Brazil)

720

  1. Top of page

Transcranial sonography in parkinsonian patients and healthy individuals in a multiethnic population

R. de C.L. Fernandes, A.L. Zuma De Rosso, M.B. Vincent, K. Silveira da Silva, N.C. de Araujo (Rio de Janeiro, Brazil)

721

  1. Top of page

The topography of brain damage at different stages of Parkinson's disease

M. Filippi, F. Agosta, E. Canu, T. Stojkovic, M. Pievani, A. Tomic, L. Sarro, N. Dragaševic, M. Copetti, G. Comi, V. Kostic (Milan, Italy)

722

  1. Top of page

T1 and T2 relaxation times from substantia nigra in Parkinson's disease and control

R. Kulinski, A. Friedman, J. Galazka-Friedman (Warsaw, Poland)

723

  1. Top of page

Cognitive correlates of white matter microstructural integrity in Parkinson's disease

C.L. Gallagher, L. Buyan-Dent, B. Bell, N. Ninman, B.D. Bendlin (Madison, WI, USA)

724

  1. Top of page

Assessment of substancia nigra echogenicity in German and Filipino population using a portable ultrasound system

C.L. Go, A. Frenzel, R.L. Rosales, L.V. Lee, R. Benecke, D. Dressler, U. Walter (Manila, Philippines)

725

  1. Top of page

Differentiation between idiopathic and atypical parkinsonian syndromes using three-dimensional magnetic resonance spectroscopy

A. Gröger, B. Bender, I. Wurster, G. Chadzynski, U. Klose, D. Berg (Tübingen, Germany)

726

  1. Top of page

Impaired functional connectivity within sensorimotor networks in patients writer's cramp

C. Dresel, Y. Li, F. Castrop, C. Zimmer, B. Haslinger (Muenchen, Germany)

727

  1. Top of page

Assessment of progressive supranuclear palsy (PSP) by FDG-PET

Y. Higashi, H. Kamada, M. Tabata (Himeji, Japan)

728

  1. Top of page

Volume and increased iron content in the basal ganglia and substantia nigra: Two potential early biomarkers of Parkinson's disease?

L. Hopes, D. Devos, C. Delmaire, P. Jissendi, D. Alain, D. Luc (Lille, France)

729

  1. Top of page

Quantitative in vivo MRI measurement of locus coeruleus degeneration in patients with Parkinson's disease

D.E. Huddleston, S. Chen, X. Chen, S. Ahn, X. Hu (Atlanta, GA, USA)

730

  1. Top of page

Effect of levodopa on neuronal activity of substantia nigra and putamen in patients with Parkinson's disease

K. Isonishi, F. Moriwaka, K. Ito, S. Kaneko, T. Kashiwaba (Sapporo, Japan)

731

  1. Top of page

Transcranial sonography findings in Gilles de la Tourette syndrome: Our experience

L. Ispierto, P. Latorre, A. Dávalos, J. Sánchez, L. Dorado, A. Planas, R. Álvarez (Badalona, Spain)

732

  1. Top of page

Hyperactive sensorimotor network and disconnected cerebellum in essential tremor: A resting state fMRI study

R. Jech, K. Mueller, A. Srp, M. Hoskovcova, O. Ulmanova, D. Urgosik, J. Vymazal, E. Ruzicka (Prague, Czech Republic)

733

  1. Top of page

Evaluating the role of non-dopaminergic receptor activity in PD with levodopa induced dyskinesia

D. Jennings, D. Russell, O. Barret, J. Batis, D. Alagille, G. Tamagnan, J. Seibyl, K. Marek (New Haven, CT, USA)

734

  1. Top of page

Evaluating longitudinal clinical and imaging markers in the PARS pre-diagnostic cohort

D. Jennings, A. Siderowf, M. Stern, S. Eberly, D. Oakes, K. Marek, The PARS Investigators (New Haven, CT, USA)

735

  1. Top of page

7T magnetic resonance spectroscopy in idiopathic Parkinson's disease

A. South, D. Debicki, J. Penner, J. Gati, A. Parrent, R. Bartha, M. Jog (London, ON, Canada)

736

  1. Top of page

Functional MRI evaluation of therapeutic STN DBS in Parkinson's disease

J.J. Kahan, L. Mancini, L. Zrinzo, M. Hariz, K. Friston, E. Holl, M. White, D. Ruge, M. Jahanshahi, T. Boertien, T. Yousry, J.S. Thornton, P. Limousin, T. Foltynie (London, United Kingdom)

737

  1. Top of page

Role of transcranial brain sonography in differentiating idiopathic Parkinson's disease from atypical parkinsonian syndromes

R.M. Kandadai, A. Kammineni, R. Borgohain, A. Jabeen, M.A. Kannikannan, J. Yarlagadda (Hyderabad, India)

738

  1. Top of page

Novel exploratory study to examine the effect of rasagiline on tissue injury in the substantia nigra using multiple-modal 3T advance MRI techniques in patients with Parkinson's disease

O. Khan, S. Krstevska, F. Bao, V. Gorden, C. Caon, E. George (Detroit, MI, USA)

739

  1. Top of page

Varieties of offending vessels in Korean patients with hemifacial spasm

Y.D. Kim, J.H. Kim, S.J. Na, K.O. Lee, B. Yoon (Daejeon, Korea)

740

  1. Top of page

Evaluation of the cerebral blood flow by 99 mTc-ECD SPECT using eZIS in hereditary spinocerebellar ataxias

K. Kimura, S. Koyano, Y. Baba, T. Takahashi, Y. Suzuki, Y. Kuroiwa (Yokohama, Japan)

741

  1. Top of page

Activated microglia in Parkinson's disease: A PET study with a novel radiotracer, [18F]FEPPA

Y. Koshimori, J.H. Ko, R. Mizrahi, P.M. Rusjan, A.A. Wilson, S. Houle, A.E. Lang, A.P. Strafella (Toronto, ON, Canada)

742

  1. Top of page

Altered fronto-striatal connectivity in Parkinson's disease (PD) using diffusion tensor imaging (DTI) tractography

Y. Koshimori, L. Christopher, A.E. Lang, S. Houle, A.P. Strafella (Toronto, ON, Canada)

743

  1. Top of page

The pattern of brain tissue loss associated with freezing of gait in Parkinson's disease

V. Kostic, F. Agosta, M. Pievani, E. Stefanova, M. Jecmenica Lukic, A. Scarale, V. Markovic, M. Filippi (Belgrade, Serbia)

744

  1. Top of page

Resting state functional connectivity in early Parkinson's disease

K. Krolikowski, R. Menke, M. Hu, K. Talbot, C. Mackay (Oxford, United Kingdom)

745

  1. Top of page

Neuroimaging correlates of clinical phenotypes in multiple system atrophy: MR DTI and PET studies using [18F]FP-CIT and [18F]FDG

C.S. Lee, S.Y. Park, S.H. Oh, S.J. Kim, J.S. Kim, Z.H. Cho (Seoul, Korea)

746

  1. Top of page

Serotonergic presynaptic terminal density in caudate nucleus inversely correlates with severity of action-postural tremor in PD

C. Loane, M. Politis, K. Wu, D.J. Brooks, P. Piccini (London, United Kingdom)

747

  1. Top of page

Drug-cue elicited frontal and limbic dysfunction in Parkinson's disease patients with dopamine dysregulation syndrome

C. Loane, M. Politis, K. Wu, S.S. O'Sullivan, Z. Woodhead, A.D. Lawrence, A.J. Lees, P. Piccini (London, United Kingdom)

748

  1. Top of page

18F-DTBZ (AV-133) PET imaging in parkin related Parkinson's disease

C.S. Lu, W.Y. Lin, K.J. Lin, I.T. Hsiao, C.J. Hsieh, Y.H. WuChou, S.C. Lai, W.L. Chung, J. Hung, T.H. Yeh, C.C. Chen, Y.Z. Huang, R.S. Chen, M.P. Kung, T.C. Yen, D. Skovronsky, Y.H. Weng (Taoyuan, Taiwan)

749

  1. Top of page

Magnetic resonance imaging (MRI) criteria of paravertebral muscle pathology in PD patients with camptocormia: A multi-observer case-control study

N.G. Margraf, A. Rohr, J. Hampel, O. Jansen, G. Deuschl (Kiel, Germany)

750

  1. Top of page

Hyponosmia and dopamine transporter (DAT) SPECT imaging

M. Rezak, M.T. McGraw, M.P. Ostrander, D. Delzell (Winfield, IL, USA)

751

  1. Top of page

Functional neuroimaging of psychogenic dystonia

A.E. Schrag, A.R. Mehta, K.P. Bhatia, R.J. Brown, R.S.J. Frackowiak, M.R. Trimble, N.S. Ward, J.B. Rowe (Cambridge, United Kingdom)

752

  1. Top of page

Localized atrophy of subcortical structures in early-stage Parkinson's disease

R.A.L. Menke, K. Szewczyk-Krolikowski, K. Talbot, M. Hu, C.E. Mackay (Oxford, United Kingdom)

753

  1. Top of page

Withdrawn by Author

 

754

  1. Top of page

Evaluation of putaminal adenosine A1 receptors in drug naïve Parkinson's disease measured with [11C]MPDX PET

M. Mishina, K. Ishii, M. Suzuki, S. Kitamura, M. Hashimoto, Y. Kimura, M. Sakata, K. Oda, J. Toyohara, S. Kobayashi, Y. Katayama, K. Ishiwata (Bunkyo, Japan)

755

  1. Top of page

Linking high-frequency trembling at the feet to hypoactivation of sensorimotor cortices and hyperactivation of prefrontal and parietal cortices during freezing of gait in Parkinson's disease

S.T. Moore, T.R. Morris, J.M. Shine, H.G. MacDougall, M. Pearson, S.L. Naismith, S.J.G. Lewis (New York, NY, USA)

756

  1. Top of page

Heterogeneous pathogenesis of primary progressive freezing gait: Insights from imaging of the dopamine transporter

A. Fasano, S. Baldari, D. Di Giuda, R. Paratore, C. Piano, A.R. Bentivoglio, P. Girlanda, F. Morgante (Messina, Italy)

757

  1. Top of page

Comparison of functional MRI based connectivity patterns in essential tremor and controls

S. Sargolzaei, H. Islam, P. Pattany, P. Kundu, M. Blanco, L. Moreno, M. Hallett, F.B. Nahab (Miami, FL, USA)

758

  1. Top of page

Thalamic projection fiber integrity in de novo Parkinson's disease

P.J. Planetta, E.T. Schulze, E.K. Geary, J.G. Goldman, D.M. Corcos, D.M. Little, D.E. Vaillancourt (Gainesville, FL, USA)

759

  1. Top of page

Neural correlates of hypersexuality in Parkinson's disease

M. Politis, C. Loane, K. Wu, S. O'Sullivan, Z. Woodhead, L. Kiferle, A.D. Lawrence, A.J. Lees, P. Piccini (London, United Kingdom)

760

  1. Top of page

Serotonergic mediated peak-dose L-DOPA-induced dyskinesias in Parkinson's disease

M. Politis, K. Wu, C. Loane, L. Kiferle, S. Molloy, P. Bain, D. Brooks, P. Piccini (London, United Kingdom)

761

  1. Top of page

Dopamine transporter uptake, daytime sleepiness and fatigue in Parkinson's disease: Exploring the role of striatal dopaminergic denervation

S.J.L. Robinson, A. Rizos, N. Mulholland, V. Gill, B. Cocoran, R. Brown, P. Martinez-Martin, A. Martin, M. Parry, K. Ray Chaudhuri (London, United Kingdom)

762

  1. Top of page

In vivo evidence of FP-CIT uptake reduction in four patients with corticobasal syndrome and normal binding at baseline SPECT scan

C. Rossi, R. Cilia, F. Vanelli, P. De Feo, U. Bonuccelli, R. Ceravolo (Pisa, Italy)

763

  1. Top of page

In vivo 1H MRS and DWI for differentiation of Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP)

Z.Z. Rozhkova, I.N. Karaban, N.V. Karaban (Kiev, Ukraine)

764

  1. Top of page

Substantia nigra hyperechogenicity in Polish parkinsonian patients

K. Sadowski, M. Serafin- Król, A. Friedman (Warsaw, Poland)

765

  1. Top of page

Functional magnetic resonance imaging (fMRI) in ‘de novo’ Parkinson's disease patients: A neuroimaging marker for the early detection of Parkinson's disease?

J.L. Robinson, J. Phillips-Sabol, G. Griehs, E. Encarnacion, M.K. Sanghera (Temple, TX, USA)

766

  1. Top of page

Dysarthria in parkinsonism: Neural or articulatory?

M. Saxena, S.S. Kumaran, V. Goyal, V. Narang, M. Behari (New Delhi, India)

767

  1. Top of page

Diffusion tensor imaging and fiber tractography in movement disorders

M. Saxena, S.S. Kumaran, V. Goyal, M. Behari (New Delhi, India)

768

  1. Top of page

Associations between brain microstructural and dopaminergic integrity in Parkinson's disease: A joint diffusion tensor and DAT imaging study

N. Schuff, K. Wu, Y. Zhang, S. Buckley, J. Seibyl, K. Marek (San Francisco, CA, USA)

769

  1. Top of page

Substantia nigra imaging in Parkinson's disease: Comparing multimodal MRI at 3 and 7 Tesla with transcranial ultrasound. Initial results of a pilot study

S.T. Schwarz, A. Blazejewska, S. Wharton, N. Bajaj, P. Morris, P. Gowland, D.P. Auer (Nottingham, United Kingdom)

770

  1. Top of page

Baseline neuroimaging characteristics of the Parkinson's progression marker initiative (PPMI) Parkinson's and healthy cohorts

J.P. Seibyl, PPMI Investigators (New Haven, CT, USA)

771

  1. Top of page

Establishment of differential diagnosis of Parkinson's-related diseases by means of brain magnetic resonance imaging

R. Sengoku, S. Matsushima, K. Bono, K. Sakuta, M. Yamazaki, S. Miyagawa, T. Komatsu, S. Omoto, S. Takagi, H. Mitsumura, M. Morita, S. Mochio (Tokyo, Japan)

772

  1. Top of page

Cerebellar involvement in dystonia: A simultaneous EMG-fMRI study in myoclonus-Dystonia

S. Sharifi, J. van der Meer, S. van der Salm, A. Nederveen, A.F. van Rootselaar, M. Tijssen (Amsterdam, Netherlands)

773

  1. Top of page

Merits and limits of 123I-MIBG cardiac scintigraphy in neurological practice

H. Shibayama, M. Takahashi, F. Katada, S. Sato, T. Fukutake (Kamogawa, Chiba, Japan)

774

  1. Top of page

Substantia nigra hyperechogenicity in LRRK2 G2019S PD patients and asymptomatic mutation carriers

M. Sierra, I. Glez-Aramburu, P. Sánchez-Juan, E. Palacio, J. Berciano, O. Combarros, J. Infante (Santander, Spain)

775

  1. Top of page

Clinical correlates of brain inflammation in Parkinson's disease: A PET study

B.S. Simpson, N. Pavese, A.F. Ramlackhansingh, D.P. Breen, R.A. Barker, D.J. Brooks (London, United Kingdom)

776

  1. Top of page

Usefulness of brain perfusion SPECT for differentiation between idiopathic Parkinson's disease and multiple system atrophy

I.U. Song, J.S. Kim, K.S. Lee, Y.A. Chung (Incheon, Korea)

777

  1. Top of page

The application of PET imaging to LRRK2 rodent models of PD

M.D. Walker, A. Milnerwood, K. Dinelle, L. Tapia, R. Korneslen, S. McCormick, A.J. Stoessl, M.J. Farrer, V. Sossi (Vancouver, BC, Canada)

778

  1. Top of page

Echogenic substantia nigra in the long-term course of Parkinson's disease

J. Spiegel, A. Runkel, J. Bürmann, K. Faßbender, U. Dillmann, S. Behnke (Homburg/Saar, Germany)

779

  1. Top of page

Regional involvement of the middle cerebellar peduncle, cingulum and corticospinal tract in parkinsonian disorders assessed using diffusion tensor imaging

Y. Surova, F. Szczepankiewicz, J. Lätt, M. Nilsson, B. Eriksson, C. Nilsson, O. Hansson, D. van Westen (Lund, Sweden)

780

  1. Top of page

White matter damage in Parkinson's disease patients with glucocerebrosidase gene mutations: A study using diffusion tensor imaging

M. Svetel, M. Filippi, K. Davidovic, F. Agosta, N. Kresojevic, L. Sarro, I. Stankovic, G. Comi, V. Kostic (Belgrade, Serbia)

781

  1. Top of page

Cerebral cortex and white matter lesions in Wilson's disease

N. Tanaka, R. Hanajima, Y. Terao, J. Goto, S. Tsuji (Tokyo, Japan)

782

  1. Top of page

Dopamine transporter SPECT scan in parkinsonian syndromes

A. Taneja, P. Khemani (Dallas, TX, USA)

783

  1. Top of page

GLucose IMaging in ParkinsonismS

L.K. Teune, D. Mudali, R.J. Renken, B.M. De Jong, M. Segbers, J.B.T.M. Roerdink, R.A.J.O. Dierckx, K.L. Leenders (Groningen, Netherlands)

784

  1. Top of page

Gray and white matter differences demonstrated by VBM and DTI among healthy first degree relatives of Parkinson's disease patients' carriers of the G2019S mutation in the LRRK2 gene

A. Thaler, A. Mirelman, M. Arzi, Y. Jacob, T. Gurevich, D. Ben Bashat, A. Orr-Urtreger, K. Marder, S. Bressman, B.R. Bloem, T. Hendler, N. Giladi, The AJ LRRK2 Consortium (Tel Aviv, Israel)

785

  1. Top of page

Progression of Parkinson's disease evaluated by perfusion brain SPECT

M. Trošt, P. Tomše, M.G. Kramberger, B.S. Zagavec, M. Grmek, N.Z. Kriznar, L. Ocepek, Z. Pirtošek (Ljubljana, Slovenia)

786

  1. Top of page

Dysfunctional reward processing in the basal ganglia is already present at the clinical onset of Parkinson's disease

J.P.M. van der Vegt, S. Zittel, K.H. Madsen, M.M. Weiss, C. Buhmann, B.R. Bloem, A. Münchau, H.R. Siebner (Nijmegen, Netherlands)

787

  1. Top of page

Abnormalities in functional and structural brain networks are evident in Parkinson's disease with and without cognitive impairment

C. Hu, S. Pool, K. Visscher, R.R. Walsh (Las Vegas, NV, USA)

788

  1. Top of page

Reduced cortical and subcortical sensorimotor activation in dystonia during a kinesthetic illusion task

S.J.A. Carr, K. Borreggine, J.L. Vitek, D. Riley, B.L. Walter (Cleveland, OH, USA)

789

  1. Top of page

Multinuclear MR spectroscopy assessment of cerebral energy metabolism in early Parkinson's disease

N. Weiduschat, X. Mao, M.F. Beal, M.J. Nirenberg, D.C. Shungu, C. Henchcliffe (New York, NY, USA)

790

  1. Top of page

18F-DTBZ PET imaging in Parkinson's disease and progressive supranuclear palsy

Y.H. Weng, K.J. Lin, I.T. Hsiao, C.J. Hsieh, W.Y. Lin, R.S. Chen, Y.Z. Huang, S.C. Lai, W.L. Chung, T.H. Yeh, T.C. Yen, M.P. Kung, D. Skovronsky, C.S. Lu (Taoyuan County, Taiwan)

791

  1. Top of page

Quantitative analysis of dopamine transporter imaging in patients with Parkinson's disease: Between freezers and non-freezers

S. You, S.R. Kim, M.J. Kim, M. Oh, J.S. Kim, S.J. Chung (Seoul, Korea)

Parkinson's disease: Behavioral disorders

792

  1. Top of page

Gait initiation in REM sleep behavior disorder and Parkinson's disease with freezing of gait

L. Alibiglou, C. Marlin, A. Videnovic, P.J. Planetta, D.E. Vailancourt, C.D. MacKinnon (Chicago, IL, USA)

793

  1. Top of page

Prevalence of anxiety in Parkinson's disease and its relation to various factors

H. Ansari, M.A. Rana, A.Q. Rana (Toronto, ON, Canada)

794

  1. Top of page

Motor tasks in an early Parkinson's population

C.A. Antoniades, K. Krolikowski, C. Kennard, M. Hu (Oxford, United Kingdom)

795

  1. Top of page

Spectrum of psychotic disorders in Parkinson's disease and association with motor and non-motor features

C.C. Aquino, F. Doná, P.C. Castro, A.C. Felício, S.M. Silva, V. Borges, H.B. Ferraz (São Paulo, Brazil)

796

  1. Top of page

Odor identification test (OIT) in Indian Parkinson's disease (PD) patients

M. Behari, J. Mathew, G. Shukla, V. Goyal, A.K. Srivastava (New Delhi, India)

797

  1. Top of page

Prospective evaluation of changes in non-motor symptoms, anxiety and depression on initiation of monotherapy of enteral Duodopa®

F. Bellante, S. Dethy, D. Zegers de Beyl (La Louviere, Belgium)

798

  1. Top of page

Clinical heterogeneity in a sample of Parkinson's disease patients with impulse control disorders

P. Bugalho, A. Oliveira-Maia, J. Vale (Lisboa, Portugal)

799

  1. Top of page

Creative thinking in patients with Parkinson's disease and healthy subjects: The artistic profession makes the difference?

M. Canesi, M.L. Rusconi, E. Reali, F. Moroni, R. Cilia, G. Pezzoli (Milan, Italy)

800

  1. Top of page

Mild affective symptoms in de novo Parkinson's disease patients: Relationship with dopaminergic dysfunction

R. Ceravolo, D. Frosini, M. Poletti, C. Pagni, S. Mazzucchi, D. Volterrani, U. Bonuccelli (Pisa, Italy)

801

  1. Top of page

Prevalence and peculiarities of neuropsychiatry in not treated non-demented Parkinson's disease

L. Chinchaladze, N. Lobjanidze, N. Akiashvili, M. Kapianidze, T. Maisuradze, M. Janelizde (Tbilisi, Georgia)

802

  1. Top of page

Dopamine dysregulation syndrome in Parkinson's disease: From clinical and neuropsychological characterization to management and outcome

R. Cilia, C. Siri, M. Canesi, D. De Gaspari, A.L. Zecchinelli, N. Meucci, C.B. Mariani, S. Tesei, G. Sacilotto, M. Zini, C. Ruffmann, G. Pezzoli (Milan, Italy)

803

  1. Top of page

Apomorphine and levodopa do not rescue parkinsonian ultrasonic vocalization deficits in rats

E.J. Doll, J.N. Shier, L.M. Grant, M.R. Ciucci (Madison, WI, USA)

804

  1. Top of page

Relationships among measures of striatal dopamine loss and ultrasonic vocalization deficits

M.R. Ciucci, N.P. Connor, T. Schallert (Madison, WI, USA)

805

  1. Top of page

Assessing hypersexuality in Parkinson's disease: Validation of a screening questionnaire

I. de Chazeron, B. Pereira, P.M. Llorca, I. Rieu, O. Blanc, P. Derost, M. Ulla, B. Debilly, F. Durif (Clermont-Ferrand, France)

806

  1. Top of page

Decision-making, impulsivity and behavioural addictions: Do Parkinson's patients jump to conclusions?

A. Djamshidian, S.S. O'Sullivan, Y. Sanotsky, S. Sharman, Y. Matviyenko, T. Foltynie, R. Michalczuk, I. Aviles-Olmos, K. Doherty, M. Selikhova, H. Bowden-Jones, E. Joyce, A.J. Lees, B.B. Averbeck (London, United Kingdom)

807

  1. Top of page

Effects of dopamine on sensitivity to social bias in Parkinson's disease

A. Djamshidian, S.S. O'Sullivan, A.J. Lees, B.B. Averbeck (London, United Kingdom)

808

  1. Top of page

Dopaminergic contributions to distance estimation in PD: A perceptual or sensorimotor deficit?

K.A. Ehgoetz Martens, C.G. Ellard, Q.J. Almeida (Waterloo, ON, Canada)

809

  1. Top of page

Feasibility of virtual exercise coach to promote walking in community-dwelling persons with Parkinson's disease

T.D. Ellis, N.K. Latham, T.R. DeAngelis, C.A. Thomas, M. Saint-Hilaire, K.L. Hendron, T. Bickmore (Boston, MA, USA)

810

  1. Top of page

Motor asymmetry in Parkinson's disease (PD) – What is the impact on impairment, disability and quality of life

R. Figari Jordan, A. Gruber-Baldini, K. Anderson, P. Fishman, S. Reich, W. Weiner, L. Shulman (Baltimore, MD, USA)

811

  1. Top of page

Correlation between novelty-seeking and harm-avoidance with depression and anxiety in Parkinson's disease

F.M.C. Fonoff, E.T. Fonoff, T. Quaranta, E.R. Barbosa, M.J. Teixeira, D. Fuentes (Sao Paulo, Brazil)

812

  1. Top of page

Telehealth delivery of software-enhanced speech therapy for Parkinson's disease

C.M. Fox, L.O. Ramig, D. McFarland, A. Halpern (Denver, CO, USA)

813

  1. Top of page

Three years' follow up study of bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease

X. Fu, L. Chen, J. Liu, Y. Liu, W. Xian, X. Ye, Y. Zheng, Z. Pei (Guangzhou, China)

814

  1. Top of page

Does ineffective foot clearance when walking distinguish fallers from non-fallers in people with Parkinson's disease?

B. Galna, S. Lord, L. Rochester (Newcastle Upon Tyne, United Kingdom)

815

  1. Top of page

The spectrum of neuropsychiatric symptoms in Parkinson's disease according to cognitive function

C.K. Ha, J.J. Park, H.K. Park, S.H. Choi (Incheon, Korea)

816

  1. Top of page

Clozapine as a potential treatment for refractory impulsive, compulsive, and punding behaviors in Parkinson's disease

A.M. Hardwick, H. Ward, A. Hassan, J. Romrell, M.S. Okun (Gainesville, FL, USA)

817

  1. Top of page

Rotigotine transdermal patch improved neuropsychiatric features (apathy, anhedonia, anxiety, and depression) and fatigue in patients with Parkinson's disease: Post-hoc analysis of five double-blind placebo-controlled studies

R.A. Hauser, P.A. Nausieda, E. Surmann, K. Moran, P. Barone (Tampa, FL, USA)

818

  1. Top of page

Can patients with Parkinson's disease learn to improve their balance responses?

K. Van Ooteghem, J.S. Frank, F.B. Horak (Portland, OR, USA)

819

  1. Top of page

Specific cerebral metabolic patterns correlate with emotional alterations in Parkinson's disease

C. Huang, M.J. Nirenberg, P. Piboolnurak, L.D. Ravdin, L. Severt, L. Solnes, M.F. Beal, C. Henchcliffe (New York, NY, USA)

820

  1. Top of page

5-HT1A receptor levels are increased in the cerebral cortex of Parkinson's disease patients whether they exhibit visual hallucinations or not

P. Huot, T.H. Johnston, N.P. Visanji, T. Darr, D. Pires, L.N. Hazrati, J.M. Brotchie, S.H. Fox (Toronto, ON, Canada)

821

  1. Top of page

Pre-post treatment effect of rasagiline on freezing of gait during controlled and free walking

F. Rahimi, A. South, D. Bell-Boucher, P. Bapat, Y. Mohammed, M. Vyas, M. Jog, L. Zhu (London, ON, Canada)

822

  1. Top of page

An impairment of visuomotor skill flexibility in Parkinson's disease

R.A. Joundi, J.S Brittain, M. Bogdanovic, T.Z. Aziz, P. Brown, N. Jenkinson (Oxford, United Kingdom)

823

  1. Top of page

Dose-dependent effect of dopamine agonists on impulse control disorders in Parkinson's disease: A longitudinal study

J. Joutsa, K. Martikainen, T. Vahlberg, V. Kaasinen (Turku, Finland)

824

  1. Top of page

Apathy in incident Parkinson's disease

T.K. Khoo, G. Duncan, A.J. Yarnall, D.J. Brooks, R.A. Barker, J.T. O'Brien, D.J. Burn (Newcastle upon Tyne, United Kingdom)

825

  1. Top of page

Depression and anxiety in incident Parkinson's disease

T.K. Khoo, A.J. Yarnall, G. Duncan, D.J. Brooks, R.A. Barker, J.T. O'Brien, D.J. Burn (Newcastle upon Tyne, United Kingdom)

826

  1. Top of page

Is the nigrostriatal dysfunction a possible predictive marker of visual hallucinations in Parkinson's disease? Evidences from a 123I-SPECT study

R. Ceravolo, L. Kiferle, D. Volterrani, E. Del Prete, U. Bonuccelli (Pisa, Italy)

827

  1. Top of page

Prevalence of depression in patients with idiopathic Parkinson's disease in Korea

W.C. Kim (Seongnam, Korea)

828

  1. Top of page

Effects of bilateral subthalamic nucleus deep brain stimulation on impulse control and repetitive behavior disorders in Parkinson's disease: Results from 89 patients

Y.E. Kim, H. Kim, H.J. Kim, J.Y. Lee, J.Y. Yun, J.Y. Kim, S.H. Paek, B.S. Jeon (Seoul, Korea)

829

  1. Top of page

Possible neuroprotective effects of atorvastatin and simvastatin (HMG-CoA) reductase inhibitors against 6-hydroxydopamine (6-OHDA) induced behavioural, biochemical and cellular alterations in rat

A. Kumar, N. Sharma (Chandigarh, India)

830

  1. Top of page

Rasagiline and its metabolites carrying secondary or primary amino groups inhibit the dopamine metabolite, 3, 4 dihydroxyphenyl acetaldehyde (DOPAL) induced α-synuclein aggregation in vitro

V.B. Kumar, M.W. Panneton, W.J. Burke (St. Louis, MO, USA)

831

  1. Top of page

Thinning of retina from nasal part associates with visual hallucinatory experience in patients with Parkinson's disease wtih intact cognition

J.Y. Lee, T.W. Kim, H.J. Kim, B.S. Jeon (Seoul, Korea)

832

  1. Top of page

The neural correlates of visual misperceptions in Parkinson's disease: Disorder of attentional networks

J.M. Shine, G.M. Halliday, S.J. Bolitho, S.L. Naismith, S.J.G. Lewis (Sydney, Australia)

833

  1. Top of page

Effect of PGC-1alpha on alpha-synuclein induced toxicity in mice

K.Y.J. Li, C. Ciron, B. Schneider, P. Aebischer (Ottawa, ON, Canada)

834

  1. Top of page

Isolated delusional disorders in Parkinson's disease

C. Linder, M. Aigner, E. Auff, W. Pirker (Vienna, Austria)

835

  1. Top of page

Spatial errors in perceived hand position increase with movement duration in Parkinson's disease and are linked to noise in sensory feedback processing

M. Miller Koop, B.C. Hill, H.M. Bronte-Stewart (Grosse Pointe Farms, MI, USA)

836

  1. Top of page

Interactions between cognition, depression and L-dopa in Parkinson's disease

C. Degroot, M.A. Bruneau, B. Mejia-Constain, C. Bedetti, O. Monchi (Montreal, QC, Canada)

837

  1. Top of page

Phenomenology and factors causing psychosis in Parkinson's disease

M.S.N. Achary, S.T. Govindappa, P. Basu, S.D. Kumarswamy, R. Ramanathan, U.B. Muthane (Bangalore, India)

838

  1. Top of page

Dual tasking in Parkinson's disease increases walking speed: The influence of repeated measures

A. Nieuwboer, L. Münks, C. Strouwen, E. Molenaars, M. Munneke, S. Keus, L. Rochester (Leuven, Belgium)

839

  1. Top of page

Evaluation of a novel cognitive behavioural intervention to reduce impulse control behaviours and associated problems in Parkinson's disease patients

D. Okai, S. Askey-Jones, M. Samuel, R.G. Brown, A. David (London, United Kingdom)

840

  1. Top of page

Prevalence of panic attacks among Parkinson's patients of South India

S. Ovallath, P. Deepa, R. Babu, N. Reshmi (Kannur, India)

841

  1. Top of page

Minor hallucinations are a frequent and even pre-motor symptom in early untreated Parkinson's disease

J. Pagonabarraga, S. Martinez-Horta, R. Fernández de Bobadilla, C. Villa, R. Ribosa, C. García, B. Pascual-Sedano, A. Gironell, J. Kulisevsky (Barcelona, Spain)

842

  1. Top of page

Addiction to levodopa: Dopamine dysregulation syndrome in Parkinson's disease

S. Pandey, M. Mehndiratta (New Delhi, India)

843

  1. Top of page

Bittersweet binge: Is compulsive eating a predictor of depression in Parkinson's disease?

M.M. Pandya, H.H. Fernandez (Cleveland, OH, USA)

844

  1. Top of page

Motor imagery of finger movements is preserved in patients with Parkinson's disease

E. Pelosin, L. Avanzino, M. Bove, C. Ogliastro, R. Marchese, G. Abbruzzese (Genoa, Italy)

845

  1. Top of page

Parkinson's disease and comorbidity with depression and anxiety disorders

M. Rakacolli, D. Dobi, F. Elezi, E. Isaraj, J. Kruja (Tirana, Albania)

846

  1. Top of page

Extrastriatal abnormalities in dopamine homeostasis in Parkinson's patients with medication-induced pathological gambling: An [11C]FLB-457 PET study

N.J. Ray, J.M. Miyasaki, J.H. Ko, S.S. Cho, F. Antonelli, M. Zurowski, G. Pellecchia, A.E. Lang, S. Houle, A.P. Strafella (Toronto, ON, Canada)

847

  1. Top of page

Prevalence of psychosis in a hospital-based Parkinson's disease Mexican sample

M. Rodríguez-Violante, A. Cervantes-Arriaga, A. Villar-Velarde, T. Corona (Mexico City, Mexico)

848

  1. Top of page

Anxiety symptoms among cognitively-intact, community dwelling Filipino patients with Parkinson's disease

R.L. Rosales, C.L. Go, M. Joya-Tanglao, A.R. Ng, M.D. de los Santos (Manila, Philippines)

849

  1. Top of page

Towards the detection of the neural correlates of Parkinson's disease sub-types using MRI

K. Rosenberg Katz, T. Herman, Y. Jacob, G. Nir, J.M. Hausdorff (Tel Aviv, Israel)

850

  1. Top of page

Visual hallucinations in photographs of visual hallucinations in Parkinson's disease (PD)

O. Vaou, M. Saint-Hilaire, J. Friedman (Boston, MA, USA)

851

  1. Top of page

The impact of age and gender on airway protection in individuals with Parkinson's disease

C.M. Sapienza, M. Okun, G. Carnaby, E. Silverman, P. Davenport (Gainesville, FL, USA)

852

  1. Top of page

Pathological alpha-synuclein oligomers: Inhibition in vitro and in vivo by anle138b

F. Schmidt, J. Levin, S. Shi, C. Prix, S. Ryazanov, A. Leonov, K. Bötzel, C. Griesinger, A. Giese (Munich, Germany)

853

  1. Top of page

Characterization and behavioral impact of a serotonergic lesion in MPTP-intoxicated monkeys

V. Sgambato-Faure, M. Beaudoin, J. Epinat, G. Jarre, S. Neumane, L. Tremblay (Bron, France)

854

  1. Top of page

Videofluorographic and patient reported outcomes of swallowing pre and post deep brain stimulation of the subthalamic nucleus in advanced Parkinson's disease

A.K. Silbergleit, F. Junn, T. Beardsley, D. Collins, L. Schultz, P. LeWitt (Detroit, MI, USA)

855

  1. Top of page

On-line processing demands of narrow corridors on gait in Parkinson's freezers and non-freezers

C.R.A. Silveira, Q.J. Almeida, D.B. Boucher, S. Witzel, E.A. Roy (Waterloo, ON, Canada)

856

  1. Top of page

A survey of the identification and management of depression in people with Parkinson's disease

A.C. Simpson, M. Samuel, R.G. Brown (London, United Kingdom)

857

  1. Top of page

Utilization of antidepressants and mental health services in patients with Parkinson's disease and depression (as measured by the PDQ-39 emotional well being score)

B.V. Stell, M. Kwasny, O.N. Oguh, T. Simuni, on behalf of the NPF QII Investigators (Chicago, IL, USA)

858

  1. Top of page

Prevalence and associates of depressive and anxious symptoms in Parkinson's disease

M. Sommerauer, S. Schreglmann, H. Vogel, G. Eisele, C. Baumann (Zurich, Switzerland)

859

  1. Top of page

Falls beyond home among people with Parkinson's disease

E.L. Stack, H.C. Roberts (Southampton, United Kingdom)

860

  1. Top of page

Transcranial sonography findings and depression in Parkinson's disease – The preliminary report

I. Stankovic, E. Stefanova, M. Mijajlovic, A. Pavlovic, N. Dragasevic, M. Svetel, V.S. Kostic (Belgrade, Serbia)

861

  1. Top of page

The impact of fear and anxiety on the severity of freezing and festination in Parkinson's disease

S.E. Starkstein, M. Merello, D. Bruce, V. Bruno, M. Wilson, S. Brockman (Fremantle, Australia)

862

  1. Top of page

Decision making & impulsivity in Parkinson's disease – A standardized task and questionnaire based study

C. Deblieck, C. Fox, T. Schonberg, I. Subramanian (Los Angeles, CA, USA)

863

  1. Top of page

Astroglial activation in the striatum of 6-OHDA-lesioned rats with levodopa-induced dyskinesias

M. Tomiyama, T. Ueno, H. Nishijima, M. Baba, F. Mori, K. Wakabayashi, J. Yamada, S. Ueno (Aomori, Japan)

864

  1. Top of page

Development of an artistic hobby into punding and explosive aggressive behavior during dopamine replacement therapy: Case report

K. Uekawa, R. Kurisaki, T. Sakamoto, Y. Yonemochi (Uki-city, Japan)

865

  1. Top of page

Morphologic changes of dendritic spines of intratelencephalic-type neurons in the motor cortex of a rat model of levodopa-induced dyskinesia

T. Ueno, H. Nishijima, A. Arai, K. Migita, J. Yamada, M. Baba, S. Ueno, M. Tomiyama (Aomori, Japan)

866

  1. Top of page

Prevalence of dopamine dysregulation syndrome in Parkinson's disease

G. Valença, R. Costa, P. Glass, N. Negreiros, L. Almeida, J. Oliveira-Filho (Salvador, Brazil)

867

  1. Top of page

Frequency of impulse control disorder symptoms in de novo Parkinson's disease patients and healthy controls

D. Weintraub, A. Siderowf (Philadelphia, PA, USA)

868

  1. Top of page

Suicide ideation and behaviors after deep brain stimulation for Parkinson's disease: Results from a randomized, controlled trial

D. Weintraub, J. Duda, K. Carlson, P. Luo, O. Sagher, F. Weaver (Philadelphia, PA, USA)

869

  1. Top of page

Anticholinergic load: Is there a cognitive cost in early Parkinson's disease?

A.J. Yarnall, T.K. Khoo, G.W. Duncan, L. Rochester, R.A. Barker, D.J. Brooks, D.J. Burn (Newcastle-upon-Tyne, United Kingdom)

870

  1. Top of page

A comparative transversal cross-sectional study of cancer prevalence in parkinsonian and non-parkinsonian population in our area

I. Ybot-Gorrín, F. Vivancos-Matellano, A. Tallón-Barranco, E. Díez-Tejedor (Madrid, Spain)

871

  1. Top of page

Impulse control disorders and depression in Parkinson's disease patients living in Afyonkarahisar, Turkey

O. Yilmaz Kusbeci, S. Gok (Afyonkarahisar, Turkey)

Education in movement disorders

872

  1. Top of page

Communication form for optimizing multimodal therapy of movement disorders

F. Adib Saberi, H. Pickenbrock, D. Dressler (Hamburg, Germany)

873

  1. Top of page

Movement disorders on YouTube: Caveat spectator

M. Stamelou, M. Edwards, A. Espay, V. Fung, M. Hallett, A. Lang, M. Tijssen, K. Bhatia (London, United Kingdom)

874

  1. Top of page

Delivering interdisciplinary PD care outside specialty centers

J.H. Carter, L.L. Mann, J. Wilhelm, A. Mooney, A. Fielder (Portland, OR, USA)

875

  1. Top of page

Driving performance and behaviors: A comparison of gender differences in drivers with Parkinson's disease

A.M. Crizzle, S. Classen, D. Lanford, I. Malaty, R.L. Rodriguez, N.R. McFarland, M.S. Okun (Gainesville, FL, USA)

876

  1. Top of page

Hemimasticatory spasm (HMS) with neuromyotonia and myokimia after radiation therapy (XRT)

M.A. Ferreira, N. Galvez-Jimenez (Davie, FL, USA)

877

  1. Top of page

MDS-UPDRS certificate training program

C.G. Goetz, G.T. Stebbins, J. McTavish, A. McGhiey (Chicago, IL, USA)

878

  1. Top of page

Developing Northumbria Parkinson's Information Service: Exploring health professionals' perceptions of information provision

K. Greenwell, R. Walker, A. Hand, S. Corbett (North Shields, United Kingdom)

879

  1. Top of page

What do medical students know about deep brain stimulation?

G. Lütjens, A. Wloch, H.H. Capelle, C. Schrader, J.K. Krauss (Hannover, Germany)

880

  1. Top of page

Knowledge of movement disorders among resident doctors and undergraduate clinical medical students at the Lagos University teaching hospital

T.A. Lawal, B.A. Idowu, O.O. Ojo, N.U. Okubadejo (Lagos, Nigeria)

881

  1. Top of page

Normal pressure hydorcephalus or progressive supranuclear palsy? A clinicopathological case series

N.K. Magdalinou, H. Ling, J.M. Schott, A.J. Lees (London, United Kingdom)

882

  1. Top of page

Early exposure in resident education: Educational needs of neurology residents in movement disorders

A.L. Molinari, D. Charles (Nashville, TN, USA)

883

  1. Top of page

Inspiring a new generation: Small group learning in movement disorders

A.L. Molinari, A. Currie, C.J. Fink, M. Turchan, B. Sidwell, D. Charles (Nashville, TN, USA)

884

  1. Top of page

HDBuzz: Empowering Huntington's disease patients through accessible education

E.J. Wild, J.B. Carroll (London, United Kingdom)

Parkinson's disease: Quality of Life/Caregiver burden

885

  1. Top of page

Quality of life in PD patients in Uruguay after a 5 years experience

B. Aguiar, R. Aljanati, M. Martinovic, V. Raggio, N. Gonzalez, A. Ojeda, V. Pomar, G. Nogueira, L. Aguerre, G. Montado (Montevideo, Uruguay)

886

  1. Top of page

Connecting with Kinect® to improve motor and gait function in Parkinson's disease

M.V. Alvarez, P.M. Grogan, M. Rodriguez (San Antonio, TX, USA)

887

  1. Top of page

Efficiency of motor rehabilitation of Parkinson's disease (PD)

I.G. Smolentseva, N.A. Amosova, O.V. Krivonos, L.P. Chupina, O.A. Maslyuk, R.F. Gubaydullina (Moscow, Russia)

888

  1. Top of page

Motor and cognitive rehabilitation of Parkinson's disease (PD) patients: Multidisciplinary approach

N.A. Amosova, I.G. Smolentseva, O.V. Krivonos, O.V. Karpova, L.P. Chupina, O.A. Maslyuk (Moscow, Russia)

889

  1. Top of page

10 year follow-up of patients with idiopathic Parkinson's disease (PD)

J.P. Bach, J. Rieke, M. Balzer-Geldsetzer, C. Noelker, W.H. Oertel, R.C. Dodel (Marburg, Germany)

890

  1. Top of page

Community ambulation in people with Parkinson's disease: Relationships with walking performance, confidence and executive function

R.M. Lamont, M.E. Morris, M.H. Woollacott, S.G. Brauer (Brisbane, Australia)

891

  1. Top of page

The nature and functional impact of sleep disturbances in incident Parkinson's disease

D.P. Breen, J.R. Evans, K. Farrell, C. Brayne, R.A. Barker (Cambridge, United Kingdom)

892

  1. Top of page

Evaluation of an educational program in Parkinson's disease: A medical and economic study

C. Canivet, N. Costa, C. Arcari, C. Mohara, H. Derumeaux, L. Molinier, F. Ory-Magne, C. Brefel-Courbon (Toulouse, France)

893

  1. Top of page

Fear of falling and future falls in people with Parkinson's disease

N.E. Allen, C. Sherrington, S.S. Paul, S.D. O'Rourke, C.G. Canning (Lidcombe, Australia)

894

  1. Top of page

The experience of pre-death grief in Parkinson's caregivers: A pilot study

J.H. Carter, K.S. Lyons, A. Lindauer, J. Malcom (Portland, OR, USA)

895

  1. Top of page

An evaluation of an upper limb/handwriting group for people with Parkinson's disease

C. Cooper, R. Stringer (Derby, United Kingdom)

896

  1. Top of page

Feasibility study of an intensive exercise and educational program for Parkinson's disease

J.M.M. Domingos, J.J. Ferreira (Lisbon, Portugal)

897

  1. Top of page

Use of electronic games as an entertaining and low cost tool for the treatment of patients with Parkinson's disease

A. dos Santos, F. Pegollo, J.E. Pompeu, R. Alencar, R. Avanzi (São Paulo, Brazil)

898

  1. Top of page

A new tool for assessment and balance training of patients with Parkinson's disease based on low cost comercial Wii balance board

A. dos Santos, F. Pegollo, R. Alencar, R. Avanzi, J.E. Pompeu (São Paulo, Brazil)

899

  1. Top of page

Surviving despite the odds: A case of Parkinson's disease in Africa after 23 years

C. Dotchin, A. Jusabani, R. Walker (North Shields, United Kingdom)

900

  1. Top of page

Impact of deep brain stimulation on quality of life in Parkinson's disease: Long-term follow-up

F. Durif, D. Morand, B. Pereira, J.J. Lemaire, P.P. Derost, M. Ulla, J. Régis, F. Fluchère, J.P. Azulay (Clermont-Ferrand, France)

901

  1. Top of page

Weight loss in patients with Parkinson's disease – The Cardiff experience

H. Warren, P. Fernando, E. Morgan, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

902

  1. Top of page

Meeting the needs of individuals with Parkinson's disease and deep brain stimulation in accordance with the National Service Framework for Long-Term Conditions (UK)

A.C. Fletcher (Oxford, United Kingdom)

903

  1. Top of page

Promoting knowledge transfer for optimal physiotherapy: Role of the Association of Physiotherapists in Parkinson's Disease Europe (APPDE)

M. Graziano, D. Jones, F. Lindop, B. Ramaswamy, M. Hubert, M. Munneke (Esch-sur-Alzette, Luxembourg)

904

  1. Top of page

Risk factors for ER and hospitalization in Parkinson's disease: An NPF quality improvement initiative (NPF-QII) study

A. Hassan, S. Wu, P. Schmidt, I.A. Malaty, M.S. Okun (Gainesville, FL, USA)

905

  1. Top of page

Development of a palliative care clinic for advanced Parkinson's disease patients and their caregivers

S.L. Heath, E.M. Lanier, G.A. Glass, C. Talmadge, E. Woodward, N.B. Galifianakis (San Francisco, CA, USA)

906

  1. Top of page

Towards a holistic model of well-being in patients with Parkinson's disease

C.S. Hurt, A. Simpson, R.G. Brown, PROMS-PD Study Group (London, United Kingdom)

907

  1. Top of page

Quality of life: What really matters to patients with Parkinson's disease?

C.S. Hurt, R.G. Brown (London, United Kingdom)

908

  1. Top of page

Optimal effect of desmopressin for nocturia in patients with Parkinson's disease

T. Ieda, T. Mihara, S. Noda, N. Iwade, T. Miyake, A. Yarita (Yokkaichi, Japan)

909

  1. Top of page

Efficacy of double-task training on gait performance in Parkinson's disease: A randomized, controlled, double-blind study

M.G. Jabre, N. Elias, R. Karam, I. Haddad, K. Habib, B.P. Bejjani (Byblos, Lebanon)

910

  1. Top of page

Falls and its impact on people with Parkinson's disease: Survey of 110 patients attending a regional clinic

T. Jawad, O. Nayeem, A. Martin, J. Johnson, L. Hughes, K. Lloyd, K.R. Chaudhuri (London, United Kingdom)

911

  1. Top of page

Model of rasagiline versus standard care for Parkinson's disease: Comparison of progression effects

S. Johnson, S.T. Wang, H. Birnbaum, E. Grubb (Boston, MA, USA)

912

  1. Top of page

Economic value of slowing Parkinson's disease to payers and patients: Modeling progression through Hoehn and Yahr stages

S. Johnson, M. Diener, A. Kaltenboeck, H. Birnbaum, E. Grubb, A. Siderowf (Boston, MA, USA)

913

  1. Top of page

Parkinson's disease patients in institutionalized care

T. Keränen, P. Keränen, K.K. Martikainen, R.J. Marttila (Kuopio, Finland)

914

  1. Top of page

The effect of exercise on different clinical severity of Parkinson's disease

H. Sung, S.M. Cheon, J.W. Kim (Busan, Korea)

915

  1. Top of page

Psychosocial impact of parkinsonian dysarthria: Relevance of a new self-evaluation scale

A. Letanneux, F. Viallet, S. Pinto (Aix-en-Provence, France)

916

  1. Top of page

Evaluation of an Otago-based exercise group for people with Parkinson's disease

F.A. Lindop, R.H. Skelly, R. Smith (Derby, United Kingdom)

917

  1. Top of page

Emotional disorders and disturbances in activities of daily living in patients with Parkinson's disease

M. Lisak, Z. Trkanjec, V. Demarin (Zagreb, Croatia)

918

  1. Top of page

Bone metabolism markers in Parkinson's disease

T. Maeda, M. Yamamoto, K. Nagata, Y. Satoh, T. Yamazaki, D. Takano (Akita, Japan)

919

  1. Top of page

Community based outreach to educate Hispanics living with Parkinson's disease in Phoenix, Arizona, USA

C.P. Martinez, M.A. Coles (Phoenix, CO, USA)

920

  1. Top of page

Reluctance to initiate medication in Parkinson's disease: A physician's perspective

T.A. Mestre, J. Sale, M. Zurowski, J. Miyasaki, C. Marras (Toronto, ON, Canada)

921

  1. Top of page

Assessing nonmotor symptoms and their influence on the quality of life of Parkinson's disease patients

M.L. Muntean, L.C. Perju-Dumbrava (Cluj-Napoca, Romania)

922

  1. Top of page

The effect of treadmill training on gait and quality of life in patients with early Parkinson's disease

A. Nadeau, E. Pourcher, P. Corbeil (Quebec, QC, Canada)

923

  1. Top of page

Shared decision making in advanced Parkinson's disease: Current clinical practice and the way forward

F.A.P. Nijhuis, J. van Heek, M.J. Faber, B. Post, B.R. Bloem (Nijmegen, Netherlands)

924

  1. Top of page

Fatigue at one-year follow up in the ParkWest study

S.O. Ongre, O.-B. Tysnes, J.P. Larsen, K. Herlofson (Arendal, Norway)

925

  1. Top of page

Effect of proprioceptive neuromuscular techniques (PNF) in balance and gait of Parkinson's patients

G. Palanikumar, S.R. Parikh (Anand, India)

926

  1. Top of page

Medical care and socioeconomic impact of L-dopa induced dyskinesia in Parkinson's disease patients in France – Results of the initial phase of the LIDIA study (Levodopa Induced Dyskinesia Impact evAluation)

C. Brefel-Courbon, F. Durif, P. Krystkowiak, F. Ory-Magne, F. Tison, F. Viallet, L.E. Willemin, I. Bourdeix, K. Rérat (Rueil-Malmaison, France)

927

  1. Top of page

Using growth models to identify PD patient sub-classes with different trajectories of health status decline

J.P. Reese, J. Klotsche, Y. Winter, W.H. Oertel, H. Irving, J. Rehm, H.U. Wittchen, R. Dodel (Marburg, Germany)

928

  1. Top of page

The impact of sleep disturbances at quality of life to patients with Parkinson's disease

C.C. Roman-Filip, L.C. Prodan (Sibiu, Romania)

929

  1. Top of page

Research on the relationship between depression and QOL in patients with Parkinson's disease

M. Saruwatari, K. Hasegawa, T. Yokoyama, E. Horiuchi, A. Kumon, E. Kaneko (Sagamihara, Japan)

930

  1. Top of page

Relaxation guided imagery as a new therapeutic tool for the treatment of motor fluctuations in Parkinson's disease's

I. Schlesinger, O. Benyakov, I. Erikh, M. Nassar, E. Sprecher (Haifa, Israel)

931

  1. Top of page

Factors contributing to spousal and offspring caregiver burden in Parkinson's disease

H. Shin, J.W. Cho, J.Y. Lee, J. Youn, J.S. Kim (Seoul, Korea)

932

  1. Top of page

The economic value of screening for early Parkinson's disease

A. Siderowf, S. Johnson (Philadelphia, PA, USA)

933

  1. Top of page

Parkinson's disease; pharmaceutical prescription patterns and impact of symptoms on QOL in two Scandinavian countries

O. Skogar, J. Lökk (Jonkoping, Sweden)

934

  1. Top of page

Depression on patients with predominant rigid-akinetic, tremor and mixed forms of Parkinson's disease: A Brazilian analysis

A.B.M. Soldati, C.S. Miguelote, L.F. Vasconcelos (Niterói, Brazil)

935

  1. Top of page

Quality of life changes as time goes by as well as with subthalamic DBS: A prospective qualitative study

A.L. Törnqvist Jensen, H. Widner, S. Rehncrona, G. Ahlström (Lund, Sweden)

936

  1. Top of page

Two year follow up of “levodopa phobia” patients after levodopa adjustment

H. Takahashi, Y. Gotoh, A. Mizuma, H. Chiba, S. Takagi (Isehara, Japan)

937

  1. Top of page

Quality of life in Parkinson's disease: Comparing efficacy of the SF-36 and PDQ-8

R. Shukla, M. Alam, B. Mohamed, E.C. Thomas, E. Morgan (Cardiff, United Kingdom)

938

  1. Top of page

The social self-management of Parkinson's disease (PD) in daily life

L. Tickle-Degnen, C. Thomas, M. Saint-Hilaire, E. Naumova, N. Ambady, T. Ellis, R. Wagenaar (Medford, MA, USA)

939

  1. Top of page

Overlooked complications of patients with DBS at nursing homes

K. Wilson, B. Tousi (Cleveland, OH, USA)

940

  1. Top of page

Benign paroxysmal positional vertigo in Parkinson's disease: Underestimated and undertreated

E. van Wensen, R.B. van Leeuwen, H.J. van der Zaag-Loonen, S. Masius-Olthof, B.R. Bloem (Apeldoorn, Netherlands)

941

  1. Top of page

Care without borders: Using telemedicine to provide specialty care to patients with Parkinson's disease around the world

V. Venkataraman, E.R. Dorsey, K.M. Biglan (Baltimore, MD, USA)

942

  1. Top of page

Edmond J Safra Visiting Nurse Faculty program: An innovative strategy to advance Parkinson's disease patient care

G.M. Vernon, L. Bunting-Perry, R. Dunlop (Philadelphia, PA, USA)

943

  1. Top of page

Non motor fluctuations in patients with Parkinson's disease

P.M. Wadia, M. Barretto, J.L. Lalkaka, S. Devare, K. Dyas, B.S. Singhal (Mumbai, India)

944

  1. Top of page

Interpersonal functioning in Parkinson's disease: A dyadic analysis of patients and caregivers

S. Mavandadi, D. Weintraub, R. Dobkin (Philadelphia, PA, USA)

945

  1. Top of page

Quality of life in Parkinson's disease in Europe: A multi-center study of the EuroPA study group

Y. Winter, S. von Campenhausen, J.P. Reese, K. Eggert, M. Balzer-Geldsetzer, K. Bötzel, E. Ruzicka, E. Gusev, A. Guekht, P. Barone, C. Sampaio, W. Poewe, W.H. Oertel, R. Dodel (Marbrug, Germany)

Surgical Therapy: Other Movement Disorders

946

  1. Top of page

Evaluation of the therapeutic profit of nucleus accumbens core on the impulsivity/compulsivity balance in rats

S. Ansquer, A. Belin-Rauscent, E. Dugast, M. Francheteau, J.L. Houeto, D. Belin (Poitiers, France)

947

  1. Top of page

Deep brain stimulation of the globus pallidus internus improves parkinsonian features of multiple system atrophy

B.K. Changizi, R. Alterman, T. Cheung, D. Ngy, C. Cho (New York, NY, USA)

948

  1. Top of page

Clinical features and results of pallidal DBS on the first Portuguese DYT6 patient

S.M. França, J. Massano, H. Costa, P. Linhares, J. Volkman, M.J. Rosas (Porto, Portugal)

949

  1. Top of page

Treatment of tremor in multiple sclerosis by thalamic deep brain stimulation

F. Hofschulte, S. Paschen, J. Raethjen, H.M. Mehdorn, J. Volkmann, G. Deuschl (Kiel, Germany)

950

  1. Top of page

Treating post-traumatic tremor with deep brain stimulation: Report of five cases

N.M. Issar, P. Hedera, F.T. Phibbs, P.E. Konrad, J.S. Neimat (Nashville, TN, USA)

951

  1. Top of page

A double-blind, randomized, controlled, crossover trial of bilateral deep brain stimulation to the globus pallidus internus in severe Tourette syndrome

Z. Kefalopoulou, L. Zrinzo, M. Beigi, M. Hariz, M. Jahanshahi, P. Limousin, E. Joyce, T. Foltynie (London, United Kingdom)

952

  1. Top of page

The effect of deep brain stimulation on cerebral palsy: A meta-analysis

A. Koy, M. Hellmich, A.M. Pauls, W.A. Marks, J.P. Lin, O. Fricke, L. Timmermann (Cologne, Germany)

953

  1. Top of page

A case of treatment-resistant symptomatic headache induced by deep brain stimulation (DBS) of the internal globus pallidus (GPi)

P. Krause, C. Gaul, A. Totzeck, C. Bruecke, J. Huebl, D. Gruber, A. Kupsch, G.H. Schneider, A.A. Kuehn (Berlin, Germany)

954

  1. Top of page

Long-term outcome of bilateral pallidal stimulation in a child with pantothenate kinase-associated neurodegeneration

S. Kumada, F. Yokochi, R. Okiyama, E. Kasai, M. Taniguchi (Tokyo, Japan)

955

  1. Top of page

Pre-operative botulinum toxin injection for movement disorder-induced cervical spondylosis

H.T. Lee (Taichung, Taiwan)

956

  1. Top of page

Transient delayed-onset limb dystonia induced by subthalamic nucleus (STN) deep brain stimulation (DBS) in primary cervical dystonia

L.C. Markun, P.A. Starr, G.A. Glass, M.M. Volz, J.L. Ostrem (San Francisco, CA, USA)

957

  1. Top of page

Successful GPi-Deep brain stimulation in Tourette syndrome (GTS) – Much more than improvement of tics

J.H. Mehrkens, K. Boetzel, B. Leitner, B. Feddersen, N. Müller, S. Dehning (Munich, Germany)

958

  1. Top of page

Cervical dystonia improves with high frequency but not with low frequency pallidal stimulation

E. Moro, B.M. Pascual-Sedano, B. Shah, Y.Y. Poon, M. Fallis, A.M. Lozano, M. Hodaie, P. Hagen, C. Brücke, G.H. Schneider, A. Kühn (Toronto, ON, Canada)

959

  1. Top of page

Factors predicting improvement in essential head tremor following deep brain stimulation

M. Moscovich, T. Morishita, C. Favilla, Z. Peng, K. Foote, M. Okun (Gainesville, FL, USA)

960

  1. Top of page

Movement related activation-inhibition signaling through pallidal and thalamic oscillations in patients with Tourette syndrome

W.J. Neumann, J. Huebl, C. Brücke, H.H. Capelle, K. Müller-Vahl, J.K. Krauss, A.A. Kühn (Berlin, Germany)

961

  1. Top of page

Improved gait in normal pressure hydrocephalus after shunt surgery depends on cadence optimization

N. Nishida, H. Toda, K. Iwasaki, M. Ishikawa (Osaka, Japan)

962

  1. Top of page

Prospective assessment of low- versus high-frequency bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) in patients with primary dystonia

J.L. Ostrem, G.A. Glass, L.C. Markun, C.A. Racine, M.M. Volz, S.L. Heath, P.A. Starr (San Francisco, CA, USA)

963

  1. Top of page

DBS treatment of DYT1 dystonia: A 10-year, 52 patient experience

F.E. Panov, J. Gologrosky, G. Connors, M. Tagliati, R. Alterman (New York, NY, USA)

964

  1. Top of page

How does deep brain stimulation of subthalamic nucleus influence self-image of patients with Parkinson's disease?

E. Papuc, B. Pawlowska, K. Obszanska, A. Cegiełkowska-Bednarczyk, E. Potembska, T. Trojanowski, Z. Stelmasiak (Lublin, Poland)

965

  1. Top of page

The usefulness of intraoperative CT for DBS surgery

Y.S. Park, W.C. Kim, H.S. Kim, S.S. Cheong (Seongnam, Korea)

966

  1. Top of page

Neglected congenital muscular torticollis: A series of 5 patients treated with surgical division of both sternal and clavicular head of SCM

A. Meshkini, R. Pezeshkan (Tabriz, Iran)

967

  1. Top of page

Underwent bilateral deep brain stimulation of the ventralis intermedius thalamic nucleus (Vim DBS) in medically refractory post trauma orthostatic tremor. Preliminary observation

R. Ribacoba, E. Suárez, J.M. Asensi, S. González, B. Lozano, F.J. Seijo (Oviedo, Spain)

968

  1. Top of page

Rethinking washout effects of deep brain stimulation in dystonia

D. Ruge, L. Cif, P. Limousin, V. Gonzalez, P. Coubes, J. Rothwell (London, United Kingdom)

969

  1. Top of page

Long-term follow-up in patients with deep brain stimulation for cervical dystonia

M.W.M. Schüpbach, H. You, I.U. Isaias, T. Loennfors-Weitzel, F. Vingerhoets, J.K. Krauss, J.M. Burgunder, E. Taub, A. Stibal, A. Kaelin-Lang (Bern, Switzerland)

970

  1. Top of page

Severe akinesia and postural instability in neuroacanthocythosis during GPi-DBS

C. Schrader, G. Lütjens, A. Saryyeva, G. Berding, L. Timmermann, J.K. Krauss (Hannover, Germany)

971

  1. Top of page

Bilateral pallidal stimulation improves chorea in a patient with antiphospholipid antibody syndrome

C. Schrader, M. Aumülller, G. Lütjens, A. Saryyeva, J.K. Krauss (Hannover, Germany)

972

  1. Top of page

Deep brain stimulation of the centromedian parafascicular nucleus in rats improve breeding-induced deficient sensorimotor gating

S.D. Angelov, J.K. Krauss, K. Schwabe (Hannover, Germany)

973

  1. Top of page

Bilateral thalamic Vim DBS for orthostatic tremor: New insights and literature review

C. Sidiropoulos, J. Schwalb, D. Taylor, J. Gorham, S. Bowyer, P. LeWitt (West Bloomfield, MI, USA)

974

  1. Top of page

Deep brain stimulation of the subthalamic nucleus in the treatment of essential tremor

S.R. Taneja, D. Ngy, R.L. Alterman, C. Cho (New York, NY, USA)

975

  1. Top of page

DBS GPi is effective in a patient with multiple old stereotactic brain lesions for generalized dystonia

D. Urgosik, R. Jech, J. Vymazal, O. Subrt, E. Ruzicka, V. Vladyka (Prague, Czech Republic)

976

  1. Top of page

Two years observation after pedunculopontine nucleus (PPN) DBS surgery of two female patients with progressive supranuclear palsy (PSP)

I. Velentzas, H. Seferis, P. Afentouli, M. Torrens, G. Tagaris (Athens, Greece)

977

  1. Top of page

Antidromic activation of cortex by clinically effective thalamic DBS for essential tremor

H.C. Walker, H. Huang, C. Gonzalez, J.E. Bryant, G.C. Cutter, E.B. Montgomery, Jr., A. Yildirim, B.L. Guthrie, R.L. Watts (Birmingham, AL, USA)

978

  1. Top of page

Body weight gain in patients with bilateral deep brain stimulation for dystonia

M.E. Wolf, C. Blahak, H.H. Capelle, T. Sauer, M.G. Hennerici, J.K. Krauss (Mannheim, Germany)

979

  1. Top of page

Deep brain stimulation in the caudal zona incerta and posterior subthalamic area is more effective than in ventral intermediate nucleus for various tremor control

T. Xie, J. Bernard, C. Ojakangas, U.J. Kang, V.L. Towle, P. Warnke (Chicago, IL, USA)

980

  1. Top of page

Effect of bilateral pallidal deep brain stimulation in primary dystonia

F. Yokochi, M. Taniguchi, R. Okiyama, S. Kumada (Tokyo, Japan)

981

  1. Top of page

Electrophysiology of the anteromedial GPi in Tourette syndrome: A case study

S.E. Zauber, S. Ahn, R.M. Worth, L. Rubchinsky (Indianapolis, IN, USA)

Choreas (non-Huntington's disease)

982

  1. Top of page

A novel sign to differentiate neuroacanthocytosis from other causes of oro-lingual dyskinesias: Case series

M.M.M. Awadh (Cairo, Egypt)

983

  1. Top of page

Painful limbs and moving digits syndrome: A 76 patient case series

A. Hassan, F.J. Mateen, E. Coon, J.E. Ahlskog (Rochester, MN, USA)

984

  1. Top of page

A novel NKX2A-mutation causing benign hereditary chorea is associated with non-progressive striatal D2-receptor dysfunction

D. Haubenberger, P. Bauer, D. Lieba-Samal, A. Zimprich, E. Auff, W. Pirker (Vienna, Austria)

985

  1. Top of page

Hemichorea after striatal infarction: Clinical correlation with reversible abnormal Tc-99m-TRODAT-1 SPECT imaging of brain

H.C. Huang, M.K. Lu (Taichung, Taiwan)

986

  1. Top of page

Bizarre gait – Functional or organic?

C. Kasemsuk, P. Jagota, S. Singmaneesakulchai, R. Bhidayasiri (Bangkok, Thailand)

987

  1. Top of page

Withdrawn by Author

 

988

  1. Top of page

Huntington's disease like phenotypes not linked to CAG repeat expansions in HTT gene

L.L. Mariani, P. Charles, C. Cazeneuve, V. Hahn-Barma, K. Youssov, D. Seilhean, L. Freeman, E. Roze, A.C. Bachoud-Lévi, A. Durr (Paris, France)

989

  1. Top of page

Nonketotic hyperglycemia induced chorea: An attempt to identify the prognostic factors

T. Mathew, S. Aroor, R. Nadig, V. Kamath, U. Murgod, R. Varghese, G.R.K. Sarma (Bangalore, India)

990

  1. Top of page

Paraneoplastic and other forms of autoimmune chorea

O. O'Toole, J.Y. Matsumoto, S.J. Pittock, J. Bower, V.A. Lennon, D.H. Lachance, R. Fealey, A. McKeon (Rochester, MN, USA)

991

  1. Top of page

JPH3 mutations cause a progressive akinetic-rigid syndrome with severe dementia and putaminal rim in a five-generation African-American family

S.A. Schneider, K. Marshall, J. Xiao, M.S. LeDoux (Lubeck, Germany)

992

  1. Top of page

Rescue GPi-DBS lead for stroke induced hemiballism remotely following STN-DBS

G. Oyama, A.J. Thompson, N. Maling, P.R. Zielman, J. Sporrer, K. Foote, M.S. Okun (Gainesville, FL, USA)

993

  1. Top of page

A case of hemichorea-hemiballismus with prominent dystonia treated with tetrabenazine and chemodenervation

C.C. Umeh, P. Nichols, L.S. Rosenthal, Z. Mari (Baltimore, MD, USA)

994

  1. Top of page

Cerebrotendinous xanthomatosis presenting as a choreic syndrome

A. Valadas, P. Pita Lobo, M. Coelho (Lisbon, Portugal)

995

  1. Top of page

An updated flow chart for the evaluation of chorea

R.H. Walker (Bronx, NY, USA)

Dystonia

996

  1. Top of page

Dystonia and complex movement disorders secondary to tuberculous meningoencephalitis

J. Aasfara, W. Regragui, E.H. Ait Ben Haddou, A. Benomar, M. Yahyaoui (Rabat, Morocco)

997

  1. Top of page

Musicians dystonia (MD) is not highly task-specific: Results from extensive motor skill testing in a German MD-group

A. Hofmann, M. Grossbach, V. Baur, J. Hermsdörfer, E. Altenmüller (Hannover, Germany)

998

  1. Top of page

Blepharospasm: Epidemiology, clinical features and therapeutic outcomes

C.C. Aquino, A.C. Felicio, P.C. Castro, R.A. Oliveira, S.M. Silva, V. Borges, H.B. Ferraz (São Paulo, Brazil)

999

  1. Top of page

Frequency of history of painful trauma in cervical dystonia and comparison of patient characteristics in those with and without such history

E. Bakken, A. Stadel, D.D. Duane (Tucson, AZ, USA)

1000

  1. Top of page

Neural network analysis of kinematic gait variables to identify psychogenic gait disorders

D.A. Ballesteros, J.F. Balej, J.E. Arena, M.J. Crespo, A.D. Rivero, M.D. Rossi, C. Cuello Oderiz, D.F. Cerquetti, M. Risk, A. Cervio, M.J. Merello (Buenos Aires, Argentina)

1001

  1. Top of page

Urinary dysfunction in patients with fixed dystonia – A prospective study

A. Batla, K.P. Bhatia, I. Pareés, P. Kassavetis, M.J. Edwards, M. Stamelou, J. Panicker (London, United Kingdom)

1002

  1. Top of page

Myoclonus-dystonia related to a mutation in the epsilon-sarcoglycan gene (SGCE) associated with epilepsy in a genetically proven Tunisian family

M. Ben Djebara, Y. Hizem, I. Belhouane, I. Abdelkefi, I. Kacem, A. Gargouri, E. Leguern, R. Gouider (Tunis, Tunisia)

1003

  1. Top of page

Diagnostic delay in cervical dystonia

K.L. Bertram, D.R. Williams (Melbourne, Australia)

1004

  1. Top of page

Late onset rest-tremor in DYT1 dystonia

M. Stamelou, M. Edwards, K. Bhatia (London, United Kingdom)

1005

  1. Top of page

Cost of cervical dystonia in the United States

L.M. Bloudek, M. Stacy, M. Schwartz, M. Brin, S. Papapetropoulos (Irvine, CA, USA)

1006

  1. Top of page

Genetic evidence for the association of the D216H (rs1801968) polymorphism in the DYT1 gene with primary dystonia in an Argentinean population

M. Caputo, C. Perandones, M. Irrisarri, L.A. Pellene, D. Corach, F.E. Micheli (Buenos Aires, Argentina)

1007

  1. Top of page

Suicide among patients with X-linked dystonia parkinsonism (XDP): A retrospective study

A.R.F. Cenina, R.D.G. Jamora, R.A. Teleg, P.V. Lee, L.V. Lee (Manila, Philippines)

1008

  1. Top of page

Clinical clues suggestive of future development of parkinsonism in adults with an initial diagnosis of primary lower limb dystonia

F.C.F. Chang, J.E. Ahlskog, K.A. Josephs (Rochester, MN, USA)

1009

  1. Top of page

Cervical dystonia subtypes: Baseline analyses from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE)

D. Charles, M. Stacy, J. Jankovic, M. Schwartz, M. Brin, S. Papapetropoulos (Nashville, TN, USA)

1010

  1. Top of page

Rapidly progressive generalized dystonia in deafness-dystonia syndrome (Mohr-Tranebjaerg) with cochlear implant and response to pallidal deep brain stimulation

L. Cif, V. Gonzalez, A.M. Moura, S. James, T. Roujeau, M. Mondain, P. Coubes (Montpellier, France)

1011

  1. Top of page

Paroxysmal kinesigenic dystonia in Lesch-Nyhan disease variant

B. de la Casa-Fages, J.R. Pérez-Sánchez, F. Grandas (Madrid, Spain)

1012

  1. Top of page

Parvocellular red nucleus – A gateway for basal ganglia influence on cerebellar action?

A. Deep, K.M. Horn, R. Dhall, A. Lieberman, A.R. Gibson (Phoenix, AZ, USA)

1013

  1. Top of page

Myoclonic dystonia as a feature of cerebrotendinous xanthomatosis

J. Lagarde, E. Roze, E. Apartis, D. Pothalil, M. Vidailhet, F. Sedel, B. Degos (Paris, France)

1014

  1. Top of page

Reduced parietal connectivity with a premotor writing area in writer's cramp

C.C.S. Delnooz, R.C. Helmich, I. Toni, B.P.C. van de Warrenburg (Nijmegen, Netherlands)

1015

  1. Top of page

Frequency of autoimmune disorders and autoimmune blood work results in cervical dystonia patients and history of autoimmune disorders in their relatives

B.M. DiVito, D.D. Duane (Scottsdale, AZ, USA)

1016

  1. Top of page

Motor cortex stimulation failed to improve dystonia or pain associated in patients with secondary focal dystonia

I. Rieu, P. Derost, S. Thobois, M. Aya Kombo, J. Xie-Brustolin, J.P. Lefaucheur, M. Vidailhet, E. Broussolle, P. Krack, J.J. Lemaire, F. Durif (Clermont-Ferrand, France)

1017

  1. Top of page

Isolated spastic dysarthria masquerading as spasmodic dysphonia in a patient with central pontine myelinolysis (CPM)

J.L. Durphy, E. Molho (Albany, NY, USA)

1018

  1. Top of page

A double blind, randomized, multicenter, crossover study to demonstrate the non-inferiority of abobotulinumtoxinA in the clinical efficacy and safety in comparison with botulinum toxin a, assuming a bioequivalence ratio of 2.5:1 units, in the treatment of cervical dystonia

G. Ehm, J.Y. Yun, B.S. Jeon, H.J. Kim (Seoul, Korea)

1019

  1. Top of page

THAP1 activates the expression of SGCE (DYT11) and represses its own expression

A. Erogullari, P. Seibler, D. Braunholz, A. Grünewald, R. Depping, J. Eckhold, M. Albrecht, A. Rakovic, T. Lohnau, G. Gillessen-Kaesbach, C. Klein, K. Lohmann, F.J. Kaiser (Lübeck, Germany)

1020

  1. Top of page

Development and validation of clinical diagnostic guidelines for primary blepharospasm

G. Ferrazzano, G. Cossu, G. Fabbrini, A. Fasano, D. Martino, F. Morgante, H.A. Jinnah, M. Hallett, A. Berardelli, G. Defazio (Rome, Italy)

1021

  1. Top of page

Prevalence, predictors, and perceived effectiveness of complementary, alternative and integrative medicine in adult-onset primary dystonia

B.M. Fleming, E.L. Schwab, S.S. Nouer, J.Y. Wan, M.S. LeDoux (Memphis, TN, USA)

1022

  1. Top of page

Discovering drugs for dystonia. Review of pharmacological targets evaluated in the MPTP-lesioned primate model of levodopa-induced dystonia

S.H. Fox, T.H. Johnston, P. Huot, J.B. Koprich, M. Silverdale, M. Hill, J.M. Brotchie (Toronto, ON, Canada)

1023

  1. Top of page

A rat knockin model of early onset DYT1 generalized dystonia displays abnormal hindlimb gait

C.T. Frenz, M. Singh, P. Shashidharan (New York, NY, USA)

1024

  1. Top of page

Procedure oriented sectional anatomy of the foot and ankle region

E. Furr Stimming, J. Harrell, H. Zhang, K. Taber, F. Chio-Tan (Houston, TX, USA)

1025

  1. Top of page

Cognitive function in primary dystonia patients treated with DBS GPi

A. Gamaleya, A. Bondarenko, A. Tomskiy, S. Buklina, N. Fedorova, V. Shabalov (Moscow, Russia)

1026

  1. Top of page

DBS GPi for primary dystonia: Behavioral and mood features

A. Gamaleya, A. Tomskiy, A. Bondarenko, S. Buklina, N. Fedorova, V. Shabalov (Moscow, Russia)

1027

  1. Top of page

Multichannel somatosensory evoked potential (SSEP) recording in writer's cramp during writing and rest

J.M. Gelauff, A.W.G. Buijink, L.J. Bour, M.F. Contarino, J.H.T.M. Koelman, A.F. van Rootselaar (Amsterdam, Netherlands)

1028

  1. Top of page

Deep brain stimulation of the interal Globus pallidus for dystonic cerebral palsy

Y. Gologorsky, F. Panov, S. Motivala, T. Cheung, R.L. Alterman (New York, NY, USA)

1029

  1. Top of page

Generation of a novel rodent model of DYT1 dystonia

K. Grundmann, T. Ott, N. Gloeckle, M. Walter, M. Bonin, H.P. Nguyen, T.K. Hauser, B. Fehrenbacher, M. Schaller, B. Nuscher, C. Haass, G. Martella, A. Pisani, Z. Yue, O. Riess (Tuebingen, Germany)

1030

  1. Top of page

Primary writing tremor with mirroring responsive to botulinum toxin

S.A. Gunzler, D.E. Riley (South Euclid, OH, USA)

1031

  1. Top of page

Cerebellar modulation of human associative plasticity

M. Hamada, N. Murase, A. Sadnicka, J.M. Galea, M.J. Edwards, J.C. Rothwell (London, United Kingdom)

1032

  1. Top of page

Prevalence of neutralizing antibodies in a large cohort of long-term treated CD patients

H. Hefter, U. Kahlen, M. Moll (Duesseldorf, Germany)

1033

  1. Top of page

Dissociation of posture and balance control demonstrated by idiopathic camptocormia

R.J. St George, V.S. Gurfinkel, J.G. Nutt, J. Kraakevik, F.B. Horak (Beaverton, OR, USA)

1034

  1. Top of page

SGCE mutations in a Taiwanese cohort of early-onset of dystonia

C.L. Huang, S.C. Lai, T.H. Yeh, Y.H. Weng, C.S. Lu (Taoyuan, Taiwan)

1035

  1. Top of page

The modulation effect of premotor suppression on premotor-motor interaction and motor plasticity in patients with dystonia

Y.Z. Huang, C.S. Lu, J.C. Rothwell, C.C. Lo, Y.H. Weng, W.L. Chuang, S.C. Lai, R.S. Chen (Taipei, Taiwan)

1036

  1. Top of page

Immunotherapy-responsive faciobrachial dystonic seizures (FBDS) associated with LGI1-antibodies: A differential diagnosis in movement disorder practice

S.R. Irani, S.A. Schneider, R. Pettingill, S.J.M. Smith, M.R. Johnson, A. Vincent (Oxford, United Kingdom)

1037

  1. Top of page

The observation of dystonia in demetia with lewy bodies (DLB)

L.J. Jaffe (San Diego, CA, USA)

1038

  1. Top of page

A randomized, double-blind, placebo-controlled study comparing the efficacy, safety and tolerability of levodopa-carbidopa (tidomet) versus placebo in patients with X-linked dystonia-parkinsonism (XDP)

R.D.G. Jamora, P.M.D. Pasco, R.A. Teleg, R.F. Villareal-Jordan, R. Borres, C. Tolentino, M.J.H. Monding, S. Sarcia, L.V. Lee (Manila, Philippines)

1039

  1. Top of page

XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia (CD) or blepharospasm in the United States – Preliminary baseline results on the health impact of CD on patients using the cervical dystonia impact profile

J.J. Jankovic, M. Thomas, A. Vasquez, K. Sethi, A. Verma, E.J. Pappert, H.H. Fernandez (Houston, TX, USA)

1040

  1. Top of page

The Dystonia Coalition: Three years of progress

A.R. Rosen, J.S. Perlmutter, C. Comella, C. Ludlow, M. Hallett, W. Galpern, J. Ferguson, L. Yan, T. Waliczeck, S. Harbick, H.A. Jinnah (Atlanta, GA, USA)

1041

  1. Top of page

Using vibration training to increase the strength of surround inhibition in healthy controls and patients with hand dystonia

P. Kassavetis, T.A. Saifee, A. Sadnicka, I. Pareés, M. Kojovic, K.P. Bhatia, J.C. Rothwell, M.J. Edwards (London, United Kingdom)

1042

  1. Top of page

Motor sequence learning and motor adaptation in primary cervical dystonia

P. Katschnig, P. Schwingenschuh, M. Davare, A. Sadnicka, R. Schmidt, J.C. Rothwell, K.P. Bhatia, M.J. Edwards (Graz, Austria)

1043

  1. Top of page

Paroxysmal kinesigenic dyskinesia in the idiopathic bilateral striopallidodentate calcinosis

S.J. Kim, E.J. Chung (Busan, Korea)

1044

  1. Top of page

Penetrance of abnormal temporal discrimination thresholds in unaffected first-degree relatives of adult onset primary torsion dystonia patients

O. Kimmich, A. Molloy, D. Bradley, R. Whelan, S. O'Riordan, R.B. Reilly, S. Hutchinson, M. Hutchinson (Dublin, Ireland)

1045

  1. Top of page

Notes from a small island: Developing a musicians' dystonia clinic in Dublin

J. Bressan, O. Kimmich, D. Bradley, F. Molloy, M. Hutchinson, S. O'Riordan, N. Tubridy (Dublin 4, Ireland)

1046

  1. Top of page

Axial dystonia as a phenotype of adult onset primary torsion dystonia

A. Molloy, O. Kimmich, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

1047

  1. Top of page

Motor cortex plasticity and eye blink conditioning are normal in secondary dystonia

M. Kojovic, I. Pareés, P. Kassavetis, C. Cordivari, F. Palomar, P. Mir, J.C. Rothwell, K.P. Bhatia, M.J. Edwards (London, United Kingdom)

1048

  1. Top of page

Health-related quality of life in primary and secondary dystonia after pallidal deep brain stimulation

N. Kovács, B. Bone, G. Deli, E. Bosnyák, F. Nagy, J. Janszky, S. Komoly, T. Doczi, Z. Illes, Z. Aschermann, E. Tasnadi, Z. Pfund, I. Balás (Pécs, Hungary)

1049

  1. Top of page

BDNF val66met polymorphism in idiopathic dystonia patients in Serbia

N.D. Kresojevic, M. Svetel, A. Tomic, V. Markovic, M. Jankovic, V. Dobricic, I. Novakovic, V.S. Kostic (Belgrade, Serbia)

1050

  1. Top of page

Familial case of speech-induced tongue-protrusion dystonia

M. Krommyda, G. Xiromerisiou, E. Ameridis, D. Tsiptsios, T. Tsironis, G. Deretzi, I. Tsiptsios (Thessaloniki, Greece)

1051

  1. Top of page

Cost per episode of care for arm spasticity and cervical dystonia: Comparison of two BoNT-A preparations in 20 countries

S. Roze, R. Marty, H. Kurth (Boulogne Billancourt, France)

1052

  1. Top of page

Antiphospholipid antibody-associated dystonia: A case report and literature review

A. Kurzweil, R. Gilbert (New York, NY, USA)

1053

  1. Top of page

XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia or blepharospasm in the United States – Preliminary baseline results for patients with blepharospasm

M.S. LeDoux, J.J. Jankovic, K. Sethi, A. Verma, E.J. Pappert, H.H. Fernandez (Memphis, TN, USA)

1054

  1. Top of page

Adult Tay-Sachs disease with extrapyramidal features associated with a novel mutation in the HEXA gene

S. Lefter, O. O'Mahony, B. Sweeney, A.M. Ryan (Cork, Ireland)

1055

  1. Top of page

Identification of a genetic risk factor for musician's dystonia

K. Lohmann, A. Schmidt, C. Hemmelmann, S. Winkler, K. Siegesmund, A. Schillert, H.C. Jabusch, M. Kasten, J. Groen, J. Hagenah, A. Münchau, K.E. Zeuner, S. Schreiber, G. Deuschl, M.A.J. de Koning-Tijssen, E. Altenmüller, A. Ziegler, C. Klein (Lübeck, Germany)

1056

  1. Top of page

A case of sporadic, generalized, late onset paroxysmal kinesigenic dyskinesia

C.C. Luca, D.A. Roque, C. Singer (Miami, FL, USA)

1057

  1. Top of page

Basal ganglia volume, dystonia severity and response to deep brain stimulation in childhood dystonia

D.E. Lumsden, J. Ashmore, G. Charles-Edwards, R. Selway, J.P. Lin, K. Ashkan (London, United Kingdom)

1058

  1. Top of page

Recognition of adult-onset dystonia over time (1970 to 2007): Data from a multicenter Italian series

A. Macerollo, H.A. Jinnah, G. Abbruzzese, A.R. Bantivoglio, R. Liguori, L. Santoro, A. Berardelli, G. Defazio (Bari, Italy)

1059

  1. Top of page

Minor effect of incobotulinumtoxin in patients with neutralizing antibodies against botulinum neurotoxin A complex

M. Marek, K. Wohlfahrt, H. Bigalke, S. Paus (Bonn, Germany)

1060

  1. Top of page

Case report: Changing phenotype of familial paroxysmal kinesigenic dystonia related to oxcarbazepine treatment

C. Galtrey, J. Kaleyias, A. Clarke, M.H. Marion (London, United Kingdom)

1061

  1. Top of page

A novel pattern of FDG-PET regional metabolic defect in focal arm dystonia

S. Marousi, G.A. Tagaris, C.E. Karageorgiou (Athens, Greece)

1062

  1. Top of page

The effect of treatment on the balance in cervical dystonia

K.K. Martikainen, P. Silvoniemi, R.J. Marttila (Turku, Finland)

1063

  1. Top of page

A comparison of the diagnosis and treatment processes of families with myoclonic dystonia in the UK and the US

K.B. McPherson, A.G. Butler (Los Angeles, CA, USA)

1064

  1. Top of page

DYT6 in Japanese patients with primary dystonia – Genetic screening and response to treatment

R. Miyamoto, H. Koizumi, H. Kawakami, T. Kawarai, R. Morigaki, Y. Mukai, K. Sato, Y. Izumi, H. Morino, H. Maruyama, S. Goto, R. Kaji (Tokushima, Japan)

1065

  1. Top of page

Using an endophenotype to evaluate the effect of environmental factors in disease penetrance of adult onset primary torsion dystonia

A. Molloy, O. Kimmich, D. Bradley, R. Reilly, S. O'Riordan, M. Hutchinson (Dublin, Ireland)

1066

  1. Top of page

Intraoral injections of botulinum toxin type A in open jaw dystonia: A novel approach for this complex disorder

M. Moscovich, R. Rodriguez (Gainesville, FL, USA)

1067

  1. Top of page

Pisa syndrome – Dystonia or parkinsonism?

E. Mulroy, A. MacCarthy, S. Gleeson, K. Roberts, T. Lynch (Dublin, Ireland)

1068

  1. Top of page

Cervical dystonia patients with an unsatisfactory treatment response to botulinum toxin; improvement after referral to a tertiairy center and polymyographic electromyography

S.W.R. Nijmeijer, H. Koelman, M. Tijssen (Amsterdam, Netherlands)

1069

  1. Top of page

Nonmotor symptoms of Segawa disease (dopa responsive dystonia)

Y. Nomura, M. Segawa (Tokyo, Japan)

1070

  1. Top of page

Faciobrachial dystonic seizures without voltage gated potassium channel (VGKC) antibodies – Seizure or paroxysmal movement disorder?

K. O'Connell, J. Kinsella, J. Williams, S. Connolly, S. O'Riordan, C. McGuigan (Dublin, Ireland)

1071

  1. Top of page

Blood flow changes after chemodenervation of the scalene muscles in patients with thoracic outlet syndrome

A. Hsu, I.R. Odderson, R.E. Zierler (Seattle, WA, USA)

1072

  1. Top of page

Genetics and neuropathology of focal dystonia

R. Paudel, T. Revesz, J. Hardy, J. Holton, H. Houlden (London, United Kingdom)

1073

  1. Top of page

Patient education in dystonia and effects on botulinum toxin treatment in Germany

S. Paus, M. Marek, W. Jost (Bonn, Germany)

1074

  1. Top of page

Evaluating facial dyskinesias with computer-aided video processing

D.A. Peterson, G. Littlewort, A. Orona, M. Bartlett, A. Macerollo, D. Martino, G. Defazio (La Jolla, CA, USA)

1075

  1. Top of page

Voxel-based morphometry of the cerebellum in primary craniocervical dystonia

C.C. Piccinin, M.C.A. Santos, L.G. Piovesana, L.S. Campos, R.P. Guimarães, A.C. Amato Filho, C.L. Yasuda, M.C. França, Jr., I. Lopes-Cendes, F. Cendes, A. D'Abreu (Campinas, Brazil)

1076

  1. Top of page

Intracortical and brainstem excitability in patients with oro-mandibular dystonia

G. Pilurzi, T.A. Saifee, K.P. Bhatia, M.J. Edwards, F. Deriu, J.C. Rothwell (Sassari, Italy)

1077

  1. Top of page

Effects of deep brain stimulation on temporal speech parameters in dystonia: Preliminary results

S. Pinto, E. Demortier, P. Guyonnaud, R. Espesser, M. Vidailhet, The French Multi-centre SPIDY3 Study Group (Aix-en-Provence, France)

1078

  1. Top of page

Magnetic resonance spectroscopy of the cerebellum in primary craniocervical dystonia

L.G. Piovesana, L.S. Campos, J.C. Somazz, G. Castellano, A.C. Amato Filho, M.C. França, Jr., I.T. Lopes-Cendes, F. Cendes, F.R. Torres, A.C. D'Abreu (Campinas, Brazil)

1079

  1. Top of page

Cholinergic dysfunction distorts synaptic integration between corticostriatal and thalamostriatal pathways in a model of DYT1 dystonia

G. Sciamanna, G. Ponterio, F. Puglisi, G. Mandolesi, A. Tassone, T. Schirinzi, D.G. Standaert, A. Pisani (Rome, Italy)

1080

  1. Top of page

Levodopa-induced dyskinesias in dopa-responsive dystonia

P. Pita Lobo, M. Coelho, J.J. Ferreira, J.M. Ferro (Lisbon, Portugal)

1081

  1. Top of page

Neuropathology of primary cervical dystonia

C.N. Prudente, J. Xiao, C.A. Pardo-Villamizar, M.S. LeDoux, H.A. Jinnah (Atlanta, GA, USA)

1082

  1. Top of page

Adult onset idiopathic focal lower extremity dystonia: A comparative phenomenological analysis of this novel task specific dystonia

R.A. Ramdhani, C. Cho, S.J. Frucht (New York, NY, USA)

1083

  1. Top of page

The effects of rehabilitation using brain techniques on musician focal dystonia

M. Ramella, G. Giacobbi, A. Castagna, R.M. Converti (Milano, Italy)

1084

  1. Top of page

Relationship of handedness to arm dystonia in CBD

A.Q. Rana, I. Siddiqui, M.A. Rana (Toronto, ON, Canada)

1085

  1. Top of page

Association of blepharospasm with parkinsonism, and essential tremor

M.A. Rana, A.Q. Rana (Toronto, ON, Canada)

1086

  1. Top of page

Pain correlates with patient global assessment of cervical dystonia severity

S.R. Eichenseer, C.L. Comella, G.T. Stebbins (Chicago, IL, USA)

1087

  1. Top of page

New systems for the assessment of visual temporal discrimination thresholds in dystonia

I. Killane, A. Malloy, K. Roberts, O. Kimmish, R. Whelan, S. O'Riordan, M. Hutchinson, R.B. Reilly (Dublin, Ireland)

1088

  1. Top of page

Efficacy of myectomy of the pretarsal and preseptal components of the orbicularis oculi and frontalis suspension for the treatment of blepharospasm resistant to botulinum toxin

R. Ribosa-Nogué, J. Pagonabarraga, M.Á. Arcediano, C. Villa, C. García-Sánchez, S. Martínez-Horta, R. Fernández de Bobadilla, A. Gironell, B. Pascual-Sedano, J. Kulisevsky (Barcelona, Spain)

1089

  1. Top of page

“Clubcutting” dystonic tremor – A novel occupational task-specific dystonia

K.A. Roberts, S.T. O'Dowd, K. O'Rourke, T. Lynch (Dublin, Ireland)

1090

  1. Top of page

Tremor dominant cervical dystonia is likely to be familial: Clinical characteristics of a large cohort

I. Rubio Agustí, I. Pareés, M. Kojovic, M.J. Edwards, K.P. Bhatia (London, United Kingdom)

1091

  1. Top of page

Internal globus pallidus stimulation and temporal discrimination thresholds in cervical dystonia – Preliminary data suggests that clinical improvement does not represent improved sensory function

A. Sadnicka, O. Kimmich, C. Pisarek, J. Galea, P. Kassavetis, T.A. Saifee, I. Pareés, T. Lampreira, L. Zrinzo, M. Hariz, J.C. Rothwell, K.P. Bhatia, P. Limousin, T. Foltynie, M. Hutchinson, M.J. Edwards (London, United Kingdom)

1092

  1. Top of page

Is synaptic plasticity normal in writer's cramp? Anodal cerebellar stimulation shows promising preliminary evidence that it can modulate PAS in dystonia

A. Sadnicka, M. Hamada, M. Kojovic, P. Kassavetis, I. Pareés, T.A. Saifee, K.P. Bhatia, J.C. Rothwell, M.J. Edwards (London, United Kingdom)

1093

  1. Top of page

Local complications of botulinum neurotoxin application in movement disorders

N. Cinar, S. Sahin, T.O. Onay, K. Batum, S. Karsidag (Istanbul, Turkey)

1094

  1. Top of page

Manual volumetry of the cerebellum and thalamus in primary cervical dystonia

M.C.A. Santos, C.C. Piccinin, L.G. Piovesana, L.S. Campos, A.C. Amato Filho, C.L. Yasuda, M.C. França, Jr., Í. Lopes-Cendes, F. Cendes, A. D'Abreu (São José dos Campos, Brazil)

1095

  1. Top of page

Effects of globus pallidus internus (GPi) DBS on quiet stance in primary multisegmental dystonia: Preliminary data

S. Sarubbo, M. Mancini, F. Latini, L. Chiari, M. Manca, G. Ferraresi, M. Sensi, M.A. Cavallo (Ferrara, Italy)

1096

  1. Top of page

Inter-hemispheric inhibition of wrist muscles is different in writer's cramp with and without mirror dystonia

V. Sattler, M. Dickler, M. Michaud, M. Simonetta Moreau (Toulouse, France)

1097

  1. Top of page

Impaired synaptic plasticity and cholinergic dysfunction in the striatum of a novel rat model of DYT1 dystonia

T. Schirinzi, G. Madeo, G. Martella, M. Maltese, O. Riess, K. Grundmann, A. Pisani (Rome, Italy)

1098

  1. Top of page

Challenges of making music: An environmental case-control study of musician's dystonia

A. Schmidt, H.C. Jabusch, E. Altenmüller, J. Möller, A. Göbel, M. Kasten, C. Klein (Lübeck, Germany)

1099

  1. Top of page

Botulinum toxin therapy in patients with oral anticoagulation: Hematoma frequency vs. other side effects

C. Schrader, P. Tacik, M. Ebke, D. Dressler (Hannover, Germany)

1100

  1. Top of page

Myofibrillar disorganization characterizes myopathy of camptocormia in Parkinson's disease

A. Wrede, N.G. Margraf, H.H. Goebel, G. Deuschl, W.J. Schulz-Schaeffer (Göttingen, Germany)

1101

  1. Top of page

Satisfaction with botulinum toxin treatment: A cross-sectional study of patients with cervical dystonia

K.D. Sethi, R. Rodriguez, B. Olayinka (Greensboro, NC, USA)

1102

  1. Top of page

Clinical characteristics of dystonia in patients with Wilson's disease; the frequency of extensor truncal dystonia

A.S. Shalash, T.Y. AbdelGhaffar, S.M. Elsayed (Cairo, Egypt)

1103

  1. Top of page

Association of rs1182 polymorphism in TOR1A with primary dystonia in Chinese population

W. Song, R. Huang, K. Chen, Y.P. Chen, B. Cao, Y. Yang, H. Shang (Chengdu, China)

1104

  1. Top of page

Association of the Val66Met polymorphism of BDNF with primary dystonia in Chinese population

Y.P. Chen, W. Song, R. Huang, K. Chen, J.P. Li, Y. Yang, H. Shang (Chengdu, China)

1105

  1. Top of page

IncobotulinumtoxinA (NT 201, XEOMIN®) administered at flexible intervals of 6-20 weeks in subjects with cervical dystonia

C. Singer, E. Pappert, A. Hanschmann, H. Fernandez (Miami, FL, USA)

1106

  1. Top of page

Cervical dystonia substantially impacts employment status, absenteeism, and presenteeism: Baseline results from Cervical Dystonia Patient Registry for the Observation of OnabotulinumtoxinA Efficacy (CD PROBE)

M. Stacy, L. Bloudek, M. Schwartz, M. Brin, S. Papapetropoulos (Durham, NC, USA)

1107

  1. Top of page

The prevalence of primary dystonia: A systematic review and meta analysis

T. Steeves, L. Day, N. Jette, T. Pringsheim (Toronto, ON, Canada)

1108

  1. Top of page

Cervical dystonias – Clinico-radiologic correlations and differentiation of torticaput and torticollis

A. Stenner, G. Reichel, A. Jahn (Zwickau, Germany)

1109

  1. Top of page

Patient experiences and awareness of the diagnosis and treatment of dystonia

N.P. Stover, E.R. Burns, T.E. Welty (Birmingham, AL, USA)

1110

  1. Top of page

A new mutant mouse with symptoms of dystonia

K.J. Sweadner, Y.B. Liu, L.J. Ozelius, A. Brashear (Boston, MA, USA)

1111

  1. Top of page

Dopa-responsive dystonia revisited: Diagnostic delay, residual signs, and non-motor signs

V. Tadic, K. Meike, N. Brüggemann, S. Stiller, J. Hagenah, C. Klein (Lübeck, Germany)

1112

  1. Top of page

Distribution of mutant torsinA in living cells

I. Toyoshima, E. Abe, S. Kamada (Yurihonjo, Japan)

1113

  1. Top of page

ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical & Health economics Outcomes Registry in Cervical Dystonia): A multicenter, observational study of dysport in cervical dystonia: Baseline data and cycle one outcomes data

R.M. Trosch, C.L. Comella, M.F. Lew, P.A. LeWitt, C. Singer, S. Russell, S. Chang, C.M. Clary, Y. Silay, C.M. Coleman, D. Marchese, J.P. Hubble (Southfield, MI, USA)

1114

  1. Top of page

ANCHOR-CD (AbobotulinumtoxinA Neurotoxin: Clinical & Health economics Outcomes Registry in Cervical Dystonia): A multicenter, observational study of dysport in cervical dystonia: Patient demographic, history, and health economics data

R.M. Trosch, C.L. Comella, M.F. Lew, P.A. LeWitt, C. Singer, D. Marchese, S. Russell, S. Chang, C.M. Clary, Y. Silay, C.M. Coleman, J.P. Hubble (Southfield, MI, USA)

1115

  1. Top of page

XCiDaBLE: A phase 4, observational, prospective trial evaluating incobotulinumtoxinA for cervical dystonia (CD) or blepharospasm in the United States – Preliminary baseline results for patients with CD

D. Truong, F. Danisi, K. Sethi, A. Verma, E.J. Pappert, H.H. Fernandez (Fountain Valley, CA, USA)

1116

  1. Top of page

Withdrawn by Author

 

1117

  1. Top of page

Withdrawn by Author

 

1118

  1. Top of page

Cerebellar cTBS repairs eyeblink conditioning in primary cervical dystonia

B.S. Hoffland, P. Kassavetis, M. Bologna, J.T.H. Teo, K.P. Bhatia, J.C. Rothwell, M.J. Edwards, B.P.C. van de Warrenburg (nijmegen, Netherlands)

1119

  1. Top of page

Dystonia in FMR1 premutation carriers

C.L. Vaughan, B. Ouyang, C.G. Goetz, E.M. Berry-Kravis, R.J. Hagerman, M.A. Leehey, D.A. Hall (Chicago, IL, USA)

1120

  1. Top of page

Botulinumneurotoxin A might improve dystonia secondary to complex regional pain syndromes (CRPS)

T. Vogt, D. Bunyatian, C. Geber, F. Birklein (Mainz, Germany)

1121

  1. Top of page

Identification of the genetic cause in the Australian family with spasmodic dysphonia (DYT4)

S. Winkler, A. Ramirez, J. Nahrstaedt, C. Hemmelmann, J. Groen, J. Hagenah, M.A.J. de Koning-Tijssen, A. Ziegler, R.A. Wilcox, C. Klein, K. Lohmann (Lübeck, Germany)

1122

  1. Top of page

THAP1 mutations and dystonia phenotypes: A metanalysis, genotype phenotype correlations and identification of novel mutations

G. Xiromerisiou, H. Houlden, N. Scarmeas, M. Stamelou, E. Kara, J. Hardy, A. Lees, P.L.V. Korlipara, P. Limousin, R. Paudel, G.M. Hadjigeorgiou, K. Bhatia (Larissa, Greece)

1123

  1. Top of page

A case of adult onset Sandifer syndrome

S. Yousuf, M.A. Rana, A.Q. Rana (Scarborough, Canada)

1124

  1. Top of page

Two novel mutations of GTP cyclohydrolase I gene and genotype-phenotype correlation in Chinese dopa-responsive dystonia patients

L. Yu, H. Zhou, F. Hu, Y. Xu (Chengdu, China)

1125

  1. Top of page

Functional and morphometric changes in the globus pallidus in writer's cramp

K.E. Zeuner, A. Knutzen, J. Götz, O. Granert, S. Wolff, D. Dressler, G. Deuschl, K. Witt (Kiel, Germany)

1126

  1. Top of page

Fatal paroxysmal non-kinesigenic dystonia

S. Zittel, C. Ganos, C. Gerloff, T. Bäumer, A. Münchau (Hamburg, Germany)

Parkinsonism (secondary and parkinsonism-plus)

1127

  1. Top of page

Influence of Middendorf breathing therapy on lung function, postural stability and well-being in patients with Parkinson's disease and Parkinson's-plus syndromes

C. Abright, G. Nübling, K. Pichler, S. Lorenzl (Munich, Germany)

1128

  1. Top of page

Diffusion tensor imaging contributes to differentiate Richardson's syndrome from progressive supranuclear palsy-parkinsonism

F. Agosta, M. Pievani, M. Svetel, M. Jecmenica Lukic, M. Copetti, A. Tomic, A. Scarale, G. Longoni, G. Comi, V. Kostic, M. Filippi (Milan, Italy)

1129

  1. Top of page

Psychogenic parkinsonism in a general neurology clinic

M. Alexeev, G. Pavlic, I. Moldovanu (Iasi, Romania)

1130

  1. Top of page

Prospective 1-year follow-up controlled study of DaTSCAN™ SPECT imaging in patients with clinically uncertain parkinsonian syndromes demonstrates changes in clinical management, diagnosis, and confidence of diagnosis

N. Bajaj, A. Kupsch, F. Weiland, A. Tartaglione, S. Klutmann, M. Buitendyk, P. Sherwin, A. Tate, I.D. Grachev (Derby, United Kingdom)

1131

  1. Top of page

Multiple system atrophy presenting like corticobasal syndrome at onset

A. Batla, M. Stamelou, K.P. Bhatia (London, United Kingdom)

1132

  1. Top of page

Clinical features and 123I-FP-CIT SPECT imaging in vascular parkinsonism and Parkinson's disease

S. Benítez-Rivero, V.A. Marín-Oyaga, D. García-Solís, I. Huertas-Fernández, F.J. García-Gómez, S. Jesús-Maestre, M.T. Cáceres-Redondo, F. Carrillo, M. Carballo, P. Mir (Seville, Spain)

1133

  1. Top of page

Burden of care among caregivers in Indian patients with Parkinson's disease

K.B. Bhattacharyya, D. Sanyal, P. Bose, A. Misra, S. Das (Kolkata, India)

1134

  1. Top of page

The impact of non-motor symptoms of Parkinson's disease on the quality of life in Indian patients

K.B. Bhattacharyya, D. Sanyal, P. Bose, A. Mishra, S. Das (Kolkata, India)

1135

  1. Top of page

Isolated backward gait disturbances as an early sign of progressive supranuclear palsy. Case report

M. Boczarska-Jedynak, D. Stompel, B. Jasinska-Myga, M. Flak, B. Czechowicz, G. Opala (Katowice, Poland)

1136

  1. Top of page

Voluntary, spontaneous and reflex blinking in multiple system atrophy

M. Bologna, L. Marsili, N. Kahn, A. Khandker Parvez, N. Modugno, C. Colosimo, G. Fabbrini, A. Berardelli (Roma, Italy)

1137

  1. Top of page

Quantitative gait analysis in parkin disease

A. Castagna, S. Frittoli, F. Del Sorbo, A. Elia, B. Reggiori, A. Albanese (Milan, Italy)

1138

  1. Top of page

Pure parkinsonism in chorea-acanthocytosis: Postmortem evidence for a striato-pallidal process without involvement of the substantia nigra pars compacta

B.S. Connolly, L.N. Hazrati, A.E. Lang (Toronto, ON, Canada)

1139

  1. Top of page

PSP-Richardson's syndrome (PSP-RS) phenotypes with severe eyelid retraction, foot dystonia, sialorrhea and cervicalgia due to retrocollis treated with botulinum toxin type A. Report of two cases

M. do D.L. da Costa, F.B.S. Caldas, L.M.C. Sarmento, A.X. Moreira, L.V. Gomes Segundo, S.G. Laurentino, J.M. Diniz, A.L.T. Bezerra, R.L. Peixoto, D.A. Paz, D.A. Paz, E.R. Barbosa (João Pessoa, Brazil)

1140

  1. Top of page

Parkinsonism in a cohort of patients with mitochondrial disorders

J. Domingos, J. Damásio, R. Taipa, C. Ramos, C. Correia, J. Barros, D. Quelhas, L. Vilarinho, M.M. Pires, M. Magalhães (Porto, Portugal)

1141

  1. Top of page

Hemiparkinsonism secondary to a contralateral globus pallidus hemorrhagic lesion

J. Domingos, B. Moreira, M. Magalhães (Porto, Portugal)

1142

  1. Top of page

Livedo reticularis in a patient with multiple system atrophy: Case report

J.R. Dutra, L.F.R. Vasconcellos, C.Q. Cunha (Ipanema, Brazil)

1143

  1. Top of page

Early onset depression, parkinsonism and cerebellar atrophy associated with heterozygous mutation of PLA2G6 gene

A.E. Elia, F. Del Sorbo, P. Soliveri, L.M. Romito, B. Garavaglia, A. Albanese (Milan, Italy)

1144

  1. Top of page

Multiple system atrophy (MSA-C) and anti-CV2 antibodies: A case of paraneoplastic association?

A. Eustathios, G. Xiromerisiou, T. Theoharis, M. Krommyda, T. Dimitrios, T. Athanasios, T. Iakovos (Thessaloniki, Greece)

1145

  1. Top of page

Bone mineral density and grip strength in a cohort of older Parkinson's disease patients attending a regional geriatric medicine clinic in North West Ireland

M.S. Farid, J. Doherty, M. Ahmed, S. Cowley, M. Ryan, P. Hickey (Sligo, Ireland)

1146

  1. Top of page

Next-generation sequence analysis of the ALS/parkinsonism-dementia complex of Guam

M.J. Farrer, C. Vilarino-Guell, P. McGeer, H. Morris, T. Siddique, J. Steel (Vancouver, BC, Canada)

1147

  1. Top of page

Familial corticobasal syndrome associated with basal ganglia hypointensities

R. Fekete, J.F. Baizabal Carvallo, A. Rivera, S. Powell, W.G. Ondo (Valhalla, NY, USA)

1148

  1. Top of page

The responsiveness to levodopa and dopamine transporter metabolism of vascular parkinsonism

X. Li, T. Feng, R. Zhang, Q. Ouyang (Beijing, China)

1149

  1. Top of page

DBS of the pedunculopontine nucleus in movement disorders with axial symptoms: Analyses of posture, gait, and local field potentials

I. Galazky, C. Kluge, T. Zähle, H.J. Heinze, J. Voges (Magdeburg, Germany)

1150

  1. Top of page

Extremely long lasting progressive supranuclear palsy: A case report

I. Gastón, P.M. Quesada, C. Caballero, L. Torné, F. García-Bragado, T. Tuñón, I. Marañón (Pamplona, Spain)

1151

  1. Top of page

A randomized, double-blind, placebo-controlled clinical trial of rifampicin in multiple system atrophy

S. Gilman, P.A. Low, D. Robertson, I. Bioggioni, R. Freeman, H. Kaufmann, S. Perlman, R.A. Hauser, W.P. Cheshire, S.L. Lessig, S. Vernino (Ann Arbor, MI, USA)

1152

  1. Top of page

Brainstem and spinal reflex studies in patients with progressive supranuclear palsy and primary progressive freezing gait

M. Kiziltan, A. Gunduz, G. Kiziltan, A. Tekeoglu, M. Sohtaoglu (Istanbul, Turkey)

1153

  1. Top of page

Diffuse Lewy body disease pathology in a patient with features of corticobasal syndrome and progressive supranuclear palsy syndrome

A. Haug, P. Boyer, B. Kluger (Aurora, CO, USA)

1154

  1. Top of page

Etiologies of parkinsonism in a large autopsy cohort

J. Horvath, P.R. Burkhard, C. Bouras, E. Kövari (Geneva, Switzerland)

1155

  1. Top of page

Transcranial sonography in pantothenate kinase-associated neurodegeneration

M. Jecmenica Lukic, M. Svetel, M. Mijajlovic, A. Pavlovic, D. Kozic, V.S. Kostic (Belgrade, Serbia)

1156

  1. Top of page

Clinical profile of parkinsonism: Study from a tertiary care referral centre

D. Joshi, A.Z. Ansari, V.N. Mishra, R.N. Chaurasia, B. Kumar (Varanasi, India)

1157

  1. Top of page

Two cases of adult onset neurodegeneration with brain iron accumulation (NBIA)

O. Dogu, H. Kaleagasi, N. Oksuz, Z. Demirtas (Mersin, Turkey)

1158

  1. Top of page

Clinical and imaging characteristics of dementia in MSA: Amyloid imaging and cortical thickness analysis

H.J. Kim, B. Jeon, J.Y. Kim, Y.E. Kim, J.Y. Yun (Seoul, Korea)

1159

  1. Top of page

Impairment of cerebral auto-regulation in multiple system atrophy and Parkinson's disease

M.J. Kim, S. Yoo, S.R. Kim, S.J. Chung (Seoul, Korea)

1160

  1. Top of page

Characterization of movement disorder phenomenology in genetically or pathologically proven frontotemporal lobar degeneration: A systematic review of the literature

B.B. Shah, M. Masellis, D. Harmic, D. Fisman, G. Kleiner-Fisman (Toronto, ON, Canada)

1161

  1. Top of page

Depression and cognitive deficits in multiple system atrophy: An analysis of the EMSA-SG natural history study cohort

F. Krismer, S. Dürr, F. Geser, K. Seppi, S. Bösch, W. Poewe, G.K. Wenning, on behalf of EMSA-SG (Innsbruck, Austria)

1162

  1. Top of page

Clinical factors related to the size of carotid arterial plaque in patients with vascular parkinsonism

J.H. Lee, S.J. Shin, H.J. Hong, H.S. You (Goyang-si, Korea)

1163

  1. Top of page

Potential contribution of cognitive testing in the diagnosis of parkinsonian disorders

W. Lee, D.R. Williams, E. Storey (Melbourne, Australia)

1164

  1. Top of page

Characterising the uncommon corticobasal syndrome presentation of sporadic Creutzfeldt-Jakob disease

W. Lee, M. Simpson, H. Ling, C. Mclean, S. Collins, D.R. Williams (Melbourne, Australia)

1165

  1. Top of page

Clinicopathological study of progressive supranuclear palsy presenting with corticobasal syndrome

H. Ling, R. de Silva, R. Courtney, L. Massey, N. Bajaj, J. Lowe, J. Holton, A. Lees, T. Revesz (London, United Kingdom)

1166

  1. Top of page

Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease

H. Ling, L. Massey, A. Lees, P. Brown, B. Day (London, United Kingdom)

1167

  1. Top of page

Symptoms of depression and anxiety: A population-based cohort to study Parkinson's disease

A. Lorwin, J. Graf, J. Vollstedt, J. Hagenah, V. Tadic, N. Brüggemann, S. Tunc, J. Hampf, L. Piskol, C. Klein, M. Kasten (Lübeck, Germany)

1168

  1. Top of page

Alien limb syndrome with dramatic response to risperidone treatment

C.C. Luca, V. Velez-Aldahondo, F.B. Nahab (Miami, FL, USA)

1169

  1. Top of page

Novel method for quantification of 3R- and 4R- tau isoforms in the cerebrospinal fluid of patients with atypical parkinsonian syndromes

N.K. Magdalinou, C. Luk, Y. Compta, M.J. Marti, A.J. Lees, R. de Silva (London, United Kingdom)

1170

  1. Top of page

Cerebrospinal fluid biomarkers in Alzheimer's disease, Parkinson's disease and atypical parkinsonism

G. Mandic Stojmenovic, I. Markovic, T. Stojkovic, I. Despotovic, M. Jecmenica Lukic, E. Stefanova, V. Kostic (Belgrade, Serbia)

1171

  1. Top of page

Two cases of young onset Parkinson's disease with unusual genetics

M. Narasimhan, L.H.A. Strens, A.J. Lindahl (Coventry, United Kingdom)

1172

  1. Top of page

CSF total-tau and phospho-tau levels are low in pallidopontonigral degeneration (PPND)

S.T. O'Dowd, P. Johansson, H. Zetterberg, T. Lynch, D.M. Walsh (Dublin, Ireland)

1173

  1. Top of page

Impulsive suicidality as a presenting feature of progressive supranuclear palsy

S.T. O'Dowd, K.A. Roberts, P. Crowley, T. Lynch (Dublin, Ireland)

1174

  1. Top of page

Clinical analysis of parkinsonism with slit ventricles in shunted hydrocephalus secondary to aqueduct stenosis

S. Okawa, H. Iwakawa, Y. Sanpei, M. Sugawara, T. Endo, H. Ohnishi (Akita, Japan)

1175

  1. Top of page

Vertical saccades in progressive supranuclear palsy (PSP): Small or slow?

S. Oravivattanakul, D.E. Riley, A.L. Chen, R.J. Leigh (Cleveland, OH, USA)

1176

  1. Top of page

Maintaining glottic opening in multiple system atrophy: Efficacy of serotonergic therapy

T. Ozawa, K. Sekiya, Y. Sekine, T. Shimohata, M. Tomita, H. Nakayama, N. Aizawa, R. Takeuchi, T. Tokutake, S. Katada, M. Nishizawa (Niigata, Japan)

1177

  1. Top of page

Delayed onset of parkinsonism after industrial toxic gases intoxication

M.Y. Park, D.H. Kim, H.J. Park (Daegu, Korea)

1178

  1. Top of page

The use of basal ganglia drugs as palliative therapy for secondary parkinsonism in malignant CNS tumor patients: A University of Florida experience

E.M. Dunbar, Z. Peng Chen, M.S. Okun (Gainesville, FL, USA)

1179

  1. Top of page

Exposure of multiple system atrophy (MSA) patients with or without orthostatic hypotension (OH) to potentially hypotensive drugs

S. Perez-Lloret, M.V. Rey, A. Pavy-Le Traon, W. Meissner, F. Ory-Magne, C. Brefel-Courbon, N. Fabre, F. Tison, O. Rascol (Toulouse, France)

1180

  1. Top of page

Value of “hot cross bun sign” in multiple system atrophy-C (MSA-C)

T.T. Pham, M. Siddiqui, I. Haq (Winston Salem, NC, USA)

1181

  1. Top of page

Grip force control in Parkinson's disease and atypical forms of parkinsonism

K.A. Neely, P.J. Planetta, J. Prodoehl, D.M. Corcos, C.L. Comella, C.G. Goetz, K.L. Shannon, D.E. Vaillancourt (Gainesville, FL, USA)

1182

  1. Top of page

A randomized, placebo-controlled clinical trial to assess the effects of rasagiline in patients with multiple system atrophy of the parkinsonian subtype

W. Poewe, P. Barone, N. Gliadi, S. Gilman, P.A. Low, C. Sampaio, K. Seppi, G.K. Wenning, For the Rasagiline-for-MSA Investigators (Innsbruck, Austria)

1183

  1. Top of page

Donepezil and selegiline to improve balance control in a case of progressive supranuclear palsy

J. McDonald, P. Corbeil, E. Pourcher (Quebec City, QC, Canada)

1184

  1. Top of page

Evaluation of supranuclear palsy rating scale in patients with progressive supranuclear palsy

N.K. Rai, V. Goyal, N. Kumar, G. Shukla, A.K. Srivastava, M. Behari (Faridabad, India)

1185

  1. Top of page

Evaluation of unified multiple system atrophy rating scale (UMSARS) in Indian MSA patients

N.K. Rai, V. Goyal, N. Kumar, G. Shukla, A.K. Srivastava, M. Behari (Faridabad, India)

1186

  1. Top of page

Accuracy of the NINDS-SPSP and the NNIPPS diagnostic criteria for the clinical diagnosis of progressive supranuclear palsy

G. Respondek, S. Roeber, C. Gaig, C. Troakes, J. Van Swieten, W.H. Oertel, G.U. Hoeglinger (Munich, Germany)

1187

  1. Top of page

Eyelid opening apraxia in multiple systems atrophy

K.A. Roberts, S.T. O'Dowd, B. Magennis, T. Lynch (Dublin, Ireland)

1188

  1. Top of page

Atypical parkinsonism in Cerebrotendinous Xanthomatosis (CTX): A family with corticobasal syndrome (CBS)

I. Rubio Agustí, M. Kojovic, M.J. Edwards, E. Murphy, R. Lachmann, K.P. Bhatia (London, United Kingdom)

1189

  1. Top of page

Validation of the French version of the multiple system atrophy health-related quality of life scale (MSA-QoL)

M. Wassilios, D. Sandrine, A. Foubert-Samier, R. Debs, A. Gerdelat Mas, V. Cochen De Cock, A.. Schrag, O. Rascol, T. François, A. Pavy-Le Traon (Bordeaux, France)

1190

  1. Top of page

Incidence and distribution of atypical parkinsonism in Olmsted County Minnesota, 1991 – 2005

R. Savica, B.R. Grossardt, J.H. Bower, W.A. Rocca (Rochester, MN, USA)

1191

  1. Top of page

Progressive supranuclear palsy – Cortico basal degeneration syndrome: A diagnostic challenge

G.J. Schmidt, E.D. Prezzi, V.H.R. Marussi, L.F.R. Vasconcellos (Rio de Janeiro, Brazil)

1192

  1. Top of page

Gait and balance dysfunction in progressive supranuclear palsy. Why do patients with PSP fall?

B.M. Schoneburg, M. Mancini, F.B. Horak, J.G. Nutt (Portland, OR, USA)

1193

  1. Top of page

Update on ephedrone induced parkinsonism with dystonia: Four year follow up

Y. Sanotsky, M. Selikhova, L. Fedorishin, Y. Matvienko, I. Komnatska, H. Grey, E. Tripoliti, A.J. Lees (London, United Kingdom)

1194

  1. Top of page

Malignant vascular parkinsonism

D.R. Shprecher, L.E. Schrock (Salt Lake City, UT, USA)

1195

  1. Top of page

Saccadometry in Parkinson's disease and multiple system atrophy

J. Sienkiewicz (Warsaw, Poland)

1196

  1. Top of page

Parkinsonism post scuba-diving

O. Sitburana (Bangkok, Thailand)

1197

  1. Top of page

Abnormalities of voice quality in progressive supranuclear palsy (PSP)

S. Skodda, W. Grönheit, U. Schlegel (Bochum, Germany)

1198

  1. Top of page

Various phenotypes of parkinsonism in patients with CADASIL

S.K. Song, J.S. Lee, J.C. Choi, J.H. Kang (Jeju, Korea)

1199

  1. Top of page

CD4+ and CD8+ T lymphocytes in Parkinson's disease and multiple system atrophy

C.H. Stevens, S. Lewis, G.M. Halliday (Sydney, Australia)

1200

  1. Top of page

Parkinsonism in hereditary diffuse leukoencephalopathy with axonal spheroids due to CSF1R gene mutation

C. Sundal, J. Van Gerpen, A. Nicholson, M. Baker, C. Wider, E. Shuster, J. Aasly, S. Spina, B. Ghetti, S. Roeber, A. Tselis, R. Swerdlow, B. Miller, S. Fujioka, R. Uitti, O. Ross, R. Rademakers, K. Josephs, D. Dickson, Z. Wszolek (Jacksonville, FL, USA)

1201

  1. Top of page

Impaired primary motor cortex LTP/LTD-like plasticity in multiple system atrophy

A. Suppa, L. Marsili, F. Di Stasio, A. Latorre, A. Khandker Parvez, C. Colosimo, G. Fabbrini, A. Berardelli (Rome, Italy)

1202

  1. Top of page

Gait analysis of patients with freezing of gait with and without parkinsonism

T. Tanahashi, T. Teramura, N. Yoshida, T. Yamamoto, Y. Suzuki, T. Nomura, T. Endo, H. Fujimura, H. Mochizuki, S. Sakoda (Suita, Japan)

1203

  1. Top of page

Multiple mitochondrial deletions and levodopa-responsive parkinsonism: A clinicopathological report

M.A. Thenganatt, R.N. Alcalay, J.P.G. Vonsattel, M. Hirano, G.M. McKhann, II, P.E. Greene (New York, NY, USA)

1204

  1. Top of page

Region-specific alterations of matrix metalloproteinase activity in multiple system atrophy

F. Tison, A. Monvoisin, W.G. Meissner, P.O. Fernagut (Bordeaux, France)

1205

  1. Top of page

Secondary parkinsonism following toxic ingestion of methanol

L. Torres, L. Apaza-Nina, C. Cosentino (Lima, Peru)

1206

  1. Top of page

Clinical characteristics in Malian patients with progressive supranuclear palsy. Preliminary observations

M. Traore, T. Coulibaly, M. Karambe, A. Sissoko, T. Coulibaly, C.O. Guinto, A.K. Traore, K. Dembele, B. Maiga, L. Cisse, H.J. Assogba, S. Traore (Bamako, Mali)

1207

  1. Top of page

Clinicopathological correlates in a PRNP P102L mutation carrier with a rapidly progressing parkinsonism and dystonia

C.C. Umeh, P. Kalakoti, M.K. Greenberg, P. Gambetti, B. Ghetti, Z. Mari (Baltimore, MD, USA)

1208

  1. Top of page

Richardson's syndrome presenting as atypical MSA: Clinico-pathologic case report

M. Vaštík, K. Farníková, L. Tucková, R. Matej, P. Kanovský (Olomouc, Czech Republic)

1209

  1. Top of page

Clinical characteristics of multiple system atrophy in our region

V. Vuletic (Zagreb, Croatia)

1210

  1. Top of page

Mood and sleep disorders among Nigerians with Parkinson's disease (PD): A 3 month interim report

U.E. Williams, E.E. Philip-Ephraim, S.K. Oparah (Calabar, Nigeria)

1211

  1. Top of page

Long-term outcome in patients with manganese-induced parkinsonism associated with ephedrone abuse

Y. Winter, J. Bezdolnij, W.H. Oertel, E. Gusev, E. Katunina (Marburg, Germany)

1212

  1. Top of page

Interhemispheric inhibition in different phenotypes of progressive supranuclear palsy

M. Wittstock, I. Pohley, U. Walter, A. Grossmann, R. Benecke, A. Wolters (Rostock, Germany)

1213

  1. Top of page

Mutations in the colony stimulating factor 1 receptor (CSF1R) cause hereditary diffuse leukoencephalopathy with spheroids

R. Rademakers, M. Baker, A. Nicholson, N. Rutherford, N. Finch, A. Soto-Ortolaza, C. Wider, A. Wojtas, M. DeJesus-Hernandez, N. Kouri, C. Sundal, E.A. Shuster, J. Aasly, J. MacKenzie, S. Roeber, H. Kretzschmar, B. Boeve, D. Knopman, R. Petersen, N.J. Cairns, B. Ghetti, S. Spina, A. Tselis, R. Uitti, P. Das, J. Van Gerpen, J.F. Meschia, S. Levy, D. Broderick, N. Graff-Radford, O.A. Ross, B.B. Miller, R.H. Swerdlow, D.W. Dickson, Z. Wszolek (Jacksonville, FL, USA)

1214

  1. Top of page

Atypical parkinsonian syndromes and fracture risk – Are patients adequately managed?

A.J. Yarnall, G.W. Duncan, T.K. Khoo, D.J. Burn (Newcastle-upon-Tyne, United Kingdom)

Restless legs syndrome

1215

  1. Top of page

Comparison of pregabalin, pramipexole and placebo effects on symptoms, limb movements and sleep maintenance in restless legs syndrome (Willis-Ekbom disease)

R.P. Allen, P.M. Becker, J. Patrick, S. Dubrava, D. Garcia-Borreguero, A. Lankford, C. Chen, L. Knapp, J. Miceli (Baltimore, MD, USA)

1216

  1. Top of page

Effectiveness and safety of rotigotine transdermal patch in restless legs syndrome: Results from a German observational study in a practice setting

C.G. Bachmann, R. Berkels, E. Schollmayer, F. Grieger, T. Lauterbach, K. Stiasny-Kolster (Göttingen, Germany)

1217

  1. Top of page

Effects of transcutaneous spinal direct current stimulation (tsDCS) in patients with idiopathic restless legs syndrome (RLS): A pilot study

A.C. Heide, M.A. Nitsche, T. Winkler, P. Walter, C.G. Bachmann (Göettingen, Germany)

1218

  1. Top of page

Restless legs syndrome in Parkinson's disease is associated with fatigue and insomnia but not daytime sleepiness: Study of 329 cases

J.A. Boot, P. Reddy, A. Douiri, S.J. Robinson, A. Rizos, A. Martin, P. Martinez-Martin, K. Ray Chaudhuri (London, United Kingdom)

1219

  1. Top of page

Impaired cortical plasticity of long-term depression after theta burst stimulation in restless legs syndrome

R.S. Chen, S.C. Lai, W.L. Chung, C.S. Lu, Y.H. Weng, Y.Z. Huang (Taipei, Taiwan)

1220

  1. Top of page

Severe restless legs syndrome and therapy with implantable infusion pump – A report of six cases

O.H. Franz, J. Haan (Moenchengladbach, Germany)

1221

  1. Top of page

Low haemoglobin is a risk factor for restless legs syndrome in pregnant women

M. Minar, H. Habanova, I. Rusnak, P. Valkovic (Bratislava, Slovakia (Slovak Republic))

1222

  1. Top of page

A comparative study of idiopathic and secondary restless legs syndrome in pregnancy

S. Miri, M. Vahdat, E. Sariri, M. Rohani, A. Sabet (Tehran, Iran)

1223

  1. Top of page

Restless legs syndrome during pregnancy: Clinical characteristics and outcomes in Iranian pregnant women

S. Miri, M. Vahdat, E. Sariri, M. Rohani, A. Sabet (Tehran, Iran)

1224

  1. Top of page

Predictors of placebo response in restless legs syndrome studies

W.G. Ondo, M. Hossain, M.F. Gordon, J. Reese (Houston, TX, USA)

1225

  1. Top of page

Globus pallidus deep brain stimulation for refractory idiopathic restless legs syndrome

W.G. Ondo, J. Jankovic, J. Jimenez-Shahed (Houston, TX, USA)

1226

  1. Top of page

Severity of restless legs syndrome is inversely correlated with echogenicity of the substantia nigra in different neurodegenerative movement disorders. A preliminary observation

J.L. Pedroso, E. Bor-Seng-Shu, P. Braga-Neto, A.C. Felicio, L.A. Dutra, H.B. Ferraz, M.J. Teixeira, G.F. do Prado, O.G. Barsottini (São Paulo, Brazil)

1227

  1. Top of page

A rare variant near a potassium channel-related gene in familial restless legs syndrome

I. Pichler, C. Schwienbacher, A. Zanon, C. Fuchsberger, A. Serafin, F. Marroni, M.F. Facheris, C. Tellgren-Roth, U. Gyllensten, J.F. Gusella, A.A. Hicks, P.P. Pramstaller (Bolzano, Italy)

1228

  1. Top of page

Restless legs syndrome outside the blood-brain barrier – Evidence from domperidone

S. Rios Romenets, Y. Dauvilliers, V. Cochen De Cock, B. Carlander, S. Bayard, C. Galatas, C. Wolfson, R. Postuma (Montreal, QC, Canada)

Tremor

1229

  1. Top of page

If there is a cognition impairment in essential tremor?

S. Badarny, G. Sinnof, W. Nassar, S. Honigman (Haifa, Israel)

1230

  1. Top of page

48, XXYY syndrome associated action tremor

H. Lote, P.G. Bain (London, United Kingdom)

1231

  1. Top of page

Comparative study of the clinical profile of community-based and hospital-based essential tremor in Lagos, Nigeria

I.A. Bankole, O.O. Ojo, N.U. Okubadejo, M.A. Danesi (Lagos, Nigeria)

1232

  1. Top of page

Psychogenic movement disorders in older people – Clinical profile and associated features

A. Batla, M. Stamelou, M.J. Edwards, I. Pareés, T.A. Saifee, K.P. Bhatia (London, United Kingdom)

1233

  1. Top of page

Modulation of orthostatic tremor during gait

C. Blahak, M.E. Wolf, H. Bäzner, H.H. Capelle, J.K. Krauss, M.G. Hennerici (Mannheim, Germany)

1234

  1. Top of page

Objective comparison of the effects of levodopa and propranolol on the Parkinson's tremor response to muscle loading

P.B. Tawadros, D. Cordato, I. Cathers, J.A. Burne (Lidcombe, Australia)

1235

  1. Top of page

Identifying different pathological tremor characteristics with a smart phone

B. Carignan, J.F. Daneault, C.E. Codere, A.F. Sadikot, C. Duval (Terrebonne, QC, Canada)

1236

  1. Top of page

Quantitative analysis of posttraumatic tremor following zona incerta stimulation

A. Castagna, M. Rabuffetti, L. Romito, A. Franzini, A. Albanese, A. Montesano, F. Maurizio (Milan, Italy)

1237

  1. Top of page

Tremor severity is a poor predictor of social disability in patients with essential tremor

P.W. Cullinane, P.J. Browne, T.K. Leahy, E.M. McGovern, T.J. Counihan (Galway, Ireland)

1238

  1. Top of page

Subtypes of tremor seen in Parkinson's disease: Effect of medication and deep brain stimulation on their behavior

J.F. Daneault, B. Carignan, C. Duval, A.F. Sadikot (Brossard, QC, Canada)

1239

  1. Top of page

Long term history of orthostatic tremor: A review of 50 patients

F. Di Biasio, S.L. Pullman, J.C. Cortés, Q.P. Yu, C. Hess, S. Fahn (Rome, Italy)

1240

  1. Top of page

Psychiatric manifestations in patients with essential tremor

N. Dragasevic, N. Kresojevic, A. Tomic, D. Pesic, M. Svetel, V.S. Kostic (Belgrade, Serbia)

1241

  1. Top of page

Reliability of The Essential Tremor Rating Assessment Scale (TETRAS)

R. Elble, P. LeWitt, K. Lyons, W. Ondo, R. Pahwa, K. Sethi, N. Stover, D. Tarsy, C. Testa, R. Tintner, T. Zesiewicz (Springfield, IL, USA)

1242

  1. Top of page

Accelerometric study of the effect of limb cooling on tremor in essential tremor patients

V. Evidente, J. Hentz, A. Duffy (Scottsdale, AZ, USA)

1243

  1. Top of page

Essential tremor and tremor associated with dystonia are two distinct clinical entities by tactile and proprioceptive temporal dicrimination tests

A. Fasano, T. Bovi, A. Di Matteo, A. Fiaschi, F. Bove, M. Fiorio, A. Berardelli, M. Tinazzi (Verona, Italy)

1244

  1. Top of page

Effects of zonisamide in essential tremor. Open-treatment trial

M. Mata, E. García-Cobos, S. Al Hussayni, P.E. Bermejo, J.J. López-Lozano (Majadahonda, Spain)

1245

  1. Top of page

Parkinson's disease in essential tremor patients: Causal or casual?

R. Garcia Ramos, E. Lopez, O. Rodriguez, C. Valencia, M.J. Catalán, J. Matías-Guiu (Madrid, Spain)

1246

  1. Top of page

Voice tremor in idiopathic Parkinson's disease (PD) and its relationship to disease variables

P. Gillivan-Murphy, N. Miller, P. Carding, T. Lynch (Dublin, Ireland)

1247

  1. Top of page

Comparison of EMG activity during stable and unstable standing and sitting in patients with primary orthostatic tremor and controls

A.D. Ha, S. Chen, N. Mahant, V.S.C. Fung (Westmead, Australia)

1248

  1. Top of page

Case report: Shunt responsive tremor due to normal pressure hydrocephalus

A.T. Hill, M.W. Cowey, W. Lee, D.R. Williams (Melbourne, Australia)

1249

  1. Top of page

LINGO1 and risk for essential tremor: Results of a meta-analysis of rs9652490 and rs11856808 polymorphisms

F.J. Jiménez-Jiménez, E. García-Martín, O. Lorenzo-Betancor, P. Pastor, H. Alonso-Navarro, J.A.G. Agúndez (Arganda del Rey, Spain)

1250

  1. Top of page

Impaired hearing in essential tremor

E. Eken, H. Kaleagasi, M. Unal, S. Bayram, E. Louis, O. Dogu (Mersin, Turkey)

1251

  1. Top of page

Micturition disturbances in essential tremor

S. Bayram, H. Kaleagasi, M. Bozlu, E. Eken, E. Louis, O. Dogu (Mersin, Turkey)

1252

  1. Top of page

Treatment of proximal upper limb tremor with botulinum toxin therapy

S.D. Kim, C. Yiannikas, N. Mahant, V.S.C. Fung (Sydney, Australia)

1253

  1. Top of page

Tremor and Klinefelter's syndrome

M. Koegl-Wallner, P. Katschnig, S. Seiler, B. Melisch, M. Trummer, R. Schmidt, P. Schwingenschuh (Graz, Austria)

1254

  1. Top of page

Phonatory instability in Parkinson's disease and essential voice tremor

K. Konstantopoulos, P. Stathis (Nicosia, Cyprus)

1255

  1. Top of page

The impact of various cognitive tasks on the activity of subthalamic nuclei and upper limb tremor

N. Kovács, I. Hernádi, G. Deli, E. Bosnyák, F. Nagy, I. Balás, J. Janszky (Pécs, Hungary)

1256

  1. Top of page

Autophagic dysfunction in essential tremor: A postmortem, case-control study

S.H. Kuo, G. Tang, K. Ma, R. Babij, J.P.G. Vonsattel, P.L. Faust, D. Sulzer, E.D. Louis (New York, NY, USA)

1257

  1. Top of page

Clinical profile of patients with tremor in a Moroccan population

L. Lachhab, W. Regragui, K. Rasmouni, E.H. Ait Ben Haddou, A. benomar, M. Yahyaoui (Rabat, Morocco)

1258

  1. Top of page

Severe tremors in a factory worker with melanoma: An unusual case of non-paraneoplastic anti-VGKC limbic encephalitis

T.T. Lim, I. Itin, S. Hantus, H.H. Fernandez (Cleveland, OH, USA)

1259

  1. Top of page

The results of thalamic DBS for the treatment of essential tremor; the Walton Centre experience

P. Milburn-McNulty, P. Eldrige, J. Osman-Farah, N. Fletcher, M. Steiger, L. Westmoreland, P. Moore, S. Alusi (Liverpool, United Kingdom)

1260

  1. Top of page

Unusual presentation of a dystonic tremor – A video case report

C. Ossig, M. Wolz, H. Reichmann, A. Storch (Dresden, Germany)

1261

  1. Top of page

Great improvement of essential tremor after subdural hematoma neurosurgery

E. Palazón-García, A.B. Perona Moratalla, S. García Muñozguren, F. Hernández Fernández, I. Díaz Maroto, E. Fernández (Albacete, Spain)

1262

  1. Top of page

A 3D gyroscope better suited than a 3D accelerometer for measuring tremor

S. Pallavaram, F. Phibbs, P. Hedera, C. Tolleson, W. Rodriguez, P.F. D'Haese, B.M. Dawant, T.L. Davis (Nashville, TN, USA)

1263

  1. Top of page

Tremor clusters in the VIM associated with essential tremor and Parkinson's disease

D.J. Pedrosa, C. Reck, M. Maarouf, L. Wojtecki, A.M. Pauls, V. Sturm, A. Schnitzler, G.R. Fink, L. Timmermann (Cologne, Germany)

1264

  1. Top of page

A meta-analysis on the effect of topiramate in essential tremor

L.A. Penaserada, C.C.E. Diesta (Makati, Philippines)

1265

  1. Top of page

Unilateral thalamic deep brain stimulation in essential tremor: Long term ipsilateral effects

Z. Peng Chen, M.S. Okun, C. Favilla, T. Morishita, K.D. Foote, A. Wagle Shukla (Gainesville, FL, USA)

1266

  1. Top of page

Mild cognitive impairment in essential tremor

M. Petrova, M. Raycheva, Y. Zhelev, O. Grigorova, L. Traykov (Sofia, Bulgaria)

1267

  1. Top of page

Corticomuscular coherence in asymptomatic first degree relatives of patients with essential tremor

J. Raethjen, A. Kostka, M. Muthuraman, M. Nahrwohld, D. Lorenz, G. Deuschl (Kiel, Germany)

1268

  1. Top of page

Relationship of resting tremor and action tremor in Parkinson's disease

A.Q. Rana, I. Siddiqui, M.A. Rana (Toronto, ON, Canada)

1269

  1. Top of page

Cognitive motor interference during dual-task gait in essential tremor

A.K. Rao, J. Uddin, A. Gillman, E.D. Louis (New York, NY, USA)

1270

  1. Top of page

Clonazepam-responsive essential palatal tremor after sinus surgery – Peripherally triggered central oscillation?

A.G. Shaikh, D.E. Riley, S.A. Gunzler (Cleveland, OH, USA)

1271

  1. Top of page

Deep brain stimulation in a man with Fragile X tremor ataxia syndrome

K.A. Roberts, S.T. O'Dowd, B. Magennis, C. Goggin, T. Lynch (Dublin, Ireland)

1272

  1. Top of page

Disorders of balance and gait in essential tremor are associated with midline tremor and age

M. Hoskovcova, O. Ulmanova, O. Sprdlik, J. Novakova, T. Sieger, R. Jech, E. Ruzicka (Prague, Czech Republic)

1273

  1. Top of page

Clinical features of parkinsonism with tremor associated with scans without evidence of dopaminergic deficit (SWEDDs)

A. Sacko, V. Moullart, C. Duru, P.E. Merle, O. Godefroy, P. Krystkowiak (Bobigny, France)

1274

  1. Top of page

Diagnosis of psychogenic tremor using a smartphone

T.A. Saifee, P. Kassavetis, L. Drougkas, G. Roussos, I. Pareés, P. Schwingenschuh, P. Katschnig, K.P. Bhatia, J.C. Rothwell, M.J. Edwards (London, United Kingdom)

1275

  1. Top of page

Hereditary spastic paraplegia, thin corpus callosum and tremor

S.A. Schneider, C.J. Mummery, M. Mehrabian, H. Houlden, P.G. Bain (Lubeck, Germany)

1276

  1. Top of page

Subjective alcohol response does not distinguish between tremor disorders

P. Schwingenschuh, M. Koegl-Wallner, S. Seiler, C. Ghadery, T. Pendl, K. Wenzel, R. Schmidt, P. Katschnig (Graz, Austria)

1277

  1. Top of page

Patients with rest-tremor and scans with ipsilateral dopaminergic deficit: (SWIDD)

M. Stamelou, M. Aguirregomozcorta, A. Antonini, P. Schwingenschuh, L. Prulovich, J.C. Dickson, M.J. Edwards, K.P. Bhatia (London, United Kingdom)

1278

  1. Top of page

Isolated palatal tremor: Reappraisal suggests psychogenic aetiology in majority of one case series

M. Stamelou, T. Saifee, M. Edwards, K. Bhatia (London, United Kingdom)

1279

  1. Top of page

Case report: The syndrome of painless moving fingers and toes

M. Symmonds, S. Omer, M.H. Marion (London, United Kingdom)

1280

  1. Top of page

Intraoperative smile in a multiple sclerosis patient with medication-refractory tremor

A.J. Thompson, M. Pastrana, Z. Peng, I. Haq, M.S. Okun (Gainesville, FL, USA)

1281

  1. Top of page

Parkinson's disease with and without anteceding essential tremor: Similar phenotypes

I. Wurster, K. Brockmann, A. Abaza, D. Berg (Tübingen, Germany)

Neuropharmacology

1282

  1. Top of page

Levodopa and motor learning in Parkinson's disease (PD): Initial results

E.D. Anderson, E. Murdock, F. Horak, J.G. Nutt (Portland, OR, USA)

1283

  1. Top of page

Flu-like and systemic symptoms following treatment with botulinum toxins: Prevalence and correlations

J.F. Baizabal Carvallo, J. Jankovic (Houston, TX, USA)

1284

  1. Top of page

Analysis of efficacy in patients with symptomatic neurogenic orthostatic hypotension treated with droxidopa and dopa-decarboxylase inhibitors

I. Biaggioni, P. Low, G. Rowse, H. Kaufmann (Nashville, TN, USA)

1285

  1. Top of page

Rasagiline prevents neurodegeneration in thiamine deficient rats – A longitudinal MRI and 1H-NMR study

V. Dror, M. Rehavi, I.E. Biton, S. Eliash (Tel Aviv, Israel)

1286

  1. Top of page

Rituximab in stiff person syndrome

P.J. Garcia-Ruiz, J. del Val, A. Herranz, S. Bellido, M.A. Aranda (Madrid, Spain)

1287

  1. Top of page

Impact of treatment with droxidopa in repeat fallers with Parkinson's disease and symptomatic neurogenic orthostatic hypotension (NOH 306A)

R.A. Hauser, W. Schwieterman, S. Isaacson (Tampa, FL, USA)

1288

  1. Top of page

Amantadine: Adverse cutaneous side-effects, a prospective follow-up study

A. Herranz, J. del Val, P.J. García-Ruiz (Madrid, Spain)

1289

  1. Top of page

Modelling Parkinson's disease by direct intranigral administration of lipopolysaccaharide

D. Hoban, E. Connaughton, C. Connaughton, G. Hogan, C. Thornton, E. Dowd (Galway, Ireland)

1290

  1. Top of page

A review of the preclinical literature for the potent and selective A2A receptor antagonist preladenant

R.A. Hodgson, E.M. Parker (West Point, PA, USA)

1291

  1. Top of page

Durability of effect with long-term, open-label droxidopa treatment in patients with symptomatic neurogenic orthostatic hypotension (NOH 303)

S. Isaacson, H. Shill, S. Vernino, C. Cioffi, R. Hutchman (Boca Raton, FL, USA)

1292

  1. Top of page

Mobile phone radiation does not induce oxidative stress in the rat brain

N. Kumar, P. Kumar, V.P. Sharma, R.A. Khan, M.Y. Khan (Lucknow, India)

1293

  1. Top of page

17-beta-estradiol: A therapeutic potential drug for Parkinson's disease

P. Kumar, R.K. Kale, S.M. Cowsik, N.Z. Baquer (New Delhi, India)

1294

  1. Top of page

Analysis of efficacy and safety outcomes in patients treated with droxidopa in combination with other drug classes

P. LeWitt, S. Gorny (West Bloomfield, MI, USA)

1295

  1. Top of page

Safety and efficacy of droxidopa in patients previously treated with midodrine

P. Low, J. Nelson, M. Stacy (Rochester, MN, USA)

1296

  1. Top of page

Integrated efficacy analysis of droxidopa in 2 double-blind, placebo-controlled phase 3 studies in patients with neurogenic orthostatic hypotension

C. Mathias, P. Low, R. Freeman, A. Hewitt, H. Kaufmann (London, United Kingdom)

1297

  1. Top of page

Serotonin syndrome: Three case reports and pathological findings

E. Mulroy, M. Farrell, T. Lynch (Dublin, Ireland)

1298

  1. Top of page

Too much and too many: Polypharmacy and mega-dosing among Nigerian psychiatric in-patients

A. Ogunwale (Abeokuta, Nigeria)

1299

  1. Top of page

Medication use in patients with multiple system atrophy (MSA) or Parkinson's disease (PD) compared to a group of patients consulting a general practitioner (GP)

S. Perez-Lloret, M.V. Rey, A. Pavy-Le Traon, W. Meissner, F. Ory-Magne, C. Brefel-Courbon, L. Ratti, N. Fabre, F. Tison, O. Rascol (Toulouse, France)

1300

  1. Top of page

Medication use in the patients of the French multiple system atrophy (MSA) reference center

M.V. Rey, S. Perez-Lloret, A. Pavy-Le Traon, W. Meissner, F. Ory-Magne, C. Brefel-Courbon, L. Ratti, N. Fabre, F. Tison, O. Rascol (Toulouse, France)

1301

  1. Top of page

Retrospective study of dose ratio of botulinum toxin a and abobotulinumtoxinA for treatment of patients with hemifacial spasm in actual practice

S. Setthawatcharawanich, P. Chongphattararot, M. Vittayakittipong, J. Taensiri (Hatyai, Thailand)

1302

  1. Top of page

A multicenter, open-label study to assess the long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension (NOH 304)

H. Shill, S. Vernino, R. Hutchman, L. Adkins, S. Isaacson (Sun City, AZ, USA)

1303

  1. Top of page

Pridopidine increases glutamatergic neuron firing in the frontal cortex

B. Gronier, N. Waters, H. Ponten, D. Klamer, S. Waters, J. Tedroff (Gothenburg, Sweden)

1304

  1. Top of page

Neuroprotective effects of liposomal-formulated curcumin [lipocurc], putative HDAC (histone deacetylase) modulator in modifying the phenotype of Park7 -knockout (Park 7- KO) rat paradigm of Parkinson's disease

K. Terpstra, S. Chiu, Y. Bureau, H. Jinuicn, M.D. Mulk, H. Rabeba, L. Helson (London, ON, Canada)

1305

  1. Top of page

Subgroup efficacy analysis: Orthostatic hypotension questionnaire composite score in patients with neurogenic orthostatic hypotension treated with droxidopa

G. Wenning, P. Low, C. Szakacs, H. Kaufmann (Innsbruck, Austria)

Drug-induced Movement Disorders

1306

  1. Top of page

A survey of tardive dyskinesia among institutionalised Nigerian patients with schizophrenia

A.O. Adelufosi, B. Fadipe (Abeokuta, Nigeria)

1307

  1. Top of page

Methcathinone (ephedrone) and manganese both reduce D2-receptor function: An animal SPECT study

A. Asser, M. Raki, J. Juurmaa, V. Krispin, M. Muldmaa, H. Rätsep, S. Põldsepp, P. Männistö, S. Kõks, K. Bergström, P. Taba (Tartu, Estonia)

1308

  1. Top of page

Olanzepine induced jaw dystonia and dysphagia – Is it a focal form of secondary paroxysmal kinesigenic dyskinesia (PKD)?

S. Bhattacharjee, A. Dutta, M. Tiwari, H. Kumar (Kolkata, India)

1309

  1. Top of page

Ephedrone encephalopathy: Correlation between clinical course and hyperintensivity of the basal ganglia on the T1-weighted MRI images

L. Chinchaladze, I. Khatiashvili, N. Lobjanidze, N. Akiashvili, T. Maisuradze, M. Megrelishvili, M. Janelidze (Tbilisi, Georgia)

1310

  1. Top of page

Contribution of decreased serotonin release to the therapeutic effects of deep brain stimulation in a rodent model of tardive dyskinesia

M.C. Creed, P.J. Fletcher, C. Hamani, J.N. Nobrega (Toronto, ON, Canada)

1311

  1. Top of page

Subacutely progressive dystonia during trastuzumab treatment in breast cancer: A case report

S. Dellapasqua, F. Del Sorbo, A. Albanese, M. Colleoni (Milan, Italy)

1312

  1. Top of page

Inpatient movement disorders: Beware of the drugs!

M. Guillan, A. Alonso-Canovas, J. Garcia-Caldentey, I. Hernandez-Medrano, A. DeFelipe, J.C. Martinez-Castrillo, I. Corral (Madrid, Spain)

1313

  1. Top of page

Comparison of non-motor symptoms between drug induced parkinsonism and idiopathic Parkinson's disease

J.S. Kim, J.W. Cho, J. Youn, H. Shin (Seoul, Korea)

1314

  1. Top of page

Is 6 months of neuroleptic withdrawal sufficient to distinguish drug-induced parkinsonism from Parkinson's disease?

T.T. Lim, H. Fernandez (Cleveland, OH, USA)

1315

  1. Top of page

The efficacy of alpha lipoic acid in treatment of movement disorders induced by manganese

N. Lobjanidze, N. Akiashvili, M. Megrelishvili, T. Maisuradze, M. Kapianizde, I. Khatiashvili, L. Chinchaladze (Tbilisi, Georgia)

1316

  1. Top of page

Capturing choreatic dyskinesias over levodopa dose cycle in Parkinson's disease

T. Mera, M. Burack, F. Bonsignore, J. Giuffrida (Valley View, OH, USA)

1317

  1. Top of page

Levodopa-induced dyskinesias are accompanied by changes in corticostriatal and thalamostriatal synapses

G.E. Meredith, Y. Zhang, N. Elias-Gonzales, D.J. Rademacher, K. Steece-Collier (North Chicago, IL, USA)

1318

  1. Top of page

Acute phenytoin-induced dyskinesia

Y. Nuñez, W. De la Cruz, S. Rafael, C. Cosentino, L. Torres (Lima, Peru)

1319

  1. Top of page

Parkinsonism followed by dystonia in a pediatric case of midbrain tumor treatred by chemotherapy and radiotherapy: An unusual presentation

M.T. Pham, G. Bernard, S. Chouinard (Montréal, QC, Canada)

1320

  1. Top of page

Prevalence and risk factors for the development of dyskinesia among Filipino patients with Parkinson's disease: A 7 year retrospective study

L.L. Shiong Shu, R.D.G. Jamora (Manila, Philippines)

1321

  1. Top of page

New abnormal movements and MRI findings associated with metroniadazole (MTZ)-induced encephalopathy (MIE), a case series

V.R. Suski, I.M. Zaydan, C. Streib (Pittsburgh, PA, USA)

1322

  1. Top of page

Case report: Acute dystonic reaction in a healthy toddler following accidental methylphenidate ingestion

J.L. Waugh (Boston, MA, USA)

1323

  1. Top of page

Dyskinesia in Jewish-Ashkenazi Parkinson's disease patients: Effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation

G. Yahalom, N. Kaplan, A. Vituri, O.S. Cohen, R. Inzelberg, E. Kozlova, A.D. Korczyn, S. Rosset, E. Friedman, S. Hassin-Baer (Tel Hashomer, Israel)

Tics/Stereotypies

1324

  1. Top of page

Stereotypy after cerebellar infarction

D. Lee, T.B. Ahn (Seoul, Korea)

1325

  1. Top of page

What makes you tic? An experimental study of Tourette-like responding in healthy individuals

M.A. van den Hout, D.J.V. Beetsma, I.M. Engelhard, M.M. Rijkeboer, D.C. Cath (Utrecht, Netherlands)

1326

  1. Top of page

Limbic and motor circuits involved in symmetry behavior in Tourette syndrome

F.E. de Vries, O.A. van den Heuvel, D.C. Cath, H.J. Groenewegen, A.J. van Balkom, R. Boellaard, A.A. Lammertsma, D.J. Veltman (Utrecht, Netherlands)

1327

  1. Top of page

Painful/-less legs with moving toes: Unilateral or bilateral involvement

M.H. Chang (Taichung, Taiwan)

1328

  1. Top of page

A de novo case of tourettism caused by citalopram in an adult patient

M.A. Ferreira, N. Galvez (Weston, FL, USA)

1329

  1. Top of page

Tic inhibition and premonitory urges are not correlated in Gilles de la Tourette syndrome

C. Ganos, U. Kahl, O. Schunke, S. Kühn, P. Haggard, C. Gerloff, V. Roessner, G. Thomalla, A. Münchau (Hamburg, Germany)

1330

  1. Top of page

Motor stereotypies in Fragile X syndrome

D. Hall, V. Kaytser, B. Ouyang, E. Berry-Kravis (Chicago, IL, USA)

1331

  1. Top of page

Gilles de la Tourette disorder and its relationship with OCD, ADHD and autism: A second order factor analysis

M. Huisman-vanDijk, D. Cath (Utrecht, Netherlands)

1332

  1. Top of page

Genetic polymorphism of BTBD9 gene in Polish patients with Gilles de la Tourette syndrome

P. Janik, M. Berdynski, A. Maruszak, A. Gogol, C. Zekanowski (Warsaw, Poland)

1333

  1. Top of page

Saccadic eye movements in Tourette syndrome

S.R. Finkelstein, R.A. Schuchard, G. Ross, J.L. Juncos (Atlanta, GA, USA)

1334

  1. Top of page

Olfactory deficits in Tourette syndrome

P. Belenghi, M. Kronenbuerger, T. Hummel, F. Schneider, J. Schulz, J. Ilgner, I. Neuner (Aachen, Germany)

1335

  1. Top of page

Diagnostic and prognostic issues in adolescents with psychogenic tics

D.G. Lichter, S.G. Finnegan (Buffalo, NY, USA)

1336

  1. Top of page

Acute catatonia during pregnancy secondary to anti NMDA-R encephalitis

A. Mc Carthy, J. Dineen, T. Lynch, K. O'Rourke (Dublin, Ireland)

1337

  1. Top of page

Paroxysmal movement disorders in multiple sclerosis – A case series

T. Mok, E. McManus, G. Crotty, A. Ryan, B. Sweeney, D. Costello (Cork, Ireland)

1338

  1. Top of page

Drugs related to Tourette-like syndrome: A case/non-case study in the French Pharmacovigilance database

S. Perez-Lloret, M.V. Rey, E. Bondon-Guitton, O. Rascol, J.L. Montastruc (Toulouse, France)

1339

  1. Top of page

Adult onset tic disorders – A case series

T.E. Knight, T. Pringsheim (Calgary, AB, Canada)

1340

  1. Top of page

Regional cerebral blood flow (rCBF) modified by deep brain stimulation (DBS) in patients with medically-refractory Tourette syndrome (TS)

C. Schmidt, F. Wilke, K.R. Müller-Vahl, C. Schrader, H.H. Capelle, L. Geworski, F.M. Bengel, J.K. Krauss, G. Berding (Hannover, Germany)

1341

  1. Top of page

Reduced GABA in the sensorimotor cortex (SMC) of patients with Tourette syndrome (TS) as measured by H-magnetic resonance spectroscopy (MRS)

S. Tinaz, J.W. van der Veen, B.A. Belluscio, K. Popli, M. Hallett, S. Horovitz (Bethesda, MD, USA)

Parkinson's disease: Dysautonomia

1342

  1. Top of page

Impact of progression of Parkinson's disease on nocturia

R. Akhtar, A.Q. Rana, M.A. Rana (Scarborough, Canada)

1343

  1. Top of page

Treatment of orthostatic hypotension in patients with idiopathic Parkinson's disease or atypical parkinsonism improves motor, balance, and cognitive function

D.E. Amariei, A.D. Hohler, D.I. Katz, T.J. DePiero, C.L. Hehl, A. Leonard, V. Allen, J. Dentino, M. Gardner, H. Phenix, M. Saint-Hilaire, T. Ellis (Boston, MA, USA)

1344

  1. Top of page

Changes in cardiovascular autonomic functions 1 year after bilateral STN- DBS in patients with idiopathic Parkinson's disease

R. Borgohain, Y.R. Arepareddy, S.R. Chalamalla, R.M. Kandadai, A. Jabeen, M.A. Kannikannan, P. Ankathi (Hyderabad, India)

1345

  1. Top of page

Stress induced-salivary alpha-amylase secretion decreases in patients with Parkinson's disease

K. Kawabe, H. Ito, K. Iwamoto, O. Kano, K. Ikeda, Y. Iwasaki (Tokyo, Japan)

1346

  1. Top of page

Parkinson's disease and lethal outdoor work

T. Kawakami, K. Fujimoto, I. Nakano (Shimotsuke-city, Japan)

1347

  1. Top of page

Comparison of lower urinary tract symptoms and urodynamic parameters between patients with Parkinson's disease and Parkinson-plus syndromes

E.S. Oh, J.M. Kim, Y.M. Joo, S.J. Jeong (Seongnam, Korea)

1348

  1. Top of page

Dysphagia in Parkinson's disease: Correlation with the cardinal symptoms of the disease

F. Loureiro, A. Dalbem, S. Trentin, I. Gomes (Porto Alegre, Brazil)

1349

  1. Top of page

Cardiovascular effects of deep brain stimulation of the subthalamic nucleus (DBS-STN) in Parkinson's disease (PD)

M. Mata, J. Toquero, J.J. Lopez Lozano (Majadahonda, Spain)

1350

  1. Top of page

Impaired cardiac response and its relationship with orthostatic hypotension in Parkinson's disease

T. Nakamura, T. Hara, Y. Mizutani, H. Watanabe, M. Hirayama, G. Sobue (Nagoya, Japan)

1351

  1. Top of page

Are we measuring postural blood pressure in our movement disorder clinics? A multicentre survey of current practice

T. Ong, R. Davies, C. Holden, I. Gunawardena (Nottingham, United Kingdom)

1352

  1. Top of page

Reduced cardiovascular risk factors and cardiovascular events in idiopathic Parkinson's disease (IPD) patients compared with controls

J.M. Rabey, G. Abruzzese, T. Prokhorov, U. Bonuccelli (Zerifin, Israel)

1353

  1. Top of page

Prevalence of autonomic dysfunctions in Parkinson's disease – No correlation with duration and motor characteristics

S.R. Schreglmann, M. Sommerauer, H. Vogel, G. Eisele, C.R. Baumann (Zurich, Switzerland)

1354

  1. Top of page

Ventilatory response to hypercapnia is impaired in mild Parkinson's disease

L.M. Seccombe, P.G. Rogers, M. Hayes, E.M. Veitch, M.J. Peters (Sydney, Australia)

1355

  1. Top of page

Can alpha-synuclein in the colon serve as a biomarker for premotor PD? Evidence from 3 cases

K.M. Shannon, A. Keshavarzian, H.B. Dodiya, S. Jakate, J.H. Kordower (Chicago, IL, USA)

1356

  1. Top of page

The frequency of autonomic failure symptoms in Parkinson's disease: Is initial presentation sympathetic or parasympathetic?

T. Stojkovic, S. DeLuka, T. Pekmezovic, M. Svetel, V.S. Kostic (Belgrade, Serbia)

1357

  1. Top of page

Mechanisms of urinary dysfunction in Parkinson's disease; participation in basal ganglia circuitry and sensory/emotional nervous systems

T. Uchiyama, T. Yamanishi, R. Sakakibara, M. Yoshiyama, Z. Liu, T. Yamamoto, C. Yamaguchi, M. Yamagisawa, Y. Higuchi, K. Hirata, S. Kuwabara (Tochigi, Japan)

Genetics

1358

  1. Top of page

Parkinson and Gaucher disease phenotype in patients with Gaucher/PD from Jerusalem, Israel

R.N. Alcalay, E. Ben Chetrit, B. Birmanns, G. Altarescu, M. Phillips, D. Elstein, A. Zimran (New York City, NY, USA)

1359

  1. Top of page

Intergenerational instability and genetic flow of the CAG repeat at the ATXN2 gene in Cuban families with spinocerebellar ataxia type 2

L.E. Almaguer-Mederos, Y. González-Zaldívar, D. Almaguer-Gotay, J.M. Laffita-Mesa, S. Mejías-Brito, D. Cuello-Almarales (Holguín, Cuba)

1360

  1. Top of page

Alpha-synuclein H50Q, a novel pathogenic mutation for Parkinson's disease

S. Appel-Cresswell, C. Vilarino-Guell, I. Yu, B. Shah, D. Weir, C. Thompson, J.A. Stoessl, M.J. Farrer (Vancouver, BC, Canada)

1361

  1. Top of page

Dystonia as a clinical feature of monosomy 18p

I. Beaulieu-Boire, S. Chouinard, P. Duquette, G. Bernard (Sherbrooke, QC, Canada)

1362

  1. Top of page

Withdrawn by Author

 

1363

  1. Top of page

Prrt2 gene mutations: From paroxysmal dyskinesia to episodic ataxia and hemiplegic migraine

A. Gardiner, K.P. Bhatia, M. Stameou, R.C. Dale, M. Kurian, S. Schneider, G.M. Wali, T. Counihan, S. Spacey, E.M. Valente, L. Silveira-Moriyama, H.A. Taive, S. Raskin, J.W. Sander, A. Lees, T. Warner, D. Kullman, N.W. Wood, M. Hanna, H. Houlden (London, United Kingdom)

1364

  1. Top of page

High throughput targeted re-sequencing in neurodegenerative diseases and movement disorders

S. Biskup, D. Boehm, H.J. Pander, M. Synofzik, L. Schöls, J. Prudlo, T. Gasser (Tuebingen, Germany)

1365

  1. Top of page

Cognitive function of asymptomatic first degree relatives of patients with Parkinson's disease who are carriers of severe GBA mutations – An fMRI study

N. Bregman, A. Mirelman, A. Thaler, E. Ash, K. Yasinovsky, T. Hendler, N. Giladi (Tel Aviv, Israel)

1366

  1. Top of page

GBA-associated PD: Neurodegeneration, altered membrane metabolism and lack of energy failure

K. Brockmann, R. Hilker, U. Pilatus, S. Baudrexel, K. Srulijes, J. Magerkurth, A.K. Hauser, C. Schulte, I. Csoti, C.D. Merten, T. Gasser, D. Berg, E. Hattingen (Tübingen, Germany)

1367

  1. Top of page

A novel genetic prediction score in myoclonus-dystonia

M. Carecchio, M. Magliozzi, M. Copetti, A. Ferraris, L. Bernardini, M. Bonetti, M.J. Edwards, I. Torrente, F. Pellegrini, C. Comi, K.P. Bhatia, E.M. Valente (Novara, Italy)

1368

  1. Top of page

Mutations in parkin and LRRK2 genes in two patients with schizophrenia

J.A. Carr, D. Niehaus, S. Bardien (Cape Town, South Africa)

1369

  1. Top of page

Association of apolipoprotein E polymorphisms and dopamine replacement therapy complications in Parkinson's disease

A. Cervantes-Arriaga, M. Rodríguez-Violante, E. Alonso Vilatela, P. Yescas, C. Poveda (Mexico City, Mexico)

1370

  1. Top of page

First stage association analysis of neuropatholically proven PD confirms MAPT as an independent risk factor for PD

G. Charlesworth, S. Gandhi, J.M. Bras, S.M. Gentleman, R. Guerreiro, J. Hardy, J.L. Holton, A. Lees, U.M. Sheerin, N.W. Wood, N.W. Wood (London, United Kingdom)

1371

  1. Top of page

Analysis of LINGO1 (rs9652490) polymorphism in essential tremor and sporadic Parkinson's disease in a Taiwanese population

P.Y. Chen, C.S. Lu, S.H. Yan, S.C. Lai, R.S. Chen, T.H. Yeh (Taipei, Taiwan)

1372

  1. Top of page

Genetic susceptibility loci, environmental exposures, and Parkinson's disease: A case-control study using interaction analysis

S.J. Chung, S.M. Armasu, K.J. Anderson, J.M. Biernacka, J.M. Cunningham, J.E. Ahlskog, R. Frigerio, D.M. Maraganore (Seoul, Korea)

1373

  1. Top of page

Molecular screening of dystonia genes in patients with SWEDDs: A new pathogenic mutation in the DYT11 gene

R. Cilia, A. Nasca, G. Marotta, C. Reale, C. Barzaghi, G. Sacilotto, G. Pezzoli, S. Goldwurm, B. Garavaglia (Milan, Italy)

1374

  1. Top of page

MAPT 347 G/C polymorphism modifies risk of a common LRRK2 variant for Parkinson's disease in Chinese

X. Dan, P. Chan, X. Feng (Beijing, China)

1375

  1. Top of page

Course & life expectancy of SPG11

S.T. de Bot, R.C. Burggraaff, J.C. Herkert, H.J. Schelhaas, B. Post, R.O. van Vliet, M.S. van der Knaap, E.J. Kamsteeg, H. Scheffer, B.P. van de Warrenburg, C.C. Verschuuren-Bemelmans, H.P.H. Kremer (Nijmegen, Netherlands)

1376

  1. Top of page

GTP cyclohydrolase 1-deficient dopa-responsive dystonia – First experience in mutation detection in Serbian patients

V. Dobricic, V. Brankovic, M. Jankovic, N. Kresojevic, A. Tomic, M. Jecmenica Lukic, N. Dragaševic, M. Svetel, I. Novakovic, V. Kostic (Belgrade, Serbia)

1377

  1. Top of page

A clinicopathological study of parkin-linked parkinsonism – A study of 5 cases and comparison with Parkinson's disease

K.M Doherty, L. Silveira-Moriyama, L. Parkkinen, D. Healy, M. Farrell, N.E. Mencacci, Z. Ahmed, F. Brett, J. Hardy, N. Quinn, T.T. Counihan, T. Lynch, T. Revesz, A.J. Lees, J.L. Holton (London, United Kingdom)

1378

  1. Top of page

Interesting case of Rett sydrome (RTT) in the daughter of a Filipino male with X-linked dystonia parkinsonism (XDP, DYT3)

L.V. Lee, R.D.G. Jamora, P.M.D. Pasco, A.R. Domingo, R. Borres, Y. Nomura, M. Segawa (Manila, Philippines)

1379

  1. Top of page

Parkin gene mutation with an autosomal dominant inheritance – A family case report

A. Drobnis, S.A. Scala, J.W. Zani, D. Apetauerova (Burlington, MA, USA)

1380

  1. Top of page

β-glucocerebrosidase gene haplotype analysis in Parkinson's disease

R. Duran, A. McNeill, J. Bras, A. Schapira, J. Hardy (London, United Kingdom)

1381

  1. Top of page

Role of variations in Mortalin in the development of early-onset Parkinson's disease

K. Freimann, V. Tadic, N. Brüggemann, J. Hagenah, K. Lohmann, C. Klein, A. Westenberger (Lübeck, Germany)

1382

  1. Top of page

Sequence alterations in the putative promoter of RAB7L1 reduce the risk for Parkinson's disease in Ashkenazi Jews

Z. Gan-Or, A. Bar-Shira, D. Dahary, A. Mirelman, M. Kedmi, T. Gurevich, N. Giladi, A. Orr-Urtreger (Tel Aviv, Israel)

1383

  1. Top of page

Mutations in PRKRA gene are a rare cause of genetic dystonia in Italy

B. Garavaglia, C. Barzaghi, V. Marras, A. Nasca, C. Reale, F. Zibordi, G. Zorzi, N. Nardocci (Milano, Italy)

1384

  1. Top of page

A novel TOR1A mutation in a patient with segmental dystonia

J. Graf, K. Lohmann, A. Ferbert, V. Kostic, E. Moro, A. Münchau, A.A. Kühn, E. Altenmüller, K. Zeuner, J. Hagenah, N. Brüggemann, C. Klein, A. Schmidt (Lübeck, Germany)

1385

  1. Top of page

Association of the adenosine receptor A2A (ADORA2A) gene with L-dopa induced dyskinesia in Parkinson's disease

L. Greenbaum, O.S. Cohen, R. Inzelberg, N. Kaplan, G. Yahalom, E. Kozlova, H. Strauss, B. Lerer, S. Hassin-Baer (Ramat Gan, Israel)

1386

  1. Top of page

Possible high frequency of G2019S LRRK2 mutation frequency among Ashkenazi Jews patients with multiple system atrophy parkinsonian type in Israel

T. Gurevich, L. Merkin, A. Orr-Urtreger, A. Bar Shira, E. Serafimova Atanasova, H. Shabtai, A. Ezra, J. Knaani, A. Hilel, A. Mirelman, N. Giladi (Tel Aviv, Israel)

1387

  1. Top of page

Genetic cause of X-linked dystonia-parkinsonism in a female patient

S. Heinitz, R. Rosales, L.V. Lee, R.D. Jamora, A.R. Ng, K. Freimann, K. Lohmann, U. Walter, I. Nagel, A. Rolfs, U. Gölnitz, G. Gillessen-Kaesbach, D. Dressler, C. Klein, A. Westenberger (Lübeck, Germany)

1388

  1. Top of page

Piloting targeted next-generation sequencing for screening the known ataxia genes: The next step for all diagnostic laboratories

J. Hersheson, A. Pittman, H. Houlden (London, United Kingdom)

1389

  1. Top of page

The role of SCARB2 as susceptibility factor in Parkinson's disease

F. Hopfner, E.C. Schulte, F. Knauf, B. Mollenhauer, P. Lichtner, A. Zimprich, B. Bereznai, M.J. Molnar, D. Haubenberger, W. Pirker, T. Brücke, A. Peters, C. Gieger, C. Trenkwalder, J. Winkelmann (Kiel, Germany)

1390

  1. Top of page

Correlation of CYP2D6 genotype with response to tetrabenazine

R. Mehanna, C. Hunter, A. Davidson, J. Jimenez-Shahed, W. Ondo, J. Jankovic (Houston, TX, USA)

1391

  1. Top of page

Genetic factor for Parkinson's disease among Pakistani population: A resemblance among all variants of patients worldwide

T. Hussain, A. Abid, Z. Jamal (Rawalpindi, Pakistan)

1392

  1. Top of page

Analysis of PITX3 gene in patients with multisystem atrophy, progressive supranuclear palsy and corticobasal degeneration

Z. Jamrozik, M. Berdynski, C. Zekanowski, A. Baranczyk-Kuzma, J. Slawek, M. Kuzma-Kozakiewicz (Warsaw, Poland)

1393

  1. Top of page

Glucocerebrosidase mutations L444P and N370S in Polish patients with early onset Parkinson's disease

A. Lugowska, A.E. Wisniewska, J. Slawek, P. Janik, A. Potulska-Chromik, D. Koziorowski, A. Friedman, M. Kuzma-Kozakiewicz, D. Hoffman-Zacharska, Z. Jamrozik (Warsaw, Poland)

1394

  1. Top of page

Wilson's disease – Results of selective approach in genetic testing

M. Jankovic, V. Dobricic, A. Tomic, N. Kresojevic, V. Ralic, M. Svetel, I. Novakovic, V. Kostic (Belgrade, Serbia)

1395

  1. Top of page

Microtubule-associated protein tau gene (MAPT1 rs1052553 is not associated with the risk for familial essential tremor

H. Alonso-Navarro, E. García-Martín, C. Martínez, J. Benito-León, O. Lorenzo-Betancor, P. Pastor, T. López-Alburquerque, L. Samaranch, E. Lorenzo, J.A.G. Agúndez, F.J. Jiménez-Jiménez (Arganda del Rey, Spain)

1396

  1. Top of page

Comprehensive genetic investigation of NBIA and complex dystonia-parkinsonism

E. Kara, G. Xiromerisiou, R. Paudel, T. Revesz, J. Holton, A. Lees, N. Wood, M.J. Edwards, P. Korlipara, T. Foltynie, K. Bhatia, J. Hardy, H. Houlden (London, United Kingdom)

1397

  1. Top of page

Genome-scale analysis of DNA methylation in Parkinson's disease patients' brains reveals hypomethylation of the cytochrome P450 2E1 gene

O. Kaut, I. Schmitt, U. Wüllner (Bonn, Germany)

1398

  1. Top of page

High COMT activity is associated with earlier age at onset in PD

S. Klebe, J.L. Golmard, R. Charfi, G. Kuhlenbäumer, C. Klein, J. Hagenah, T. Gasser, I. Wurster, S. Lesage, D. Lorenz, G. Deuschl, M. Saad, M. Martinez, F. Durif, P. Pollak, P. Damier, F. Tison, A. Dürr, P. Amouyel, J.C. Lambert, C. Tzourio, C. Maubaret, F. Charbonnier-Beaupel, K. Tahiri, M. Vidailhet, A. Brice, J.C. Corvol (Paris, France)

1399

  1. Top of page

Analysis of GWAS-linked GAK locus in ethnic Chinese

Y.H. Koh, W.L. Au, L.C. Tan, K.M. Prakash, E.K. Tan, Y. Zhao (Outram Road, Singapore)

1400

  1. Top of page

The SNCA gene two novel missense mutations in Parkinson's disease

D. Koziorowski, M. Jurek, J. Poznanski, D. Hoffman-Zacharska, A. Friedman (Warsaw, Poland)

1401

  1. Top of page

Two faces of the same coin: Benign familial infantile seizures and paroxysmal kinesigenic dyskinesia caused by PRRT2 mutations

K.R. Kumar, A. Schmidt, K. Redyk, A. Grunewald, M. Leben, A. Munchau, C.M. Sue, J. Hagenah, H. Hartmann, K. Lohmann, H.J. Christen, C. Klein (Luebeck, Germany)

1402

  1. Top of page

CAG analysis, haplotypes, unstable repeats, recombination, pedigrees, gene dosage, genotype-phenotype relationship and genetics polymorphisms in the SCA2 (ATXN2) locus

J.M. Laffita-Mesa, L.C. Velázquez-Pérez, Y. Vázquez Mojena, V. Kourí, A. Martínez, A. Miranda, L. Peña Serrano, D.A. Cuello Almarales, R. Aguilera Rodriguez, V. Berovides (Holguin, Cuba)

1403

  1. Top of page

Movement disorders in cerebrotendinous xanthomatosis (CTX)

O. Lagha-Boukbiza, C. Lecoq, C. Marcel, N. Collongues, C. Tranchant (Strasbourg, France)

1404

  1. Top of page

Novel PRRT2 mutations in a Taiwanese cohort with paroxysmal kinesigenic dyskinesia

S.C. Lai, C.S. Lu, R.S. Chen, H.S. Wang, W.Y. Lin, Y.H. Weng, H.C. Chang, T.H. Yeh (Taoyuang, Taiwan)

1405

  1. Top of page

Genetic investigation of Parkinson's disease in South Wales

C. Lunn, M. Willis, V. Newsway, M. Wickremaratchi, J. Pearson, Y. Ben-Shlomo, N. Williams, H.R. Morris (Cardiff, United Kingdom)

1406

  1. Top of page

Pure parkinsonism caused by ATXN2 mutation in a Chinese family

X. Lu, Z. Cen, J. Cao, Z. Ouyang, B. Wang, D. Ren, Z. Wang, B. Zhang, W. Luo (Hangzhou, China)

1407

  1. Top of page

PRRT2 mutations are a major cause of paroxysmal kinesigenic dyskinesia in the European population

A. Méneret, D. Grabli, C. Depienne, C. Gaudebout, F. Picard, A. Dürr, I. Lagroua, D. Bouteiller, M. Vidailhet, A. Brice, E. Roze (Paris, France)

1408

  1. Top of page

Dementia/parkinsonism and multiple sclerosis in a large Mennonite kindred

K. Markopoulou, M.L. Filipi, D.W. Dickson, Z.K. Wszolek, R. Rademakers, B.A. Chase (Glenview, IL, USA)

1409

  1. Top of page

Genetic analysis of paroxysmal dystonic choreoathetosis (PDC/PNKD); patient and hamster model study

H. Matsuo, S.E. Sander, M. Hamann, A. Richter, T. Hamada, A. Nakayama, Y. Utsumi, Y. Kawamura, H. Onoue, K. Kaida, Y. Kobayashi, K. Kamakura, N. Shinomiya (Tokorozawa, Japan)

1410

  1. Top of page

Is anything lying behind parkin heterozygous mutations?

N.E. Mencacci, R. Labrum, A. Haworth, M. Sweeney, A. Pittman, M. Stamelou, N.A. Fletcher, P. Jarman, K.P. Bhatia, H. Houlden, N.W. Wood, J. Hardy (London, United Kingdom)

1411

  1. Top of page

The G2019S mutation in the LRRK2 gene is associated with specific gait dynamics changes in patients with Parkinson's disease

A. Mirelman, T. Gurevich, A. Weiss, A. Bar-Shira, M. Zelis, S. Bressman, K. Marder, A. Orr-Urtreger, J.M. Hausdorff, N. Giladi, AJ LRRK2 Consortium (Tel Aviv, Israel)

1412

  1. Top of page

The prevalence of cancer in patients with Parkinson's disease who are carriers of the G2019S mutation in the LRRK2 gene

A. Mirelman, T. Gurevich, A. Thaler, K. Yasinovsky, Y. Doyev, L. Bar Gil, A. Bar Shira, A. Orr-Urtreger, N. Giladi (Tel Aviv, Israel)

1413

  1. Top of page

Homozygosity and copy number variant analysis in multiple system atrophy

K.Y. Mok, A. Sailer, L. Schottlaender, MSA Study Consortium (London, United Kingdom)

1414

  1. Top of page

Genome wide association study in cervical dystonia

K.Y. Mok, D. Kasperaviciute, S.A. Schneider, S.M. Pickering-Brown, M. Silverdale, M.J. Edwards, K.P. Bhatia, J. Hardy (London, United Kingdom)

1415

  1. Top of page

Reduced arm swing in ultrasound-based gait analysis is a subtle motor sign in heterozygous PINK1 mutation carriers

L. Nürnberger, S. Chen, J. Hagenah, S. Baudrexel, J. Roggendorf, R. Hilker, C. Klein (Frankfurt, Germany)

1416

  1. Top of page

Founder effect of PANK2 1583C>T (T528M) mutation in Serbian pantothenate kinase-associated neurodegeneration patients

M. Svetel, I. Novakovic, M. Hartig, V. Dobricic, C. Beaubois, M. Krajinovic, V. Kostic (Belgrade, Serbia)

1417

  1. Top of page

Is the brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism associated with impulsive-compulsive behaviours in Parkinson's disease?

S.S. O'Sullivan, P. Cheshire, A. Djamshidian, K. Bertram, D.R. Williams, A.J. Lees, T. Foltynie (Cork, Ireland)

1418

  1. Top of page

Contiguous gene deletions involving the SGCE gene: A clinical description

K.J. Peall, A.J. Waite, M.A. Kurian, M. Smith, H. Pall, T. Nestor, M.D. King, D.J. Blake, M.J. Owen, H.R. Morris (Cardiff, United Kingdom)

1419

  1. Top of page

Brain-derived neurotrophic factor (BDNF) polymorphisms and risk of Parkinson's disease

T. Peeraully, P. Kumar, Z. Yi, E.K. Tan (Singapore, Singapore)

1420

  1. Top of page

GWAS-linked GAK locus in Parkinson's disease in Han Chinese and meta-analysis

L. Li, X. Chang, X. Mao, J. Zhang, D. Zhao, R. Peng, E.K. Tan (Chengdu, China)

1421

  1. Top of page

Mosaicism of alpha-synuclein gene rearrangements: Report of 2 unrelated cases of early-onset parkinsonism

C. Perandones, J.C. Giugni, D.S. Calvo, G.B. Raina, L. De Jorge Lopez, V. Volpini, M. Radrizzani, I. Fernandez Mata, F.E. Micheli (Ciudad Autonoma de Buenos Aires, Argentina)

1422

  1. Top of page

PINK1-dependent mitophagy in dopaminergic neurons does not require LC3 conversion

A. Rakovic, K. Shurkewitsch, P. Seibler, D. Krainc, C. Klein (Lübeck, Germany)

1423

  1. Top of page

The broad phenotypic spectrum of Machado Joseph disease: Spastic paraparesis as a clinical presentation of SCA3

S.A. Rodríguez Quiroga, D. Gonzalez Morón, T. Arakaki, N.S. Garretto, M.A. Kauffman (Buenos Aires, Argentina)

1424

  1. Top of page

Whole-genome sequencing in familial Parkinson's disease

O.A. Ross, A.I. Soto-Ortolaza, S. Rayaprolu, A. Strongosky, D.W. Dickson, Z.K. Wszolek (Jacksonville, FL, USA)

1425

  1. Top of page

First genome-wide association study in multiple system atrophy

A. Sailer, on behalf of the MSA GWAS Consortium (London, United Kingdom)

1426

  1. Top of page

Knowledge of and interest in genetic information among Parkinson's disease patients and caregivers

K. Sakanaka, N.H. Chakiryan, G. Cabrera, M.L. Orbe Reilly, C.H. Waters, K.S. Marder, R.N. Alcalay (New York, NY, USA)

1427

  1. Top of page

Japanese 2nd GWAS identifies strong association at a novel risk locus and MCCC1 for Parkinson's disease

W. Satake, K. Yamamoto, Y. Ando, A. Takeda, H. Tomiyama, H. Kawakami, K. Hasegawa, F. Obata, M. Watanabe, A. Tamaoka, K. Nakashima, S. Sakoda, M. Yamamoto, N. Hattori, M. Murata, Y. Nakamura, T. Toda (Kobe, Japan)

1428

  1. Top of page

Exome sequencing in familial multiple system atrophy

L.V. Schottlaender, A. Sailer, A. Tucci, K. Mok, H. Ling, V. Plagnol, N. Quinn, J.L. Holton, T. Revesz, A.J. Lees, O. Kaut, I. Schmitt, N. Wood, U. Wüllner, S. Scholz, A.B. Singleton, J. Hardy, H. Houlden (London, United Kingdom)

1429

  1. Top of page

Linkage analysis and exome sequencing in autosomal dominant Parkinson's disease

C. Schulte, K. Brockmann, S. Biskup, S. Lesage, D. Berg, A. Brice, T. Gasser (Tuebingen, Germany)

1430

  1. Top of page

Characterization of PINK1 mutant iPS cell-derived dopaminergic neurons

P. Seibler, D. Krainc, A. Moser, H. Terlau, C. Klein (Lübeck, Germany)

1431

  1. Top of page

Multi-centered clinico-genetic analysis of VPS35 gene in Parkinson's disease

M. Sharma, J. Ioannidis, J. Aasly, M. Farrer, D.M. Maraganore, T. Gasser, R. Kruger (Tuebingen, Germany)

1432

  1. Top of page

Large-scale replication and heterogeneity in Parkinson's disease genetic loci

M. Sharma, J.P.A. Ioannidis, J.O. Aasly, M. Farrer, D.M. Maraganore, T. Gasser, R. Kruger (Tuebingen, Germany)

1433

  1. Top of page

PRRT2 gene mutations in a large family with paroxysmal kinesigenic dyskinesia and co-segregation with migraine with aura

U.M. Sheerin, M. Stamelou, G. Charlesworth, T. Shiner, S. Spacey, E.M. Valente, N.W. Wood, K. Bhatia (London, United Kingdom)

1434

  1. Top of page

Delta deletion in patients with idiopathic Parkinson's disease

A.N. Taravari, F. Mexhiti (Skopje, Macedonia, The Former Yugoslav Republic of)

1435

  1. Top of page

Targeted resequencing of the SNCA region in Parkinson's disease

L. Pihlstrøm, E. Dietrichs, M. Toft (Oslo, Norway)

1436

  1. Top of page

Mutation analysis for PLA2G6 in patients with Parkinson's disease/frontotemporal type of dementia

H. Tomiyama, H. Yoshino, K. Ogaki, L. Li, C. Yamashita, Y. Li, M. Funayama, R. Sasaki, Y. Kokubo, S. Kuzuhara, N. Hattori (Tokyo, Japan)

1437

  1. Top of page

Whole exome sequencing in progressive supranuclear palsy: Role of rare coding variation

A. Tucci, D. Hernandez, R. de Silva, V. Plagnol, J. Hardy, A. Singleton (London, United Kingdom)

1438

  1. Top of page

Genotype-phenotype correlations in spastic paraplegia type 7

K.L. van Gassen, C.D.C.C. van der Heijden, S. de Bot, E.J. Kamsteeg, L.H. van den Berg, C.C. Verschuuren-Bemelmans, J.H. Veldink, H. Scheffer, B.P.C. van de Warrenburg (Nijmegen, Netherlands)

1439

  1. Top of page

Evidence of EIF4G1 and EIF4F-complex variations involvement in Parkinson's disease

K. Nuytemans, G. Bademci, S. Zuchner, C. Jauregui, A. Dressen, D.D. Kinnamon, A. Mehta, Y. Pasco, A. Avarim, A. Diaz, L. Wang, F. Nahab, C. Singer, W. Hulme, I. Konidari, Y. Edwards, J. Haines, M. Davis, A. Cummings, G. Beecham, E. Martin, W.K. Scott, J.M. Vance (Miami, FL, USA)

1440

  1. Top of page

Investigation of essential tremor and Parkinson's disease in families

R. Hanna Al-Shaikh, S. Fujioka, A.J. Strongosky, O. Ross, Z. Wszolek (Jacksonville, FL, USA)

1441

  1. Top of page

Glucocerebrosidase L444P mutation confers genetic risk factor for Parkinson's disease in central China

Y. Wang, N. Xiong, C. Chen, J. Huang, T. Wang (Wuhan, China)

1442

  1. Top of page

MAPT rs242562 and GSK3β rs334558 are associated with Parkinson's disease in a central Chinese cohort

L. Yu, N. Xiong, J. Xiong, J. Huang, T. Wang (Wuhan, China)

1443

  1. Top of page

Identification of novel THAP1 sequence variants in patients with blepharospam

G. Xiromerisiou, E. Kara, H. Houlden, E. Tsironi, E. Dardiotis, M. Dardioti, G. Hadjigeorgiou (Larissa, Greece)

1444

  1. Top of page

The first trial of genetic diagnosis of DYT-1 and DYT-5 dystonia in Belarus

O.A. Yacuts, K.A. Mosse, S.A. Likhachev, I.V. Pleshko (Minsk, Belarus)

1445

  1. Top of page

Identification of C9orf72 hexanucleotide repeat expansion in a Taiwanese cohort with disorders of amyotrophic lateral sclerosis and frontotemporal dementia

T.H. Yeh, B. Traynor, Y.H. Weng, H.C. Kuo, S.C. Lai, C.L. Huang, C.S. Lu (Taipei, Taiwan)

Basic Science

1446

  1. Top of page

Running wheel prevents the development of L-DOPA-induced dyskinesias and abnormal striatal DARPP-32 signaling in 6-OHDA-hemiparkinsonian mice

A.S. Aguiar, Jr, A. Latini, R.D.S. Prediger (Florianópolis, Brazil)

1447

  1. Top of page

Inflammatory responses are attenuated in incidental Lewy body disease

R.S. Akhtar, J.M. Milber, J.V. Noorigian, L.R. White, H. Petrovitch, G.W. Ross, J.E. Duda (Philadelphia, PA, USA)

1448

  1. Top of page

Expression of synaptophysin and synaptotagmin-XI proteins in normally aging human substantia nigra pars compacta

P.A. Alladi, A. Mahadevan, S.K. Shankar, T.R. Raju (Bangalore, India)

1449

  1. Top of page

Identification of kinetic biomarkers in Parkinson's disease

M.J. Aminoff, C.W. Chadwick, P.Y.A. Wong, K.H. Husted, S. Liu, V. Liu, L. Kohlstaedt, J. Protasio, T. Riff, D. Boban, M. Killian, L. Epling, E. Sinclair, J. Peterson, R.W. Price, M.K. Hellerstein, P. Fanara (San Francisco, CA, USA)

1450

  1. Top of page

Statistical properties of the neuronal discharge along a surgical tract in the normal rat under chloral-hydrate anesthesia

D.S. Andres, H. Bocaccio, D. Cerquetti, M. Merello, R. Stoop (Zurich, Switzerland)

1451

  1. Top of page

Interhemispheric interactions in healthy professional musicians and non-musicians

T. Bäumer, J. Kroeger, M. Wolfram, R. Liebnau, A. Schmidt, C. Klein, A. Münchau (Hamburg, Germany)

1452

  1. Top of page

Acupuncture-induced dopaminergic neuron protection and motor function improvement mediated by phosphatidylinositol 3-kinase/Akt signaling pathway in the mice with MPTP-induced Parkinson's disease model

H. Bae, S.N. Kim, A.R. Doo, J.Y. Park, H.J. Park (Seoul, Korea)

1453

  1. Top of page

Assessing neural oscillatory activity in patients with Parkinson's disease

M. Brookes, M. Stephenson, D. Price, L. Martin, P. Gowland, S. Wharton, D. Auer, A. Blazejewska, S. Schwarz, N. Bajaj, P. Morris (Nottingham, United Kingdom)

1454

  1. Top of page

The Parkinson's disease protein DJ-1 binds metals and protects against metal induced cytotoxicity

B. Björkblom, J. Maple, M. Ökvist, D. Piston, X.M. Xu, C. Brede, J.P. Larsen, S.G. Møller (Stavanger, Norway)

1455

  1. Top of page

GDNF replacement augments motor impairments and nigrostriatal dopamine deficits in 12 month old mice with a partial deletion of GDNF

H.A. Boger, G.A. Gerhardt, A.C. Granholm, O.M. Littrell (Charleston, SC, USA)

1456

  1. Top of page

Loss of function of the Parkinson's disease-associated mitochondrial chaperone mortalin in cellular models translates into age-dependent phenotypes in the first in vivo mortalin knockdown model

L.F. Burbulla, D. Woitalla, O. Riess, R. Krüger (Tübingen, Germany)

1457

  1. Top of page

Increased level of IL-10 in cerebrospinal fluid of patients with Parkinson's disease

L.S. Campos, F. Pradella, F.V. Glehn, R.O.F. Paula, A.L.F. Longhini, G.A. Morais, D.S. Tsukada, L. Piovesana, A. Moraes, C.O.S. Farias, A.S. Farias, A. D'Abreu, L.M.B. Santos (Campinas, Brazil)

1458

  1. Top of page

Intracellular urate modulates vulnerability of dopaminergic neurons

S. Cipriani, C.A. Desjardins, T.C. Burdett, Y. Xu, K. Xu, M.A. Schwarzschild (Boston, MA, USA)

1459

  1. Top of page

Withdrawn by Author

 

1460

  1. Top of page

“What do these numbers mean?” Decoding assessment results from an interdisciplinary Parkinson's rehab team

J.M. Dean (Longmont, CO, USA)

1461

  1. Top of page

Neuroprotective effect of bee venom against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in neuroblastoma SH-SY5Y cells

A.R. Doo, S.N. Kim, S.T. Kim, J.Y. Park, S.H. Chung, B.Y. Choe, Y. Chae, H. Lee, C.S. Yin, H.J. Park (Seoul, Korea)

1462

  1. Top of page

MyD88 deficiency results in both cognitive and motor impairments in mice

J. Drouin-Ouellet, M. LeBel, M. Filali, F. Cicchetti (Quebec, QC, Canada)

1463

  1. Top of page

A potential role for mRNA surveillance in Parkinson's disease?

A. Henderson, D. Chow, H. Yin, T.G. Beach, T. Dunckley (Phoenix, AZ, USA)

1464

  1. Top of page

Parkin dysfunction results in defective depolarization-induced exocytosis and reorganization of cytoskeleton

H. Eguchi, M. Ohara-Imaizumi, K. Tsukaguchi, S. Sato, M. Funayama, S. Saiki, T. Hatano, S. Kubo, S. Nagamatsu, N. Hattori (Bunkyo, Japan)

1465

  1. Top of page

Investigation of the mechanisms of α-synuclein secretion in vivo

E. Emmanouilidou, T. Papasilekas, K. Gerozissis, P.C. Ioannou, K. Vekrellis (Athens, Greece)

1466

  1. Top of page

Influence of dual task and freezing of gait on obstacle crossing behaviour of patients with Parkinson's disease

F.P. Faria, Q. Almeida, J. Jones (Waterloo, ON, Canada)

1467

  1. Top of page

Astroglial activation induced by different forms of α-synuclein

L. Fellner, K. Schanda, M. Reindl, W. Poewe, G.K. Wenning, N. Stefanova (Innsbruck, Austria)

1468

  1. Top of page

Characterization of adult neurogenesis in a transgenic mouse model of multiple system atrophy

P. Fuchs, L. Aigner, W. Poewe, G.K. Wenning, N. Stefanova (Innsbruck, Austria)

1469

  1. Top of page

ATP13A2 mutations impair mitochondrial function in fibroblasts from patients with Kufor-Rakeb syndrome

A. Grünewald, B. Arns, P. Seibler, A. Rakovic, A. Münchau, A. Ramirez, C.M. Sue, C. Klein (Lübeck, Germany)

1470

  1. Top of page

Survival but not proliferation of neural precursor cells is reduced in the MPTP model of Parkinson's disease

T. Grimm, J.C.M. Schlachetzki, B. Winner, B. Ferger, J. Winkler (Erlangen, Germany)

1471

  1. Top of page

The impact of patient age on patterns of diagnosis and treatment among patients with Parkinson's disease

B. Grubb, M.J. Lage (Kansas City, MO, USA)

1472

  1. Top of page

The impact of patient sex on patterns of diagnosis and treatment among patients with Parkinson's disease

B. Grubb, M.J. Lage (Kansas City, MO, USA)

1473

  1. Top of page

The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein

T. Hasegawa, M. Konno, T. Baba, N. Sugeno, A. Kikuchi, E. Miura, A. Takeda (Sendai, Japan)

1474

  1. Top of page

DJ-1 associates with synaptic membranes

T. Hatano, Y. Usami, S. Kubo, S. Imai, S. Saiki, S. Sato, Y. Ohba, H. Ariga, J. Shen, N. Hattori (Tokyo, Japan)

1475

  1. Top of page

Effect of L-dopa treatment on heart sympathetic innervation in parkinsonian monkeys

J.E. Yuste, P. Almela, F. Ros-Bernal, C. Barcia, E. Fernández-Villalba, M. Milanés, V. Bautista-Hernández, M. Laorden, M.T. Herrero (Murcia, Spain)

1476

  1. Top of page

Mild dopaminergic lesions are accompanied by robust changes in subthalamic nucleus activity

M.L.F. Janssen, D.G.M. Zwartjes, S.K.H. Tan, R. Vlamings, A. Jahanshahi, T. Heida, G. Hoogland, H.W.M. Steinbusch, V. Visser-Vandewalle, Y. Temel (Maastricht, Netherlands)

1477

  1. Top of page

Behavioral and histological analysis of a partial double lesion model of MSA-P

C. Kaindlstorfer, J. Garcia, C. Winkler, A. Marsch, G.K. Wenning, G. Nikkhah, M. Döbrössy (Innsbruck, Austria)

1478

  1. Top of page

A rodent model for direct visualization of α-synuclein oligomers in the nigrostriatal system

L.V. Kalia, H. Dimant, S.K. Kalia, L.N. Kibuuka, D. Ebrahimi-Fakhari, N.R. McFarland, P.J. McLean (Toronto, ON, Canada)

1479

  1. Top of page

Towards a new monkey model of advanced Parkinson's disease

C. Karachi, D. Grabli, B. Hayat, M. Monfort, D. Tandé, E.C. Hirsch, C. François (Paris, France)

1480

  1. Top of page

Enteric and central nervous system pathology in a novel mouse model: Implications for pathogenesis in pre-motor Parkinson's disease

L.P. Kelly, P.M. Carvey, R.A.E. Bakay, J.H. Kordower (Chicago, IL, USA)

1481

  1. Top of page

Parkinson's disease mouse model and the acupuncture treatment: How does it improve motor function in an aspect of synaptic dopamine availability

S.N. Kim, A.R. Doo, J.Y. Park, Y. Chae, I. Shim, H. Lee, W. Moon, H. Lee, H.J. Park (Seoul, Korea)

1482

  1. Top of page

Dynamin GTPase activity decreases alpha-synuclein uptake in neuronal and oligodendroglial cells

M. Konno, T. Hasegawa, T. Baba, E. Miura, N. Sugeno, A. Kikuchi, M. Aoki, A. Takeda (Sendai, Japan)

1483

  1. Top of page

Withdrawn by Author

 

1484

  1. Top of page

Intact olfaction as hallmark feature of multiple system atrophy: Experimental evidence

F. Krismer, Y. Li, G.K. Wenning, N. Stefanova (Innsbruck, Austria)

1485

  1. Top of page

Withdrawn by Author

 

1486

  1. Top of page

Deep brain stimulation of the entopeduncular nucleus in rats prevents apomorphine-induced deficient sensorimotor gating

D.K. Posch, K. Schwabe, J.K. Krauss, G. Lütjens (Hannover, Germany)

1487

  1. Top of page

The contribution of the self PolyQ load [somatic mosaicism] in the CNS to the onset, disease duration and progression rate of SCA2 and phenotypic delineation

J.M. Laffita-Mesa, Y. Vázquez Mojena, D.A. Cuello Almarales, L.C. Velázquez-Pérez (Holguin, Cuba)

1488

  1. Top of page

Epigenetics and ataxin-2 locus

J.M. Laffita-Mesa, P. Bauer, V. Kourí, L. Peña Serrano, J. Roskams, D. Almaguer-Gotay, J. Aguiar Santiago, Y. González-Zaldívar, L.C. Velázquez-Pérez, J. Montes Brown (Holguin, Cuba)

1489

  1. Top of page

Treatment for patients diagnosed with Parkinson's disease: Differences based upon diagnosing physician

B. Grubb, M.J. Lage (Groton, CT, USA)

1490

  1. Top of page

High precision isotope measurements show poorer control of copper metabolism in parkinsonism

F. Larner, B. Sampson, M. Rehkamper, D.J. Weiss, J. Dainty, S. O'Riordan, T. Panetta, P.G. Bain (London, United Kingdom)

1491

  1. Top of page

Human α-synuclein activates transcription factor Nrf2 in microglia. Implications in the inflammatory processes of PD

I. Lastres-Becker, N.G. Innamorato, A. Cuadrado (Madrid, Spain)

1492

  1. Top of page

Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model

P.H. Lee, H.J. Park, J.Y. Shin (Seoul, Korea)

1493

  1. Top of page

Pathological alpha-synuclein oligomers: Induction in vitro and in vivo by ferric iron

J. Levin, F. Schmidt, K. Schinke, C. Prix, S. Shi, T. Hoegen, H.A. Kretzschmar, K. Boetzel, F. Kamp, A. Giese (Munich, Germany)

1494

  1. Top of page

SIRT4 is upregulated in patients with Parkinson's disease and Lewy body dementia

C.C. Luca, D. Eldick, S. Garamszegi, D. Mash (Miami, FL, USA)

1495

  1. Top of page

Alpha-synuclein as a biomarker of Parkinson's disease: A systematic review

N. Malek, D. Swallow, K. Grosset, D. Grosset (Glasgow, United Kingdom)

1496

  1. Top of page

LRRK2 and autophagy: Molecular targets for Parkinson's disease?

C. Manzoni, S. Dihanich, A. Mamais, H. Cai, R. Bandopadhyay, P.A. Lewis (London, United Kingdom)

1497

  1. Top of page

The protective role of AMPK and Akt signalling in α-synuclein neurotoxicity in vitro

I.D. Markovic, M.Z. Dulovic, M.D. Jovanovic, L.M. Harhaji-Trajkovic, G. Tovilovic, L. Stefanis, M. Xilouri, V.S. Trajkovic, V.S. Kostic (Belgrade, Serbia)

1498

  1. Top of page

Changes in EEG activity during deep brain stimulation support antidromic activation of cortical neurons in a biophysical model

J. Modolo, A.W. Thomas, A. Legros (London, ON, Canada)

1499

  1. Top of page

Modelling Parkinson's disease by chronic systemic exposure of α-synuclein overexpressing rats to the pesticide, rotenone

P.J. Mulcahy, A. O'Doherty, T. O'Brien, D. Kirik, E. Dowd (Galway, Ireland)

1500

  1. Top of page

Development and characterisation of a novel model of Parkinson's disease by sequential intra-nigral administration of AAV-α-synuclein and the pesticide, rotenone, in the rat

P.J. Mulcahy, A. O'Doherty, T. O'Brien, D. Kirik, E. Dowd (Galway, Ireland)

1501

  1. Top of page

No loss of mitochondria and an increase in recessive Parkinson's proteins are found in sporadic Parkinson's disease

K.E. Murphy, A.A. Cooper, G.M. Halliday (Sydney, Australia)

1502

  1. Top of page

Evaluation of Braak staging in at-risk individuals for Parkinson's disease

P. Basu, S.T. Govindappa, D.K. Subbukrishna, U. Muthane, U. Muthane (Bangalore, India)

1503

  1. Top of page

Limited cleavage by matrix metalloproteinase 9 promotes tau oligomer formation

G. Nübling, J. Levin, B. Bader, L. Israel, H. Kretzschmar, S. Lorenzl, A. Giese (Munich, Germany)

1504

  1. Top of page

Specific binding of tau oligomers to lipid membranes detected by confocal single particle fluorescence

E. Plesch, G. Nübling, J. Levin, F. Kamp, A. Giese (Munich, Germany)

1505

  1. Top of page

Phosphorylation by GSK-3β modulates tau oligomer formation and co-aggregation with α-synuclein

G. Nübling, B. Bader, J. Levin, J. Hildebrandt, H. Kretzschmar, A. Giese (Munich, Germany)

1506

  1. Top of page

Cyclic polymer structure shows high potential for neuronal transfection

B. Newland, E. Dowd, W. Wang, A. Pandit (Galway, Ireland)

1507

  1. Top of page

Reversibility of heterosynaptic cortical plasticity in human primary motor cortex

Z. Ni, C. Gunraj, P. Kailey, R. Chen (Toronto, ON, Canada)

1508

  1. Top of page

Defects in PINK1 are part of Alzheimer's disease pathogenesis and associate with alterations in the mitochondrial fission protein Drp1

A.P. Kiely, A.M. Moloney, C. O'Flanagan, M.F. Coakley, C. O'Neill (Cork, Ireland)

1509

  1. Top of page

Unmyelinated axons are more vulnerable to degeneration than myelinated axons of the cardiac nerve in Parkinson's disease

S. Orimo, T. Uchihara, T. Kanazawa, Y. Itoh, K. Wakabayashi, A. Kakita, H. Takahashi (Tokyo, Japan)

1510

  1. Top of page

Influence of perturbation velocity on balance control in Parkinson's disease

L.B. OudeNijhuis, W. Nanhoe-Mahabier, J.H.J. Allum, B.R. Bloem (Nijmegen, Netherlands)

1511

  1. Top of page

Unmasking adenosine 2A receptors (A2A-Rs) in monkey basal ganglia output neurons by using cholera toxin

S. Sierra, A.J. Rico, N. Luquin, V. Gómez, E. Roda, J.L. Lanciego (Pamplona, Spain)

1512

  1. Top of page

The E3 ligase Nedd4 participates in the internalization process of alpha-synuclein

N. Sugeno, T. Hasegawa, M. Konno, E. Miura, T. Baba, A. Kikuchi, M. Aoki, A. Takeda (Sendai, Japan)

1513

  1. Top of page

Neuropathology of PGC-1α deficiency recapitulates features of mitochondrial encephalopathies but not of neurodegenerative disorders

L. Szalardy, D. Zadori, I. Plangar, P. Weydt, L. Vecsei, P. Klivenyi, G.G. Kovacs (Szeged, Hungary)

1514

  1. Top of page

Serum level of inflammatory factors in patients with Parkinson's disease

S. Szlufik, D. Koziorowski, R. Tomasiuk, A. Friedman (Warsaw, Poland)

1515

  1. Top of page

A case of familial amyloid polyneuropathy with parkinsonism

S.R. Taneja, W. Tse (New York, NY, USA)

1516

  1. Top of page

Symptoms of peak dose dyskinesia are associated with an increased tendency for lTD expression on the indirect striatal ouput pathway

S.L. Thiele, B.J. Chen, J.M. Brotchie, J.E. Nash (Scarborough, ON, Canada)

1517

  1. Top of page

Investigation of the role of mitochondrial dysfunction in Parkinson's disease in patients with mutations in the parkin gene

C. van der Merwe, J. Blanckenberg, B. Loos, F. Henning, D. Lombard, C. Kinnear, J. Carr, S. Bardien (Stellenbosch, South Africa)

1518

  1. Top of page

Oxidative stress in Parkinson's disease compared to other neurodegenerative diseases

R. Duran, B.J. Morales, F.J. Barrero, F.J. Gutierrez, F. Vives (Granada, Spain)

1519

  1. Top of page

Dopaminergic modulation of corticostriatal transmission in monkeys

Y. Ma, Y. Smith, T. Wichmann (Atlanta, GA, USA)

1520

  1. Top of page

Targeting the CMA pathway ameliorates alpha-synuclein mediated neurodegeneration

M. Xilouri, O.R. Brekk, P. Themistoklis, K. Vekrellis, L. Stefanis (Athens, Greece)

1521

  1. Top of page

Implication of autophagy in Parkinson's disease: Rotenone-based models

N. Xiong, M. Jia, J. Xiong, J. Huang, T. Wang (Wuhan, China)

1522

  1. Top of page

α-synuclein BAC transgenic mice as a model for Parkinson's disease manifested decreased anxiety-like behavior

H. Yamakado, Y. Moriwaki, N. Yamasaki, T. Miyakawa, J. Kurisu, K. Uemura, H. Inoue, M. Takahashi, R. Takahashi (Kyoto, Japan)

1523

  1. Top of page

Cell cycle regulation promotes survival of dopaminergic neurons in experimental Parkinson's disease

T. Yasuda, K. Yoshikawa, S. Przedborski, Y. Mizuno, H. Mochizuki (Suita, Japan)

1524

  1. Top of page

Parkin interacting proteins are modifiers of drosophilaparkin and Pink1 mutant phenotype

A. Zanon, I. Pichler, A. Rakovic, C. Schwienbacher, C. Weichenberger, F.S. Domingues, A.A. Hicks, P.P. Pramstaller, C. Klein (Bolzano, Italy)

Parkinson's disease: Phenomenology

1525

  1. Top of page

p62 staining inclusions in an MSA-P phenotype – A new neurodegenerative entity?

N. Akhtar, R. Shafei, J. Lowe, N. Bajaj (Nottingham, United Kingdom)

1526

  1. Top of page

Hyposmia in Parkinson's disease

M.V. Alvarez, P. Grogan (San Antonio, TX, USA)

1527

  1. Top of page

What does tremor lateralization have to do with handedness?

M.V. Alvarez, P. Grogan (San Antonio, TX, USA)

1528

  1. Top of page

Adapting the Sniffin' Sticks olfactory test to diagnose Parkinson's disease in Estonia

E. Antsov, S. Kilk, L. Silveira-Moriyama, L. Kadastik-Eerme, T. Toomsoo, T. Paju, A. Lees, P. Taba (Tartu, Estonia)

1529

  1. Top of page

Connectivity patterns derived from resting state fMRI predict bradykinesia and rigidity in Parkinson's disease

S. Appel-Cresswell, N. Baradaran, S.S. Galley, A. Liu, Z.J. Wang, M.J. McKeown (Vancouver, BC, Canada)

1530

  1. Top of page

Rigidity in Parkinson's disease is associated with a distributed motor subnetwork

N. Baradaran, S.J. Palmer, A. Liu, Z.J. Wang, M.J. McKeown (Vancouver, BC, Canada)

1531

  1. Top of page

Preclinical detection of Parkinson's disease in subjects with REM behavior disorder using eye tracking

M.S. Baron, G.T. Gitchel, S. Raman, W.A. Wetzel (Richmond, VA, USA)

1532

  1. Top of page

Clinical correlations of nonmotor symptoms in Parkinson's disease

E.M. Bassetti, C.F. Nogueira, R.R. Sfalsini, M.S.G. Rocha (Sao Paulo, Brazil)

1533

  1. Top of page

Progressive cortical degeneration in Parkinson's disease

D. Benninger, J. Dukart, J. von Meyenburg, S. Thees, C. Bassetti, D. Waldvogel, S. Kollias, K. Iseki, B. Draganski (Lausanne, Switzerland)

1534

  1. Top of page

Measuring functional progression of Parkinson's disease

R.L. Boehm, Q.J. Almeida (Waterloo, ON, Canada)

1535

  1. Top of page

Motor symptoms in early stage, old-age onset Parkinson's disease: A two years follow-up study

P. Bugalho (Lisboa, Portugal)

1536

  1. Top of page

Gait dysfunction in Parkinson's disease and normal-pressure hydrocephalus: A comparative study

P. Bugalho, L. Alves, R. Miguel (Lisboa, Portugal)

1537

  1. Top of page

Recurrent falls in Parkinson's disease: A narrative review

A.K. Schwarzel, N.N. Allen, C.G. Canning (Lidcombe, Australia)

1538

  1. Top of page

A systematic review of the occurrence of psychotic features in people with Parkinson's disease

R. Caslake, A. Emeka, C. Counsell (Aberdeen, United Kingdom)

1539

  1. Top of page

Apraxia of eyelid opening in Parkinson's patient with STN-DBS – A novel solution

D.T.M. Chan, C.K.Y. Lau, C.X.L. Zhu, W.S. Poon (Hong Kong, Hong Kong)

1540

  1. Top of page

Prevalence and characteristics of pain in Korean Parkinson's disease patients

S.M. Choi, G.J. Yoon, H.J. Jung, B.C. Kim, K.H. Choi, T.S. Nam, J.T. Kim, S.H. Lee, M.S. Park, M. K. Kim, K.H. Cho (Gwangju, Korea)

1541

  1. Top of page

Non motor symptoms in Parkinson's disease

S.A. Rodriguez Quiroga, C. Christie, V. Díaz Arangunde, M. Mancuso, T. Arakaki, J. Toibaro, N.S. Garretto (Buenos Aires, Argentina)

1542

  1. Top of page

Fear of falling in Parkinson's disease

E. Cubo, N. Pérez Mariscal, N. Herrera (Burgos, Spain)

1543

  1. Top of page

Freezing of gait in Parkinson's disease under virtual reality conditions studied with a novel treadmill system: A pilot trial

K. Czarnecki, K. Iseki, C.R. Collins, P.T. Ghosh, H.S. Park, J.W. Yoon, M. Hallett (Bethesda, MD, USA)

1544

  1. Top of page

Postural stability in Parkinson's disease – The impact of visual control

B. Czechowicz, M. Boczarska-Jedynak, G. Opala (Katowice, Poland)

1545

  1. Top of page

Acute decompensation of Parkinson's disease

V.K. Datieva (Moscow, Russia)

1546

  1. Top of page

The overall burden of non motor symptoms in Moldavian Parkinson's disease patients

N. Diaconu, G. Pavlic (Chisinau, Republic of Moldova)

1547

  1. Top of page

Parkinson's disease viewed as an acquired archaic nervous system dysfunction: Evidence from comparative anatomy and ethology

N.J. Diederich, A. Parent (Luxembourg-City, Luxembourg)

1548

  1. Top of page

Olfactory dysfunction in pathologically confirmed incidental Lewy body disease and Parkinson's disease

E. Driver-Dunckley, C. Adler, J. Hentz, H. Shill, J. Caviness, M. Sabbagh, V. Evidente, B. Dugger, T. Beach (Scottsdale, AZ, USA)

1549

  1. Top of page

Glucocerebrosidase mutations influence the natural history of PD in a community-based incident cohort

S. Winder-Rhodes, J.R. Evans, M. Ban, C. Williams-Gray, T. Foltynie, S. Mason, S. Sawcer, R. Barker (Cambridge, United Kingdom)

1550

  1. Top of page

Risk factors and course of freezing of gait in Parkinson's disease: A 12-year population based study

E.B. Forsaa, J.P. Larsen, T. Wentzel-Larsen, G. Alves (Stavanger, Norway)

1551

  1. Top of page

Asymmetry of gait in parkinsonian patients and its role in the development of freezing

G. Frazzitta, G. Pezzoli, G. Bertotti, G. Riboldazzi, R. Rovescala, R. Maestri (Montescano, Italy)

1552

  1. Top of page

Etiology of Parkinson's disease--Quo vadis? Forgotten path of muscle afferents

D. Gobinathan, L. Dosado (Singapore, Singapore)

1553

  1. Top of page

Dysphagia in de novo drug naive Parkinson's disease in comparison to advanced PD stages: A videofluoroscopical and clinical study

M. Hahne, B. Leineweber, B. Griewing, W. Jost, H. Reichmann (Bad Neustadt, Germany)

1554

  1. Top of page

Performance of alternating hand tapping and its relation to gait and postural disturbances in Parkinson's disease

T. Herman, H. Bernad, N. Giladi, J.M. Hausdorff, M. Plotnik (Tel Aviv, Israel)

1555

  1. Top of page

On the influence of dopaminergic striatal innervation on upper limb locomotor synergies

I.U. Isaias, J. Volkmann, A. Marzegan, G. Marotta, P. Cavallari, G. Pezzoli (Milano, Italy)

1556

  1. Top of page

Characterization of gait freezing in Parkinson's disease using a novel foot-sensor based methodology in laboratory and in patients' homes

F. Rahimi, A. South, D. Bell-Boucher, P. Bapat, Y. Mohammad, L. Zhu, M. Vyas, M. Jog, M. Jog (London, ON, Canada)

1557

  1. Top of page

Retrocollis develops in the end stage Parkinson's disease

K. Kashihara, T. Imamura, M. Ohno, S. Kawada (Okayama, Japan)

1558

  1. Top of page

Association between olfactory dysfunction and neuropsychiatric manifestations in Parkinson's disease (PD)

N. Kawashima, K. Hasegawa, E. Horiuchi, T. Yokoyama, A. Kumon, A. Matsunaga, M. Saito (Fujisawa, Japan)

1559

  1. Top of page

Quantification of speech impairment in Parkinson's disease

T. Khan, J. Westin, P. Funk, M. Dougherty (Borlange, Sweden)

1560

  1. Top of page

Frozen shoulder and Parkinson's disease

M. Khara, A.Q. Rana, B. Alenazi, M.A. Rana (Toronto, ON, Canada)

1561

  1. Top of page

Subthreshold noisy galvanic vestibular stimulation normalizes motor responsiveness to visual error feedback in Parkinson's disease

D.J. Kim, A. Ashoori, E. Ty, M. Oishi, M.J. McKeown (Vancouver, BC, Canada)

1562

  1. Top of page

Homozygous parkin gene mutant carrier without definite signs of Parkinson's disease

B. Koentjoro, J.S. Park, A.D. Ha, C.M. Sue (Sydney, Australia)

1563

  1. Top of page

The “floating door sign” in Parkinson's disease (PD)

O.C. Kulkarni, K. Czarnecki, D. Tarsy (Boston, MA, USA)

1564

  1. Top of page

Is there any relationship between motor fluctuation and the weather in patients with advanced Parkinson's disease?

R. Kurisaki, Y. Yonemochi, T. Sakamoto, K. Uekawa (Uki, Japan)

1565

  1. Top of page

Patterns of daily ambulatory activity are different in early Parkinson's disease compared with controls

S. Lord, A. Godfrey, B. Galna, D. Burn, L. Rochester (Newcastle upon Tyne, United Kingdom)

1566

  1. Top of page

Camptocormia (kamptokormia) in patients with Parkinson's disease – An own subtype of Parkinson's disease?

S. Lorenzl, K. Bötzel, B. Schoser, G. Nübling (Munich, Germany)

1567

  1. Top of page

Non-motor symptoms are less prevalent in young-onset Parkinson's disease

V. Markovic, M. Svetel, T. Pekmezovic, V. Kostic (Belgrade, Serbia)

1568

  1. Top of page

Unexplained lower limb pain syndrome in Parkinson's disease: A variant of central pain

A. Martin, S. Robinson, M. Parry, A.H.V. Schapira, A. Rizos, C. Clough, K. Ray Chaudhuri (London, United Kingdom)

1569

  1. Top of page

Improvement of freezing of gait with amantadine in a patient with oculopharangeal muscular dystrophy and parkinsonism

A. McGarry, K. Biglan (Camden, NJ, USA)

1570

  1. Top of page

An observational study of the impact of early versus delayed treatment on quality of life in Parkinson's disease

D.J.M. McGhee, R. Caslake, C.E. Harris, C.E. Counsell (Aberdeen, United Kingdom)

1571

  1. Top of page

Finger tapping ‘off’ performance in Parkinson's disease is detected by digital signal processing

M. Memedi, J. Westin, D. Nyholm (Falun, Sweden)

1572

  1. Top of page

Measuring arm swing during gait in patients with Parkinson's disease using wearable sensors – A feasibility study

A. Mirelman, A. Peruzzi, E. Gazith, K. Yasinovsky, M. Zelis, N. Giladi, J.M. Hausdorff, M. Plotnik (Tel Aviv, Israel)

1573

  1. Top of page

The relationship of motor and non-motor symptoms of apathy in idiopathic Parkinson's disease

F. Ozer, M. Gurbuz, L. Hanoglu, S. Sitrava-Gunenc, F. Genc, B. Kul (Istanbul, Turkey)

1574

  1. Top of page

National Parkinson Foundation Quality Improvement Initiative (NPF-QII): Risk factors for falls in Parkinson's disease (PD)

S.A. Parashos, C.L. Wielinski, on behalf of the NPF QII Investigators (Golden Valley, MN, USA)

1575

  1. Top of page

Could pain be a reason for misdiagnosis of Parkinson's disease?

G. Pavlic, I. Moldovanu (Chisinau, Republic of Moldova)

1576

  1. Top of page

Evidence-based virtual reality treadmill system for gait research and rehabilitation of patients with Parkinson's disease

A.I. Perez-Sanpablo, A. Gonzalez-Mendoza, I. Quiñones-Uriostegui, A. Alessi-Montero, S.R. Leon-Hernandez, A.L. Dotor-Llerena (Mexico City, Mexico)

1577

  1. Top of page

Multimodal assessment of vocal cord function in early Parkinson's disease and essential tremor

L.D. Perju-Dumbrava, D. Phyland, K.K. Lau, P. Finlay, V. Antonopoulos, P.A. Kempster, P.G. Bardin, S.L. Stuckey, D. Thyagarajan (Clayton, Australia)

1578

  1. Top of page

The relationship between Parkinson's disease severity and posturography

A. Peterson, F. Horak, M. Mancini (Portland, OR, USA)

1579

  1. Top of page

Availability of olfactory bulb and olfactory tract in brain specimens in a brain bank

L. Silveira-Moriyama, A. Kingsbury, H. Ayling, J.L. Holton, W. Sterlacci, A. Petrie, S. Rajan, W. Poewe, H. Maier, M.T.H. Ezquerro, T. Revesz, A.J. Lees (London, United Kingdom)

1580

  1. Top of page

Baseline findings and Parkinson's disease prognosis

A.H. Rajput, M.L. Rajput, A.H. Rajput (Saskatoon, SK, Canada)

1581

  1. Top of page

Impairment of brain vessels may contribute to mortality in patients with Parkinson's disease

I. Rektor, D. Goldemund, P. Bednarík, K. Sheardová, Z. Michálková, S. Telecká, M. Dufek, I. Rektorová (Brno, Czech Republic)

1582

  1. Top of page

Early morning off periods in Parkinson's disease: Characterisation of non motor patterns and treatment effect: An international study

A. Rizos, B. Kessel, P. Martinez-Martin, P. Odin, A. Antonini, A. Martin, I. Koch, T. Klemencic Kozul, P. Reddy, S. Robinson, C. Falup-Pecurariu, A. Douiri, S. Lindvall, K. Ray Chaudhuri (London, United Kingdom)

1583

  1. Top of page

Comparison of clinical and behavioral measures distinguishing and predicting parkinsonian syndromes in REM sleep behavior disorder patients

M. Schiess, Q. Liang, B. Copeland, E. Furr-Stimming, R. Castriotta (Houston, TX, USA)

1584

  1. Top of page

Handwriting as an objective tool for Parkinson's disease diagnosis

I. Schlesinger, M. Samuel, S. Zlotnik, S. Rosenblum (Haifa, Israel)

1585

  1. Top of page

Withdrawn by Author

 

1586

  1. Top of page

Abnormalities of voice quality in the course of disease progression in Parkinson's disease

W. Grönheit, U. Schlegel, S. Skodda (Bochum, Germany)

1587

  1. Top of page

Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease

P. Solla, A. Cannas, F.C. Ibba, F. Loi, R. Puddu, M. Corona, G. Orofino, M.G. Marrosu, F. Marrosu (Monserrato, Italy)

1588

  1. Top of page

Cognitive correlates of freezing phenomenon in Parkinson's disease

E. Stefanova, M. Jecmenica Lukic, F. Agosta, V. Spica, M. Filippi, V. Kostic (Belgrade, Serbia)

1589

  1. Top of page

Predictive factors for nonmotor fluctuations in Parkinson's disease: Results from the NoMoFlu-PD study

A. Storch, C.B. Schneider, M. Wolz, Y. Stürwald, A. Nebe, P. Odin, A. Mahler, G. Fuchs, W.H. Jost, R.K. Chaudhuri, R. Koch, H. Reichmann, G. Ebersbach (Dresden, Germany)

1590

  1. Top of page

Effect of novel toe stretcher device on foot dystonia in patients with Parkinson's disease

D.C. Taylor (West Bloomfield, MI, USA)

1591

  1. Top of page

Thermal and mechanical pain thresholds in patients with fluctuating Parkinson's disease

L. Vela, R. Cano de la Cuerda, A. Fil, E. Muñoz-Hellin, Y. Macias Macias, R. Ortiz-Gutierrez, C. Fernandez-de las Peñas (Alcorcon, Spain)

1592

  1. Top of page

Relationship between midbrain sonography findings and non-motor symptoms in Parkinson's disease

S. Kleinschmidt, K. Busse, I. Gemende, F. Rimmele, R. Benecke, U. Walter (Rostock, Germany)

1593

  1. Top of page

Substantia nigra hyperechogenicity is not related to hyposmia or five-year course of hyposmia in Parkinson's disease

K. Busse, S. Kleinschmidt, C. Wunderlich, I. Gemende, R. Benecke, U. Walter (Rostock, Germany)

1594

  1. Top of page

Association between the UPDRS and falls and near falls in Parkinson's disease

S.A. Parashos, C.L. Wielinski, M.A. Nance, C. Erickson-Davis, S. Lenarz (Golden Valley, MN, USA)

1595

  1. Top of page

Visual symptoms in Parkinson's disease; a patient survey

E.J. Williams, B.L. Kessel (Romsey, United Kingdom)

1596

  1. Top of page

The CamPaIGN study of incident Parkinson's disease: Natural history over the first 10 years

C.H. Williams-Gray, S.L. Mason, J.R. Evans, T. Foltynie, R.A. Barker (Cambridge, United Kingdom)

1597

  1. Top of page

Pramipexole-induced camptocormia in Parkinson's disease: 8 reversible cases

M. Yamamoto, Y. Okuma, T. Maeda, K. Kimura (Takamatsu, Japan)

1598

  1. Top of page

Evaluation of videofluoroscopic findings that contribute to aspiration in patients with Parkinson's disease

T. Yamamoto, M. Murata (Kodaira, Tokyo, Japan)